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I.   Abstract 
 
Inflammation of the airways can be life threatening for those with T helper type 2 (Th2)-mediated 
allergies or allergic asthma. Despite the increasing prevalence of allergic diseases, there are no 
current vaccinations to prevent allergies. Desensitisation via allergy immunotherapy (AIT) is the 
only disease-modifying treatment available. This involves slowly building up a specific-tolerance to 
the allergic substance (allergen) through either subcutaneous injection or oral absorption. Yet 
allergy patients rarely undertake AIT as is it costly, time consuming and can increase the risk of life 
threatening anaphylaxis. These discouraging factors arise from the poorly optimised targeting of the 
current routes of AIT that do not target immunotherapy primarily to tolerant-inclined cells in order 
to maximise an allergen-specific tolerance response. 
 
Building allergen-specific tolerance is often similar either before (vaccination therapy) or after 
(desensitisation therapy) allergen sensitisation. Specific-tolerance is established when tolerant-
inclined cells, such as skin epidermal Langerhans cells (LCs), present allergens to the immune 
system alongside tolerant signalling. Targeting the therapy to the skin has been notoriously 
challenging with current needle and syringe or topical patch methods. However, microprojection 
array (MPA) patches have begun to demonstrate rapid delivery of vaccine therapeutics as well as 
specific cell targeting into the upper layers of the skin.   
 
Immunisation with high-density (i.e. above 1,000 (1k) projections (p)/cm2) dermal-targeted MPAs 
(dMPA) have previously been shown to induce pro-inflammatory and specific-IgG responses at a 
fraction of the injectable dose. As an increase in IgG correlates with a decrease in IgE during AIT, I 
hypothesised that the dMPA-therapy could specifically inhibit IgE in a desensitisation model. After 
initial results, I further hypothesised that a MPA that delivered allergen primarily to the epidermal 
LCs (eMPA) would prevent Th2 inflammation in a vaccination model, similar to that seen in a 
healthy immunity against allergens. Therefore, different designs of dMPAs were tested in 
desensitisation therapy and eMPAs in preventative vaccination therapy with an ovalbumin (OVA)-
based, IgE-mediated, airway hypersensitivity mouse model. 
 
First, conical-shaped dMPAs of two densities (21k or 10k p/cm2) delivered OVA at application 
energies of either 170 mJ or 100 mJ to the skin of OVA sensitised BALB/c mice. Desensitisation 
with the very high density 21k-dMPA significantly increased unwanted Th2 responses including 
airway eosinophilia and anti-OVA IgE. Based on these results, the dMPA was tailored to reduce the 
impact on the skin by halving the projection density to 10k and using an application energy of 100 
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mJ. Despite the increased anti-OVA IgG1 and IgG2a, the anti-OVA IgE continued to persist. Yet, 
both airway eosinophilia and the level airway mucus was significantly reduced at day 87 in 10k-
dMPA-100 mJ treated mice. To date, the association between repeated OVA-dMPA treatments 
(without adjuvants) on preventing airway eosinophilia and mucus has not been reported. 
 
Second, after establishing a strong correlation between decreased dMPA density and Th2-mediation 
of the immune response, I aimed to test a low inflammatory eMPA in vaccination. To date, no MPA 
design was reported to successfully target therapeutics to the epidermis of mouse skin. To ensure a 
shallow (~15 µm) but consistent epidermal delivery, projection tips were widened from the pointed 
conical shape to a slit-like shape, increasing the tip surface area. Slit-shaped eMPAs applied at 30 
mJ resulted in significantly less erythema and epidermal inflammation than dMPAs. Analyses of the 
inguinal skin draining lymph nodes found that eMPAs (with or without OVA) significantly 
increased LC migration, but not dermal dendritic cell migration. This is the first report of MPAs 
targeting the mouse epidermis and preferentially activating LC migration. 
 
Third, various doses of OVA delivered by low-impact eMPAs were applied to naïve mice to test 
prevention of Th2 airway inflammation. Compared to the positive control (80-200 µg), the eMPA 
prevented airway eosinophilia in up to 60% of mice and anti-OVA IgE in 75% of those mice with a 
significantly lower dose (0.4 µg). Additionally, mice vaccinated with eMPAs had significantly less 
airway mucus and obstructions even when challenged with a chronic sensitisation model. Therefore, 
unlike other transdermal quick-delivery devices, the eMPA showed promise in preventing airway 
hypersensitivity by delivering just the allergen. 
 
In conclusion, by reducing the impact on the skin, both dMPAs and eMPAs applied to mouse skin 
reduced airway inflammation. Only desensitisation with 10k-dMPAs at 100 mJ reduced airway 
eosinophilia, suggesting high densities and/or application energies are too Th2-mediated to prevent 
eosinophilia. Similarly, only vaccination with fewer eMPA repeats applied with lower doses 
prevented airway inflammation, suggesting that eMPA vaccination is dependent on the level of 
impact on the skin and dose delivered. These findings show promise for the future use of high-
density MPAs as a skin deliver device of allergen against airway hypersensitivity but highlights the 
importance of understanding the new variables such as application energies and overall impact the 
MPA design has on the skin during MPA delivery of allergen. 
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CD Cluster of differentiation 
CpG CG rich regions of DNA 
Da Dalton 
DAMP Danger-associated molecular patterns 
DAPI 4′,6-diamidino-2-phenylindole 
DC Dendritic cell 
dDC dermal dendritic cell 
dLN skin draining lymph node 
dMPA Dermal-targeted microprojection array 
DPM Disintegrations per minute 
DPX Dibutylphthalate polystyrene xylene  
EAACI European Academy of Allergy and Clinical Immunology 
ELISA Enzyme-linked immunosorbant assay 
eMPA Epidermal-targeted microprojection array 
EPI Epidermal powder immunisation 
EPIT Epicutaneous allergy immunotherapy 
EU Endotoxin unit 
39 
 
FAC Foetal calf serum in phosphate buffered saline  
FCS Foetal calf serum 
FSC-A Forward scatter - area 
g Gram 
G Gauge 
h Hour 
H&E Hematoxylin and eosin 
HMD House dust mite 
i.d. Intradermal injection 
i.m. Intramuscular injection 
i.n. Intranasal inhalation 
i.p. Intraperitoneal injection 
i.t. Intratracheal injection 
IDIT Intradermal allergy immunotherapy 
IFN Interferon 
Ig Immunoglobulin 
IL Interleukin 
ILC Innate lymphoid cells 
ILIT Intralymphatic allergy immunotherapy 
iTreg Induced Treg cell 
k Thousand 
LC Langerhans cell 
LPS Lipopolysaccharide 
LSM Light scanning microscope 
LTB Heat liable toxin B subunit 
M, mM Molar, millimolar 
MCP Monocyte chemoattractant protein 
MHC I/II Major histocompatility complex - type 1 or type 2 
Mig Migratory 
min Minute 
MIP Macrophage inflammatory protein 
mJ Millijoule 
mm, mg Millimeter, milligram 
MPA Microprojection array 
MUC Mucin 
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NBF Neutral buffered formalin 
ng nanogram 
O+AH Ovalbumin in aluminium hydroxide suspension gel  
O+Im Ovalbumin in Imject alum adjuvant 
OVA Ovalbumin 
p p-value 
P.L.E.A.S.E. Precise Laser EpidermAl SystEm 
p/cm2 projections per centimetre squared 
P/eMPA Projectile application of eMPA 
PBS Phosphate buffered saline 
PBS-T Tween-20 in phosphate buffered saline 
PCA Passive cutaneous assay 
QS-21 Quillaja saponaria extract 21 
R2 "R squared", Coefficient of determination 
RANTES Regulated on activation, normal T cell expressed and secreted 
Res Resident 
RT Room temperature 
s.c. Subcutaneous injection 
SCIT Subcutaneous allergy immunotherapy 
SD Standard deviation  
SDS sodium dodecyl sulfate 
SEM Scanning electron microscope 
SLIT Sublingual allergy immunotherapy 
SSC-A Side scatter - area 
t Time point 
TEWL Trans epidermal water loss 
TGF Transforming growth factor 
Th0 T helper naïve cell 
Th1 T helper type 1 cell 
Th2 T helper type 2 cell 
TLR Toll-like receptor 
TMB 3,3',5,5'-Tetramethylbenzidine 
TNF Tumour necrosis factor 
Treg T helper regulatory cell 
TS Tape stripped skin 
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µm, µg, µl  Micrometer, microgram, microliter 
USA United States of America 
V Vaccination 
v/v Volume per volume 
w/v Weight per volume 
WAO World Allergy Organisation 
WHO World Health Organisation 
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Chapter 1 
 
1 Introduction 
 
1.1 Context of study 
 
Allergies affect 20% of human world population [1] and are on the rise worldwide [2, 3]. Allergies 
are caused by an unbalanced or inflammatory T helper type II cell (Th2) immune reaction to 
innocuous substances termed allergens [4]. Despite millions of healthy patients forming a tolerant 
immune response to allergens by exposure through the skin, gut and airways, there is currently no 
means of allergy vaccination to replicate this process and avoid allergy sensitisation. Once 
sensitised to an allergen, allergy immunotherapy (AIT) treatment can permanently reduce 
symptoms but only for some allergies (particularly allergies of the airways, e.g. grass pollen) [5]. Of 
these, success can range from 30-95%, depending on the allergen [6, 7]. Approved routes and 
regimens for AIT include either injections of allergen into the subcutaneous tissue of the skin up to 
80 times (SCIT) or absorption under the tongue (sublingual) taken daily (SLIT); both routes slowly 
build up immune tolerance over 3-5 years [8]. High costs and inconvenient regimens lead to a low 
6% of allergic patients undertaking SCIT or SLIT [9, 10]. In addition, SCIT can result in a life-
threatening anaphylaxis shock that also deters allergic patients [11].  
 
In response to the broad success rate and low usage rate, several more delivery routes have been 
assessed for AIT. These include delivering the allergen via injection into the lymph node (ILIT), 
injection into the dermal layer of the skin (IDIT) and absorption into the epidermal tissue of the skin 
(EPIT) [9]. Both ILIT and EPIT have shown positive preliminary results to reduce patient 
symptoms with significantly less repeats than SCIT or SLIT, however, IDIT has been inconsistent 
[12-14]. The downside to ILIT is that it requires an invasive and precise injection by trained staff 
and specialised equipment. On the other hand, EPIT can be self-administered like the SLIT, 
negating the need for regular medical appointments. EPIT delivers to a high concentration of 
tolerant-inclined cells, such as Langerhans cells (LCs), in the upper layers of the skin [15]. A recent 
clinical trial by DBV Technologies showed that peanut allergen EPIT could maintain a safe and 
successful AIT result in children for peanut allergen where other routes have been deemed less safe 
[16]. However, devices tested for EPIT currently require long application times (hours-days), 
reducing the dosing accuracy which is important to maintain for AIT [17, 18]. 
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To overcome slow absorption therapeutic delivery into the skin, several rapid delivery devices have 
been developed, the most cost effective and practical of these being the microprojection array 
(MPA) patch [19]. The MPA can be made to a variety of designs, materials and application 
methods, while predominantly delivering therapeutics within seconds (sec) to minutes (min) into 
mouse [20, 21] or human [22] skin. MPAs can also be applied by the patient and are painless 
relative to conventional injections [23, 24]. Despite several reports showing that immunisation with 
high-density MPAs (> 1k projections/cm2) can activate therapeutic specific immune responses with 
100-fold less dose than injectable immunisation in mice (therefore a safer dose), they have never 
been tested in the delivery of allergen [25]. In mice, MPAs deliver therapeutics within a slow 
dissolving coating (taking minutes to hours) to the aforementioned dermal layer of the skin 
(dMPA). Slower absorption has previously shown to result in less uptake of therapeutic into the 
blood circulation, reducing the dangers of systemic reactions for AIT [26]. Although the lower dose 
required by a dMPA and the slower absorption may suffice to improve dermal-based AIT over 
IDIT, additional MPA designs are still required to target allergen delivery to the more tolerant-
inclined (but very thin) upper epidermal layer of the skin. Within the mouse model, an epidermal 
MPA (eMPA) has yet to be reported.  
 
This thesis focuses on utilising high-density, solid projection MPAs coated with the model allergen, 
ovalbumin (OVA), and applied with a spring-loaded applicator to the skin of mice. The OVA 
therapy was delivered either before sensitisation of mice (allergy vaccination) or after sensitisation 
of mice (allergy desensitisation) in an airway hypersensitivity model. The characteristics of each 
MPA was thoroughly assessed to ensure that differences in immune results could be attributed to 
features of the MPAs. A multitude of treatment regimens were evaluated to improve both immunity 
balance and airway health. 
 
These studies improved the understanding of the mechanisms behind high-density MPA delivery 
and immunity. This includes, the effect of MPA density, surface area, penetration depth and 
application energy on the level of skin cell death, type of antibody production, skin inflammation 
and airway inflammation. Skin delivery routes add a multitude of new variables to assess that are 
not found in SCIT, SLIT or ILIT. These new skin route variables include different types of immune 
cells targeted, delivery process used and the level of local skin inflammation during allergen 
delivery, each of which were assessed in this thesis. The results from testing a variety of high-
density MPAs to delivery allergen adds important data to these new variables and helps better 
define the maximum thresholds (and dependencies) for each variable to improve skin-based AIT for 
airway hypersensitivity.  
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1.2 Hypotheses, aims and key findings 
 
This thesis first reviews the current literature on the prevention of allergies, particularly airway 
allergies in Chapter 2. The review includes the current approved immunotherapeutic routes 
available as well as experimental routes of administration with a focus on the use of skin delivery 
devices. Following this is the materials and methods used in this thesis (Chapter 3). After which, the 
three main hypotheses are separated into four research chapters that each include the results and 
discussion of multiple studies (Chapter 4-7). The main thesis hypotheses, aims and key findings for 
each chapter are outlined in Schematic 1-1. 
 
In brief, Chapter 4 begins with assessing whether delivery of a model allergen, OVA, via high-
density dMPAs could protect mice in an airway hypersensitivity model. By comparing two 
densities at two different application energies, results indicated desensitisation with dMPAs 
somewhat favoured conditions that had a lower impact on the skin (i.e. lower density and lower 
application energy).  That is, lower impact dMPAs protected to the airways against Th2 
inflammation, however, no dMPA protected against systemic Th2 allergy antibody production 
(anti-OVA IgE). Therefore, Chapter 5 systematically assessed the impact of density of the dMPA 
(ranging from 30k to 5k projections/cm2) on the skin and the subsequent immunity. As the number 
of impacted (dead) cells in the skin decreased with decreasing density, so did the level of Th2-
mediated immunity (IgG1). Therefore, Chapter 6 reassessed the high-density MPA design so that it 
could deliver OVA with minimal impact to the skin. This lead to a shallow, low-inflammatory 
eMPA that primarily targeted LCs, which have been previously shown to assist in allergy 
desensitisation. From here, Chapter 7 utilised a shorter allergy vaccination mouse model to screen 
different doses and vaccination regimens of OVA delivered by the eMPA. These studies found that 
an eMPA vaccination favoured a low OVA dose administered through a less repeats to protect 
against Th2 airway inflammation as well as somewhat preventing the anti-OVA IgE antibody 
production. Chapter 8 then summarises the key findings of the thesis and outlines how the 
limitations of each study were overcome as well as what additional projects could continue to 
advance the use of high-density MPAs in allergy prevention. 
 
Collectively, this thesis confirms that a summation of high-density MPA variables that affect the 
impact on the skin (e.g. density and application energy) must equate below a maximum threshold to 
provide allergen-specific protection against airway inflammation. However, only the eMPAs with 
the lowest tested impact on the skin protected against a systemic response. 
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Schematic 1-1: Layout of thesis hypotheses and aims including key finding of each research 
chapter. Where very high densities refer to 21k+ p/cm2, high application energies refer to 170+ mJ, 
lower densities refer to 5-10k p/cm2, lower application energies refer to 100 mJ and below, large 
tip surface area is in the range of 0.06 mm2 and the highest eMPA dose tested was 8 µg of OVA. 
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Chapter 2 
2 Literature review 
 
2.1 Introduction to allergy  
 “Allergy” was first described by von Pirquet in 1906 [27], although the disease had been observed 
earlier. Allergy is defined as an altered immunological response to an innocuous substance, termed 
an allergen [4]. Allergens cover a broad range of substances that target either the airways, skin, 
intestinal tract or a combination of these. The most common allergens including grass, pollens, 
animals, dust, insects, foods and latex (see Table 2-1 for common allergens). The historical 
presence of allergic diseases was first notably recorded in 1870. The history of allergies that follows 
is discussed in Platts-Mills et al. [28] review on allergy epidemics, covering from the year 1870 to 
2010. To summarize, the first commonly reported allergies were to grass and pollen allergens in the 
1870’s. Following this was a gradual increase of indoor insect fragment, indoor animal and food 
allergies between 1960 - 1990. Interestingly, there has been a significant boost in allergy prevalence 
since the 1970’s (Figure 2-1), particularly with food-based allergies (not shown). The initialisation 
of allergies correlates with industrialisation of agricultural practices, increased hygiene practices, 
the move from outdoor to indoor children activities and a decrease in aerobic fitness (supported by 
mouse models, [29]), all of which are factors of consideration for the continuing increase of 
allergies [28, 30, 31].  
 
By becoming sensitised to at least one allergen, patients are susceptible to developing either 
urticaria (skin), allergic/atopic eczema (skin), allergic rhinitis (airway), allergic asthma (lung), 
allergic conjunctivitis (eye), food allergy (mucosal and intestinal) and/or other specific allergies [1]. 
Allergic reactions can manifest in a variety of symptoms internally and externally. These include 
itchiness, nasal mucus congestion and secretion, irritation of the eyes, coughing, sneezing, skin 
rashes, skin pustules, difficulty in breathing (due to constriction of airways or inflammation of 
oesophagus), fatigue, headache, nausea, vomiting, fever and can result in a life threatening 
anaphylactic shock [12, 32]. Overall, allergy reactions result in varying levels of discomfort, sleep 
deprivation, reduced quality of life, less productivity and modified lifestyles in an attempt to avoid 
exposure [33].  
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Figure 2-1: Increasing prevalence of allergies such as asthma, allergic rhinitis and atopic eczema 
[3]. 
 
Table 2-1: List of specific common allergens (based on Australian allergies). Information is 
gathered from the Australasian Society of Clinical Immunology and Allergy (ASCIA) website [34]. 
Groups of 
allergens 
Types of allergen origins Sensitisation 
Grasses Sorghum halepense (‘Johnson grass’), Paspalum notatum 
(‘Bahia grass’), Phleum pratense (‘Timothy grass’), 
Phalaris aquatic (‘Canary grass’), Dactylis glomerata 
(‘Orchard grass’), Poa pratensis (‘Kentucky bluegrass’), 
Lolium perenne (Ryegrass’), Poa annua (‘Winter grass’), 
Cynodon dactylon (‘Couch grass’).  
Airways 
Pollens Callitris columellaris (‘White Cypress Pine’), Echium 
plantagineum (‘Patterson’s Curse), Ambrosia 
artemisiifolia (‘Ragweed’) and Parthenium 
hysterophorus (‘Parthenium weed’) 
Airways 
Animals Cats (specifically sebum secreted from skin glands) and 
Dogs (specifically saliva). 
Airways and 
Skin 
Insect 
fragments 
(dust) 
Dermatophagoides farina (‘Dust mite’), 
Dermatophagoides pteronyssinus (‘Dust mite’), and 
Periplaneta australasiae (‘Australian cockroach’)*. 
Airways and 
Skin 
Insect bites 
and stings 
Apis mellifera (‘European honey bee’), Myrmecia 
pilosula (‘Australian Jack Jumper ant’), Vespula 
Skin 
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germanica (‘European Wasp’), Ixodes holocyclus 
(‘Paralysis tick’) 
Foods Cow’s milk, Egg, Peanuts, Tree nuts, Sesame, Soy, Fish, 
Shellfish, Wheat and Food preservatives (e.g. sulphites). 
Intestinal and 
Skin 
*Note: Cockroach allergy is based on country, most common cockroach allergies come from 
Blattella germanica (‘German cockroach’) and Periplaneta Americana (‘American cockroach’). 
 
2.1.1 Factors that contribute to allergy susceptibility 
Several hypotheses have been reported to account for the increase in allergies, all of which relate to 
the effects of westernisation [35]. These include increased hygiene (‘hygiene hypothesis’), 
decreased airway, skin and gut microflora (‘microbiome hypothesis’) and change in exposure to 
allergens (‘exposure hypothesis’). Hygiene resulting in increased allergies is a complex factor to 
assess and directly effects the microbiome and exposure hypotheses. However, a combination of 
accepting the germ theory and water chlorination in developed nations from the 1920’s begins a 
significant increase in hygiene [28]. This led to an increased use of soap and exfoliation tools in the 
westernised cities that temporarily depletes the skins outer protective layer now known to increase 
susceptibility to allergy sensitisation. As such, developed cities such as New York reported 10-13% 
increased allergic prevalence between 1932 and 1950. Alongside this timeframe was a shift to more 
indoor activities and an increased awareness of the downsides to parasitic worm (helminth) 
infections [36]. Those non-infected became prime populations of increased allergy prevalence [37]. 
On the flip side, populations infected with helminths correlate well with reduced allergy prevalence, 
as most recently reviewed by Fitzimmons et al. [37]. This is largely believed to be because helminth 
infection activate very similar immune pathways as allergic sensitisation does. Where repeated 
infection leads to a stronger anti-helminth response that is thought to support the subjects against 
subsequent allergies. Overall, increased hygiene leads to two major lifestyle changes, decreased 
exposure to parasitic and microbial elements and changes in allergen exposure.  
 
The microbiome encompasses all the microbial species that are inhaled or reside on the skin and gut 
in any given person. Although disregarded for many years, its regulation and activation of the 
immune system are quickly becoming apparent [38]. The most noteworthy study is that of the 
Amish and Hutterites. Whereby, despite very similar living conditions away from other societal 
influences within the United States of America (USA), the Amish develop significantly less 
allergies than the Hutterites [30]. This is likely due to the Hutterites industrialisation of farming 
resulting that leads to less farmyard exposure to infants and children. A cross sectional study by 
Riedler et al. [39], also found significant differences between children that were exposed to a 
farming environment within the first year and those who were not. They found farm exposure had 
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2.4-fold less prevalence of atopic dermatitis, 4-fold less hay fever and 11-fold less asthma. Children 
who continued farming exposure up to 5 years of age had even less prevalence relative to those 
exposed within their first year [39]. In 2007, Debarry et al. [40] isolated and analysed two species’ 
of bacteria from cow-shed dust, Acinetobacter lwoffii F78 and Lactococcus lactis G121, for their 
potential protection against allergy sensitisation. They found both stains had strong anti-allergy 
properties when applied in a in a mouse allergy model. Although the presence of A. lwoffii on the 
skin of atopic dermatitis and healthy patients did not differ, healthy patients had strong correlations 
between the concentration of A. lwoffii and the concentration of anti-allergy signals [41]. This study 
of  A. lwoffii is also highlights the relationship between skin exposure and airway immunity in 
allergies. The cross-talk between the skin and the gut mucosal immunology is also well documented 
[42]. An allergy study found children with more gut colonisation of Lactobacilli strains within the 
first two months of life had less allergy prevalence by 12 months of age [43]. These findings 
persisted in Swedish and Estonian children with allergies who maintained significantly less 
intestinal Lactobacilli [44]. However, it is important to note that not all bacteria strains are 
beneficial to prevent allergies and some patients even form sensitisations to microbiome bacteria. 
As such, the same Swedish and Estonian children with allergies had higher ratios of aerobic, 
intestinal micro-organisms [44]. And some bacterial infections (e.g. Chlamydia trachomatis and 
Mycoplasma pneumonia) have been associated with exacerbated allergic asthma [45]. Importantly, 
excessive removal and lack of microbial exposure does not benefit the balanced nature of the 
immune system.  
 
The exposure threshold to sensitise to any given allergen is very difficult to assess and depends on 
dose, route, frequency and age of the subject, not to mention the effects of multiple allergen 
exposures. None-the-less, changes in living behaviour has changed peoples’ exposure to the 
environment, such as filtered air and less outdoor activity. As elegantly outlined by Holt & Thomas 
[46], the dose of exposure to inhaled allergens appears to rely on a biphasic protection pattern 
(Figure 2-2). Whereby very low doses (often seen in allergen avoidance) and high doses (similar to 
daily exposure) both result in higher protection against airway allergies than doses in between these. 
The concentration of different indoor inhaled allergens considered ‘low’, ‘medium’ or ‘high’ may 
be similar.  For example, protection against sensitisation was reported from homes with high house 
dust mite (30 µg/g) and cat allergen (>23 µg/g) while lower doses (medium) had higher 
sensitisation rates (10-19 and 5-9 µg/g respectively) [47-49]. Additionally, exposure of the majority 
of inhaled allergens at any dose (not pet allergens, [50]) before the age of 2 years old [47], including 
maternal exposure between 3-7 months in utero [51, 52], results in higher allergy prevalence. On 
the other hand, food allergens such as cow’s milk (after 4 months old), egg (before 6 months), 
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peanut and shellfish (both before 10 months) are recommended to be introduced between 4-10 
months of age to increase protection [53]. This differs according to culture where Asian infants, 
such as those studied in Singapore, maintained protection against food allergens despite exposure 
after 10+ months old [53]. In addition to exposure to different doses of allergen, exposure to 
different doses of a common endotoxin, lipopolysaccharide (LPS), can significantly alter allergic 
susceptibility [54]. LPS is found in the shell of gram-negative bacteria. By comparing the mean 
level of endotoxin units (EU) that 9-24 month old infants were exposed to at home, high doses of 
endotoxin (e.g. 1,035 EU/ml) were significantly more protective against sensitisation than medium 
doses (e.g. 468 EU/ml) [55]. This was supported by airway hypersensitivity tests in mice where 
administration of 10 EU (low dose) or 1,000,000 EU (high dose) was protective while 1,000 EU 
(medium dose) was not [56]. Ideally, the combination of these findings could assist in developing a 
controlled allergen exposure in the form of an allergen vaccine. Yet, controlling exposure to inhaled 
allergens and/or endotoxin is difficult enough to assess under scientific conditions let alone by an 
individual, and so only avoidance is recommended to those that may be of high risk to sensitisation. 
 
Figure 2-2: Biphasic relationship of inhaled dose to risk of sensitisation, as presented in Holt et 
al. [46] 
 
Mechanistically, increased hygiene reduces the bodies opportunity to develop tolerance against 
allergens, essentially resulting in avoidance practices that are not likely to be upheld in the long 
term. While, high exposures of both particular microbial components [57] and inhaled allergen 
result in boosted T helper type I cell (Th1) responses or regulatory T cell (Treg) responses well 
known to prevent allergic Th2 immune responses as discussed in more detail below. Although, once 
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allergically sensitised, many of these practices and exposures no longer provide protection and 
some even switch over to aggravating allergic symptoms [58]. 
 
2.1.2 Guidelines to prevent allergies 
The 2004 report by the World Allergy Organization-IAACI (WAO) recommended that an easy-to-
use guide be developed for the prevention of allergies in early infants [59]. This time frame is one 
of the most controlled times of a person’s life, making it easier to implement. Since then, there have 
been several studies and guides on the association of maternal factors, infant diet, infant exposure 
and other factors that correlate highly with the development or prevention of allergic diseases. The 
following guidelines were sourced from WAO, Australiasian Society for Clinical Immunology and 
Allergy (ASCIA) and the European Academy of Allergy and Clinical Immunology (EAACI). Most 
guidelines refer to healthy infants and are often revoked when dealing with high risk infants of 
whom have a sibling or parent with a history of allergies [60].   
 
Maternal exposure to outdoor inhaled allergens has been linked to foetal antibody sensitisation and 
so avoidance may be beneficial [51], but this does not extend to food allergies. Pregnant mothers 
are advised (by WAO, ASCIA and EAACI) not to remove allergenic foods from their diet during 
pregnancy or breast feeding. There is a general consensus that allergen related food should not be 
introduced before 4 months old. However, EACCI reports that there is conflicting evidence to 
support either withholding or encouraging food-based allergen exposure after 4 months old [60]. 
While WAO and ASCIA recommend a one-by-one allergenic food introduction between 4-11 
months old with frequent upkeep of consumption after initial exposure. Evidence for this is 
particularly strong for preventing peanut allergies [61]. The WAO and EAACI do not recommend 
the supplementation of vitamin D at any stage to supposedly reduce the risk of allergies [60, 62]. It 
is highly recommended by all to avoid smoking during pregnancy or during infancy. In conflict to 
ASCIA and EAACI, a 2016 report by WAO recommends the inclusion of prebiotic 
supplementation for infants that are not exclusively breastfed [63]. Prebiotics for this group has 
improved probiotic gut bacteria that in turn reduced the risk of asthma, food allergy or recurrent 
wheezing. ASCIA does not advise against the use of pre or probiotics. ASCIA advises that there is 
no need to remove pets from the household during infancy while WAO suggests removal for high 
risk infants. Overall, further consistency of consensus is required in order to provide adequate 
guidelines on allergen and microbial exposure. This may require continent specific guidelines due 
to differences in available allergens. 
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2.1.3 Types of allergies  
Allergy sensitisation (or hypersensitivity) is subtyped into four categories (I, II, II, IV) [64]. Each 
subtype mediates immune inflammation to innocuous substances but differs based on the source of 
allergen. Type I and IV allergens are externally sourced (such as those listed in Table 1), while type 
II, III involve self-immune components. Subtype I, II and III are mediated by antibodies that are 
made from immunoglobulin (Ig) protein released by B cells (lymphocytes that mature in bone 
marrow). Antibodies consist of two parts, one that defines the subtype of antibody (A/α, E/ε, G/γ or 
M/µ) and another that fits specifically to the body of the allergen (e.g. anti-allergen). Although both 
I and IV react to external allergens, type I is antibody dependant (i.e. an antibody response to the 
allergen triggers the hypersensitivity) while type IV is antibody independent (i.e. immune cells react 
directly to the allergen). Like type I, type II is also antibody dependant, however, these antibodies 
cross-react with components of the immune cells (i.e. anti-allergen + components). Similarly, type 
III is antibody dependant, however, the antibodies themselves form clusters with the allergen and 
the immune system reacts to the whole cluster. This thesis will focus specifically on subtype I 
hypersensitivities that are mediated by IgE antibodies. IgE is a subtype of antibody discovered in 
1966 that naturally increases Th2 responses during parasitic invasion [37, 65].Though the majority 
of allergies are mediated by IgE, other diseases such as allergic asthma, allergic rhinoconjunctivitis, 
allergic conjunctivitis, urticaria, angioedema, sweat itch, atopic dermatitis, and anaphylaxis are also 
associated with IgE [66]. IgE hypersensitivity can manifest either locally or systemically from 
exposure to the skin, eyes, nasal cavity, intestinal tract or airways. In this thesis, I will focus on IgE-
mediated allergies of the airways and the treatments thereof while drawing comparisons from all 
IgE-mediated studies. Treatment studies that do not improve anti-allergen IgE response but do 
prevent Th2-based airway inflammation may also benefit non-allergic diseases such as other forms 
of asthma, chronic obstructive pulmonary disease and cystic fibrosis [67].  
 
2.1.4 Allergy prevalence 
Together, allergies effect 30-35% of children [68] and over 20% of the whole world wide 
population at some stage in their life [1, 59]. Although about 75% of food allergies resolve by age 
of 20 [68], this is not the case for airway allergies and allergic asthma [69]. In Australia alone, one 
million absent school days are reported each year due to allergic asthma [59]. An IgE-mediated 
reaction is the most common diagnosis of atopic allergic diseases, affecting 20-40 % of people in 
developed nations [2, 70, 71]. IgE allergic disease has significantly increased in prevalence 2-3 fold 
since the 1980s [72]. This costs the Australian economy over $7 billion per year with only 15 % of 
that cost supported by health care and 48 % is spent by allergic individuals.  
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An anaphylactic shock is the most common cause of death for allergies and reports suggest it has 
increased from 1-3 deaths / million people in 2005 [73] to 1-5.5 deaths / million people in 2013 [74] 
worldwide (approximately 6500-19000 increased to 7200-39000 deaths/year). Of these, 21.9 
Australians die per year from anaphylaxis (0.99 deaths / million in 2013) [75]. The most common 
IgE mediated airway disease is allergic asthma [72]. Where 50% of asthmatic adults and 80% of 
asthmatic children are affected by allergic asthma [59]. Approximately 250,000 asthmatics 
worldwide suffer unavoidable deaths each year [1]. There are no definitive genetic associations with 
IgE-mediated allergies. However, those with one allergic parent or sibling are 30% more likely to 
also contract an allergy and this likelihood doubles with those with two allergic parents [76], though 
this also depends on the ethnicity of the parent [77]. 
 
2.1.5 Stages of allergic disease 
Allergic sensitisation is a two-step process. Firstly, subjects are exposed to an allergen in such a 
way that is taken up in a Th2 priming environment by antigen presenting cells (APCs) (details 
discussed in section 2.2.3). This leads to a proliferation of allergen-specific Th2 cells that activate B 
cells to class switch to IgE producing memory B cells and so the patient is ‘sensitised’. Primary 
prevention methods or treatments aim to prevent this stage of sensitisation (Figure 2-3). Secondly, 
sensitised patients are exposed to the allergen again in any form of environment (not necessarily in 
a Th2 priming environment) and the circulating anti-allergen IgE binds to the allergen to mount a 
response. IgE binding leads to the symptomatic response of allergic disease (e.g. sneezing, hives 
etc.). Secondary prevention aims to prevent disease onset before symptoms arise. Following this, 
subsequent allergen exposure leads to disease progression such as airway remodelling. Whereby 
tertiary prevention treats the allergic response from disease progression [59, 78]. The most common 
intervention is tertiary treatment and includes both symptom relief and immune modulation such as 
anti-histamines and allergy immunotherapy respectively.  
 
 
Figure 2-3: Stages of prevention and associated allergic disease progression. 
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2.2 Immunology of healthy and allergic responses 
2.2.1 Innate immune barriers 
To prevent non-self substances from constantly entering the human body, the first and foremost 
barrier is a physical layer of both keratinocytes over the skin and mucus over the epithelium 
(airways). Keratinocytes are tightly locked together, dehydrated cells layered in an overlapping 
structure to prevent molecules over 500 daltons (Da) entering [79]. If this barrier is weakened or 
disrupted, allergens can pass through easier, increasing the chance of an adaptive immune response. 
Unlike the resistant keratinocytes, mucus is a gel-like coating that absorbs the plethora of inhaled 
particles and is then cleared away [80]. Reduced levels of mucus can result in increased 
inflammation and allergen sensitisation, whilst reduced clearing of mucus leads to chronic 
asthmatic symptoms. The primary innate immune cells that reside below keratinocytes are dendritic 
cells (DC) and mast cells, and below mucus are epithelial cells [80, 81]. These cells are equipped 
for immediate response if contact is made between the cell and the allergen. Responses include 
recognition by Toll-like receptors (TLRs) of pathogen-associated molecular patterns (i.e. from non-
self biologics), and danger-associated molecular patterns (DAMPs) (e.g. cell or tissue damage). 
When allergen alone is taken up by these receptors, Th2 sensitisation is more likely but, when in 
combination with other signals such as endotoxins, the response can become more balanced 
between Th1 and Th2. Dysfunction in these barriers positively correlate with increased allergic 
susceptibility [81]. 
 
2.2.2 Adaptive/ healthy immune barriers 
If allergens bypass the innate immune barriers they are taken up, processed, and presented by APCs 
to T-cells (lymphocytes that mature in the thymus). In healthy individuals, this reaction leads to the 
generation of allergen-specific regulatory type 1 T cells and interleukin-10 (IL-10)-secreting T cells 
that prevent the development of allergic inflammation [82]. Other immune processes initiated in 
some healthy people include the generation of protective IgG1 and/or IgG4 antibodies [83-85]. 
TLRs such as TLR-9 that activate IgG producing B cells can be activated by increased bacterial 
presence, reinforcing the importance of a healthy microbiome. Overall healthy responses to 
allergens, which in this case are innocuous substances, is either no response, a regulatory response 
or a balanced Th1:Th2 response [82].     
 
2.2.3 Mechanism of IgE-mediated allergies 
A type-I allergy is defined by an increased Th2 cytokine profile that leads to increased allergen-
specific IgE and eosinophil levels [4]. When a sensitising dose of allergen bypasses the innate 
immune barriers, it is taken up by APCs such as Langerhans cells (LCs) and other DCs residing in 
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the skin, intestinal tract and/or airways [84, 86] (Figure 2-4). Under an inflammatory signalling 
environment, loaded APCs process and present the allergen to naïve T cells via class II major 
histocompatibility complex receptors (MHC II). Specific Th2 cells proliferate and release IL-4 and 
IL-13 that activate B cells to class switch into anti-allergen IgE producing B cells [84]. This 
finalises primary sensitisation. Individuals that are sensitised to allergens develop a memory 
response for allergen-specific cluster of differentiation (CD)4+ Th2 cells as well as an impaired 
allergen-specific Treg response, reducing their ability to suppress Th cell expansion and activation 
[87, 88]. The CD4+ Th2 cells release type-2 cytokines, including (but not limited to) IL-4, IL-5, IL-
13 and IL-25 [36, 89]. The initiation of Th2 cells to release cytokines during a subsequent exposure 
results in symptomatic allergic disease. IL-5 is a growth and terminal differentiation factor for 
eosinophils [90]. Both eosinophils and Th2 cells release IL-25 that induce group 2 innate lymphoid 
cells (ILC2) [91]. ILC2 cells have already been implicated in allergic exasperation as a strong 
source of IL-5 and IL-13 along with several other Th2 type cytokines, despite only being discovered 
in the last decade [91]. IL-13 induces pro-inflammatory mucus production [92], while both IL-4 and 
IL-13 activate naïve B cells to class switch to IgE producing B cells [93]. IgE has a relatively short 
half-life (1-3 days) while circulating that can be extended when bound to mast or basophil cells in 
the skin [94]. Allergist’s exploit this by applying controlled doses to pricked skin, whereby positive 
sensitisation will result in localised vasodilation causing a measurable amount of reddening 
(erythema) and swelling (oedema). During the early phase of reaction, circulating anti-allergen IgE 
binds and cross-links to FcɛRI (high-affinity) receptors expressed by granulocytes such as mast and 
basophil cells and FcɛRII (low-affinity) receptors eosinophil cells, causing these specialised cells to 
de-granulate [95-97]. De-granulation releases various pro-inflammatory mediators, including 
histamine, prostaglandins and leukotrienes that result in bronchoconstriction, vascular permeability 
and mucus production [98]. This is commonly followed by a late-phase reaction of loaded APCs 
reactivating CD4+ Th2 cells to release Th2 cytokines. Reactivated Th2 cells (alongside an absence 
of Tregs) promote more granulocytes as well as structural cells to promote features of airway 
remodelling and airway narrowing [99, 100]. 
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Figure 2-4: Simplified immune mechanism of sensitisation. Where allergen is taken up by APC in 
a Th2 priming environment that leads to allergen-specific Th2 cell proliferation, activation of anti-
allergen IgE production and induction of ILC2 cells. Upon a second allergen exposure, 
granulocytes such as eosinophils and mast cells are primed to release granules containing irritants 
that lead to symptomatic responses. See section 2.2.3 for supporting references. 
 
Specific features of airway allergies involve hyper-production of mucus, presence of plugging (or 
obstruction), and/or increased cellular influx into the peribronchial space of the airways (Figure 
2-5). Airway mucus is an innate barrier released by goblet cells to protect epithelial cell from 
pathogen infection (particularly viral infection). The majority of mucus is made from a range of 
globular proteins (70-80% by weight) that form complexes with mucins (20-30% by weight) in a 
salt-water solution. Mucins are responsible for the gelation of mucus [101]. Airway mucus consists 
of two mucins, MUC5B and MUC5AC, which are also preserved in murine airway mucus [102]. 
Airway mucus is promoted by infiltrating Th2 and ILC2 cells that release IL-13 to promote trans-
differentiation of Clara cells into goblet cells [67]. By testing the effects of mucus hyper-production 
alone in a MUC5AC-transgangic mouse model, airway mucus alone does not promote airway 
plugging nor peri-bronchial cellular infiltration [102]. However, a lack in mucus transport, i.e. 
clearing, results in dehydration of stagnant mucus that start to form airway plugging when 
comprised of 8% or more solids per volume [102]. Cilia, which are significantly lacking in inflamed 
airways, are the small beating structures on ciliated cells responsible for the transport and clearing 
of mucus. The exact mechanism of cilia clearing is not known but it is clear from histological 
examination post mortem that the ratio of engorged goblet cell to cilia cell surface area within the 
alveolar is significantly increased [67, 102]. Due to a lack of clearance, mucus plugging is one of 
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the main diagnosis of fatal asthma [103]. Inflamed airways also have large concentrations of 
inflammatory cells within the bronchial alveolar lavage fluid (BALf) and peribronchial space. The 
most common types of cells found are CD4+ Th2 cells and eosinophils [104, 105], mast cells also 
infiltrate in chronic cases [106]. Because eosinophilia within the airways is usually non-existent, it 
is used as a diagnostic tool for asthma. 
 
Figure 2-5: Examples of airway inflammation within mouse lung histology section (5 µm thick) 
stained for MUC5AC mucus (pink) and counterstained cells with hematoxylin (blue). See section 
2.2.3 for supporting references. 
 
2.2.4 Inducing IgE-mediated allergies in mouse models 
Animal models negate the need for patient recruitment and significantly enhance sampling 
capability, subject repeatability and control over allergen and microbial exposure. Mice are the most 
commonly used animal model to analyse allergy sensitisation, progression, mechanism and 
treatment thereof. This is because allergy sensitisation can be induced in the skin, airways and 
intestinal tract of mice just as in patients [106]. The mouse immune response to sensitisation 
follows a very similar mechanism to that described in section 2.2.3 [107]. A comprehensive study 
on the different strengths of allergic biomarkers per strain suggested BALB/c mice are the most 
optimal strain for allergic studies [108]. BALB/c mice are a common white haired breed of mice, 
easily accessible to the broader scientific community. Compared to other strains, sensitised BALB/c 
mice respond with the highest levels of total BALf cells, neutrophils, eosinophils, IL-10, IL-4 and 
CD4+CD25+ T cells; moderate levels of airway hyper-responsiveness, macrophages and CD4+ 
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cells; but relatively low levels of IgE and interferon (IFN)-γ, although both were still significantly 
higher than baseline [108]. In addition, a variety of cell types, signalling factors and structural 
changes are reported from Th2 sensitised BALB/c mice (Table 2-2). A large number of transgenic 
and knockout BALB/c mice have assisted the discovery several key mechanisms of allergies [106]. 
A prime example of these is the OT-II mouse that responds with a high Th2 cell population upon 
exposure to ovalbumin (OVA) [109, 110]. These mice are particularly useful because mice do not 
come naturally sensitised to allergens. It can take several weeks to initiate the Th2 cell expansion 
and, especially in the case of OVA, requires additional adjuvants (immune boosters) such as 
aluminium hydroxide suspension gel (AH) (Table 2-3). For a comprehensive review on adjuvants 
and their respective immunities, please see Reed et al. [111]. The airways are commonly sensitised 
by priming the system with 1-3 allergen + adjuvant intraperitoneal (i.p.) or subcutaneous (s.c.) 
injection/s (Table 2-3). Although strong sensitisation requires at least two administrations and 
further boosting by aerosol, intratracheal (i.t.) or intranasal (i.n.) inhalation can encourage more 
persistent airway remodelling that is also seen soon after inhalation challenge [26, 109, 112]. The 
skin (epicutaneous) is becoming a more common priming route for highly successful airway 
sensitisation, particularly when tape stripped before application [113-115]. The advantage of skin 
sensitisation is it does not require chemical or microbial adjuvants (although many would argue tape 
stripping is method of physical adjuventation) and it is similar to human sensitisation methods. 
Airway sensitisation can somewhat be primed by high doses of inhalation delivery [116-118], 
however it does not produce particularly strong nor consistent sensitisations relative to the 
injectable sensitisations (Figure 2-6). Importantly, injectable sensitisations control the known dose 
deposited which is not the case for inhalation nor skin delivery. Aerosols depend on the time 
exposed, e.g. 20 min, but even when the same time and concentration (1% w/v OVA) is used 
reports vary from 3.5 ± 0.4 µg [119] to 10.3 µg [120] deposited into the lungs. I.n. depends on the 
technique used (reports range from 5.6% to 36% of the given dose) and skin depends on both the 
time applied and the technique used [117, 121]. Strength of sensitisation is generally more 
consistent per route when a challenge is included (Figure 2-6Ai) except for 3x i.p. protocols (Figure 
2-6Aii). Persistent (up to 99 days), strong sensitisation (high success) can be achieved by 
administering ≥ 2x s.c. or ≥ 3x i.p. sensitisation injections within a 6 week period (Figure 2-6B). 
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Table 2-2: High success Th2 biomarkers of airway hypersensitive mice. TNF: Tumour necrosis 
factor. 
Biomarker Increased by sensitisation Decreased by sensitisation or unchanged (uc) 
Airway 
features 
Penh values [112, 122-125] 
Peribronchial cellular infiltrate  [26, 100, 
109, 112] 
Goblet cell hyperplasia [26, 100, 104, 109, 
112] 
Collagen [112] 
Mucus [112] 
Hyperresponsivness [112, 122-
125] 
Cells 
Eosinophils [26, 100, 104, 109, 120, 122-
127] 
Neutrophils [100] 
IgE+CD200R+ Basophils [128] 
Total BALf cells [26, 100, 104, 109, 124] 
CD4+IL-5+ [109] 
CD11c+CD11b+MHCII+ DCs [109] 
Lymphocytes (24 weeks) [104] 
Macrophages [109, 120](uc) 
CD3+CD4+CD25+Foxp3+ 
Treg [126] (uc)  
CD4+IL-10+ [124] (uc) 
CD4+CD25+Foxp3+ [125] 
Total BALf cells (18 weeks) 
[100] 
Anti-
allergen 
antibodies 
IgE [120, 124-128] 
IgG1 [120, 124, 126, 127] 
IgG2a (day 81) [124, 126, 129] 
IgG1:IgG2a [122] 
IgG2a (day 24) [126] 
IgG2a [128] 
Cytokines 
IL-4 [26, 104, 112, 122, 126, 128] 
IL-5 [26, 104, 112, 122, 124, 126, 128] 
IL-13 [112, 122, 126] 
IL-10 [126, 127] 
IFN-γ [126], (16 weeks) [100] 
Eotaxin [112, 122] 
TGF-β [100, 104, 112] 
TNF-α [104] 
IFN-γ [26, 122, 128] 
 
 
 
 
 
Despite countless reports of OVA-based airway hypersensitivity in mice, it is seldom an allergen of 
human allergic asthma [130]. Nevertheless, the use of OVA as an allergen in mouse models 
simplifies the study of allergy mechanisms and treatments. Particularly in relative comparison 
experiments such as different allergy treatment routes. This is because OVA can be purchased in an 
endotoxin-free form, low endotoxin form, smaller OVA fragments (peptides), radio- or 
fluorescently- conjugated, while many anti-OVA antibodies are readily available. With low batch to 
batch variability, OVA is a much easier to compare results to those published around the world.  
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Table 2-3: Reported OVA sensitisations in BALB/c mice. Success rating based on increase of two or more Th2 biomarkers (‘High’), at least one Th2 
biomarker (‘Medium’), a mixed increase of Th2 and Th1 or Treg biomarkers (‘Low’) or no increase in Th2 biomarkers (‘None’). A dMPA is a dermal-
targeted microprojection array device that deposits allergen into the skin, i.d. intradermal injection, i.m. intramuscular injection. 
Study 
Sensitisation Challenge Sample day Success 
Route Dose (µg) Adjuvant Repeats    
[131] s.c. 50 - ×2 - 28 None 
[132] 
i.p. 10 100 µl AH ×2 1% aerosol ×6 
1% aerosol ×12-36
42 
84 
Low 
None 
[133] 
i.p. 
s.c. 
i.m. 
dMPA 
25 
25 
25 
~25 
0.25 mg AH 
0.25 mg AH 
0.25 mg AH 
- 
×3 
×3 
×3 
×3 
- 
- 
- 
- 
28 
28 
28 
28 
Medium 
Low 
Low 
None 
[134] 
s.c. 
s.c. 
0.28 
28 
1 mg AH 
1 mg AH 
×6 
×6 
- 
- 
99 
99 
High 
None 
[118] i.n. 10 - ×4 1% aerosol ×2 23 Low 
[135] i.p. 10 AH ×2 
- 
1% aerosol ×6 
1% aerosol ×12 
1% aerosol ×18 
1% aerosol ×24 
63 
35 
49 
63 
77 
Low 
Low 
Medium 
Medium 
Medium# 
[113] 
i.d. 
s.c. 
skin* 
2 
2 
~200 
- 
- 
- 
×6 
×6 
×6 
- 
- 
- 
18 
18 
18 
Low 
Medium 
Medium# 
[136] 
i.p. 
i.p. 
i.p. 
i.p.  
10 
100 
50 
15 
- 
- 
- 
- 
×1 
×1 
×6 
×20 
- 
- 
- 
- 
45 
45 
45 
45 
None 
Low 
High 
High 
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i.n. 
skin 
50 
~50 
- 
- 
×6 
×6 
- 
- 
45 
45 
High#
High# 
[117] 
i.n. 
i.n. 
i.p. 
0.1 
100 
100 000 
- 
- 
1.6 mg AH 
×15 
×15 
×3 
1% aerosol ×6 
1% aerosol ×6 
1% aerosol ×5 
32 
32 
37 
Low 
High 
High# 
[104] i.p. 10 1.5 mg AH ×3 
1% aerosol ×24 
1% aerosol ×2 
105 
28 
Low 
High 
[112] 
i.p. 10 200 µl AH ×2 5% aerosol ×3 
5% aerosol ×9 
5% aerosol ×15 
5% aerosol ×15 
24 
35 
55 
80 
Medium 
High 
Medium 
Medium 
[137] i.n. 10 120 µl AH ×3 10 µg i.n. ×3 27 Medium 
 [116] aerosol 1% - ×20 - 45 Medium 
[138] 
i.p. 
s.c. 
10 
10 
1.5 mg AH 
- 
×3 
×3 
1% aerosol ×3 
1% aerosol ×3 
29 
29 
Medium 
High 
[139] i.p. 1 4 mg AH ×2 1% aerosol ×3 65 High 
[140] i.p. 10 1 mg AH ×2 
1% aerosol ×3 
20 µg i.n. ×3 
50 µg i.n. ×3 
100 µg i.n. ×3 
200 µg i.n. ×3 
18 
18 
18 
18 
18 
Medium 
Medium 
High 
High# 
High 
[126] s.c. 10 1.6 mg AH ×2 10 µg i.n. ×1 21 High 
[128] i.p. 50 Imject ×3 - 28-84 High 
[122] s.c. + i.n. 10 + 10 1.6 mg AH ×2 + ×1  0.1% aerosol ×3 69 High 
[127] i.p. + aerosol 1 + 0.2% 0.27 mg AH ×3 + ×2 1% aerosol ×3 94 High 
[123] i.p. 20 2 mg AH ×2 1% aerosol ×3 32 High 
[124] 
i.p. 10 2.25 mg Imject ×2 1% aerosol ×3 30 
58 
High 
High 
[125] i.p. 10 2.25 mg AH ×2 1% aerosol ×3 46 High 
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[120] s.c. 1, 0.1, 0.1 1 mg AH ×3 2.5% aerosol ×6 58 High 
[109] i.p. 100 200 µl AH ×2 100 µg i.n. ×1 11 High 
[26] i.p. 10 500 µl AH ×2 10 µg i.t. ×2 24 High 
[100] i.p. 10 1.5 mg AH ×3 1% aerosol ×12-24 46 - 90 High 
[141] Skin ~100 - ×3 - 50 High 
[114] Skin ~100 - ×3 100 µg skin* ×2 67 High 
[115] Skin* ~400 - ×3 100 µg i.n. ×3 34 High 
*Skin was tape stripped before application.  
#Success of the relatively highest Th2 result within a study.  
~ denotes exact delivery amount is unknown. 
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Figure 2-6: Plotted representation of Table 2-3 of each report based on given success. (A) Plot per 
route (i) with or (ii) without challenge. (B) Plot per route (with or without challenge) of success on 
given sample day. Reports with multiple challenge regimens were isolated to the highest success 
group.  
 
 
2.2.5 Mechanism of airway inflammation in mouse models 
Once Th2 sensitisation is established, airway hypersensitivity and inflammation can be induced by 
exposing the airways via i.n., i.t. or aerosol inhalation. Airway challenges result in similar immune 
functions as airway allergy or allergic asthma. By using these models, the mechanism behind 
airway inflammation has been further elucidated. For instance, intravenous (i.v.) injection of 
inducible Treg cells (CD4+CD25+ FoxP3+, iTreg cells) before i.n. challenge of allergen 
significantly protected against both peri-bronchial cellular inflammation and mucus production 
[142]. This was due to the iTreg downregulation of Th responses as confirmed by less IFN-γ (Th1), 
IL-5 (Th2) and IL-17A (Th17) cytokine production in draining lymph nodes. Another study found 
that iv injection of Th2 cells (CD4+ T cells stimulated with allergen, IL-2, IL-4 and anti IFN-γ) 
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after i.n. challenge increased mucus production [143]. Mucus persisted when IL-4 independent Th2 
cells were injected, but not when Th1 cells were injected. This suggests mucus is stimulated by Th2 
cells but not by IL-4 (i.e. not by IgE-based signalling) meaning mucus can be stimulated by allergen 
without an increase in IgE. Interestingly, in a transgenic model of mice that over expressed mucus 
in the lungs, inflammatory cell infiltrates into the BALf did not increase [102]. Like in naïve mice, 
hyper-mucus BALf maintained 88.3 ± 2.8% macrophages, 1.35 ± 0.2% neutrophils, 0.02 ± 0.01% 
eosinophils and 1.6 ± 0.4% lymphocytes. Indicating that although mucus can be stimulated by (non-
IL-4) Th2 cells, it does not promote a Th2 infiltration. 
 
 
2.3 Treatments of IgE-mediated airway sensitisation 
In order to treat anti-allergen IgE mediated disease, the immune system requires specific 
modulation so that it no longer responds to allergens with a Th2/IgE-based response. This process is 
called immunomodulation and requires the administration of immunotheraputics. In essence, 
primary prevention immunotherapy to prevent sensitisation would be an allergy vaccine or 
immunisation. While secondary/tertiary prevention immunotherapy to prevent disease progression 
(i.e. to desensitise) is termed allergy immunotherapy (AIT). However, AIT currently available is 
limited only to those with mild, not chronic conditions. Both immunotherapies aim to modulate the 
immune system to become a balanced immune response against the allergen, similar to that seen in 
healthy people (see sections 2.2.1 and 2.2.2). To do so, both rely on the administration of unreactive 
doses of allergen to build immune tolerance [5, 144]. A more recent alternative to immunotherapy 
is the use of allergen-independent downregulation or blocking of specific Th2 biomarkers (e.g. IgE) 
or upregulation of specific Th1 signals to downregulate Th2 responses [145]. This new process has 
led to promising immunomodulating treatments for asthma [146] and can assist in allergy 
desensitisation [147]but had not yet proven to treat allergic patients alone. Hence, Th2 
downregulation will be summarised below, however, this thesis will focus on allergen-dependant 
immunotherapies. 
 
2.3.1 Blocking and/or downregulation of Th2 biomarkers 
A multitude of suppressants for Th2 biomarkers has shown promise in the mouse model [145]. 
Unfortunately, some do not translate well from mouse to patients. This includes treatments against 
IL-13, IL-5 or CD23 receptor (low affinity for IgE) that provide only limited protection, or 
treatments blocking either IL-4 or the spleen tyrosine kinase (activates mast cell degranulation) that 
had no effect [145]. This highlights slight differences in the mechanism or redundancy behind some 
Th2 responses between mouse and human. However, Nguyen et al. [145] summarised several 
65 
 
successful mouse suppressants that have also downregulated Th2 biomarkers and/or reduced 
symptoms in patients. Some examples include suppressants that block or inhibit IL-9, Chemokine 
receptor (CCR)-3, IL-4 plus IL-13, APC-dependent Th2 stimulation of CD4+ T cells (Suplatast) or 
IgE (Omalizumab) [145]. Additionally, drugs that activate toll-like receptors TLR-4, TLR-9 or 
TLR-8 to enhance Th1 responses, have downregulated Th2 responses and/or symptoms in both, 
mouse models and patients. Of these successful drugs only anti-IgE has been approved in a 
multitude of countries. 
 
After pre-clinical trials were completed in the early 1990’s, the first anti-IgE for human use 
(Xolair™) was approved in 2002 within Australia by joint efforts of Tanox, Genentech and 
Novartis [148]. Xolair™, now known as Omalizumab, is only approved for patients with perennial 
allergic asthma from age 6+ [147]. Additional tests also show Omalizumab can benefit patients with 
non-atopic asthma, occupational asthma, severe persistent allergic asthma, allergic rhinitis, allergic 
bronchopulmonary aspergillosis, acute atopic dermatitis, chronic spontaneous urticarial, 
mastocytosis (during venom AIT), peanut anaphylaxis, exercise anaphylaxis and food allergies 
[146]. Providing protection or not providing protection against symptoms after administering 
Omalizumab also provides additional insights into the mechanisms behind IgE-mediated and non-
IgE-mediated diseases. This includes confirming the association of IgE in specific immediate 
hypersensitivity in the mouse model in 1993, an important mechanism to this day [149]. Although 
Omalizumab is not a proven replacement for AIT, co-administration may increase AIT availability 
to those with chronic conditions [147].  
 
There are no set durations for treatment with Omalizumab as it is based on response rate [146], but 
generally 1-4 s.c. injections are administered per week. Studies in mice recommend sublingual 
administration of Omalizumab (liquid placed under the tongue) could work as a less invasive 
administration route [150]. Circulating IgE can be reduced as early as 24-48 h after the first 
administration and symptoms can start to decline as early as one month of treatment. The prolonged 
effect has not been fully assessed but the most promising study showed that six years of treatment 
resulted in three subsequent years of protection in cat allergy patients [151]. This is because 
Omalizumab binds to FcεRI receptors, blocking IgE activation of basophils, mast cells and DCs, it 
in turn downregulates expression of FcεRI leading to milder responses even after the therapy is no 
longer circulating [152].  
 
Some recent reports indicate that Omalizumab treatment also leads to reduced airway inflammation 
and remodelling, two parameters crucial for tertiary prevention of airway allergies. This includes 
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reduced thickening of the reticular basement membrane and reduced airway eosinophilia after 12 
months of treatment [153]. Ex-vivo pre-treatment of airway smooth muscle cells also prevented 
inflammatory cell proliferation, collagen type-I deposition and fibronectin growth after challenged 
with allergic serum [154]. Another allergic airway study that also found significant improvements 
in other symptoms, however, there was no improvement in lung function (measured by forced 
expiratory volume) within the 1-36 months after the six years of treatment stopped [151]. More 
systematic studies that assess effect of Omalizumab dose on airway inflammation and lung function 
are required to confirm effects on airway remodelling. 
 
 
2.3.2 Building tolerance by vaccination treatment 
As aforementioned in section 2.1.1, there are several factors that can result in healthy tolerance to 
allergens during de novo allergen exposure. Briefly, these include balanced hygiene practices, 
sufficient microbial and parasitic exposure and appropriate low or high dose of inhaled allergen and 
endotoxin – generally after the age of 2 years old. Values attributed to these factors vary greatly 
between infants of low risk and infants of high risk. Here I will focus on the most available 
population, infants of low risk. Obviously, obtaining the correct balance between all of these factors 
can be very difficult to control for inhaled allergens. Interestingly, despite over 200 years of 
vaccination to prevent infectious diseases (by delivering inactive forms of the disease substance), 
allergy vaccination is scarcely mentioned. None-the-less, food allergen exposure of recommended 
doses at recommended ages of infancy provides a promising outlook for a self-administered allergy 
vaccination for primary prevention (Figure 2-3) of food allergies. Allergy vaccination used here 
refers administering therapy for primary prevention (i.e. to avoid sensitisation) and is not to be 
confused with some literature that uses the term allergy vaccination for AIT e.g. [155, 156]. 
 
To date, there are no approved allergy vaccinations because until recently, it was highly 
recommended to avoid allergens [157]. The procedure for allergy vaccination would depend on the 
mechanism targeted. For example, targeting allergen specific Treg stimulation may require many 
administrations of pure allergen, while targeting a balanced response with a Th1 booster may 
require less administrations of allergen mixed with a dose of endotoxin (e.g. 100 µg LPS in mice 
[56]). Additionally, mice administered with the Th1 cytokine IFN-γ can prevent ILC2 cell 
proliferation before an asthma induced rhinovirus infection [158]. A possible example of an 
allergen vaccination procedure in practice would be the food allergen guidelines that recommend 6 
g of peanut every week from 4 – 60 months old [61, 157]. However, this long-term exposure 
procedure resonates more so with AIT procedures than what occurs during a healthy exposure of 
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inhaled allergens. Yet, AIT may assist in allergy prevention of additional sensitisations beyond 
those treated for [159-162]. Alternatively, prevention of airway inflammation and Th2 sensitisation 
has been reported from short term inhalation studies in mouse models since 1981 [121, 163]. 
 
 
2.3.2.1 Experimental allergy vaccination 
Allergy vaccination (or tolerance) experiments in mice ideally include three phases, 1. Building 
tolerance (vaccination), 2. Th2 sensitisation and 3. Challenge (e.g. airway challenge). The success 
of mouse airway allergy vaccination studies was based on systemic and airway Th2 biomarkers 
(Table 2-4) and strength of protocol (i.e. inclusion of phases 2 and/or 3). This rating system limited 
the success of some studies that only presented systemic anti-OVA antibody results without 
assessing the airways [113, 120, 121, 133, 163-165]. Vaccination studies can provide adequate 
assessment of Th2 protection as early as 11 days after the first vaccination, and the average 
reporting day for medium and high success studies was at day 39. As both primary and tertiary 
prevention aim to build similar allergen-specific immune tolerance and/or balance, short 
vaccination studies could be a good proxy to screen for AIT therapies in the mouse model, without 
having to complete an entire AIT protocol. Table 2-5 summarises allergy vaccination studies in 
BALB/c mice with OVA, although most do not include all three phases and many are not presented 
as allergy vaccinations. One study was even presented as a failed sensitisation without 
acknowledging possible positive tolerance results [118]. Assessment of tolerance first began with 
prevention of anti-OVA IgE [121, 163]. In studies that challenged the airways, additional 
prevention of airway eosinophilia was sought (e.g. [119]). Th2-mediated airway inflammation and 
remodelling is a prime indicator of disease progression but decreases in IgE and eosinophilia are not 
always associated with less airway inflammation (section 2.2.5). Therefore, the strongest 
preventative vaccinations not only prevented anti-OVA IgE and airway eosinophilia but also airway 
inflammation, such as airway mucus hyper production [26, 109, 119]. 
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Table 2-4: Th2 biomarkers for prevention of airway hypersensitivity in mice that were sensitised 
and/or challenged. Grey highlighted biomarkers are associated with Th1-mediated responses and 
are mostly present only when a Th1 adjuvant is included (e.g. CpG). 
Biomarker Increased by vaccination or unchanged (uc) Prevented increase by vaccination 
Airway 
features 
Peribronchial cellular infiltrate 
[56, 118, 144] 
Hyperresponsiveness [116] 
Sinus inflammation [116, 118] 
Peribronchial cellular infiltrate [26, 166] 
Goblet cell hyperplasia [118, 166] 
PAS+ [26, 56, 109, 118, 144] 
Cells 
Adoptive suppression from spleen 
cells [121] 
Total BALf cells [56] 
Neutrophils [56] 
Macrophages  [109] 
Lymphocytes  [109] 
Total BALf cells [26, 56, 99, 109, 118, 
166, 167] 
Eosinophils [26, 56, 99, 109, 118, 119, 
166] 
Neutrophils [56, 166] 
CD3+CD4+CD69-T1ST2+ cells [166] 
CD4+ cells  [109] 
CD4+ IL-5+ cells [109] 
Tregs [109] 
 
Anti-
allergen 
antibodies 
IgG2a [26, 56, 119, 144, 166](uc) 
IgG1 [120] [119, 144](uc) 
IgG [144] 
IgE [56, 116, 118-120, 144, 166, 167] 
PCA (IgE) [121, 163, 165, 168] 
IgG [116] 
IgG1 [118, 166] 
Cytokines 
IFN-γ [26, 56, 144] 
TNF-α [26] 
IL-13 [56, 166] 
IL-5 [26, 56, 144, 167] 
IL-4 [26, 167] 
Other  Footpad swelling [168] 
 
 
 
 
Table 2-5: BALB/c (female) experimental vaccinations against OVA-based airway 
hypersensitivity. According to Success ratings: (High) prevented both Th2 antibody and Th2airway 
response after sensitisation and challenge, (Medium) prevented either Th2 antibody or Th2 airway 
response after sensitisation and challenge or vice versa, (Low) prevented any Th2 response without 
sensitisation and/or challenge, (None) no change in Th2 based responses. Where indicated by the 
study, aerosol dose deposited into the lungs was recorded in brackets. dMPA, dermal-targeted 
microprojection array, i.d. intradermal injection, i.m. intramuscular injection, LTB, heat liable 
toxin B subunit, O+AH, OVA and AH, HDM, house dust mite. 
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Study 
Preventative Vaccination Sensitisation 
and/or 
Challenge 
Sample 
day Success Route OVA dose 
(lung) 
Repeats Additions 
[164]ε i.n. 100-2000 µg  ×3 - s.c. O+AH 
×1-4 
15-52 None 
[117] i.n. 
i.n. 
0.1 µg  
100 µg  
×15 
×15 
- 
- 
1% ×6 
1% ×6 
32 
32 
None 
None 
[99] i.n. 25 µg ×5-35 - - 49 Low 
[113]ε Skin* 
i.d. 
s.c. 
200 µg ? 
0.2 - 20 µg  
0.2 - 20 µg   
×6 
×6 
×6 
- 
- 
- 
- 
- 
- 
18 
18 
18 
None 
Low 
None 
 [121]ε i.n. 
Aerosol 
 (5 min) 
10 µg (3.6) 
1% (1.4 µg) 
×8 
×8 
- 
- 
i.p. O+AH ×2 
i.p. O+AH ×2 
77 
77 
None 
Low 
 [163]ε Aerosol  
(6 h) 
0.01% 
0.01% 
×0-4 
×5-12 
- 
- 
i.p. O+AH ×2 
i.p. O+AH ×2 
140 
140 
None 
Low 
[133]ε i.m. 
s.c. 
dMPA 
i.p. 
dMPA 
25 µg 
25 µg 
19.2 µg  
25 µg 
- 
×3 
×3 
×3 
×3 
×3 
AH 
AH 
- 
AH 
- 
- 
- 
- 
- 
- 
28 
28 
28 
28 
28 
Low 
Low 
Low# 
None 
Low 
[165] Aerosol 1% 
10% 
×6 
×6 
- 
- 
i.p. O+AH ×1  
i.p. O+AH ×1 
68 
68 
None 
Low 
[168]ε i.n. 
i.n. 
i.n. 
10 µg  
1000 µg  
10 µg  
×1 
×1 
×1 
- 
- 
E. coli 
LTB 
s.c. O+AH 
×1  
s.c. O+AH 
×1 
s.c. O+AH 
×1   
28 
28 
28 
None 
Low# 
Low 
 
[166] Aerosol 
(20 min) 
1% 
1% 
1% 
1% 
×10 
×10 
×25 
×25 
- 
HDM 
- 
HDM 
- 
- 
1% ×3 
1% ×3 
12 
12 
97 
97 
Low 
None 
Medium 
None 
[120]ε Aerosol 
(20 min) 
0.0025% 
0.05%  
1% (10.3 µg) 
0.0025 – 1% 
×10 
×10 
×10 
×10 
- 
- 
- 
0.5% AH 
s.c. O+AH 
×3 
s.c. O+AH 
×3 
s.c. O+AH 
×3 
s.c. O+AH 
×3 
35 
35 
35 
35 
None 
Medium# 
Medium# 
None 
[56]  
i.n. 
i.n. 
i.n. 
 
100 µg  
100 µg 
100 µg 
 
×3 
×3 
×3 
LPS 
<0.001 µg 
0.1 µg 
100 µg  
 
25 µg i.n. ×4 
25 µg i.n. ×4 
25 µg i.n. ×4 
 
21 
21 
21 
 
Medium# 
None 
Medium 
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[118] i.n. 
i.n. 
i.n. 
 
10 µg  
10 µg  
10 µg  
×4 
×4 
×4 
- 
Carbon 
Traffic 
particles 
1% ×2 
1% ×2 
1% ×2 
23 
23 
23 
Medium 
Medium# 
None 
 
[167]ε i.n. 
i.n. 
100 µg  
100 µg 
×3 
×3 
- 
Protein-
free diet 
All groups 
[s.c. O+AH 
×1 and i.n. 
×2] 
11 
11 
Medium 
None 
[119] Aerosol  
(20 min) 
0.001% 
0.01% 
0.1% (0.4 µg) 
1% (3.5 µg) 
1% (3.5 µg) 
×10 
×10 
×10 
×10 
×10 
- 
- 
- 
- 
- 
i.p. O+AH ×1  
i.p. O+AH ×1 
i.p. O+AH ×1 
i.p. O+AH ×1 
i.p. O+AH ×1 
and 1% ×1 
50 
50 
50 
50 
50 
None 
Low 
Low 
Low 
High 
 
[144] dMPA 
dMPA 
dMPA 
s.c. 
0 µg 
19.2 µg 
19.2 µg 
25 µg 
×3 
×3 
×3 
×3 
- 
- 
CpG 
Al 
All groups 
[i.p. O+AH 
×2 and i.n. 
×3] 
70 
70 
70 
70 
None 
None 
High 
Medium 
[26] s.c. 
Skin 
Skin  
10 µg 
~10 µg   
~10 µg  
 
×2 
×2 
×2 
- 
CpG 
- 
[i.p. O+AH 
×2 and 10 µg 
i.n. ×2] 
44 
44 
44 
None 
Medium 
High 
[109] i.n. - ×1 E. coli i.p. O+AH ×1 
and i.n. ×1 
14 High 
#   Success of the relatively highest prevention result within a study.  
‘?’ unknown delivered dose.  
ε   Report only assessed systemic response, not airways specifically.  
* Skin was tape stripped first. 
 
Of the studies listed in Table 2-5, there was no difference between route of vaccination and strength 
of tolerance (Figure 2-7A). Both inhaled (aerosol and i.n.) and skin routes presented regimens that 
could either prevent Th2 sensitisation with high or no success, while little success was seen from 
injectable routes. Without additions to the vaccination, only 1% Aerosol (x10) [119] had high 
success in protecting against Th2-based airway sensitisation. When separating out successful 
studies (low – high) from non-successful studies and plotting each against the total dose delivered 
during vaccination, both the aerosol and injection routes seemed to favour higher doses while skin 
delivery may favour lower doses to induce protection (Figure 2-7B). That is, the median total dose 
of successful aerosol studies is 9% (e.g. 1% x9) which is 3-fold higher than compared to 3.02% of 
non-successful aerosol studies; median of successful injectable studies is 75 µg which is 1.5-fold 
higher when compared to non-successful 49 µg; median successful skin studies is 20 µg which is 
2.9-fold lower than compared to non-successful 57.6 µg. It is important to note that delivered values 
for most skin studies are based on the total dose applied but not necessarily delivered into the skin, 
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where delivered dose would be less than presented here. Together, these studies suggest that skin-
based routes are likely to be more cost effective as less allergen is needed.  
 
Delivery by i.n. had no difference between success groups for dose administered nor between 
number of repeats. This indicates that protection by i.n. relies on different variables such as 
endotoxin dose or possibly even technique of administration [56]. As such, the three i.n. vaccination 
studies that prevented both Th2 antibodies and Th2 airway inflammation included vaccination with 
1) Only E.coli [109], 2) 4x 10 µg OVA [118] or 3) 3x 100 µg with less than 1 ng of LPS (10 EU) 
[56]. All three i.n. studies were challenged but only the E.coli vaccination was sensitised prior 
challenge (confirming high success with Th1 inducing substance). Together, these studies suggest 
vaccination via the i.n. route should ideally be administered at 10-100 µg of OVA repeated at least 
3x but not as many as 15x [117]. It is important to note that dose and route recommendations for 
OVA do not necessarily translate to other allergens such as house dust mite [99]. 
 
The most successful skin route vaccination studies listed in Table 2-5 were from vaccinations using 
dermal-targeted microprojection arrays [144] (dMPAs, discussed in section 2.5 ) or epidermal 
powder immunisation with pressurized microparticle delivery (EPI, PowderJect ND) [26]. Delivery 
by dMPA only provided protection against anti-OVA IgE, airway IL-5 and airway mucus when 
CpG was added, which is a known Th1 adjuvant [144, 169]. Opposing results were reported by 
delivery with EPI, where OVA-only delivery provided better protection than OVA and CpG. 
Indicating differences in immunity between the dermis and epidermis and the dMPA and EPI (see 
section 2.4.1). On the other hand, the least successful skin route resulted from tape stripped skin 
[113]. This was to be expected as high inflammatory tape stripping is used in enhancing Th2 
sensitisation (Table 2-3) [113-115]. Therefore, delivery into skin can result in protective tolerance 
but is both dose-dependent and inflammatory-dependent.   
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Figure 2-7: Plotted representation of Table 2-5 of each study based on given success rating. (A) 
Plot of success per route (B) Plot of total dose of vaccination (dose x repeats) of successful 
(High/Medium/Low, H/M/L, filled symbols) and unsuccessful study routes (None, open symbols). 
Injectable routes include s.c., i.p. and intramuscular injection, skin routes include skin, dMPA and 
intradermal injection. 
 
2.3.3 Desensitisation by allergy immunotherapy treatment 
Desensitisation by AIT was first published by Noon and Freeman in 1911 [170]. At this early stage, 
they found patients could tolerate higher doses of grass pollen when repeated subcutaneous 
administration started with low doses that were subsequently increased. These days, AIT has been 
shown to increase tolerance of higher doses of allergen as well as reduce symptoms, prevent further 
disease progression and increase quality of life scores. The overall procedure administers unreactive 
doses of allergen repeatedly over several years to build up tolerance and prevent further disease 
73 
 
progression. AIT is currently the only approved therapy to modulate the immune response for 
tertiary prevention. Approved AIT routes include subcutaneous injection immunotherapy (SCIT) 
and sublingual absorption immunotherapy (SLIT). There are also several drugs available for 
temporary relief of symptoms that sometimes lead to tertiary prevention (not discussed here). 
Despite over a century of clinical use, mechanisms of AIT have only recently been examined and 
are still up for debate [171]. Originally, inducing Th1 responses to block Th2 was perceived as the 
main mechanism for AIT [172]. Nowadays, although AIT has shown to increase Th1 responses 
initially [78, 172], the end goal is to ensure a balanced response to the allergen is regulated by Tregs 
[173]. Effects of the AIT can maintain protection beyond the administration of the therapy by either 
directly or indirectly by promoting Treg responses to allergens. Tregs are also speculated to 
maintain lower numbers of ILC2 cells after 8-36 months of AIT [174]. To elicit Treg allergen 
specific responses, the allergen must be delivered to APCs in a tolerogenic (not inflammatory) 
environment. The highest concentrations of APCs reside in the upper layers of the skin (epidermis 
and dermis), the airway epithelium and the intestinal tract [175]. Since the subcutaneous tissue 
(deep skin layer) contains few APCs, alternative routes for AIT are now under examination. These 
routes include SLIT (under the tongue), oral (ingested), intradermal (IDIT, dermal skin layer), 
epicutaneous (EPIT, epidermal skin layer), transcutaneous (epidermal and dermal skin layers) and 
intralymphatic (ILIT, lymph node) [9]. To date, both SCIT and SLIT (only since 1998) are 
approved routes in Australia, Asia and Europe, whilst the USA only approved the SLIT route in 
2014, but neither treat all allergies. Below I discuss SCIT and alternative skin-based delivery routes 
for AIT.  
 
2.3.3.1 Approved routes of allergy immunotherapy 
SCIT is more common than SLIT, offers an effective and persistent treatment, and is available for 
insect venom, house dust mite, grass, pollen, mould and animal dander allergies. The rate of success 
of desensitisation by SCIT differs between allergens and between patients. For example, insect 
venom AIT is highly efficient (95%, [6]) but seasonal inhaled allergen AIT is only 30-40% efficient 
[7]. There are many inconsistencies to overcome in human clinical trials to the point that AIT 
efficiency is still contested [176]. None-the-less, it is the only successful therapy available to reduce 
allergic symptoms and progression [177]. In Australia and Europe, SCIT includes an aluminium-
based adjuvant to boost immunotherapy since the 1930’s [178, 179]. Due to the conflicting immune 
responses from aluminium-based adjuvants, the USA do not include an adjuvant in their approved 
SCIT [178]. However, aluminium-based adjuvants in humans enhance both Th1 and Th2 immunity, 
boosting anti-allergen IgG antibodies that block IgE [111]. Alternatively, the addition of the Th1-
mediated CpG adjuvant to house dust mite SCIT has shown great promise in phase I/IIa trials [180]. 
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In Australia the SCIT protocol starts with a 1/1000th of the final dose of the allergen combined with 
aluminium based adjuvants injected into deep subcutis tissue (Figure 2-8). S.c. injections occur 
weekly until the final dose is reached (approx. 6 months), followed by monthly maintenance doses 
for 2-4 years [181]. This equates to almost 70 long appointments with specialist practitioners. Faster 
(‘ultra-rush’) SCIT regimens can be implemented, particularly with venom allergies. However, they 
are to be used with caution due to the increased likelihood of side effects [182]. Dose is also an 
important factor in SCIT where low doses can be ineffective [183] and high doses increase the risk 
of systemic delivery and anaphylaxis [5]. Although this dose dependency has not been confirmed 
for all allergens, it has generally been accepted that the higher the dose the longer the protective 
effects of AIT continue [7]. 
 
Figure 2-8. Graphic representation of skin layers targeted by hypodermic needles and 
microprojection arrays adapted from Hegde et al. [184]. The skin comprises of four layers (strata), 
from the surface inwards, these are the stratum corneum, viable epidermis, dermis and the subcutis. 
Allergens delivered to the dermis, subcutis and muscles target varying concentrations of DCs that 
are capable of migrating to draining lymph nodes to present allergens to T cells. Not to scale. 
 
Mechanistically, SCIT starts with an unreactive dose of allergen to promote the generation of  iTreg 
cells that suppress allergen specific Th2 cells [173]. Successful AIT commonly induces anti-
inflammatory cytokines such as IL-10 and IL-12, that contribute to the generation of iTreg cells [84, 
Nanopatch AMPA 
Stratum Corneum 
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124, 185]. IL-10-producing Tregs initiate class-switching of B-cells to IgG producing B-cells [186]. 
IgG antibodies (IgG4 in humans) compete with IgE binding to FcεRI receptors and reduce the 
allergic reaction [107, 127, 187]. Reduced binding to IgE-activated receptors downregulates their 
expression leading to suppression of granulocytes such as mast cells, basophils and eosinophils 
[188]. DCs of patients that have reached the maintenance dose of SCIT have restored TLR9 innate 
function [189]to release more IFN-α, block Th2 development [190]. After several years of 
maintenance treatments, anti-allergen IgG4 surpasses anti-allergen IgE leading to protection after 
SCIT is discontinued [173]. For follow up after AIT, Kouser et al. [177] has reviewed several key 
biomarkers important for relapse of sensitisation or continued protection. 
 
 
Figure 2-9: Simplified immune mechanism of both sensitisation (top) and desensitisation 
(bottom). Where administration of the allergen through immunotherapy is taken up by APCs and 
either presented to naïve T cells (Th0) in either a Th1 environment or Treg environment that 
subsequently block Th2 and ILC2 proliferation and eosinophils and mast cell degranulation, 
reducing allergic response and symptoms. Incudes the use of a microprojection to deliver 
immunotherapy that causes necrotic cell death in the skin adding DAMPs to activate allergen 
uptake by APCs. See section 2.3.3 for supporting references. 
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Despite its success, SCIT is undesirably time consuming and costly and these are the main two 
factors listed by patients for non-compliance [191]. Treatment regimens convince only ~6% of 
allergic patients to undergo SCIT [9, 10] and compliance to complete an SCIT course is about 23-
50% [192, 193]. SLIT can alleviate the excessive visits to specialists as it is self-administered but 
the medication costs and dosing repeats are higher, reducing compliance to complete SLIT down to 
7% [192]. Ideally, increasing immunogenicity of SCIT would reduce the number of administrations 
for SCIT. Immunogenicity could be increased by increasing the dose [194]. However, this decreases 
safety so an alternative solution is required  [11, 195]. Doses could be safely increased by refining 
hypoallergenic allergen peptides but this may reduce efficiency from patient to patient due to 
allergy diversity and would be costly to set up [196]. Adding aluminium-based adjuvants increases 
site localisation of allergen to immune cells [197], but its inclusion does not reduce number of 
administrations required. Alternatively, immunogenicity could be increased by targeting more APC 
cells (e.g. LCs and DCs) effectively. Targeting more APCs efficiently would require alternative 
routes for administration such as the upper layers of the skin. Skin immunisations have previously 
proven to be effective at significantly lower doses [198]. If several doses are still required for 
optimal APC targeting, the combination of a reduced dose for safety and the ability for patients to 
self-administer (like SLIT) to the skin would also favour a better AIT compliance [191]. Thus, to 
improve on SCIT participation, AIT requires a shorter and more cost effective treatment plan, 
ideally self-administrable.  
 
As with all allergy studies, the mouse model is heavily used to understand the mechanisms behind 
successful AIT and to test alternative treatments. Allergy desensitisation experiments in mice 
ideally include three phases, 1. Induce Th2 sensitisation, 2. Desensitisation therapy and 3. 
Challenge (e.g. airway challenge). The BALB/c mouse strain can be sensitised to varying degrees 
(see section 2.2.4) and so is used to test a multitude of AIT variables. These include administration 
route, dose, adjuvants and timing. As eluded to in sections 2.2.4, 2.2.5 and 2.3.1, mouse immunity 
in allergic pathways is similar to that in humans. Yet there are some key differences when it comes 
to AIT, that is, where human IgG4 is upregulated, mouse IgG2a is upregulated and administration 
of aluminium-based adjuvants only elicits Th2 responses in mice (not a Th1/Th2). Furthermore, 
although IgG4 in humans is a Th2 antibody known to block IgE binding to receptors, IgG2a in mice 
is a Th1 antibody that promotes downregulation of Th2 responses [199, 200]. Thus, successful 
mouse desensitisation often leads to a combination of boosted, but balanced IgG1 (Th2) and IgG2a 
(Th2) response that blocks/downregulates IgE receptors [124, 128, 201, 202]. For additional 
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differences between mice and human immunity, please see [203]. Overall, many of the biomarkers 
for mouse AIT (Table 2-6) are similar or the same as those seen in human AIT [177]. 
 
Mouse SCIT is usually administered to the subcutaneous of the neck while SLIT continues to be 
administered under the tongue, although specialised techniques are required to ensure the mouse 
does not swallow prematurely [204]. To achieve similar desensitisation results as three SCIT 
administrations, Hesse et al. [204] administered 40 SLIT doses. Therefore, SCIT as a positive 
control for AIT in the mouse model will be used in this thesis. A few model studies of mouse SCIT 
are outlined in Table 2-7. In general, an OVA-based SCIT desensitisation course in mice starts two 
weeks after the last sensitisation and can be repeated 3-14 times at intervals of one week. This is 
then followed by a challenge to either the airways (i.n. or aerosol), skin (surface of ear, foot or hair 
removed area) or intestinal tract (fed) – depending on the allergy assessed. As in patients, mouse 
SCIT is dose-dependent, where low doses (totals of 30 – 113.4 µg) [26, 201, 205]do not desensitise 
unlike higher doses (totals of 200 – 3000 µg, median 800 µg). Interestingly, ultra-rapid 
desensitisation of 21 doses over 7 days did not result in very successful desensitisation, despite a 
high total dose of 1050 µg [128]. Although this is likely due to the short experimental timeframe 
(mice assessed the day after last desensitisation) that did not allow for anti-Th2 mechanisms to 
respond. Therefore, these studies results recommend a minimum of three administrations of SCIT 
given weekly to an accumulative dose over 200 µg of OVA for successful desensitisation. 
 
Table 2-6: SCIT desensitisation biomarkers of studies rated as ‘high’ success. 
Biomarker Increased by desensitisation or unchanged (uc) Decreased by desensitisation 
Airway 
features 
- 
Penh [122, 124, 125, 132, 139, 205] 
Skin 
features 
- 
Epidermal thickness [206] 
Skin eosinophils [206] 
Skin anaphylaxis [128] 
Cells 
CD4+ FoxP3 cells [206] 
CD4+CD25+FoxP3+ [126, 128, 
201] 
CD4+ IL-4+ cells [206] 
Proliferation index [128] 
Eosinophils [122, 124, 125, 139, 201, 
202, 205] 
Total BALf cells [124] 
Anti-
allergen 
antibodies 
IgG4 [206] 
IgG1 [124, 128, 201, 202] 
IgG2a [124, 126, 128, 201, 202] 
IgE [124-126, 128, 139, 201, 202, 
205, 206] 
IgG1 [139, 205] 
 
Cytokines 
IL-10 [128, 201, 206], [124](uc) 
FoxP3 [206] 
IL-4 [122, 128, 202, 205, 206] 
IL-5 [122, 124, 126, 128, 202] 
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 IL-10 [126, 202] 
IL-13 [122, 126, 205, 206] 
IFN-γ [202], [128](uc) 
Eotaxin [122] 
 
 
 
Table 2-7: Examples of OVA-based BALB/c subcutaneous allergy immunotherapy 
desensitisation for airway allergies. Success rating based on two or more desensitised biomarkers 
(‘High’), at least one desensitised biomarker (‘Medium’), a mix of desensitised and sensitised 
biomarkers (‘Low’) or no desensitised biomarkers (‘None’). Challenge default is 1% OVA for 15-
30 min unless otherwise stated. O+AH, OVA and AH, O+Im, OVA and Imject Th2 adjuvant.  
Study Sensitisation 
SCIT 
Challenge Sample day Success Dose 
(µg) 
Repeats Additions
[201] i.p. O+AH ×2 14.18 ×8 - 500 µg i.n. ×3 45 None 
[26] i.p. O+AH ×2 10 ×6 - 10 µg i.n. ×2 85 None 
[139] i.p. O+AH ×2 25 ×8 - 1% aerosol ×1 65 Medium 
[205] i.p. O+AH ×3 
(low vitamin 
D mice) 
10  
100 
1000 
×3 
×3 
×3 
- 
- 
- 
i.p. ×2 
i.p. ×2 
i.p. ×2 
99 
99 
99 
None 
Medium 
Medium# 
[128] i.p. O+Im ×3  
i.p. O+Im ×3 
i.p. O+Im ×3 
50 
50 
50 
×21 
×14 
×9 
[All i.p. 
route for 
AIT] 
- 
- 
- 
42 
63 
98 
Low 
High 
High# 
[122] s.c. O+AH ×2  
+ i.n. x1 
100 ×8 1 mg AH 0.1% aerosol ×3 69 High 
[124] i.p. O+AH ×2 
i.p. O+AH ×2 
1000 
1000 
×3 
×3 
- 
- 
Aerosol ×3 
Aerosol ×3 
34 
62 
High 
High# 
[125] i.p. O+AH ×2 1000 ×3 - Aerosol ×3 46 High 
#Success of the relatively highest SCIT result within a study.  
 
 
2.3.3.2 Experimental skin routes for allergy immunotherapy 
To reduce the burden of long term, repetitive and costly AIT, alternative routes have been tested 
both clinically and in mouse models. Alternative routes that target high concentrations of APCs and 
low vacuolisation include ILIT, IDIT and EPIT. Targeted skin APCs mature based on the local 
inflammatory environment and migrate to skin draining lymph nodes (dLN) to activate downstream 
process, while ILIT entails direct injection of unadjuvanted allergen into the superficial lymph node 
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of the patient (e.g. inguinal or ‘groin’) [9, 12]. ILIT has successfully use up to 1000-fold less dose 
with as little as three administrations and no reported side effects [207, 208]. This supports that 
lower doses are required when allergen is delivered to a high concentration of APCs and naïve T 
cells in a low inflammatory environment. ILIT is a promising alternative route for AIT, however, it 
requires specialised training and ultrasound guiding injection equipment leading to a patient 
compliance of only 27 % [12, 191]. Alternative routes for allergy immunotherapy have been 
extensively reviewed [9, 171, 193, 209-211], therefore this review will focus on key findings for 
skin-based IDIT and EPIT.  
 
Desensitisation via the IDIT route was first reported in 1926 using an non-standardised dose [212]. 
It consists of repeated injections into the dermis layer of the skin (Figure 2-8). Due to the success of 
SCIT, the next study of IDIT was not reported until 2012 with 2000-fold dose sparing [213]. Both 
studies treated grass pollen allergic patients to 90% inhibition of symptoms with no systemic side 
effects. Rotiroti et al. [213] also assessed the effect of number of repeats to find that six repeats 
(total dose of 42 ng) was significantly better at desensitisation than 1-2 repeats. Dose sparing is 
likely attributed to the 100-fold uptake of allergen into the dLNs from intradermal injections (i.d.) 
relative to s.c. injections [214]. Unfortunately, a comprehensive phase II clinical trial using a similar 
protocol to the 2012 test (total 49 ng) resulted in worsening of symptoms and deemed IDIT 
clinically insufficient [14]. Lack of Th2 inhibition via the dermis may be due to the presence of 
activated mast and basophil cells in allergic skin that respond to anti-allergen IgE, creating a Th2 
environment for the surrounding APCs [81]. Histamine reactivity tests support this concept as 
dermal deep penetration (e.g. i.d. or lancet prick 1-2 mm deep) resulted in strong reactions, while 
shallow epidermal penetration (e.g. 0.1 mm deep) or tape stripping do not result in local reactions 
[215].  
 
Allergen delivered to the dermis of naïve mice (i.e. mice without circulating anti-allergen IgE) does 
not mediate a Th2 response and so reactivity and worsening of symptoms will likely only occur 
when IDIT is given to sensitised patients but may still be useful in allergy vaccination [113]. If this 
is the case, one would assume that IDIT in combination with a pre-administration of anti-IgE in 
sensitised patients may assist in reducing immediate responses and allow the allergen to be taken up 
in a lower inflammatory environment. The dermis is also vacuolated, albeit the diameter of mouse 
dermal capillaries is about 12.5-fold smaller than subcutaneous capillaries [216]. None-the-less, 
delivery to blood circulation must be minimised to avoid systemic responses [9]. To combat the 
inflammation of the dermis, delivery of less immunogenic peptides of allergens can result in 
successful desensitisation in mice after just one administration [217]. Peptide IDIT translated well 
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to patients, indicating longer time periods between repeats significantly improves desensitisation 
[218]. However, despite increased APC targeting and lymph node uptake, delivering whole allergen 
solutions to the dermis by IDIT currently does not result in desensitisation in allergic patients.  
 
The skin’s top viable layer, the epidermis, also contains a high-density of APCs, such as tolerant-
inclined LCs, and it contains few granulocytes and is not vascularised, making it another suitable 
candidate for alternative AIT [219]. Unlike IDIT and SCIT invasive injections, EPIT is non-
invasive and can be self-administrable, increasing tolerability by the patients. The caveat to non-
invasive topical applications to the skin is that the stratum corneum is very resistant to absorption 
into the viable epidermis, as discussed later in section 2.4.1. However, a multitude of delivery 
devices have overcome this resistance by either increasing the humidity of the stratum corneum 
(hydration), removing the stratum corneum (removal) or penetrating past the stratum corneum 
(penetration) (see section 2.4 for more detail). Although EPIT was conceptualised in 1921, the 
hypothesis that skin is an immunogenic organ was not accepted until 1983 by World Health 
Organisation (WHO) this delayed the first clinical EPIT until 2009 [171].  
 
Markers of success in clinical trials differ significantly than in mouse studies as listed in Table 2-8. 
Since 2009, there have been at least two successful clinical devices reported: an absorbance pouch 
[13, 17] and a hydrating chamber (Viaskin®, DBV technology, Bagneux, France) [18, 220] (Table 
2-9). Mostly grass pollen (specifically Phl p 5 from Timothy grass) EPIT has been studied in 
patients with promising results from just 4-12 applications. The 15 cm2 absorbance pouch was 
applied to tape stripped and so utilised a stratum corneum removal approach with low-medium 
success (Table 2-9). The Viaskin® was originally tested with tape stripping, but found intact skin 
sufficiently absorbed the allergens [126] and increased the safety for peanut EPIT [221]. There had 
been no successful AIT available for peanut allergies until the Viaskin® test that provided increased 
protection in up to 48% of participants with no adverse reactions [220]. Both devices were able to 
be applied by the patient, limiting the need for excessive specialist appointments. A current 
downside of EPIT, relative to SCIT (0.5 min) and SLIT (5 min) would be the excessive application 
time of 8-48 h. In addition, EPIT studies have failed to report the exact dose delivered to the 
epidermis, making it difficult to compare dosing regimens. None-the-less, EPIT is currently 
providing an easy to use, non-invasive, tolerable, efficient and (above all) safe alternative route to 
AIT.  
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Table 2-8: Symptomatic and biomarkers of successful EPIT in patient trials.  
Biomarker Increased by 
desensitisation 
Decreased by desensitisation 
Allergic symptoms - 
Itching [13] 
Sneezing [13] 
Nasal obstruction [13, 18] 
Rhinorrhea [13, 18] 
Lung  [13] 
Visual analog scale (VAS) [13] 
Dyspnoea [18] 
Use of rescue medication [18] 
Reactivity - 
Conjunctival provocation test (CPT) [13] 
Skin prick test (SPT) [13, 17, 220] 
Allergen challenge [220] 
Nasal provocation test (NPT) [17] 
Local reaction - 
Pruritus [13, 17] 
Erythema [13, 17, 220] 
Eczema [13, 17] 
Wheal [13, 215] 
Th2 biomarkers IgG4 [220] IgE [220] 
 
Using mouse models for EPIT has added to the understanding of the additional variables EPIT 
entails. A caveat to using the mouse for EPIT is the removal of hair to gain direct access to the skin. 
Hair is ideally removed by electric clippers followed by a depilatory cream after which mice should 
rest 24-72 h to restore the stratum corneum. Removing hair down to the root should not affect the 
majority of tolerant-inclined epicutaneous cells targeted by EPIT, the LCs, as only 1-3% total LCs 
reside in the hair follicle [219]. Although the exact delivery dose into the epidermis is generally not 
reported it is assumed to be less than the applied dose. In comparison to SCIT, EPIT can desensitise 
at lower doses [26, 206] and provide stronger protection than SLIT [202]. Also, in vivo transfer of 
Treg cells produced from EPIT found they continued to suppress Th2 responses while Tregs from 
oral fed-AIT and SLIT treated mice did not [222]. This may be due to the difference in 
concentration of LCs between the mouth (buccal mucosa, mouse: 690, human: 567 LC/mm2) and 
the back/trunk skin (mouse: 880, human: 740 LC/mm2) [223, 224]. Furthermore, the LC 
concentration also differs between the neck, trunk, arms/legs and palm/sole in both mice and human 
skin. While different methods of removing the stratum corneum in studies with high EPIT success 
found the delivered dose required via penetration (10-25 µg) was significantly less than the applied 
dose via hydration (100 µg) (Table 2-9). So, in addition to the dose of allergen, the dose of 
adjuvant, the number of repeats and timing of repeats assessed for SCIT and SLIT, additional EPIT 
variables include:  
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  1)  A lower magnitude of dose than SCIT/SLIT. 
  2)  Lower Treg readings may be acceptable since skin Tregs may be stronger than those produced 
through other routes. 
  3)  Different sites of skin application will result in targeting different concentrations of LCs and,  
  4)  The method of bypassing the stratum corneum may affect the dose required. 
In extension to this, the size of the EPIT device and time left of the skin will also effect the number 
of LCs targeted.  
 
In addition to grass pollen and peanut allergies tested in clinical studies, EPIT has also desensitised 
mice to OVA and house dust mite. High success in house dust mite desensitisation was achieved 
from penetrating the stratum corneum via a dMPA device (total dose 100 µg) [206], while 
delivering house dust mite via Viaskin was less effective (total 800 µg) [122] and SCIT was not 
effective at the same low dose as the dMPA [206]. The dMPA used considerably less house dust 
mite allergen than what is required for successful mouse SCIT (total 750-1000 µg) [204, 206]. 
Successful immunity by a variety of dMPAs has been widely reported for infectious vaccines (see 
section 2.5) but this is the first study to report their use in AIT [206]. In this study, dMPAs were 
made from 76 dissolvable 270 µm tall projections over ~1 cm2 and affixed to the mouse with 
adhesive plaster for 2 h. Measuring water loss (TEWL) indicated that the micro holes caused by the 
projections penetrating the skin had closed up by 2 h post removal of the dMPAs. By delivering 
allergen alone the dMPA had significantly reduced epidermal swelling, skin eosinophilia and sera 
IgE levels and increased sera IgG4 levels after just 10 repeats.   
 
OVA based EPIT has been delivered by Viaskin® [122, 126, 225] and well as by EPI [26, 139] and 
ablative micro-fractional laser (AFL) [201]. When Viaskin® treated mice were challenged orally 
(fed) [225] the protection was low, however, airway challenged mice had much higher success 
[122, 126]. Mice treated with EPI had OVA delivered via high velocity OVA-micro particle 
penetration. EPI was significantly more effective with higher doses (total dose 150 µg [139]) than 
lower doses (total 60 µg) and was not boosted by the addition of CpG [26]. Mice treated with AFL 
had OVA delivered via a topical patch of solid coating dried in the shape matching the micro-holes 
in the stratum corneum that were removed by fractional laser [201]. After a single application of the 
AFL OVA delivery, OVA-specific Treg levels were significantly higher than s.c. delivery of the 
same dose. The removal of the upper layers of skin using this method is surprisingly low 
inflammatory. This is likely due to the vaporisation of dead cell matter negating the inflammatory 
signalling from said dead cells. As such, additional adjuvants (CpG with 1,25-dihydroxyvitamin D3) 
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were required to boost the desensitisation response which reduced both Th2 biomarkers and airway 
inflammation. Overall, EPIT has so far desensitised mice to a variety of allergies by long 
applications of hydration devices or with faster applications by penetration or removal devices such 
as EPI, AFL and dMPAs but titrations of delivered dose, timing, repeats and optimal methods of 
bypassing these stratum corneum are still required.  
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Table 2-9: Skin route for AIT of clinical trials in allergic patients and desensitisation of airway allergens in BALB/c mice. Success rating based on 
two or more desensitised biomarkers (‘High’), at least one desensitised biomarker (‘Medium’), a mix of desensitised and sensitised biomarkers (‘Low’) 
or no desensitised biomarkers (‘None’). Day 0 of human studies starts at first desensitisation, day 0 of mouse studies starts at first sensitisation. SCIT 
or SLIT that was included in the study as a direct comparison was (also) included here. TS, tape stripping; HDM, house dust mite; VD, 1,25-
dihydroxyvitamin D3; Rap, rapamycin, O+AH; OVA and AH. 
S
p
e
c
i
e
s
 
Study Allergen Sensitisation 
Desensitisation 
Challenge Sample day Success 
Bypass of 
Stratum 
corneum 
Dose 
(µg) 
Repeats 
Application 
time 
Additions 
H
u
m
a
n
 
[215] 
- - 
Penetration at 
1000 µm 
Penetration at 
100 µm 
Removal 
0.01 
 
0.01 
 
0.01 
×1 
 
×1 
 
×1 
15 m 
 
15 m 
 
15 m 
Histamine 
 
Histamine 
 
Histamine 
- 
 
- 
 
- 
- 
 
- 
 
- 
None 
 
Low 
 
Low# 
[13] Grass 
pollen - 
Removal (TS) 
Removal (TS) 
Removal (TS) 
~3 
~15 
~30 
×11 
×11 
×11 
8 h 
8 h 
8 h 
- 
- 
- 
- 
- 
- 
533 
533 
533 
Low 
Low 
High 
[220] Peanut 
- 
Hydration 
Hydration 
~100 
~250 
×365 
×365 
24 h 
24 h 
- 
- 
5044 mg food 
challenge (or 
10-fold) 
365 
365 
Low 
Medium 
[17] Grass 
pollen - 
Removal (TS) 300 IR 
(~25) 
×4 48 h - - 575 Medium 
[18] Grass 
pollen - 
Hydration ~11.25 ×12 24 h - - 99-129 High 
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[26] OVA i.p. O+AH ×2 
i.p. O+AH ×2 
i.p. O+AH ×2 
Penetration at 
16.5 µm 
{SCIT} 
10 
10 
10 
×6 
×6 
×6 
Instant 
Instant 
- 
- 
CpG 
- 
10 µg i.n. ×2 
10 µg i.n. ×2 
10 µg i.n. ×2 
85 
85 
85 
Low 
Low 
None 
[225] OVA 
(C3H/He
J mice) 
Skin 100 µg 
×6 
Hydration 
Hydration 
~100 
~100 
×8 
×8 
48 h 
48 h 
- 
- 
Ingested ×1 
Ingested ×2 
98 
126 
Low# 
Low 
[201] OVA All groups 
[i.p. O+AH 
×2] 
 Removal at 
25 µm 
50 
50 
50 
×3 
×3 
×3 
2 h 
2 h 
2 h 
CpG 
CpG+VD 
CpG+Rap 
500 µg i.n. ×3 
500 µg i.n. ×3 
500 µg i.n. ×3 
45 
45 
45 
Low 
High 
Low 
[122] OVA 
 
Grass po 
 
HDM 
s.c. O+AH ×2  
+ i.n. ×1 
s.c. G+AH ×2  
+ i.n. ×1 
s.c. H+AH ×2  
+ i.n. ×1 
Hydration 
 
Hydration 
 
Hydration 
~100 
 
~100 
 
~100 
×8 
 
×8 
 
×8 
48 h 
 
48h 
 
48h 
- 
 
- 
 
- 
0.1% aerosol ×3 
0.1% aerosol ×3 
0.1% aerosol ×3 
69 
 
69 
 
69 
High 
 
High 
 
Low 
[206] HDM 
(NC/Nga 
mice) 
All groups 
[Skin 100 µg 
HDM ×3] 
Penetration 
{SCIT} 
{SCIT} 
10 
10 
100 
×10 
×10 
×10 
2 h 
- 
- 
- 
- 
- 
- 
- 
- 
56 
56 
56 
High 
None 
High# 
[202] Grass 
pollen 
s.c. G+AH ×2  
+ i.n. ×1 
{SLIT} 
Hydration 
100 
~100 
×8 
×8 
30 m 
48 h 
- 
- 
Aerosol ×3 
Aerosol ×3 
63 
63 
High 
High# 
[139] OVA i.p. O+AH ×1 Penetration at 
16.5 µm 
25 ×6 instant - 1% aerosol ×3 65 High 
 
[126] OVA s.c. O+AH ×2  
+ i.n. ×1 
Hydration ~100 ×8 48 h - - 84 High 
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2.4 Skin immunotherapy 
The skin has been used in drug delivery and immunotherapy for over one hundred years [171]. This 
is because skin is easy to access and (although not found until much later) contains the structures 
required to drain into the circulatory and/or lymphatic system. Delivery to blood circulation better 
targets whole body delivery while lymphatic delivery better targets the immune system. Common 
invasive delivery techniques include i.v. for fast delivery to circulation, s.c. for a slower delivery to 
both circulation and the lymphatics and i.d. for more precise delivery to the lymphatic system. All 
three injections require specialised training for delivery, negating the possibility of self-application 
by patients. On the other hand, topical application of small drugs can be absorbed into circulation 
and applied at the patient’s time of convenience. These small drugs can cover a broad range of 
needs such as, nicotine addition, hormone imbalance, pregnancy prevention, hypertention, 
parkinson’s disease and motion sickness, just to name a few [226]. Unfortunately, for larger 
therapeutics (such as AIT) the barrier must first be hydrated [227], penetrated [228, 229] or 
removed [230, 231] to effectively bypass the stratum corneum. A broad spectrum of skin delivery 
devices has been developed to meet these needs. The effect of these devices on skin immunity are 
discussed below.  
 
 
2.4.1 Skin composition 
The skin forms a protective barrier between the external and internal environment of the body. As 
aforementioned, it comprises of four layers (strata), from the surface inwards, these are the stratum 
corneum, viable epidermis, dermis and the subcutis (technically known as the hypodermis). 
Together, the non-viable stratum corneum and viable epidermis make the epidermis. The stratum 
corneum is a layered, structural barrier of cornified keratinocytes containing keratin [232]. An 
average stratum corneum is 5 µm thick in healthy mice (15 µm in humans, Figure 2-10) [233], can 
resist absorption of particle formulations with molecular weights above approximately 500 Da and 
is hydrophobic when exposed to 85% relative humidity or less [226, 234]. To put this in 
perspective, OVA is 44,000 Da, as are many therapeutic proteins [235]. 
 
The viable epidermis adds an additional immunologically active barrier that ranges from 15-25 µm 
thick in mice (~100 µm in humans, Figure 2-10) [233]. LCs make up 3-8% of the epidermal cells 
and are the only professional APCs found in the epidermis (see section 2.4.2 for more on LCs) [219, 
236]. However, reports in last 20 years or so have demonstrated additional immune signalling from 
surrounding keratinocytes [237]. As such, keratinocytes can release both non-inflammatory and 
pro-inflammatory signals and will bias from the former to the latter as the skin is increasingly 
stressed (e.g. friction to scarification, see section 2.4.3) [175].   
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At ~200 µm thick (~2300 µm in humans, Figure 2-10) [233] the dermis contains the majority of 
immune cell types within the skin including dermal DCs (dDC), dermal macrophages, mast cells 
and several types of T cells amongst a network of collagen, elastin, thin capillaries and hair follicles 
[219]. Of these, dDC and dermal macrophages are the professional APCs of the dermis in healthy 
skin but are joined by plasmacytoid dDCs in unhealthy skin [238]. Importantly, the dermis contains 
a large source of circulating Treg cells that are imperative for building specific immune tolerance 
(the main aim for AIT) [239]. Not only are Tregs present in the skin but, when compared ex vivo to 
an equal number of Tregs sourced from the lung, mouse skin Tregs have significantly stronger 
suppressive properties against pro-inflammatory signals than lung Tregs [240]. Due to the lack of 
hair on mouse ears, some epicutaneous delivery are performed on ear skin instead of removing hair 
from the back of the mouse. In these instances, it is important to note that the dermis of mouse ear 
skin contains significantly more mast cells and macrophages and significantly less T cells than back 
skin [219]. As mast cells are particularly strong responders in allergic sensitisation, this differential 
distribution in the mouse is very important to consider for EPIT delivery [95, 241]. 
 
Figure 2-10: Graphical representation of the average reported skin strata thickness of mouse and 
human skin. Mouse skin has an average of 5 µm thick stratum corneum, 20 µm thick epidermis and 
200 µm thick dermis while human skin has an average of 15 µm thick stratum corneum, 100 µm 
thick epidermis and 2,300 µm thick dermis. Data sourced from Wei et al. [233] 
 
The majority of the subcutis is less immunogenic, consisting of fibroblasts, adipose cells and 
macrophages [204]. Despite the lack of immunogenicity in the subcutis, this thick layer 
(millimetres) is easily accessible via s.c. injections. A substance injected subcutaneously that 
consists of therapeutics larger than 22,000 Da is mostly transported to the draining lymph nodes 
rather than the blood circulation [242]. Peak allergen concentration in mouse serum occurs around 8 
h after s.c. injection leading to possible late-phase side effects [221]. As delivering allergen therapy 
88 
 
into circulation significantly increases the chance of anaphylaxis [11], this thesis focuses on 
delivering allergen to the upper layers of the skin. 
 
The composition and immunity of mouse and human skin is very similar (Figure 2-11). Some 
differences that may affect translation of EPIT from mouse to patients includes additional mouse 
dendritic epidermal T cells (DETCs) and γɗ T cells, both of which drive additional pro-
inflammatory responses in skin inflammation [175, 243]. As mice have more types of skin cells that 
respond to skin inflammation, EPIT delivery devices for mice may require lower inflammatory 
mechanisms than those translated to humans. For instance, tape stripping before application of 
mouse skin leads to boosted sensitisation [113, 115] while tape stripping of human skin assisted in 
EPIT [17]. Additionally, the diffusion coefficient of (in-vivo) mouse skin is 10-fold slower than in 
(ex-vivo) human skin [244] and so the dose of allergen required for mouse EPIT may be different 
by an order of magnitude than required for patients (depending on the delivery mechanism).  
 
Figure 2-11: Comparison of resident immune cells and relative skin strata thickness between (a) 
mouse and (b) human skin. Skin strata are not comparably to scale between mouse and human. 
Image sourced from Pasparakis et al. [243]. 
 
2.4.2 Langerhans cells 
Human LCs are homologous to mouse LCs, serving very similar functions in both immune systems 
[245]. The overall density of epidermal LCs is also very similar between mouse (of back skin, ear 
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skin and buccal mucosa of A/Jax mice) and humans (of face, neck, trunk, arm and leg skin) 
averaging 833 and 785 LCs/mm2, respectively [223, 224]. However, the density of LCs greatly 
depends on the location. For example, human palm and sole skin have as few as 267 ± 56 LC/mm2, 
while the face and neck have as many as 976 ± 31 LC/mm2. The LC density in skin also differs per 
mouse strain where an average density of ear skin is 830 LC/mm2 in BALB/c mice but only 522 
LC/mm2 in C57BL/6 mice [246]. This may play a big role in why BALB/c mice are superior to 
C57BL/6 mice in both allergy sensitisation and desensitisation. Studies in mice show that LCs 
maintain numbers constantly but do circulate 15-20% of LC from the epidermis to the dLNs every 
24 h [247]. Trauma to the skin, such as tape stripping, enhances this migration from the affected 
area to about 85% of LCs migrating from the epidermis to dLNs within 24 h [247]. These same LCs 
can then leave the dLNs within 48 h of arriving. These differences in density and migration patterns 
are important variables to consider before testing new EPIT devices or regimens. 
 
Epidermal LCs play an important role in both immune defence and (as more recently discovered) in 
immune tolerance for skin infections, inflammations and tumours. Immune defence by LCs includes 
non-specific release of pro-inflammatory signals via TLRs and other pattern recognition receptors 
as well as recognising non-self-substances such as allergen. Up-take of allergens causes LCs to 
migrate out of the skin and present to T cells, leading to activation of the humoral system to 
produce anti-allergen antibodies and the suppression of immune tolerance [248]. LCs can cross 
present allergen via the MHC I receptor to activate CD8+ T cell response or MHC II receptor to 
activate CD4+ T cell response [236]. This makes them a promising target for both cancer 
immunotherapy (requires CD8+ T cells) and vaccination against infectious diseases (requires CD4+ 
T cells) or allergic sensitisation (either CD8+ or CD4+ T cells) [249]. To induce an antibody 
response, the minimal number of LC activation required is about 1,000 LCs [250]. Although this 
equates to the total LCs within an area of 1.2 or 1.3 mm2 in mouse or human skin respectively, even 
under excessive skin inflammation conditions (e.g. 30x tape stripping) only a maximum of 63 ± 
11% of LCs migrate out of the skin [251]. Therefore, under lower inflammatory delivery 
conditions, a much larger surface area of skin would need to be targeted to result in the antibody-
favouring conditions brought by LCs. In contrast, therapeutics that do not require the induction of 
antibodies may need to target fewer LCs.  
 
In the early 2000’s, LCs of healthy skin were determined as inductors of tolerance during a steady 
state [252]. Immune tolerance by LCs includes routinely encountering substances (self and non-
self) and presumably presenting to the 0.5-2 billion resident memory Treg cells within mouse skin  
[253]. LCs with innocuous substances loaded into MHC II receptors can also migrate out of the skin 
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and proliferate allergen-specific Treg cells responsible for suppression of immune defence [254, 
255]. The difference between MHC II loaded LCs activating Th2 or Treg proliferation is still 
unclear and neither is the primarily location of LC and Treg interaction (skin or lymph node?) 
[254]. Nevertheless, the difference is likely a result of accompanying signals (possibly from 
keratinocytes) and the level of MHC II expression of the LC surface. Despite not yet fully 
understanding how LCs and Tregs interact, LCs have been associated with dampening 
inflammation and mediating tolerance in contact hypersensitivity [256] and specifically causing 
Treg cell expansion during glucocorticosteroid treatment (an immunosuppressant) [257]. 
 
The fine balance between activating either defence (immunity) or tolerance by LCs has only been 
somewhat investigated [236, 258, 259]. What is known is that during the steady state, keratinocytes 
downregulate LC migration (IL-10) and promote LCs to produce receptor activator of NF-κB ligand 
(RANKL) and transforming growth factor β (TGF-β) to mediate resident memory Tregs [237, 258]. 
The leading support of evidence for skin cells switching from tolerance to defence activation is 
during the addition of danger signals from microbial components and danger signals from 
surrounding keratinocytes [258]. Keratinocytes release danger signals (e.g., TNF-α, IL-1β, IL-4, IL-
6, IL-12, monocyte chemoattractant protein-1 (MCP-1) etc. - see reference for full list) when 
stimulated by mediators such as allergens, irritants, endotoxin and physical abrasions [237]. More 
specifically, TNF-α and IL-1β increase the level of MHC I/II expression on LCs, a defining feature 
of maturation of the cell and MCP-1 is one of many chemoattractants keratinocytes excrete to 
promote LC migration to dLNs [237]. Release of IL-4, IL-5 and IL-6 (in the presence of IL-4) 
promotes Th2 differentiation, while release of IL-12 promotes Th1 differentiation during antigen 
presentation from LCs (or any APC) to T and B cells [113, 260]. Therefore, the local micro-
environment affects the keratinocyte response, which in turn skews the response of LCs and other 
resident immune cells in the skin to either maintain immune tolerance or activate immune defence. 
However, further titrations of stimulation factors from keratinocytes would greatly assist in defining 
parameters for skin deliver devices of both tolerant and pro-inflammatory therapies. 
 
2.4.3 Effects of skin stress caused by epicutaneous allergy immunotherapy devices on immunity 
As eluded to the introduction to section 2.4 to access the upper layers of the skin (epidermis and 
dermis) requires either hydration, penetration or removal of the stratum corneum. Each of these 
techniques results in different stresses and/or impacts on the skin and therefore different immune 
responses. That is, the skin is not in a state of constant vigilance and instead requires pro-
inflammatory signals to respond defensively (e.g. sensitisation). These signals can vary greatly and 
include but are not limited to: excessive levels of cell death (above homeostasis), loss of stratum 
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corneum protection, recognition of foreign substances and release of out-sourced pro-inflammatory 
signals (e.g. blood) from non-invasive exposure (e.g. to heat, cold or ultra violet rays). Variations of 
these signals allow the skin to both sensitise and desensitise against allergens. This was eloquently 
exploited by Tordesillas et al. [225] who increased the stress in the mouse skin to sensitise (tape 
stripping) and then used low impact skin delivery to desensitise (hydration). The first 
device/method used to bypass the skin for AIT was by Vallery-Radot in 1921 who stratified the 
stratum corneum with a sharp object to deliver allergen and alleviate a patient of horse hair allergies 
[171]. This method is known as scarification and was mainly used to quickly bypass the stratum 
corneum for skin prick testing (SPT) of sensitisation (before lancets were used) and therefore is 
rarely recorded in EPIT. To define the level of stress produced by varying delivery techniques and 
devices, I have assessed each by their reported erythema 24 h after application on mouse skin 
(Table 2-10).  
 
Table 2-10: Impact of minimally invasive skin devices tested in allergy. Erythema at site of 
application measured by the Draize score [261] 24 h after application and my association to the 
level of impact that has stressed the skin. Scoring is based on both published images and 
annotations of device erythema at or near 24 h post application during allergen-only delivery in 
non-sensitised skin.  
Draize score at  
t = 24 h 
0 (at t = 0 h) 0 1 2 3+ 
Application 
impact defined as: 
Very Low Low Medium High Very High 
Skin allergy 
devices 
Viaskin [122] 
i.d. [262] 
Low 
density 
dMPA 
[206, 263, 
264] 
AFL [265] 
EPI [266, 
267] 
Scarification  
[262] 
 
Tape 
stripping 
x6  [215] 
Tape 
stripping 
x35 [268] 
 
Very low levels of stress/impact on the mouse skin from allergen delivery are defined here as 
applications to the skin that result in a Draize score of ‘0’ at t = 0 and thereafter. These include 
topical application to intact skin (of small molecules not assessed here), ultrasound-enhanced 
permeability (not yet tested in allergic disease, [269]) or Viaskin® [126, 221, 222, 225], so long as 
the applied therapies do not include skin irritants (e.g. oil and acetone [108]). Of these, only 
Viaskin® has been successfully used in EPIT with a very low impact on the skin as depicted in 
Figure 2-12. Viaskin® is a raised topical patch with a small chamber that builds the humidity of the 
applied intact skin to increase permeability of the dry coated allergen. Hydration that increases the 
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relative humidity above 85% causes an amino acid rearrangement in the keratin filament and 
protein structures, leading to increased water uptake and macroscopic swelling of the keratinocyte 
cells [227]. This in turn increases permeability of other substances, such as allergens. Hydration on 
intact skin is reported to deliver primarily to the epidermis [126]. In this study, allergens are mostly 
taken up by CD11b+CD11c+ DCs and some B220+ B cells in epidermis. Allergen-DCs migrate out 
of epidermis by 24 h after EPIT application and into dermis or dLNs. Of the allergen-DCs that 
migrate to lymph nodes, 45% are CD11b+CD11c+F4/80+MHC II+CD205highCD83highCD86high 
CD103- DCs (i.e. migrating, mature, antigen presenting DCs). Despite this activated state, allergen-
restimulation of these DCs results in no significant increase in IL-5, IL-10 nor IL-4 Th2 cytokines, 
which is promising for AIT. The other 55% of allergen-DCs were immature, raising the question 
whether this balance of mature and immature allergen-DCs is important in maintaining a tolerant 
rather than inflammatory response. Importantly, intact skin avoids allergen uptake into the blood 
[221]. The downsides to topical applications like Viaskin ®, are imprecise dosing of the allergen 
and lengthy application times, making it difficult to translate to the clinic. 
 
Low and medium levels of stress/impact on the mouse skin from allergen delivery are defined here 
as applications that result in some erythema at t = 0 but a Draize score of ‘0’ at t = 24 h. These 
include EPI, AFL and low-density dMPAs applied by hand (Figure 2-12). These devices each inflict 
micro wounds to the skin in the applied area causing the skin to act on pro-inflammatory 
stimulation form cell death and wound healing processes on a micro scale [270, 271]. Level of cell 
death was not assessed for these devices however, the micro nature of these devices to bypass the 
stratum corneum kept the pro-inflammatory responses to a minimum (relative to a larger skin 
wound). EPI hyper accelerates freeze-dried microparticles of 38-53 µm in diameter into the skin (to 
put this in context, an average cell diameter is 5 .2 µm). As such, EPI delivery into the epidermis 
increased MCP-1, TNF-α, IL-10 and IL-6 with no change in Th1 IFN-γ and IL-12p70 cytokines 
[26, 139]. This is a mixed result for EPI in EPIT as MCP-1 suppresses Th2 mediated responses 
[272] and IL-10 assists in desensitisation, while TNF-α enhances Th2 responses [273] and IL-6 (in 
the presence of IL-4) upregulates Th2 cell proliferation [260]. This could attribute to the mixed 
success of EPI in EPIT [26, 139].  
 
AFL delivery relies on a two-part system of first, removing micro sections of the skin with a Precise 
Laser EpidermAl SystEm or P.L.E.A.S.E.® then second, applying a patch with allergen dry coated 
in the complementary shape of the AFL array [201]. The P.L.E.A.S.E® can be set to various 
number of pulses resulting in various depths of penetration. When set to 4-8 pulses delivery occurs 
primarily in the epidermis of mouse skin but also produces mixed responses for EPIT [274]. That is, 
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allergen delivered by AFL is taken up by MHC II+CD11b+CD207- DCs that present to Th cells 
and induce antibody production, which is unwanted for EPIT. This leads to increased anti-OVA IgE 
production when applied without Th1 adjuvants such as CpG, the latter requiring a minimum of 30 
µg [274]. On the other hand, OVA-only AFL maintains low IL-4, IL5, IL-10, IL-6, TNF-a (Th2 and 
pro-inflammatory cytokines). This mixed response is, in part, because AFL does result in some 
leakage of allergen into blood circulation at a similar level to i.d. injection making it less effective 
without additional adjuvants [201].   
 
Lastly, dMPA delivery simultaneously delivers coated allergen to sites of micro penetration that 
cause micro-wounds within the epidermis and dermis [206]. dMPAs can be made in a variety of 
designs and applied with a variety of energies and are therefore associated with various immune 
responses from changing these parameters (see section 2.5). These micro-holes result in an increase 
in water loss (indicating a breach in the stratum corneum) that resolves itself by 2 h post removal of 
the dMPA. Application of Kim et al.’s [206] low-density dMPA did not increase the atopic 
dermatitis score, maintained low skin eosinophils, low epidermal thickening and continued to repair 
the stratum corneum within 2 h even after 8 twice-weekly applications. This dMPA also maintained 
low IL-4, IL-13 Th2 cytokines and CD4+IL-4+ Th2 cells while increasing regulatory signals such 
as IL-10, Foxp3 and CD4+Foxp3+ cells in skin. These responses are atypical of dMPAs or dermal 
delivery (see section 2.5) and lead us to suspect that most of delivery for this design of dMPA may 
reside in the epidermis rather than the dermis. However, without penetration data of the device it is 
difficult to conclude. 
 
High levels of stress/impact on the mouse skin from allergen delivery rarely results in EPIT success 
but can be useful for sensitisation (Table 2-3). Devices that elicit high inflammation in the skin 
include tape stripping and high-density dMPAs (not yet tested in allergic disease). Similar to AFL 
removal, tape stripping removes the stratum corneum and so some of the delivered allergen is taken 
up into blood circulation (peak 2 h after application) [221]. This is achieved by repeatedly applying 
a new piece of adhesive tape to the same area of the skin. Each repeat typically removes 0.5-1 µm 
of stratum corneum and so mice require significantly less repeats than humans for the full stratum 
corneum to be removed [275]. Because of this, tape stripping human skin can be differentiated into 
partial removal, assisting in allergen uptake [13, 17] and assessment of treatment of atopic 
dermatitis [276], or full removal of the stratum corneum to activate Th2 responses [277]. Tape 
stripping and high-density dMPAs cause a physical adjuvant effect that activates the immune 
response without the use of chemical or microbial based substances [17]. Physical adjuvantation 
instead relies on the natural response to barrier breakage and cell death such as necrosis (physically 
94 
 
Figure 2-12: Example images of the effect of very low-medium impact, non-invasive skin devices 
tested in EPIT on skin erythema. Images sourced from the following: Viaskin ® on mice [122], 
low-density dMPA on mice [278], AFL on mice [265], EPI on Macaque [279] and on Porcine 
[267]. 
 
damaged, dying cells) to attract immune regulators and stimulators alike. For example, skin wounds 
result in release of nucleic acids from necrotic keratinocyte cells that increase pDC infiltration 
[280]. pDCs recognize the acids via TLR9 receptor and then release IFNs to prompt a Th1 response 
[281]. Hence, a lack of pDCs in mice significantly increases the Th2-mediated airway 
hypersensitivity to OVA [282]. Tape stripping also increases pro-inflammatory IL-1, IL-6, IL-8, 
TNF-α  and Th1-mediated IL-12 and IFN-γ levels in the skin [17]. This leads to a 2.5-fold influx of 
CD11c+MHC II+ DCs after 48 h and induces epidermal thickening up to 60 h while depleting the 
skin of a portion of protective LCs that are not fully replaced until about day 20 [251, 283]. Overall, 
tape stripping delivery effectively bypasses the mouse stratum corneum and induces a Th2-
mediated environment during allergen uptake, optimal for sensitisation.  
 
 
2.5 Microprojection arrays 
2.5.1 Effect of microprojection design on skin penetration 
The first microprojection array (MPA) was reported by Henry et al. [284] in 1998. After 10 seconds 
of application of a high-density MPA (150 µm tall) onto excised skin (Figure 2-13) then removal, 
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the permeability to a topically applied solution increased 10,000-fold. In the past two decades, a 
variety of MPA designs have been reported in the delivery of drugs and therapies to the skin, these 
have been extensively reviewed [19, 22, 229]. In brief, an MPA has been defined as a solid or 
flexible base with multiple sharp protrusions/projections/microneedles on its surface (generally less 
than 1 mm tall each) that is applied to intact skin in such a way that the projections penetrate into 
the skin [285]. These projections can be made of solid material that is coated with allergen, 
dissolvable material containing allergen within or solid but hollow to allow micro injections of 
allergen solution. As i.d. injection has not resulted in promising IDIT, here this review will focus on 
MPAs with dissolvable coatings or dissolvable projections.  
 
Figure 2-13: First reported microprojection array penetrating through excised skin, arrows 
indicate tips of projections. Image sourced from Henry et al. [284] 
 
There are several variables to consider when designing an MPA, these include: material of MPA, 
length of projections, projection tip design, number of projections, density of MPA, means of 
application to the skin and application time. Solid MPAs that are made from polycarbonate [286], 
stainless steel [133], glass [19], or silicon [287] material or dissolvable MPAs made from a mixture 
of carboxymethylcellulose, sodium hyaluronate and/or polyvinylpyrrolidone [206, 288] are each 
allergically inert materials. MPA projection design can range from 40 µm (0.04 mm) tall [216] to 
3,000 µm (3.0 mm) tall [22], though the majority of MPAs are less than 1,000 µm tall  [19] (Figure 
2-14). The height of the projection alters the maximum depth the MPA can penetrate the skin. For 
instance, MPAs of 250 µm tall applied to human skin reported primarily epidermal penetration 
(eMPA)  [289], while MPAs of 400-900 µm tall penetrated into the human dermis (dMPA)  [23, 
232]. Conversely, no eMPA has been reported for mouse skin, the closest being a 40 µm tall MPA 
of which the average penetration was 27 ± 9 µm into the mouse epidermal/dermal junction [290]. 
Several mouse dMPAs have been reported with projection heights ranging from 110-650 µm tall 
[291, 292]. Most of both mouse and human MPAs tested are dMPAs. The difference between the 
height of the MPA projections and the different strata penetrated and delivered to can complicate 
96 
 
translation from pre-clinical mouse studies to clinical human studies, as the skin strata thickness is 
significantly different between the two species (see Figure 2-10 above).  
 
Figure 2-14: The shortest and one of the tallest microprojection array projections reported. 
Images sourced from [216] and [293] respectively. 
 
Projection shape has been varied somewhat but all MPA projections consist of a wide base that 
tapers into a sharp tip (see [19, 22]). Some also contain a column in between the base and tip to 
increase the height of the projection (Figure 2-15). Both conical pointed tip shapes and blade-like 
slit tip shapes (Figure 2-15) have been shown to penetrate the skin [25, 294, 295]. However, when 
comparing these two tip shapes with the same total projection surface area, slit tip shapes penetrate 
deeper into the skin [25]. Other tip shapes have also provided varying degrees of penetration 
efficiency [23]. The tip point can vary greatly, especially between solid MPAs and dissolvable 
MPAs. Whereby, tip widths for solid projections range from 0.5-50 µm [133, 295] while 
dissolvable tip widths range from 4.0-28.9 µm (Figure 2-15) [206, 296]. The total penetrating tip 
surface area will affect the level of resistance from the skin, therefore the design of the tip shape 
and width also effect the penetration depth at a given application energy. 
 
Increasing MPA density can significantly increase its penetrating surface area and in turn affect the 
application energy required to penetrate the skin. MPA density can range from just five steel 
projections in a row [232] to 30,000 projections in a cm2 [297]. Here, I have defined MPAs with 
densities equal to or below 1,000 (1k) projections/cm2 (p/cm2) as ‘low-density’ and MPAs above 1k 
p/cm2 as ‘high-density’ for a given geometry. As density increases, the application energy required 
to ensure the same depth of skin penetration must be increased [216]. This can also be presented as 
energy per projection (mJ, calculated from mass multiplied by velocity) in studies assessing the 
same projection design of different densities. For example, conical pointed, silicon MPAs with 100 
µm tall projections were applied at 23.8 mJ (for 5k p/cm2), 45.4 mJ (10k p/cm2) and 90.3 mJ (21k 
p/cm2) energies that each equate to 0.027-0.029 mJ/projection [216]. Additionally, as the density 
decreases, projection height must increase to overcome the elasticity of the skin (Figure 2-16). 
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Therefore, although density has often been chosen arbitrarily (or based on manufacture limitations), 
it can affect the application energy required to either puncture the skin or penetrate to a particular 
depth. 
 
Figure 2-15: Examples of reported microprojection array projections shapes, tip widths and 
dissolvable material. Images sourced from (in reading order) [216], [25](x2), [284], [288] and 
[293]. 
 
Figure 2-16: Schematic depicting effects of decreasing the microprojection array projection 
density without increasing the height and with increasing the height on the projections.  
 
MPAs can be applied in a variety of application methods, affecting the penetration depth, 
consistency of application, usability of the MPA and cost of the overall device (MPA ± applicator). 
In general, increasing the application energy (mJ) increases the penetration depth until maximum 
depth is acquired [23]. The maximum depth depends on both projection length and the breaking 
stress of the skin, where skin is assumed to be incompressible due to the high water content in the 
skin [298]. Breaking stress of skin varies between the skins strata and also between the given strata 
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[298]. This stress often prevents MPAs from delivering to the maximum length of the projection 
and depends on the application energy used [264, 295]. Therefore, it can be difficult to assess the 
MPAs penetration depth without knowing the application energy (often not reported) or without 
penetration analysis data of the skin (e.g. histological assessment of skin after coated MPA delivery 
[25]. To date, MPAs have been applied to skin by hand [295, 299], with a static set mass [300], 
with a tension/snap device [19, 301] or with a spring-loaded applicator device [295]. All 
applications can penetrate at a consistent depth within a study, however, the use of an applicator 
rather than application by hand allows for better comparisons between studies as they have 
repeatable application parameters.  
 
Unlike i.d. injections, which are difficult to administer into the thin layer of skin, MPAs can be self-
applicable. An MPA applied by hand is the easiest to pass onto patients for self-application can be 
self-applied with up to 97% repeatability of the researcher application [23, 299]. Static masses 
require the application to be horizontal and stationary for a period and so are less likely to be used 
in the clinic. A spring-loaded applicator in combination with a use of product pamphlet similar to 
that given for the cosmetic Dermaroller® [22]. However, requiring an additional applicator device 
is currently considered one of the few downsides to MPA delivery, mainly due to cost [23, 302]. In 
terms of cost, application by hand may be more cost effective than application with an additional 
device, though this depends on the delivery efficiency of the therapeutic. Low delivery efficiencies 
will require higher pre-loaded doses to be coated onto/into the MPAs that will also increase the cost 
of the delivery device.  
 
The MPA delivery device was first tested to increase the speed of delivery past the stratum corneum 
[284]. Since then, the application time of MPAs has been tested from 10 seconds [303] to 2 h [206] 
on mouse skin. In general, solid projections are applied for less time (0.16-5 min [232, 303]) than 
dissolvable MPAs (5-120 min [206, 304]). Encapsulation of the drug into microparticles can retard 
the release of the drug even further, taking days to dissolve [305]. Timing of application is vitally 
important to maintain good patient compliance, as such, Cohn et al. [306] found that allergy drugs 
that required more than 15 min of the patients’ time were less likely to be either used (especially 
repeatedly) or applied for the correct amount of time. Norman et al. [301] reported an additional 
21% of patients would consider being vaccinated if there was a self-administrable MPA option and 
64% of patients would rather self-vaccinate if given the option. The ability of patients to replicate 
proper application of MPAs is high (93-97%) [20, 23]. Therefore, MPAs are clearly a diverse subset 
of deliver devices producing a range of new mechanistic variables to activate the immune system.  
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2.5.2 Mechanism of dermal-targeted microprojection arrays 
Similar to i.d. injection, the dMPA relies of penetrating the stratum corneum to deliver therapeutics 
to the viable cell strata below. Yet, there are several key differences between therapeutic delivery 
mechanisms using an dMPA and an i.d. injection including the medium the therapeutic is delivered 
in, the volume and surface area of the device within the skin and the changes to vacuolisation. Both 
solid and dissolvable dMPA deliver therapeutics within a gel-like coating, usually with a cellulose 
base (e.g. methylcellulose, [25, 307, 308]) and can contain sugars to increase the stability of either 
the therapeutic protein and/or the physical structure of the coating [304, 309]. These coatings 
require hydration time to dissolve, resulting in a slower release of therapeutic into the skin than i.d. 
injection (or hollow MPA injection) [310]. Therefore, if coatings do not enter the hydrated skin 
strata, it is less likely to dissolve off the MPA (Figure 2-17). Increasing the time the therapeutic is 
present in the skin (rather than taken up by blood circulation), increases its interaction time with the 
skin immune cells to which it was targeted to. This mechanism enhances the immune response to 
the applied dose and may be part of the reason behind the dose sparing effects seen in dMPAs 
compared to i.d. injection [271, 311-313]. Additionally, slow release of allergen may overcome the 
quick response of the primed dermal mast cells seen in IDIT (section 2.3.3.2). However, the 
diffusion coefficient for mouse epidermis is 10-fold slower than human epidermis [244]. Therefore, 
although dissolvable coating adds an advantage to skin immune targeting, a device translated from 
mouse to human may require coatings with a lower dissolvability to see the same temporal effect.  
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Figure 2-17: Scanning electron micrographs of projection shape and coating morphology. (Top) 
bare silicon MPA projections (middle) subsequently coated with methylcellulose based therapeutic 
(bottom) that is partially removed after application into the skin. Image sourced from Crichton et 
al. [25]. 
 
Unlike the single insertion of an i.d. injection, dMPAs penetrate multiple smaller areas of the 
stratum corneum and cause multiple mirco-wounds in the skin (Figure 2-18). This parameter can 
change the volume of cells displaced and therefore approximately the level of cells killed during 
application impact. Depending on the design of the dMPA, the volume displaced in the skin can be 
significantly smaller or larger than that of an i.d. injection. For example, Carey et al. [312] reported 
nine different types of low-density MPAs that ranged from 0.0018 mm3 (16 × 100 µm tall) to 
0.1123 mm3 (36 × 300 µm) projection volumes, which are either much smaller or similar to a 31G 
needle inserted 2 mm into the skin (i.d., 0.0928 mm3) [314]. Although this only represents volume 
displaced at 100% penetration efficiency, whereby most MPAs will displace less than their total 
projection volume. For example, high-density dMPAs (21k projections × 100 µm tall) have a 
0.1322 mm3 projection volume; however, the average penetration depth of these dMPAs was 
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measured at 40 µm deep (applied with 69 mJ) and so the applied volume is actually 0.0528 mm3 
[291]. Overall, displaced volume often does not differ from that of an i.d. injection. 
 
Figure 2-18: Comparison of 31 G needle used for intradermal injection with high-density 
microprojection array (21k p/cm2). (Top) Device comparison of overall size and surface area. 
(Bottom) Schematic of proposed localisation of therapeutic delivered (“Vaccine”) and the surface 
area of live and dead cells it contacts. Images sourced from Depelsenaire et al. [271]. 
 
A higher density will increase the application surface area into the skin. Increasing the surface area 
will increase the resistance (friction) and the number of stress points and so would require a higher 
total MPA application energy (but not a higher application energy per projection as eluded to in 
section 2.5.1). In comparison to a 31G needle inserted 2 mm into the skin (1.409 mm2), the total 
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surface area for the recently mentioned low-density dMPAs was 0.272 mm2 (16 projections × 100 
µm) and 2.592 mm2 (36 projections × 300 µm) while the example high-density dMPA was 273.3 
mm2 (3,360 projections × 100 µm). High-density dMPAs therefore result in a significantly larger 
surface area of impact in the skin; it could also deliver the therapeutic coating to a much larger 
surface area of skin cells.   
 
By applying pressure to the skin and penetrating the skin, it is common for dMPAs to visibly 
increase the level of vascularisation to the skin, increasing the erythema score. Erythema scores 
increase when either the blood vessels within the skin dilate or are ruptured, this increases blood 
flow into the skin, uptake of antigens into circulation and increased wound healing inflammation. 
As aforementioned in section 2.4.3, the erythema of low-density eMPAs is low. This entails an 
increase of reddening to a Draize score of 0-1 within the first few hours (h) of application that is 
restored (Draize score = 0) by 24 h after application [206, 263, 264]. This is similar to low-density 
dMPA reports of erythema in human subjects [301, 315]. In mice, high-density dMPAs increased 
erythema in the skin (to approximately Draize score = 2, unpublished) within the first few hours of 
application and was subsequently restored by 48 h after application [290]. In human subjects high-
density dMPAs also increased erythema to an average Draize score of 2 within the first few hours 
then persisted at a Draize score = 1 until day 3-7 [289]. A significant flaw in these comparisons 
between low-density and high-density applications is that these low-density MPAs were each 
applied by hand while the high-density dMPAs were applied with a spring-loaded applicator (~ 95-
97 mJ), significantly increasing the application energy used. Therefore, despite a difference 
seeming to eventuate between the two types of dMPAs, currently I can only conclude that low-
densities applied at low application energies induce less erythema than high-densities applied at 
higher application energies. 
 
2.5.3 Microprojection array immunity  
MPAs tested in the mouse model have successfully immunised with a variety of vaccines (see Table 
2-11) as well as assisted the delivery of nanoparticles [313, 316] and liposome-encapsulated siRNA 
[317]. Even vaccination into the inner cheek (buccal mucosa) with an MPA suggests significantly 
better immune targeting than oral delivery [307]. More recently, MPAs have been used to deliver 
allergen (OVA or house dust mite) to either prevent allergic airway sensitisation [133, 144] or 
desensitise (EPIT) against induced atopic dermatitis [206]. The resulting immune responses from 
MPAs is vastly enhanced in comparison to various injections. This is due to differences in 
therapeutic delivery mechanisms as discussed in section 2.5.2. The differences in mechanism leads 
to differences in level of induced skin inflammation and the localisation of the therapy with said 
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inflammation. As MPA design range is vast and not all reports of MPA immunity include 
mechanistic data, the connections between MPA design and the enhanced immune response is not 
yet fully understood. What is clear though is the larger surface are of the MPAs, particularly in the 
high-density MPA range, increases the level of cell death in the skin. This was best assessed by 
Depelsenaire et al. [271] who compared a 31G i.d. injection that increased the percent of skin dead 
cells by 0.8% (from application), to dMPAs with 1,600 projections that had a significantly higher 
percentage in the same 16 mm2 of mouse skin (5.8%). Furthermore, doubling the projection density 
(3,360 projections applied), almost doubled the percent of dead cells within the area (13.9%). By 
keeping the total projection surface area the same, Crichton et al. [25] found that dMPAs with wider 
projections (1,280 projections in 16 mm2) had more dead cells per projection and so induced a 
similar percent of total dead skin cells as the thinner projections (3,360 projections). Therefore, a 
combination of the number of projections and the surface area of the projections will affect the level 
of cell death within the skin. As the response of the keratinocyte skin cells to physical impacts is 
similar between mice and human skin (see section 2.4.3) it provides a mechanistic advantage to 
translate MPAs between the two species [318]. 
 
By increasing the number of dead cells localised with the deposited therapeutic, the level of anti-
therapy IgG significantly increased between i.d. > 1,600 dMPA > 3,360 dMPA > wider dMPA 
[271, 295]. Increasing specific IgG response via injectable routes requires the addition of chemical 
or microbial adjuvants that can result in different immune responses between mice and humans 
[111, 197]. Table 2-11 outlines that most dMPAs tested in mouse vaccination studies (without 
additional adjuvants) have produced strong anti-antigen IgG, IgG1, IgG2a [133], IgG2b [263], 
IgG2c, and/or IgG4 responses or a mild boost in IgG2a [144, 263] or IgG3 [133] responses 
(depending on antigen and mouse species). Other types of studies have also found increases in anti-
antigen IgA [319] and IgE [144] antibodies. Interestingly, a study of low-density dMPAs applied at 
different depths into the dermis with different densities all resulted in the same level of IgG boost, 
suggesting, so long as the same dose of therapeutic is delivered into the dermis (within a dissolving 
formula), a similar immune response will result [264]. So far, only low-density dMPAs have 
increased either immune defence (e.g. cytokines and antibodies) or immune tolerance (e.g. 
CD4+Foxp3+ Treg cells), while high-density dMPAs have only reported upregulation of immune 
defence such as infiltrating cells and antibodies. However, it is difficult to draw conclusions 
between differential immune responses produced by low-density and high-density dMPAs as 
neither have been assessed for many biomarkers or systematically compared.  
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Table 2-11: Mouse biomarkers of the skin or dLN (l) and specific antibody release from 
successful (solid or dissolvable) low-density or high-density microprojection array applications 
with various therapeutics (without additional adjuvants). Therapeutic: malaria vaccine [312], 
West Nile virus vaccine [320], Influenza [20, 21, 25, 198, 263, 271, 307, 308, 321, 322], OVA [20, 
133, 144, 264, 286, 294, 295, 323], herpes simplex virus-2 [324], house dust mite [206, 325], 
diphtheria toxoid [313]. RANTES, regulated on activation, normal T cell expressed and secreted; 
TNF, tumour necrosis factor; MIP, macrophage inflammatory protein.  
Biomarker Increased by application Decreased by 
application 
Specific antibodies 
Low-density 
MPA 
IL-1 [312] 
IL-1 β [321] 
IL-10 [206] 
Foxp3 [206] 
TNF [312] 
MIP-1α [321] 
MCP-1 [321] 
RANTES [312] (l) 
CD4+Foxp3+ cells [206] 
 
IL-10 [312](l) 
TGF-β  [312] 
Eosinophils 
[206] 
IL-4 [206] 
IL-13 [206] 
CD4+IL-4+ 
cells [206] 
 
IgG [133, 144, 198, 263, 
264, 286, 309, 313, 322, 
325] 
IgG1 [133, 144, 198, 263, 
309, 313] 
IgG2a [133, 144, 263, 309] 
IgG2b [263, 309] 
IgE [144] 
IgG4  
[206] 
Less IgE [206] 
H.I. titre [198, 309, 322] 
High-density 
MPA 
CD11b+F4/80+ 
macrophages [25] 
CD11b+Ly6C+Ly6G+ 
Neutrophils [25] 
(none 
reported) 
IgG [20, 21, 25, 291, 294, 
295, 303, 307, 308, 320, 
324] 
IgG1 [308]  
IgG2c [308] 
H.I. titre [21, 307, 323] 
IgA [291, 307] 
 
A major difference between low-density and high-density dMPA delivery is the number of APCs 
targeted within the applied area. For example, Fernando et al. [291] calculated that a 16 mm2 dMPA 
applied targets an area with roughly 8,600 LCs in C57BL/6 mouse skin. Within this area the 3,364 
applied pointed projections could contact about 1,000 LC cell bodies and up to 5,000 LCs total 
(accounting for dendrite spread). By decreasing the density of dMPAs with similar projection sizes, 
the number of LCs directly targeted by the dMPAs therapeutic coating will decrease. Both low-
density and high-density [300, 320] dMPAs applied to skin report LC migration out of the skin. 
This starts around 16-24 h and continues to 48-72 h after application at which point the percent of 
migration out of the skin plateaus. However, low-density dMPA (placebo) plateaued around 57% 
LC migration [232], while high-density dMPA (placebo) plateaued around 80% LC migration 
[300]. LC migration from low-density dMPAs was supported by del Pilar et al. [321], who found 
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increased release of LC migration cytokines (IL-1 β and macrophage inflammatory protein (MIP)-
1α) and chemokine MCP-1. LC migration can also be greatly affected by the addition of 
therapeutics (e.g. West Nile virus vaccine [232]) The raw effects of dMPA density on LC and other 
skin APCs migration is an important variable in immunity that requires further investigation. 
 
While antibody responses are key for most vaccinations, dMPAs have also elicited a strong CD8+ T 
cell response, ideal for vaccination of tuberculosis, HIV and malaria as well as cancer 
immunotherapy [316, 323]. As such, low-density dMPA vaccination increases spleen CD8+ T cells 
that primarily produce IFN which in turn result in protection in up to 50% of mice after a fatal 
malaria challenge (similar to i.d.) [312]. Another low-density dMPA vaccination study found spleen 
cells primarily express MHC II receptors and respond with significantly higher levels of Th1 IFN-γ 
and Th2 IL-4 than intramuscular injection (i.m.) vaccination [263]. High-density dMPAs also 
increased spleen CD8+ T cell proliferation significantly more than the OVA dose-matched 
intramuscular injection [323]. Thus, MPAs can clearly assist in CD8+ T cell expansion but whether 
high-density dMPAs are better than low-density dMPAs is still to be assessed.  
 
 
2.6 Summary of the literature review 
Delivering the allergen therapy via the skin route has shown promise for both vaccination and 
desensitisation of airway-based allergies. In humans successful devices include scarification, tape 
stripping and Viaskin®. In mice successful experimental devices include Viaskin®, EPI, AFL and 
low-density MPAs. Although, some devices listed either differed in response depending on allergen 
or required the use of Th1-based adjuvants to elicit lower Th2 responses. Of the skin devices used 
thus far in the field of allergy therapy, there are three variables to consider: 1) The targeting 
capability to tolerant APCs (such as LCs in the epidermis), 2) The level of skin inflammation 
induced by the device and, 3) The speed at which the device delivers antigen (Figure 2-19). To date, 
there are no devices available that can meet all three criteria in the mouse model, critically limiting 
the translation of LC targeted immunotherapies from preclinical to clinical. Neither the high-density 
dMPA nor an eMPA for mice has been tested before in the allergy-based mouse models. If an 
eMPA could be designed to induce low inflammation during delivery of allergen and provide 
protection against airway allergy hypersensitivity it could fill the missing gap in devices for mice 
for the aforementioned variables, as suggested by Figure 2-19. 
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Figure 2-19: Skin delivery devices tested in mice for allergy therapy. Each is sorted into one of 
seven categories based on their reported application time, impact of the skin and delivery depth. 
Includes un-tested (italicised) devices and their hypothetical positioning high-density dermal MPA 
(dMPA) and epidermal MPA (eMPA). 
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Chapter 3 
 
3 Materials and methods 
This chapter outlines the methods, materials and equipment used to perform the experiments of 
Chapters 4-7. Details of procedures that used several different regimens and were optimised 
throughout the thesis are presented within the results chapters. 
 
 
3.1 Animals 
Female 6-8 week old BALB/c mice were obtained from the Australian Research Council (Perth, 
Australia) and female 10-16 week old Wistar rats were obtained from the University of Queensland 
Biological Resources. Animals were maintained in accordance with The University of Queensland 
Animal Ethics guidelines. All experimental procedures were approved under ethics AIBN/556/12, 
AIBN/042/16 and AIBN/043/16 (Appendix 10.10-12). When applying MPAs, animals were 
anaesthetised by intraperitoneal injection with a Ketamine (50 mg/kg) and Xylazil (10mg/kg) mix 
(both Troy laboratories, Smithfield, Australia) and its action reversed with atipamezole (Antisedan; 
Pfizer, Australia) diluted 1:10 in phosphate buffered solution (PBS) delivered at 1 mg/kg. For 
intranasal application or retro-orbital blood sampling, mice were anaesthetised with inhalational of 
methoxyflurane (Ceva Delvet Pty Ltd, Australia).  Twenty-four hours prior to MPA application, 
dorsal and flank hair was removed using electric hair clippers (Wahl, Stirling IL, USA), then 
chemically removed with a depilatory cream (Nair, Church & Dwight, Trenton NJ, USA). After 24 
h, histological analysis of the Nair skin compared to naïve skin found that Nair did not affect the 
skin’s thickness or induce cellular infiltration as shown in Figure 3-1 and as previously reported 
[326]. All injections were performed using a 31 gauge (G) needle. For multiple application studies, 
mice were individually identified for tracking purposes. 
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Figure 3-1: Representative haematoxylin and eosin stained skin histology of (top) naïve skin and 
(bottom) skin with hair removed with Nair. Nair removal was repeated on the same area on five 
different days (day 0, 7, 12, 21 and 28) then skin was excised on day 29. Black arrows in inset point 
out nucleated cells (none are neutrophils) with 60 cells present in naïve and 70 cells present in the 
Nair inset examples. Scale bars: 200 µm.  
 
 
3.2 Microprojection array fabrication 
3.2.1 Silicon microprojection array fabrication 
Silicon MPAs were fabricated as previously described [327] with assistance from the Australian 
National Fabrication Facility Queensland Node. Briefly, silicon MPAs were manufactured using a 
deep reactive ion etching process on a 1mm, 6” Si wafer prepared with SU-8 photoresist. Conical-
shaped MPAs were etched to make 90-210 µm (H) x 40 µm (W) projections at a variety of 
densities: 5,000 (5k), 10k, 21k and 30k projections/cm2 (p/cm2). Slit-shaped MPAs were etched to 
make 110 µm (H) x 70 µm (W) x 30 µm (D) projections at a variety of densities: 0.9k, 3.5k and 7k 
p/cm2. Silicon MPAs were imaged using secondary scanning electron microscopic (SEM) imaging 
(Hitachi, SU3500) (see Figure 3-2A-B for conical and slit-shaped projection examples). Silicon 
MPAs were diced to 4 x 4 mm using a 0.1 mm nickel blade EVG dicer and treated with oxygen 
plasma (Harrick Plasma) prior to formulation coating to increase wettability. The number of actual 
projections delivered per MPA density once diced to 4 x 4 mm is listed in Table 3-1. 
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3.2.2 Polycarbonate microprojection array hot embossing 
To fabricate polycarbonate MPAs, a method similar to that in Yeow et al. [327] was used. A 
polydimethylsiloxane (PDMS) mould was made by pouring a 1:12 Sylgard-184 mixture over a 
salinized silicon master (using trichloro(octadecyl)silane, Sigma Aldrich 104817) in a 14.5 cm petri 
dish. After removing bubbles using a vacuum (80 PSI), the mould cured for 2 days at room 
temperature (RT), was removed from the dish and then further cured for 30 min at 150 °C. The 
raised edge of the mould was removed with scissors. Compression moulding was performed in an 
EVG-520 semi-automated hot embossing tool (bottom platen, 1 mm polycarbonate foil, PDMS 
mould, top platen, 1 mm graphite pad). The embossing procedure was as such: high evacuate mode, 
heat both top and bottom sides to 150 °C at 20 °C/min, wait 1 min, heat both to above 198 °C, wait 
5 min, piston pressure to 3500 N, wait 20 min, cool both at max rate, when both below 100 °C 
purge vent, release piston, cool at max rate to below 50 °C. Thin tipped silicon masters (below 1 
µm) or using the PDMS mould over 5 repeats required 3,600-4,000 N pressure to continue to 
produce a flat slit surface (Appendix 10.13). Finally, polycarbonate MPAs were diced to 4 x 4 mm 
using a 0.1 mm nickel blade EVG dicer and treated with oxygen plasma prior to formulation 
coating to increase wettability. Polycarbonate MPAs were sputter-coated with iridium then imaged 
using backscatter scanning electron microscopic (BS-SEM) imaging (Hitachi, SU3500) (see  
Figure 3-2C-D for conical and slit-shaped projection examples). 
 
 
Figure 3-2: Representative images of microprojection array design. Secondary SEM image of 
silicon masters of (A) conical-MPA projections and (B) slit-MPA projections. BS-SEM image of hot 
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embossed polycarbonate MPAs coated in iridium of (C) conical-MPA and (D) slit-MPA. Scale bar 
for A-D:100 µm. 
 
Table 3-1: Number of projections (p) applied per microprojection array density 
p/cm2 
(100 mm2) 
0.9k 3.5k 5k 7k 10k 21k 30k 
Number p per 
16 mm2 
140 560 800 1120 1600 3360 4800 
 
Projection parameters were measured from BS-SEM images. Surface areas and volumes that were 
displaced in the epidermis were estimated from measuring at least 10 projections (imaged by SEM) 
as per Figure 3-3 using the equations below. The average thickness of mouse epidermis (26 µm) 
was calculated from histology sections of paraffin embedded skin (section 3.5.4). This was used to 
determine the height (H) variable in each equation. Note the only the cylinder section of conical 
projections was present in the epidermis after application and so difference in penetration depth (i.e. 
standard deviation) resulted in no change to surface area or volume in the epidermis per MPA 
design.  
 Lateral surface area of a cone: ܣ ൌ ߨݎ√ܪଶ ൅ ݎଶ	 × number of projections (µm2) 
 Lateral surface area of a cylinder: ܣ ൌ 2ߨݎ26 × number of projections (µm2) 
 Surface area of a slit, i.e. 2 × trapezoid + 2 × equilateral triangle surface areas = 
  ቆ2 ൬ቀଶ଻ାௐଶ ቁܪ൰ቇ ൅ ൬2 ቀ
ு∗஽
ଶ ቁ൰ × number of projections (µm2) 
 Volume of cylinder: ܸ ൌ 	ߨݎଶ26 × number of projections (µm3) 
 Volume of trapezoid: ܦܪሺଶ଻ାௐଶ ሻ × number of projections (µm3) 
 Surface area of conical tip: ܣ ൌ ߨݎଶ	ሺݓ݄݁ݎ݁	ݎ ൌ ்௜௣	ௐଶ ሻ 
 Surface area of slit tip: ܣ ൌ ܶ݅݌	ܹ ൈ 27 
 
Table 3-2: Average measured width and depth of slit-MPA projection depending on height (top 
down). 
height (µm) 10 15 20 25 30 35 40 45 50
width (µm) 30 32 35 38 41 44 47 51 56
depth (µm) 4 6 8 10 12 17 21 25 30
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Figure 3-3: Measurements made of each projection type. Includes measurements made for width 
(W), height (H), width of tip (Tip W), and, if applicable, depth (D). 
 
 
3.3 Coating of therapeutic onto microprojection arrays 
3.3.1 Ovalbumin coating 
MPAs were coated as previously described [303] with a final concentration of 1% w/v 
methylcellulose (HG 60) in 100 mM PBS. Either ovalbumin (OVA, Sigma, Grade V, 98% purity, 
filtered through 0.22 µm) diluted in PBS or PBS alone (placebo) was added to the coating solution. 
Filtered OVA was used in sterile conditions, stored at -20, freeze-thawed a maximum of three times 
or kept at 4 °C for up to 7 days. To coat, plasma cleaned MPAs were fixed in place using a vacuum 
and 7 µl (slit-MPA) or 8 µl (conical-MPA) of solution was added and dried with a jet stream of 
nitrogen gas at 23 °C at 16 L/min. MPAs were rotated clockwise until solution was in line with top 
of projections then rotated counter clockwise for 20 sec followed by a 100 sec drying period clock 
wise at 18 L/min. Coating consistency was evaluated photographically using a 2.0 MP digital 
microscope camera (Appendix 10.14) and scanned by BS-SEM. 
 
112 
 
3.3.2 Fluvax 2016 coating 
Commercial Fluvax (2016) was coated as per 3.3.1 using a PBS (60-70 mM) based 0.1% w/v 
methylcellulose (HG 60) with 0.5% w/v trehalose, 0.5% w/v sucrose, and 0.3% w/v L-histidine 
coating solution (8 µl/MPA). Coating protocol differed slightly: 18 L/min clockwise until solution 
was in line with projections then 10 seconds counter clockwise then 100 seconds drying at 
16 L/min. 
 
 
3.4 Application process of microprojection arrays to skin 
Due to high-density and short length projection design, these MPAs required assistance during 
application for consistent puncture into the skin. Hair is removed as per 3.1 before any application. 
All applications were performed with spring-loaded dynamic applicators and application energies 
(expressed in mJ) assume no losses in the system, i.e. energy (E) per application was calculated 
using E = ½ × mass × velocity2, assuming no friction. Two applicators were tested; the “push-
through” applicator that requires an additional stand to hold it in place during release, and the 
“projectile” applicator that is hand held.  
 
3.4.1 Push-though application 
To prepare the skin for application, a fold of flank skin was extended and fixed as described in 
Coffey et al. [290]. The push-through applicator was held in place by a stand (Figure 3-4A) and, 
once the spring load was released, the MPA was accelerated over 1-2 mm of space before 
contacting the top of the skin fold. The plunger could follow though up to 3 mm into the skin fold, 
causing indentation marks where the MPA was applied and to the skin under the fold. The 
applicator consists of multiple fixed points of spring compression (Figure 3-4B), each of which 
have been calibrated to a known velocity using a high-speed camera (using Photron FASTCAM 
software). The skin was applied to at its natural tension (Figure 3-4C). The MPA was removed after 
2 min, after which the desired dose of formulation was deposited in the mouse skin, as confirmed 
previously [303]. A maximum of eight (8) applications were applied per mouse without applications 
overlapping (Figure 3-4D). The 36 g plunger of the push-through applicator was loaded to deliver 
MPAs with application velocities (and energies) of 0.9 m/s (15 mJ), 1.3 m/s (30 mJ), 1.8 m/s (60 
mJ), 2.3 m/s (100 mJ) or 3.1 m/s (170 mJ) which have been previously shown to assist high-density 
MPAs to penetrate mouse skin [295]. 
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Figure 3-4: Push-through application device. (A) Applicator and stand set up. (B) Example of 
adjustable spring-loaded push-through applicator on flank skin fold. (C) Side view of skin fold with 
MPA applied. (D) Example of multi-application with push-through applicator. 
 
3.4.2 Projectile application 
The MPA was loaded into a holding cassette as per [289]. This applicator was originally designed 
to deliver 10 x 10 mm sized MPA to taut skin on a human forearm. Changes were made to the set 
up in the cassette to accommodate the 4 x 4 mm MPA. These included a fresh 12 mm carbon tab 
fixed to the top of a 10 x 10 mm magnetic patch construct with a 1.2 mm thick 4 x 4 mm spacer in 
the centre and a 4 x 4 mm carbon tab atop the spacer to fix the applied MPA (see Figure 3-5A). 
With the mouse resting flat on its stomach, the loaded projectile applicator was placed onto an area 
of skin away from the ribs and spine. The applicator was orientated in downward direction without 
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losing contact with the skin (see Figure 3-5B). The projectile applicator mobilises the 4 x 4 mm 
MPA affixed to the 10 x 10 mm MPA (weighing 0.54 g), without the cassette, over a 4-5 mm space. 
The applicator velocity is fixed by the internal spring and spacer configuration. It was originally 
tested at 12 m/s without the 1.2 mm spacer but resulted in poo contact of the carbon tab similar to 
represented in Figure 3-5C. For better consistency, it was finalised for epidermal targeting at 18 m/s 
with the 1.2 mm spacer (see average contact of carbon tab, Figure 3-5D). The MPA was removed 
after 2 min and the underlying carbon tab was checked to confirm contact on skin. Note that due to 
the large adhesion area (12 mm diameter) a maximum of only four (4) applications per mouse could 
be completed without overlap. 
 
Figure 3-5: Modified projectile application device. (A) In-lab conversion of 10 x 10 mm MPA patch 
construct to a 4 x 4 mm MPA patch construct. (B) Projectile applicator positioning on mouse flank. 
(C) Example of improper application due to either low velocity or partial loss of contact of 
applicator before application. (D) Representative of correctly applied projectile application. 
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3.5 Characterisation of microprojection array delivery 
3.5.1 Delivery efficiency 
To determine delivery efficiency of coating, 14C-OVA (Bioscientific, cat: ARC0431-5uCi) was 
added to the coating solution (200 Becquerel or 12 000 disintegrations/min, DPM, per MPA). After 
MPA application the skin application area was immediately swabbed with a Q-tip moistened with 
PBS then the skin was excised post mortem. The radioactivity content of swabs and skin was 
ascertained as previously described [21]. Briefly, swabs were washed in 2 ml PBS and skin was 
dissolved in 2 ml of Soluene-350 (cat: 6003038, Perkin Elmer) overnight. Then 10 ml of a liquid 
scintillation cocktail called Ultima Gold (cat: 6013119, Perkin Elmer) was mixed in with a vortex 
mixer. The DPMs were counted immediately using a liquid scintillation counter to either 0.5 % 
accuracy or for 10 min. Percentage of DPMs was calculated from an average of 3-4 positive 
controls (7 µl coating solution in 2 ml PBS). Average percentage from skin + swabs was considered 
the total delivery while average percent of skin alone was used to calculate the delivery efficiency 
and delivered dose. 
 
3.5.2 Penetration depth 
Fluorescent penetration tracks in skin were measured using histology to quantify penetration depth 
of projections in skin. Polycarbonate MPAs were coated with an OVA-based formulation including 
0.05% w/v yellow-green 200 nm FluoSpheres (F8811, Thermo Fisher Scientific, USA), applied to 
mouse skin for 2 min and penetration depth analysed as previously published [290]. Briefly, excised 
skin was fixed in 10% v/v neutral buffered formalin (NBF, Thermo Fisher Scientific, Scoresby, 
VIC, Australia) for 2 h at RT, before being frozen in optimal cutting temperature cutting compound. 
Using the histology rotary microtome at the Queensland Brain Institute histology facility, a 
minimum of three 20 µm thick cyro-sections from 3 mice were imaged at 20x and analysed using 
the Zeiss confocal microscope light scanning microscope LSM510 (set up as in Figure 3-6) with 
Zen software (2010). Only MPA conditions that resulted in visual fluorescent penetration were 
imaged. MPAs that penetrated primarily into the epidermis were termed eMPAs and those that 
penetrated primarily into the dermis were termed dMPAs. 
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Figure 3-6: Confocal LSM set up for microprojection array penetration. (A) with chameleon laser 
and (B) without chameleon laser. 
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3.5.3 Skin erythema 
In the majority of cases, skin was photographed immediately after application, some application 
sites were also photographed at 24, 48, 72 h and 7 days after application (area marked with non-
toxic sharpie). Where required, photos were analysed using the Draize Index scoring for erythema 
of the skin (Figure 3-7) [261, 262, 328]. 
 
Score Description 
0 No erythema 
1 Very slight erythema (barely perceptible) 
2 Well-defined erythema 
3 Moderate to severe erythema 
4 Severe erythema (beet redness) 
 
Figure 3-7: Table of Draize Index scoring from Draize, J. H. [261] for erythema of applied skin 
sites on BALB/c mouse flank skin. Underneath, representative images of MPA-applied skin for 
each Draize score, scale bar: 1 mm. 
 
3.5.4 Skin thickness histology 
Viable epidermal swelling was quantified after MPA or a 20 µl i.d (31 G needle) injection. Applied 
skin was excised (~2 mm deep) at t = 24 or t = 72 h, fixed (10% v/v NBF for 2 h), embedded in 
paraffin and sectioned to 10 µm thick (n = 3 mice with n = 4 sections each). Sections were stained 
with Haematoxylin (HHS32, Sigma-Aldrich) and Eosin (E4009, Sigma-Aldrich) (H&E) and 
mounted under dibutylphthalate polystyrene xylene (DPX 3197, Ajax Finechem Pty Ltd). The 
staining procedure consisted of the following:  
1) Dry slides at 35 °C for 15 min 
2) Remove wax by immersing in xylene bath #1 for 10-15 min 
3) Immerse in xylene #2 for 10-15 min  
4) Immerse in absolute ethanol (100% v/v) #1 for 6 min 
5) Immerse in absolute ethanol #2 for 5 min 
6) Immerse in 70% v/v ethanol for 3 min  
7) Rinse in tap water for 1min  
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8) Stain in Hematoxylin for 8 min 
9) Rinse with tap water briefly 
10) Activate bluing by immersing in bicarbonate solution until blue  
11) Stain in Eosin by dipping 10 times  
12) Rinse in water briefly 
13) Dehydrate by dipping in 70% ethanol 10 times 
14) Immerse in absolute ethanol #2 for 5 min 
15) Immerse in absolute ethanol #1 for 5min 
16) Xylene #1 for 5 min 
Stained sections were imaged with an Aperio ScanScope XT slide scanner and epidermal and 
dermal thicknesses were measured at 20x using ImageScope software. The thickness of skin 
subjected to each application condition was compared to naïve skin of three mice. Note here that 
skin thickness in paraffin-embedded sections were consistently thinner than cryo-sections and so 
comparisons were made to naïve skin within respective embedding mediums. 
 
 
3.6 Discrimination of viable / non-viable cells via microscopy 
To discriminate between live and dead cells, the viability dyes Acridine Orange and Ethidium 
Bromide were used as described in Depelsenaire et al. [271], with the following adaptions for 
thicker flank skin compared to ear skin as previously used. Briefly, flank skin after application of 
OVA-coated eMPAs and dMPAs or after intradermal injection (i.d.) was excised immediately after 
euthanasia with at least 3 mm excess border around the site. Skin was submerged under a mixture of 
Acridine Orange (15 µg/ml) and Ethidium Bromide (50 µg/ml) in PBS and incubated at 37 °C for 
1.5 h. MPA-applied skin was imaged using the Zeiss LSM510 confocal microscope (20x, 40-70 µm 
deep at 1 µm z-stack intervals). Ethidium Bromide-stained dead cells were quantified using Imaris 
software (assuming a 5.18 µm cell diameter). The number of dead cells within an MPA contact area 
of 16 mm2 were extrapolated from 3-4 3D-images (1.095-1.460 mm2) of each application repeat 
site. 
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Figure 3-8: Confocal LSM set up for cell viability imaging  
 
The number of dead cells in 16 mm2 of skin were extrapolated from 3-4 3D-images (1.095-1.460 
mm2) of each application repeat (Figure 3-9A and B). MPA applied skin was imaged once in the 
centre (‘Y’), twice in the internal area (‘X’ and ‘Z’) and once over the edge (‘W’) (Figure 3-9A). 
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Skin injected via i.d was imaged once at the insertion site (‘Y’) and twice within the surrounding 
“naïve” skin (‘X’ and ‘Z’) (Figure 3-9B). Skin cells stained with ethidium bromide were quantified 
using Imaris software (assuming a 5.182 µm cell diameter) as per Figure 3-9C for “X”, “Y” and “Z” 
sites and Figure 3-9D for “W” sites. The total number of 20x images required to cover 16 mm2 is 
44.8. As such the following two equations were determined based on area of differential coverage. 
Three (3) mice were imaged for each skin delivery device. 
 MPA non-viable cell quantification: ൬ቀ௑ା௒ା௓ଷ ቁ ൈ 29.23൰ ൅ ሺܹ ൈ 15.57ሻ 
 i.d. non-viable cell quantification:	ܻ ൅ ൬ቀ௑ା௓ଶ ቁ ൈ 43.8൰ 
 
Figure 3-9: Method of quantification and representative images for assessing number of non-
viable cells. (A) Schematic of MPA cell viability in the applied area of the skin with slightly larger 
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penetration dots towards the edge to represent the increase of cell death at the edge area of the 
MPA application. Four z-stack images were captured at 20x magnification, three images, as 
represented by ‘X’, ‘Y’ and ‘Z’ were captured within the consistent internal area and one edge 
image ‘W’ was captured. (B) Schematic of cell viability after i.d, three images were captured, one 
at the insertion site, ‘Y’, and two in the surrounding bleb area, ‘X’ and ‘Z’, scale bar for A-B: 1 
mm. Example of image processing for non-viable cell quantification of (C) whole image or (D) 
partial image. (i) Compressed z-stack image imported into Imaris software. (ii) Channel selection 
of non-viable cells and (iii) Imaris conversion of cells (assuming 5.18 µm cell diameter) into 
quantifiable dots. (Dii) Selection of MPA applied area for conversion. Scale bar for C-D: 200 µm 
 
 
3.7 Sensitisation to ovalbumin 
For the purposes of this thesis, to “sensitise” is to prime the immune system to produce an OVA-
specific Th2 response. Sensitisation regimens of mice are outlined within each study of Chapters 4 
and 7. 
 
3.7.1 Intraperitoneal injection with aluminium hydroxide 
Mice were injected i.p. with 10 µg OVA and 1 mg of aluminium hydroxide-suspension-gel (AH) 
(Serva) in 100 µl with the first administration into the right side (alternating sides for multiple i.p.). 
The stock of AH was concentrated x2 by spinning for 5 min at 4,000 g, removing half the total 
volume from the supernatant and remixing in remaining supernatant to give a concentration of ~13 
mg/ml in suspension. A mixture of 100-200 µg/ml OVA and concentrated AH were shaken 
thoroughly for 30 min before injecting. Mice became lethargic for 30-60 min after the injection, 
after which their behaviour returned to normal.  
 
3.7.2 Intranasal inhalation 
I.n. was also tested for mouse sensitisation via intranasal (i.n.) administration as previously 
reviewed in [136]. A 0 µg or 50 µg dose of OVA in 20 µl of PBS was administered under 
methoxyflurane anaesthesia. Mice were restrained loosely at a 30 ° angle and 10 µl was quickly 
applied to each nostril. Mice were then held supine and the solution was pushed up the nasal cavity 
by carefully patting the nose from the nostrils to between the eyes for 10 seconds. They were then 
returned to the cage at which point most were immediately awake and fully functional. Daily 
repeated i.n. administrations alternated starting nostril each day. 
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3.7.3 10k-170mJ dermal microprojection array 
To test the mouse sensitisation capabilities of high impact dMPA, dMPAs were coated with OVA 
and applied as per 3.4.1 at 170 mJ. 
 
 
3.8 Desensitisation to ovalbumin 
Desensitisation regimens of mice are outlined within each study of Chapter 4, see Figure 3-10 for 
general schedule. Desensitisation procedures followed a twice-weekly or weekly schedule. 
Desensitisation began 1-2 weeks after sensitisation (see 0). Placebo or OVA desensitisation 
treatments via subcutaneous injections (s.c.) were performed under methoxyflurane anaesthesia 
while desensitisations via dMPAs were performed as per 3.4.1 at application energies of either 100 
mJ or 170 mJ. Each desensitisation s.c. or dMPA coating solution was made fresh on the day of use 
and dMPAs were coated as per section 3.3. Hair was removed every 2 weeks as per section 3.1 
from either half of the mouse back (twice-weekly treated) or a quarter of the mouse back (weekly 
treated). All mice were observed for 10 min of wake time after each application to ensure there 
were no immediate adverse effects. 
Figure 3-10: Schematic of general schedule of a desensitisation regimen. Mice were first 
sensitised via i.p. then rested 7-14 days before hair was removed with Nair 24 h prior to 
desensitisation and removed every 14 days. Mice were then rested for 1-7 days after the last 
desensitisation before challenged with three i.n. then culled 1 day after last challenge. 
 
 
3.9 Vaccination with ovalbumin to prevent airway hypersensitivity 
Vaccination regimens of mice are outlined within each study of Chapter 7, see Figure 3-11 for 
general schedule. Vaccination procedures were based on previously published work by Holt et al.  
[165] where mice were exposed to OVA via aerosol inhalation once every day for 10 days. Starting 
at least 24 h after hair removal (section 3.1), vaccinations were given within the first 10 days, then 
rested for 7 days before either a 1x or 2x i.p. sensitisation event (see Figure 3-11). This was 
followed by an airway challenge (section 3.10). Positive control vaccination groups (i.n. route) 
delivered 10-100 µg OVA delivered 2-8 times alongside test routes of 0-1µg OVA delivered 4-8 
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times. Test vaccination routes delivered OVA by either i.n., i.d. injection, epidermal-MPA (eMPA) 
or the eMPA applied with the projectile applicator (P/eMPA). All mice were observed for 10 min of 
wake time after each application to ensure there were no immediate adverse effects. 
 
Figure 3-11: Schematic of general schedule of a vaccination regimen. Hair of mice was removed 
with Nair at least 24 h prior to first vaccination. Mice were vaccination with the 10 days following 
then rested for 7 days before sensitisation via i.p. Mice were then rested for 9 days after the last 
sensitisation before challenged with 3-6 i.n. then culled 1 day after last challenge. 
 
 
3.10 Ovalbumin airway challenge 
Desensitised mice were rested for 1-7 days after the last desensitisation treatment before challenge. 
Vaccinated mice were rested for 9 days after the last sensitisation i.p. before challenge to 
compliment the beginning of anti-OVA IgE production [116, 117, 165] and lung inflammation 
[109]. Mouse were challenged with 50 µg of OVA in 20 µl of PBS administered i.n. Challenge 
occurred daily for 3 days and sample collection started 22-24 h after the last challenge (see section 
3.7.2 for i.n.). Vaccination 8 tested a chronic challenge of 6 days of daily i.n. administrations.  
 
 
3.11 Cell differentiation of bronchial alveolar lavage fluid 
Bronchial alveolar lavage fluid (BALf) was collected according to Foo et al. [292]. Briefly, 0.8 ml 
of cold 0.1% bovine serum albumin (BSA, Sigma-Aldrich cat: A5503) in PBS was injected into the 
lungs via a trachea tube and washed in and out thrice. Approximately 0.6 ml BALf solution is 
collected (with 0.2 ml lost in the process) and stored on ice for a maximum of 3 h. Cells were 
centrifuged at 900 g for 5 min, supernatant was removed and flash frozen in liquid N2 and stored at 
-80. Red blood cells were lysed with 0.3 ml red blood cell lysis buffer (90ml NH4Cl (0.83 g NH4Cl 
in 100 ml, pH 7.2) + 10 ml Tris base (0.206 g tris base in 10 ml, pH 7.65), autoclaved) for exactly 3 
min at RT. Lysis was stopped with 1 ml cold BSA solution. Cells were centrifuged again and 
resuspended in 100 µl or either BSA solution or FACs buffer (1% foetal calf serum, FCS, in PBS). 
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The cell concentration was counted using a hemacytometer (Sigma-Aldrich cat: Z359629) using 
0.4% Trypan blue solution (Thermo Fisher cat: 15250061). 
 
3.11.1 Light microscopy 
A total of 1-10 x104 BALf cells resuspended in BSA solution were centrifuged onto Superfrost Plus 
slides (Thermo Fisher cat: SF41296SP) at 500 rpm for 5 min using a Cytospin (Thermo Shandon 
Cytospin4). Slides were stained using Rapid Stain kit (Amber Scientific cat: RS-500) as per kit 
instructions. Briefly, slides were fixed with 10 dips in methanol-surfactant solution, then stained 
with 4-6 dips in Eosin and 2-3 dips in Azure B. Slides were patted dry on filter paper and 
differentially counted for macrophages, eosinophils, neutrophils, lymphocytes and other cells under 
the light microscope at 40x magnification. Counting was performed blinded. Results were plotted as 
a percentage of the total of 300 cells counted for each sample. 
 
3.11.2 Flow cytometry 
A minimum of 1 x105 BALf cells resuspended in FACs buffer. Cells were spun at 1600 rcf and 
supernatant discarded. Fc receptors were blocked with 1:50 purified rat anti-mouse CD16/CD32 
(clone 2.4G2) for a least 15 min at RT. Surface staining was performed by incubating cells with mix 
of the following, each diluted to a final 1:200 in FACs buffer: anti-Ly6G-FITC (cat: 551460 clone 
IA8), anti-Siglec F-AF647 (cat: 562680, clone: E50-2440), anti-MHCII-BV510 (cat: 107635   
clone: M5/114.15.2), anti-B220-PE (cat: 12-0452-85 clone RE3-6B2), anti-CD3-PE (cat: 12-0031-
85 clone 145-2C11), anti-CD11b-PerCP-Cy5.5 (cat: 550993, clone: M1/70). Cells were washed in 
150 µl of FACS buffer spun at 1600 rcf and supernatant discarded. Resuspended cells were spiked 
with 1:1000 4′,6-diamidino-2-phenylindole (DAPI) live/dead differentiator then were run 
immediately on the BD LSR Fortessa flow cytometer and analysed with FACSDiva software. See 
Figure 3-12 for set up and gating. Gated populations were plotted as a percentage of the total live, 
single cells per sample. 
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Figure 3-12: Gating for BALf cell differentiation. Singlets were gated into live cells from DAPI- 
(BUV496-) cells. Live cells were further gated into small (FSC-Alow) lymphocytes (B220+CD3+), 
neutrophils (B220-CD3-CDllb+Ly6G+) and eosinophils (B220-CD3-Sig F+) and large (FSC-Ahigh) 
macrophages (MHC II+). 
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3.12 Anti-OVA IgE via passive cutaneous anaphylaxis assay 
This method was adapted from Kendall et al. [139]. Briefly, cardiac bleeds from mice were 
centrifuged at 10,000 g for 5 min twice to collect serum which was stored at -20 °C. Anti-ova IgE 
was analysed via rat passive cutaneous anaphylaxis assay (PCA). Approximately 40 µl of serum 
diluted 2-fold from neat to 1:128 in PBS was injected i.d. in a marked grid on the clipped back of 
female Wistar rats under ketamine/xylazine anaesthetic. The rat was injected intravenously via the 
tail vein under anaesthetic 24 h later with a 2 ml solution of 0.5 % Evans blue and 2 mg/ml OVA. 
Endpoint readings of the last dilution where extravasation of dye was visible were plotted after 15-
30 min then the rat was euthanised.  
 
 
3.13 Anti-OVA IgG subtypes via ELISA 
Enzyme-linked immunosorbent assays (ELISAs) were performed as previously described [303]. 
Briefly, the Nunc Maxisorp flat bottomed 96-well ELISA plates (cat: 44-2404-21, Thermo Fisher 
Scientific) were coated with 50 µl of 20 µg/ml OVA in 0.1 M sodium bicarbonate buffer. Plates 
were incubated overnight at 4 °C then blocked with 4 mg/ml BSA in PBS. The serum was serially  
from 1:100 down to 1:204,800 before transferring 50 µl onto ELISA plates. Bound antibody was 
detected by the addition of horseradish peroxidise conjugated to either goat anti-mouse IgG (Life 
Technologies cat: G21040), goat-anti-mouse IgG1 (Invitrogen cat: A10551) or goat anti-mouse 
IgG2a (Invitrogen cat: A10685). The colour was developed using either ABTS substrate (2,29-
azino-bis3-ethylbenzthiazoline-6-sulfonic acid) (Sigma-Aldrich cat: A-1888), which was stopped 
with 1% SDS (sodium dodecyl sulfate) before reading absorbance at 405 nm; or with TMB 
substrate (3,3’,5,5’-tetramethylbenzidine) (Surmodies BioFX cat: TMBW-1000-19), which was 
stopped with 1M phosphoric acid and read at 450 nm. Readings were taken using a BMG 
LABTECH GmbH Omega plate reader. Endpoints were calculated by removing the background 
from each value (i.e. average PBS reading used as background) and graphing the highest serum 
dilution that yielded an optical density of more than 2 standard deviations above the average 1:100 
naïve serum reading. 
 
 
3.14 Quantification of MUC5AC and obstruction in lung histology 
The middle lobe of the lung harvested from mice from most vaccination experiments was fixed in 
10% NBF overnight at 4 °C, embedded in paraffin and sectioned 5 µm (n = 1-2 sections). Sections 
were de-paraffinised as per section 3.5.4 then processed for antigen retrieval by boiling in a 
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pressure cooker for 10 min in citrate buffer. After washing in cool water then in 0.5% Triton X in 
PBS, sections were Fc blocked with 10% goat serum in PBS for 20-30 min.  
To stain: 
1) Anti-MUC5AC (cat: MA1-35706) was diluted at 1:500 in 10% FCS (in PBS) and incubated 
overnight at RT 
2) Slides were washed with 0.6% tween-20 in PBS then 0.05% tween-20 in PBS then TBS 
(tris-buffered solution)  
3) Incubated with secondary anti-mouse Fc conjugated to alkaline phosphatase (cat: A3562) at 
1:200 in 10% FCS PBS for 45-90 min at RT 
4) Slides were washed with 0.6% tween-20 (in PBS) then 0.05% tween-20 (in PBS) then TBS 
5) Sections were stained with fresh, filtered Fast Red (cat: F4648) for 10-45 min 
6) Sections were counter-stained with Heamatoxylin  
Slides were imaged under the Aperio slide scanner (20x) within 24 h. Each airway was evaluated 
cell by cell for MUC5AC stain presence or absence and results were averaged over the total number 
of airways (e.g. airway 1 = 80%, airway 2 = 50%, airway 3-5 = 0%, graph = 26%). Whole sections 
were analysed for number of obstructions of non-epithelium cell clusters or mucus plugs. Some 
whole sections were analysed for peribronchial inflammatory cell clusters that surrounded more 
than 50% of the airway circumference. Number of airways with obstructions/plugs or peribronchial 
cell inflammation were expressed as a percentage of the total number of airways in the given lung 
section. 
 
 
3.15 Anti-Fluvax IgG subtypes via ELISA 
ELISAs were performed as described in section 3.13 with plates coated with 3 µg / ml Fluvax 2016 
in 0.1M sodium bicarbonate buffer. The colour development was performed using TMB substrate 
read at 450 nm. Endpoints were calculated as per section 3.13. 
 
 
3.16 Enumeration of Langerhans cells in inguinal draining lymph nodes 
Flow cytometry was used to identify skin APCs migrating to the inguinal draining lymph nodes 
(dLNs) after eMPA or dMPA application. Total number of skin DCs and the number of LC and 
dermal-DC (dDC) subsets were quantified per dLN at either t = 24, 48 or 72 h after a PBS-coated 
MPA (left dLN) and a 0.1 µg OVA MPA application (right dLN). dLNs were processed 
individually, however, based on Kool et al. [329], an ipsilateral cross over of cell migration from 
skin application can make up to 20% of the opposite dLNs cell content. dLN were digested with 
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collagenase D (1 mg/ml) and DNase I (0.2 mg/ml) for 30 min at 37oC. dLNs were individually 
homogenised, washed through a 0.22 µm strainer and resuspended in sterile 0.1% FCS in PBS 
dilution buffer. Live/dead Aqua (cat: L34966, Thermo Fisher) was used for live/dead differentiation 
and anti-mouse monoclonal antibody against CD16/32 (2.4G2, cat:553142, BD Pharmingen) was 
used to block exposed Fc sites. Then anti-mouse monoclonal antibodies against CD11c-PE/Cy7 
(N418, cat:25-0114-82, eBioscience), CD11b-APC/Cy7 (M1/70, cat:101226, BioLegend), CD326 
(EpCAM)-APC (G8.8, cat:118214, BioLegend), MHC II-FITC (M5/114.15.2, cat11-5321.85, 
eBioscience) were added, and associated isotypes were used for spleen cell controls. Cells were 
incubated, washed and analysed as previously published [330]. Cells were acquired using the 
Gallios cytometer and analysed with Kaluza software. 
 
 
3.17 Quantification of IL-5 levels in BALf 
IL-5 was quantified in some vaccinated positive and negative control samples.  
ELISA plates were: 
1) Coated with 0.5 µg/ml rat anti-mouse IL-5 (cat: BD-554434) in 0.1 M sodium carbonate 
buffer (pH 9.2) overnight at 4°C 
2) Washed three times with PBS-T (PBS with 0.2% tween-20) 
3) Blocked with 3% BSA in PBS-T at RT for 90 min  
4) Washed three times with PBS-T  
5) Loaded with standards and samples. Standards were mouse IL-5 (cat: BD-554581) serially 
diluted from 10 to 0.078 ng/ml. BALf samples were serially diluted from 1:1 to 1:128 in 3% 
BSA (in PBS-T)  
6) Incubated at RT for 90 min 
7) Washed five times with PBS-T 
8) Loaded with rat anti-mouse IL-5 conjugated to biotin (cat: BD-554390) at 0.5 µg/ml  
9) Incubated at RT for 60 min 
10) Loaded with streptavidin conjugated to horse radish peroxidase (R&D Systems cat: 890803) 
diluted to 1:5000 in PBS-T 
11) Incubated at RT for 60 min.  
12) Washed five times with PBS-T 
13) Developed with ABST substrate which was stopped with 1% SDS and read at 405 nm.  
Concentrations were calculated from the standard curve using hyperbola interpolation (GraphPad 
7). (see Appendix 10.15 for fitting). 
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3.18 Eotaxin-2 levels in BALf 
Eotaxin-2 was measured as per mouse CCL24/Eotaxin-2 (MPIF-2) kit instructions (DuoSet ® 
ELISA, cat: DY528). BALf samples were analysed without prior dilution. To confirm the validity 
of the BALf readings, some snap-frozen left lung lobes were homogenised with a tissue-tearor 
while insuring the sample remained cold. Homogenates of lung were analysed at a 1:80 dilution. 
The colour development was performed using TMB substrate by incubating at RT for 4.5 min, 
stopped with 1M phosphoric acid and read at 450 nm. Concentrations were calculated from a 
standard curve (1000 – 7.8 pg ml, log2) using GraphPad 7 hyperbola interpolation (see Appendix 
10.16 for fitting). 
 
Figure 3-13: Mouse lung lobe nomenclature. In most experiments the right mid lobe was collected 
for histology. Sometimes the left lung lobe was also collected for cytokine analysis. Imaged sourced 
from Cook [331]. 
 
 
3.19 Instrumentation 
3.19.1 Hitachi 3500 scanning electron microscope 
The MPA was prepared for SEM by attaching onto a 12 mm aluminium stub with a carbon tab. 
Each imaging session set-up was manually adjusted for optimal wobbler, beam alignment, 
brightness and contrast. All images were acquired with aperture 4 (smallest aperture) for maximum 
depth focus and tilted to a 45 ° angle with tilt-mag adjustment function on. Polycarbonate MPAs 
were imaged under low vacuum (30 Pascal), 5 K beam with the secondary detector. Alternatively, 
they were sputter coated before methycellulose-based coating with 15 nm of iridium ebeam (Jeol-
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3000FC Auto fine coater) and imaged under high vacuum (600 Pascal), 15 K beam with the 
backscatter detector. Silicon MPAs were also imaged with a 15 K beam with the backscatter 
detector. Secondary images record topography of the surface while BS-SEM images distinguish 
between electron-dense materials (i.e. iridium and silicon) and less electron-dense materials (i.e. 
allergen coating), where the higher the density, the brighter the image. 
 
3.19.2 Zeiss confocal / multi-photon laser scanning microscope 
Using a 20x air objective, the confocal was set up as per Figure 3-6 and Figure 3-8. Note here that 
mid-way through the studies, the Chameleon laser was disconnected and so autofluroesence from 
the dermal collagen was no longer collected. 
 
3.19.3 Flow cytometry instruments 
3.19.3.1 BD LSR Fortessa 
The first BD LSR Fortessa unit is part of the School of Biomedical Sciences analytical facility. 
Note here that the unit was moved and thoroughly cleaned out between Vaccination 4 and 
Vaccination 5 results. The unit is used once every 3-14 days by various groups. It is cleaned after 
each use with about 1 ml of FACs clean and FACs rinse and kept under milli Q water (OM 18.2). 
The second BD LSR Fortessa unit is part of the Translational Research Institute flow core facility. 
This was used for Vaccination 6, 7 and 8. The unit is cleaned daily with about 1 ml bleach, 1 ml 
FACs clean and 1 ml FACs rinse then kept under milli Q water. BALf samples were analysed at 
about 1,000 events/sec, recording 100,000 events per sample. Samples were gated using FACs 
DIVA software as shown in Figure 3-12.  
3.19.3.2 BC GALLIOS 
The BC GALLIOS unit is part of the Translational Research Institute flow facility. The unit is 
cleaned daily with about 1 ml bleach, 1 ml FACs clean and 1 ml FACs rinse then kept under milli Q 
water. Samples were gated using Kaluza Analysis software. Skin dLN samples were analysed at 
about 2,000-4000 events / sec, recording 90% of the volume on the sample (~4.5 min). See Chapter 
6 for gating. 
 
 
3.20 Statistics 
Statistics were performed in Graphpad Prism (version 6 or 7 for Windows; GraphPad 140 Software, 
La Jolla, CA) using unpaired t-tests with Welch’s correction between two groups. Statistical 
differences between multiple comparable groups was assessed using an unpaired one-way analysis 
of variance (ANOVA), annotations in the figure legend were included when Gaussian distribution 
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was assumed. P-values of ≤ 0.05 were considered significant. All values are expressed as mean ± 
standard deviation (SD) unless otherwise stated. All groups that were significantly different to 
another group within the graph was denoted with asterisks: *p ≤ 0.05, **p ≤ 0.01, *** p ≤ 0.001, 
**** p ≤ 0.0001. All non-significant results (p > 0.05) have no symbol in graphs or ‘ns’ in tables.  
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Chapter 4 
 
4 A study of microprojection array design and application to skin for reducing airway 
eosinophilia in a mouse model 
 
This chapter was written in a standalone paper format (excluding methods) whereby studies were 
presented in chronological order. 
 
Summery 
The top strata of the skin is a more practical and viable route for delivery of AIT than s.c. injection. 
A cost effective and quick delivery device known to upregulate anti-allergen IgG without additional 
adjuvants is the high-density, dermal-targeted microprojection array (dMPA). Despite the promising 
characteristics of the high-density dMPA, this device had not yet been tested in AIT. As the design 
range of a high-density dMPA can vary greatly, Chapter 4 focussed on two densities and two 
application energies of dMPAs. These included the 21k p/cm2 and a 10k p/cm2 applied with either 
170 mJ or 100 mJ of energy. Results indicated that the level of anti-OVA IgG antibodies did not 
protect against the production of IgE. However, an increased level of protection against airway 
inflammation negatively correlated with the level of impact the dMPA had on the skin (i.e. a 
combination of the density and application energy). From this, the 10k dMPA applied at 100 mJ led 
to the most promising results in a mouse airway hypersensitivity model. 
 
4.1 Introduction 
An IgE-mediated sensitisation (type-I) is the most common type of allergic disease, affecting 20% 
of the world population [1]. Desensitisation by AIT was first reported by Noon and Freeman in 
1911 [170] and is the only immunomodulating therapy approved to treat IgE allergies since it [332]. 
AIT is available via two routes, sublingual absorption (SLIT) and SCIT. In practice, both routes 
repeatedly administer the allergen over 3 – 5 years to induce systemic, specific immune tolerance. 
Biomarkers used to determine the success of desensitisation in patients include: decreased 
degranulation (e.g. mast and basophil cells); increased Treg and Th1 cells [177]; increased specific-
IgG4 leading to an eventual decrease in specific-IgE and decreased infiltrating granulocytes (such 
as eosinophils) [173]. These markers are similar in mice, though IgG4 is replaced with an increase 
in IgG2a:IgG1 in BALB/c mice. Both SCIT and SLIT reduce symptoms and the need for rescue 
medication – especially in allergies that affect the upper airways (e.g. grasses, pollens and dust 
mites) [13, 18], however, both have their downsides. Whilst being more cost effective, SCIT is 
inappropriate for those with a fear of needles, requires frequent visits to a clinician, and on the rare 
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occasion can result in an anaphylactic shock [11]. SLIT often causes an itchy mouth, requires 
expensive high doses (e.g. Actair continuation TRT 100IR ~AUD$100 / month) and is currently not 
approved for allergies such as mould, animal dander and insect venoms [192]. AIT completion rates 
are low, averaging 23% for SCIT and only 7% for SLIT [192]. The risk of anaphylaxis in SCIT and 
the high cost of SLIT are important factors to address in order to increase the accessibility of AIT. 
The risk of anaphylaxis stems from, in part, high vascularisation of the subcutis, while, high costs 
of SLIT is due to the need for many repeats – possibly from low absorption through the oral 
mucosa. Ideally, delivery of the therapy should be targeted to a low-vascularised tissue suitable for 
tolerance activation such as the upper layers of the skin. 
 
The non-viable stratum corneum, viable epidermis and dermis make up the upper layers of the skin. 
The epidermis is not vascularised while the dermis is minimally vascularised (relative to the 
subcutaneous below [216]), reducing the risk of a systemic reaction. APCs assist in allergen-
specific signalling and so are key targets for immunotherapy. The sole resident APC of the 
epidermis is Langerhans cells (LC), while the dermis circulates several resident APCs such as dDC 
[219]. In healthy skin, LCs continuously survey the epidermis for foreign antigens and can prime T 
cell responses to promote immune tolerance, and are thus an ideal target for eliciting 
desensitisation. Another promising target for AIT are langerin+ dDCs of the dermal strata that 
maintain important roles in the induction of IgG2a/b/c antibody subtypes in mice [333]. 
Experimental skin-based human AIT also suggests dDCs may assist in Th1-mediated responses 
[209]. To deliver to epidermal LCs and dDCs, therapy must pass the resistant stratum corneum.  As 
the stratum corneum is a physical barrier to invading pathogens, it has low absorption properties, 
especially of substances above approximately 500 Da [79]. Thus, delivering therapeutics past the 
stratum corneum requires alternative delivery devices to hydrate, remove or penetrate it. One type 
of device under thorough investigation in skin delivery is the (trans-) dMPA patch. 
 
dMPAs can be designed to deliver from 28 µm deep in mouse skin [290] up to potentially 3,000 µm 
deep in human skin [22] with as little as five projections  [232] to as many as 30,000 (i.e. 30k) 
p/cm2 [297]. Here I define low-density as ≤ 1k p/cm2 and high-density as > 1k p/cm2. The 
application of dMPAs can be either static or dynamic, resulting in a range of erythema on the skin. 
Static applications are altered by the applied mass while dynamic applications are altered by both 
applied mass and velocity. Variations in the dMPA application technique can result in a range of 
skin inflammations such as erythema.  
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Most dMPAs have been tested in mouse vaccination studies, producing strong antigen-specific IgG 
[264, 313, 319, 325, 334], IgG1 [144, 263, 308, 325, 334, 335], IgG2a [133], IgG2b [263], IgG2c 
[308] and/or IgG4 [206] responses or a mild boost in IgG2a [144, 263, 325, 334] or IgG3 [133] 
responses (depending on antigen and mouse species). An additional advantage of dMPAs is that 
many of these responses required considerably lower doses than respective injections. Depelsenaire 
et al. [271] showed that a single high-density (21k p/cm2) dMPA vaccination induced significantly 
more anti-Fluvax IgG than vaccination with half the projection density (10k). Halving the 
projection density halved the number of dead cells (mostly necrotic), suggesting cell death 
pathways contribute to the generation and magnitude of specific IgG responses [271]. Conversely, 
single low-density (0.14k and 0.51k p/cm2) dMPA vaccination at a range of depths all resulted in 
similar levels of anti-OVA IgG [264]. Suggesting that ranging the density of high-density dMPAs 
affects the level of specific-IgG produced but not of low-density dMPAs. 
 
There have been several reviews suggesting that the practicality of using dMPAs for allergy 
desensitisation may be beneficial [22, 336, 337] but only one study that has tested dMPA 
desensitisation [206]. Kim et al. [206] delivered Dermatophagoides farina (dust mite) using low-
density dMPAs in a mouse desensitisation model. They applied 76 coated projections that resulted 
in successful desensitisation and demonstrated therapy dose sparing (10-fold less than SCIT). 
Despite evidence that higher projection densities lead to stronger specific-IgG responses [271] and 
accelerated LC egress from of the epidermal tissue [300], high-density dMPAs have never been 
tested in allergy desensitisation. In addition to a less invasive route, dose sparing from dMPA 
allergy desensitisation would decrease the risk of life threatening side effects and be more cost 
effective. Therefore, I hypothesised that allergy desensitisation may benefit from a low dose (i.e. 
lower than required for SCIT), high-density dMPA. 
 
In this chapter, I aimed to test high-density dMPAs in an airway challenged OVA desensitisation 
mouse model. First, I tested very high-density (21k p/cm2) dMPAs in desensitisation. Second, I 
aimed to set up a more persistent sensitisation model. Third, I tested the effect of half the projection 
density (10k p/cm2) on initiating Th2 sensitisation using a high application energy. Last, I combined 
the findings from the first three aims to test 10k dMPAs applied at a medium application energy in 
desensitisation. Of the four high-density dMPA conditions assessed, only 10k dMPAs applied at 
medium application energy resulted in less airway inflammation after an airway challenge. Despite 
boosted specific IgG1 and IgG2a, specific-IgE was not reduced using this model. Demonstrating 
that dMPAs can reduce locally challenged effects of a Th2 sensitisation (but not systemic), 
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provided the density and application energy are less than 21k p/cm2 and 170 mJ respectively in a 
mouse model. 
 
 
4.2 Methods 
See the following sections for relevant methods for Chapter 4: 
 3.1 Animals 
 3.2 Microprojection array fabrication: of 16 mm2 silicon 21k and polycarbonate 10k p/cm2. 
 3.3 Therapy coating of microprojection arrays 
 3.4 Application process of microprojection arrays – (3.4.1 push-through application) 
 3.5 Delivery characterisation of microprojection arrays 
 3.7 Sensitisation (see Table 4-2 and Table 4-3 for groups) 
 3.8 Desensitisation (see Table 4-1 and Table 4-4 for groups) 
 3.10 Challenge 
 3.11.1 Cell differentiation of bronchial alveolar lavage – by light microscopy 
 3.12 Anti-ova IgE via passive cutaneous anaphylaxis assay 
 3.13 Anti-ova IgG subtypes via ELISA 
 3.14 Quantification of MUC5AC and obstruction in lung histology 
 3.19.1 Hitachi 3500 scanning electron microscope 
 3.19.2 Zeiss confocal / multi-photon laser scanning microscope 
 3.20 Statistics 
 
 
4.3 Results 
4.3.1 High density (21k p/cm2) dermal-targeted microprojection arrays do not desensitise Th2 
allergic mice 
High density 21k p/cm2, silicon dMPAs (Figure 4-1) applied to ear skin were previously shown to 
produce high levels of anti-antigen IgG [303] and so were tested here for OVA desensitisation. Here 
I tested both high (170 mJ) and medium (100 mJ) application energies as both have resulted in 
boosted IgG responses. To characterise the 21k dMPA, BS-SEM images were assessed for coating 
consistency. As previously reported, the 21k dMPA was evenly coated (darker areas) with an OVA-
based methylcellulose solution (Figure 4-1A). The 21k-170 mJ delivered a significantly higher 
proportion of the coated formulation (Figure 4-1B) than the 21k-100 mJ (p = 0.0002, Figure 4-1B). 
The difference in delivery was visually apparent from the respective BS-SEM as less coating (dark) 
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was removed from the 21k-100 mJ than the 21k-170 mJ application (Figure 4-1C). Using this data, 
I calculated the average dose to load onto the 21k dMPAs in order to dose match the two treatment 
conditions in the following desensitisation study. 
 
Figure 4-1: Characteristics of desensitisation 21k dermal-targeted microprojection array ear skin 
delivery. (A) BS-SEM of uncoated silicon (bright) and OVA-coated silicon (dark) 21k dMPA, (B) 
Average delivery into ear skin used to match dose delivered in the 21k desensitisation, n = 4 (C) 
BS-SEM after application at 100 and 170 mJ. Scale bars: 200 µm (array) and 10 µm (projection). 
 
The first objective was to assess if 170 mJ or 100 mJ application energy was more effective for 21k 
dMPA desensitisation. A regimen of sensitisation, desensitisation and challenge was constructed to 
test this (Figure 4-2). Mice were first sensitised with a common 2x i.p. regimen (see section 2.2.4) 
with OVA absorbed to AH, rested for a week then treated weekly for four weeks. A relatively short 
treatment protocol was used, as 21k dMPAs were previously reported to significantly boost IgG 
after a single application. Treatment groups of 21k-100mJ and 21k-170mJ were compared to 
sensitised mice (Table 4-1). The mice were treated with a 50th – 100th of the SCIT dose used in mice 
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previously [128, 139]. As per Kendall et al. [139] mice were challenged the day after the last 
treatment. 
 
Figure 4-2: Desensitisation timeline using 21k dermal-targeted microprojection array on ear skin. 
Mice were sensitised twice with 10 µg ova and 4 mg AH (i.p.) on days 0 and 14 followed by four 
weekly desensitisation treatments using dose-matched dMPAs (0.5 µg) applied at 100 or 170 mJ 
application energy. Mice were challenged 24 h after the last treatment daily (i.n. 100 µg) for three 
days then culled 24 h after the last challenge. 
 
Table 4-1: Desensitisation groups of 2x intraperitoneal sensitised mice treated for OVA allergy 
desensitisation at a weekly interval using 21k dermal-targeted microprojection arrays on mouse 
ear. Nomenclature of treatment group names are as follows: (route of desensitisation) – 
(application energy) – (Total days of experiment). 
 
21k p/cm2 
desensitisation 
groups 
Sensitisation 
Desensitisation  
Route Repeat 
Ova 
dose 
Interval 
Total 
dose 
N 
i.p. OVA+AH-D47 
or ‘Sensitised-D47’ 2x i.p. of 
10 µg OVA 
+ 4 mg AH 
- - - - 0 µg 5 
21k -100mJ-D47 21k 
dMPA 
ear 
X4 
0.1 µg 1 / week 0.4 µg 4 
21k -170mJ-D47 0.1 µg 1 / week 0.4 µg 6 
 
Samples collected on day 47 of the 21k dMPA desensitisation were analysed for cell differentiation 
(BALf) and anti-OVA antibody endpoints (sera). There was no significant difference between the 
BALf cell subtypes (Figure 4-3A) or the production of anti-OVA IgE, IgG1 or IgG2a antibodies 
(Figure 4-3B) between the Sensitised-D47 and the 21k dMPA desensitised groups. In general, the 
combined average of the BALf eosinophils (14.5 ± 6.6%) was particularly low for an airway 
hypersensitivity model. Of the IgG response, anti-OVA IgG1 was the dominate subtype. Sensitised-
D47 and 21k-100mJ-D47 groups elected similar OVA-IgG1 (1,228,800 ± 579,200 and 1,228,800 ± 
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709,400 respectively) and -IgG2a (92,800 ± 83,200 and 51,200 ± 44,300 respectively) responses 
(outlier removed from Sensitised-D47 IgG2a). However, 21k-170mJ-D47 desensitisation had 
stronger IgG responses with the highest OVA-IgG1 (3,276,800 ± 2,317,000) and significantly more 
IgG2a (p = 0.0303, 212,100 ± 146,100) average endpoints. Taken together, the 21k desensitisation 
indicated key findings that required further optimisation. The first key finding is that 2x i.p. 
sensitisation (day 0 and 7) does not activate strong airway eosinophilia nor consistent OVA-IgE at 
day 47. The second is that silicon 21k dMPA (ear) cannot reduce type I OVA-sensitisation after 
four doses, despite high anti-OVA IgG1 and IgG2a. These findings are addressed later in greater 
detail in sections 4.3.2 and 4.3.3 respectively. 
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Figure 4-3: Desensitisation BALf cells and sera antibodies using 21k dermal-targeted 
microprojection array ear skin delivery. The first group was untreated (Sensitised-D47). (A) BALf 
cells differentially counted using diff quick staining. (B) Anti-OVA IgE was analysed using rat PCA 
assay and anti-OVA IgG1 and IgG2a was analysed using ELISA (TMB substrate). There were no 
significant differences, n = 4-8. 
 
4.3.2 Setting up a strong and persistent sensitisation in BALB/c mice 
As earlier findings in section 4.3.1 concluded that a 2x i.p. sensitisation was not consistent at 
activating Th2 biomarkers, a stronger sensitisation regimen had to be established. As outlined in 
section 2.2.4, a 3x i.p. sensitisation model results in a stronger Th2 persistence. As AH- induced 
Th2 sensitisation of the airways is not representative of how airway allergic patients are sensitised, I 
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also tested a OVA-only airway sensitisation method [117]. Swedin et al. [140] found that 4x i.n. of 
20 - 200 µg resulted in high eosinophilia and Nelde et al. [136] found that at least 4x i.n. of 50 µg 
resulted in both high eosinophilia and anti-OVA IgE, so both i.p. and i.n. protocols were tested for a 
stronger sensitisation protocol. Figure 4-4 outlines the two sensitisation protocols tested with and 
without OVA (see Table 4-2 for groups). The length of persistence required was determined by 
assuming that eight, twice per week (63 days, Figure 4-4A) or once per week (87 days, Figure 
4-4B) dMPA treatments were to be tested. As such, hair was also removed with Nair cream on the 
same days that it would be required for the upcoming desensitisation. 
  
Figure 4-4: Timelines to compare intraperitoneal or intranasal sensitisation at day 63 and 87. 
Timelines included similar procedures as a mock (A) twice a week and (B) once a week 
desensitisation treatment plan. Mice were either i.p. OVA-AH x3 or i.n. OVA x4, hair was removed 
fortnightly by Nair (N) then challenged i.n. x3 (50 µg) before sample collection on day 63 or day 
87. 
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Table 4-2: Sensitisation groups of intraperitoneal or intranasal sensitisation till day 63 (for twice-
weekly treatments) or day 87 (for weekly treatments). Nomenclature of treatment group names are 
as follows: (route of desensitisation) – (application energy) – (Total days of experiment). 
Sensitisation 
groups 
Sensitisation 
Route Repeat Days 
Ova 
dose 
AH 
dose 
N 
i.n. PBS-D63 
i.n. x4 
D0, D5, 
D10, D14 
0 µg 0 mg 4 
i.n. PBS-D87 0 µg 0 mg 4 
i.n. OVA-D63 50 µg 0 mg 6 
i.n. OVA-D87 50 µg 0 mg 6 
i.p. AH-D63  
i.p. x3 
D0, D7, 
D14 
0 µg 1 mg 4 
i.p. AH-D87  0 µg 1 mg 4 
i.p. OVA+AH-D63 
or ‘Sensitised-D63’ 
20 µg 1 mg 6 
i.p. OVA+AH-D87 
or ‘Sensitised-D87’ 
20 µg 1 mg 6 
  
Samples collected on day 63 or 87 of the sensitisation test were analysed for cell differentiation 
(BALf) and anti-OVA IgE endpoints (sera). There were no significant differences between the 
BALf cell subtypes between PBS groups (i.n. versus i.p.) or OVA groups (i.n. versus i.p.). The 
mean ± SD results of the i.n. PBS groups were considered similar to a naïve response [338]. 
Therefore, groups were statistically compared to the relative i.n. PBS group. Both i.n. PBS-D63 and 
i.n. PBS-D87 BALf cells consisted mostly of macrophages (93.6 ± 2.2% and 86.0 ± 15.6% 
respectively). Adding AH (i.p. AH-D63/87) led to some neutrophils at days 63 (25.7 ± 27%) and 
day 87 (26.5 ± 15.3%). There was a significant shift in cell differentiation when adding OVA to 
sensitisation for both i.n. and i.p.  Adding OVA to the sensitisation increased BALf eosinophils at 
both day 63 and day 87 for both i.n. (17.3 ± 9.5%, p = 0.0078 and 29.7 ± 7.3%, p = 0.0008 
respectively) and i.p. (20.6 ± 6.8%, p = 0.0008 and 21.7 ± 9.8%, p = 0.003 respectively) 
sensitisation. Eosinophil responses were not promoted in i.p. AH respective to i.p. OVA+AH at day 
63 (p = 0.001) nor day 87 (p = 0.0036). There was no significant lymphocyte difference between 
groups. Together, both i.n. and i.p. sensitisation presented here elicited consistent eosinophil based 
inflammation of the airways, similar to that seen in other 3x i.p. [138] and i.n. [140] sensitisations. 
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Figure 4-5: BALf cell differentiation after intraperitoneal or intranasal sensitisation. Percent of 
differential BALf cells after i.n. or i.p. (PBS vs OVA) sensitisation using protocol from Figure 4-4 at 
(A) day 63 and (B) day 87, n = 3-6. 
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The total number of BALf cells collected was generally higher in each OVA group compared to its 
respective PBS group (Figure 4-6A). Although, due to large variations between samples, this trend 
was generally not significant except between i.n. PBS-D87 and i.n. OVA-D87 (p = 0.023). 
Production of active OVA-IgE was only present in i.p. OVA+AH-D63/D87 groups (Figure 4-6B). 
Compared to the other three groups combined, i.p. OVA+AH significantly increased OVA-IgE 
endpoint titre at day 63 (p = 0.005) and day 87 (p = 0.0002) (Figure 4-6B). These results indicate 
that 3x i.p. OVA+AH sensitisation regimen was the only protocol to succeed in both cellular 
inflammation in the airways and a systemic Th2 sensitisation, persisting up to day 87.Therefore the 
i.p. OVA+AH was used as a Th2 sensitisation model for the following desensitisation. For 
reference, the combined average of i.p. OVA+AH-D63/87 sensitisation is: 43.5 ± 17.5% 
macrophages, 32.3 ± 11.4% neutrophils, 21.1 ± 8.0% eosinophils, 2.2 ± 1.8% lymphocytes and 18.6 
± 8.5 anti-OVA IgE endpoint. 
 
Figure 4-6: BALf cellular influx and sera anti-OVA IgE of intraperitoneal or intranasal 
sensitisation. (A) Total cells collected from each BALf at day 63 or 87 respectively. (B) Titres of 
anti-OVA IgE analysed from rat PCA assay, n = 3-6. 
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4.3.3 Dermal-targeted microprojection arrays applied at 170 mJ induced sensitisation 
As pointed out in section 4.3.1, the 21k dMPA enhanced Th2-mediated responses. This was likely 
due to the high levels of pro-inflammatory signalling previously reported from 21k dMPAs. 
Additionally, the ear skin of mice contains 2.5-fold more mast cells (a strong allergic cell) than 
mouse flank skin [219]. As such, I tested the Th2 sensitisation capability of half the projection 
density (10k) applied to mouse flank skin using the sensitisation protocol established in section 
4.3.2 (Figure 4-4). This test is based on a concept tested by Shakya et al. [133], whereby if a dMPA 
condition is able to sensitise mice, then it is not likely to assist in desensitisation (and vice versa).  
Using a very similar protocol to Shakya et al., mice were sensitised as per the previous test then 
challenged two weeks after the last sensitisation (approximate peak IgE production, [112, 117]) 
before sample collection on day 31 (Figure 4-7). To test if reducing the density alone would result 
in Th2 sensitisation, only the high application energy was applied. As dMPAs cannot be coated 
effectively with AH, the 10k-170mJ-D31 was compared against both i.p. OVA-D31 and i.p. 
OVA+AH-D31 groups (Table 4-3).  
 
Figure 4-7: Timeline for assessment of dermal-targeted microprojection array 10k-170 mJ 
sensitisation potential in mice. Hair was removed by Nair (N) 24 h before each application. 
Sensitisation (i.p. OVA+AH) was compared to dose matched i.p. OVA (10 µg) and 10k-170mJ 
dMPA (10 µg OVA) delivery on days 0, 7 and 14. Mice were challenged with 50 µg OVA on days 
28-30 (i.n.) and samples collected on day 31.  
 
Table 4-3: Sensitisation test groups for analysis of 10k-170mJ dMPA sensitisation potential 
Sensitisation 
groups 
Sensitisation 
Route Repeat Days 
Ova 
dose 
Al(OH)3 
dose 
N 
i.p. OVA-D31 i.p. 
x3 D0, D7, D14 10 µg 
0 mg 3 
i.p. OVA+AH-D31 
or ‘Sensitised-D31’  
i.p. 
1 mg 3 
10k-170mJ-D31 10k dMPA 0 mg 3 
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To ensure all 10k dMPAs used in the allergy tests were consistent, 10k dMPAs were hot embossed 
into polycarbonate material from a silicon master. Hot embossed polycarbonate conical dMPAs 
(Figure 4-8A, uncoated) were more blunt than the silicon conical dMPAs of  
Figure 3-2. To characterise the polycarbonate 10k dMPA, BS-SEM images were assessed for 
coating consistency.  Despite half the number of projections of the 21k desensitisation (4.3.1), 
coating with the same volume of formula continued to cover projections consistently (Figure 4-8A, 
coated). To determine if applied polycarbonate 10k dMPAs differed significantly like the silicon 
21k dMPAs, both 100 mJ and 170 mJ was characterised. Both 10k-100 mJ and 10k-170mJ 
deposited coating in the dermis as captured by BS-SEM and visualised by fluorescent particle 
delivery (Figure 4-8B). By measuring the penetration tracks from histological sections (represented 
in Figure 4-8B), each application energy resulted in similar delivery depths (100 mJ: 75.2 ± 26.3 
µm and 170 mJ: 83.1 ± 32.3 µm, Figure 4-8C). Likewise to the 21k dMPA, the 10k dMPA 
delivered significantly more of the OVA coating when applied at 170 mJ than 100 mJ (p = 0.0002, 
Figure 4-8D). So, although polycarbonate dMPAs were more blunt, coating continued to be 
delivered to the dermal layer of the mouse flank skin when using both 10k-100 mJ and 10k-170 mJ 
dMPAs. 
 
As the 170 mJ 10k deliver efficiency had a coefficient of variation of 34%, the mean delivery of 
each sensitisation day was assessed to accurately match the i.p. dose to the delivered dose of the 
10k-170mJ-D31. Using left over coating formula of each 10k-170mJ-D31 sensitisation day, 14C-
OVA was added afterwards and coated to determine deliver efficiency for each sensitisation day. 
Percent delivered of the 100 µg originally coated was used to match the i.p. doses, i.e. day 0 i.p. 
dose = 13.4 µg, day 7 dose = 14.7 µg and day 14 dose = 11.75 µg (Figure 4-9).  
 
148 
 
Figure 4-8: Conical polycarbonate 10k dermal-targeted microprojection array delivery 
characteristics into mouse skin. (A) BS-SEM of uncoated iridium plated polycarbonate (bright) 
and OVA-coated (dark) 10k dMPA, scale bar: 200 µm. (B) BS-SEM after application at 100 and 
170 mJ (scale bar: 200 µm) and multi-photon scan of flank skin (20 µm thick) after dMPAs coated 
with fluorescent particles were applied, scale bars: 200 µm (array and skin) and 50 µm (skin X4). 
Skin section (X4) includes trace of epidermal-dermal junction (yellow line), fluorescent particles 
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(green) and auto-fluorescent collagen (blue) in the dermis. (C) Measured penetration tracks to 
quantify average penetration depth, plot includes average mouse skin layer depths for stratum 
corneum ‘StC, viable epidermis ‘VE’ and dermis ‘D’, n = 94-120. (D) Average delivery into ear 
skin used to dose match dMPA deliveries to other groups, n = 9-18. 
 
Figure 4-9: Assessment of 10k dermal-targeted microprojection array sensitisation delivery of 
each dose. After determining delivery efficiency each sensitisation day, i.p. doses were matched to 
percent delivered by patches that were coated with 100 µg, n = 4. 
 
To determine the level of skin inflammation from applying a 10k dMPA at 170 mJ, photographs 
were taken of most 10k-170mJ-D31 applications at t = 0 h for sensitisation and 14C dMPA checks. 
Representative photos were capture 24 h after dose 3. Day 7 photos were taken of dose 1 and 2. A 
representative image of the erythema at each time point is shown in Figure 4-10A. Erythema of all 
photos available was scored using the Draize Index (see Methods 3.4) and plotted in Figure 4-10B. 
10k-170mJ-D31 dMPAs averaged a high erythema score of 2.8 ± 0.8 at t = 0. Erythema persisted at 
t = 24 h (2.3 ± 0.5) then significantly reduced by 7 days (0 h p = 0.0001 and 24 h p = 0.029). 
Therefore, 170 mJ push-through application was denoted as a ‘high’ application impact as defined 
from Table 2-10. 
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Figure 4-10: Assessment of erythema from 10k-170mJ dermal-targeted microprojection array 
applications. (A) Representative erythema of 170 mJ 10k applications at t = 0 h, 24 h and 7 days 
after application, scale 5mm. (B) Quantification of erythema from photos taken at 0 h, 24 h and 7 
days after application, n = 3 - 17. 
 
Samples collected on day 31 were analysed for cell differentiation (BALf) and anti-OVA antibody 
endpoints (serum). There was no significant difference between the BALf cells of the sensitised 
10k-170mJ-D31, i.p. OVA-D31 and i.p. OVA+AH-D31 groups (Figure 4-11A). In general, i.p. 
OVA+AH-D31 had the highest BALf eosinophil influx (44.7 ± 6.3%) out of all three groups. This 
level of eosinophilia matches that of i.p. OVA+AH-D63/87 levels. Induction of anti-OVA IgE was 
generally only present in i.p. OVA+AH-D31 (21.3 ± 9.2%) at similar a level to i.p. OVA+AH-
D63/87. In comparison, both i.p. OVA-D31 and 10k-170mJ-D31 groups (OVA-only) also had 
elevated eosinophilia to 18.44 ± 17.8% and 35.6 ± 20.3% respectively. However, neither OVA-only 
group significantly increased anti-OVA IgE endpoint titre (0.0 ± 0.0 and 5.3 ± 2.3 respectively). 
Overall, the 10k-170 mJ activated more OVA-specific eosinophilia and anti-OVA IgE than naïve 
groups (i.n. PBS-D63/87 of section 4.3.2) but these levels were noticeably less than Sensitised-D31, 
21k-100 mJ desensitisation and 21k-170 mJ desensitisation. Therefore, allergy desensitisation 
would likely benefit from a lower pro-inflammatory dMPA than 10k-170 mJ, such as a 10k-100 mJ 
dMPA.  
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Figure 4-11: Assessment of dermal-targeted microprojection array sensitisation BALf cells and 
sera IgE using 10k-170mJ-D31 for mouse flank skin delivery. (A) Day 31 percent of differential 
BALf cells after 3x i.p. vs 3x 10k-170 mJ dMPA sensitisation then challenge protocol (Figure 4.8A). 
(B) Titres of anti-OVA IgE in serum, n = 3. 
 
4.3.4 dMPAs applied at 100 mJ reduced airway inflammation 
Taking the results together from sections 4.3.1, 4.3.2 and 4.3.3, it was likely that halving the 
projection density alone was not enough to reduce Th2 activation. Therefore, a lower application 
energy was tested to reduce pro-inflammatory signalling (10k-100 mJ dMPA). Desensitisation was 
examined using the previously established 3x i.p. sensitisation regimens (Figure 4-4). An important 
difference to note here between the two desensitisation tests (21k and 10k p/cm2) is the total 
desensitisation dose delivered is significantly higher for this 10k dMPA desensitisation (40 µg) than 
the 21k dMPA desensitisation (2 µg). To avoid removing hair regrowth, hair was removed by Nair 
from 25-50% of the mouse back every fortnight at least 24 h before application. Dose matched 
OVA or PBS 10k-100 mJ dMPAs and s.c. injection desensitisation treatments were applied in twice 
a week or once a week regimen as per Figure 4-12. Both twice weekly [206] and once weekly (e.g. 
[139]) are common repeat intervals for mouse desensitisation tests (see section 2.3.3). PBS s.c. 
groups were considered as sensitised controls for each timeline (see Table 4-4). Mice remained 
healthy regardless of group, as supported by no significant difference of final mouse weight per 
group (combined mean = 22.92 ± 1.05 g, Figure 4-13). 
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Figure 4-12: Desensitisation timelines for twice a week and once a week 10k dermal-targeted 
microprojection array treatments applied at 100 mJ into mouse flank skin. Mice were sensitised 
with three i.p. (10 µg OVA + 1 mg Al(OH)3) then hair was removed fortnightly starting on day 27. 
Mice were treated with 0 µg or 5 µg OVA via either s.c. or 10k-100mJ (A) twice per week and 
culled on day 63 or (B) once per week and culled on day 87. Before sample collection, mice were 
challenged with three daily i.n. (50 µg). 
 
Table 4-4: Desensitisation groups of 3x intraperitoneal sensitised mice treated for OVA allergy 
desensitisation at a weekly or twice-weekly treatment interval using 10k dermal-targeted 
microprojection arrays on mouse flank. Nomenclature of treatment group name is as such: (route 
administered)-(total dose)-(harvest day). 
10k desensitisation 
groups 
Sensitisation 
Desensitisation 
N 
Route Repeats 
Ova 
dose 
Interval 
Total 
dose 
Sensitised-D63 
(i.e. s.c.-0-D63) 
3x i.p. of 10 µg 
OVA + 1 mg 
Al(OH)3 
s.c. x8 
0 µg 2 / week 0 µg 4 
Sensitised-D87 
(i.e. s.c.-0-D87) 
0 µg 1 / week 0 µg 4 
s.c.-40-D63 5 µg 2 / week 40 µg 6 
s.c.-40-D87 5 µg 1 / week 40 µg 6 
10k-0-D63 x8 0 µg 2 / week 0 µg 4 
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10k-0-D87 10k 
dMPA 
0 µg 1 / week 0 µg 4 
10k-40-D63 5 µg 2 / week 40 µg 6 
10k-40-D87 5 µg 1 / week 40 µg 6 
 
Figure 4-13: Final mouse weights for desensitisation study. Mice were weighed immediately after 
overdose was administered after sensitisation, desensitisation and challenge on day 63 or day 87, 
n = 3-6. 
 
To determine the level of skin inflammation from applying a 10k dMPA at 100 mJ, photographs 
were taken of most 10k-100mJ weekly applications at t = 0 h for desensitisation doses. 
Representative photos were taken 24 h after the 5th dose (day 57). Day 7 photos were taken of dose 
1, 3, 4, 5 and 6 (at day 35, 49, 56, 63, 70). A representative image of the erythema at each time 
point is listed in Figure 4-14A. Erythema of all photos available was scored using the Draize Index 
(Methods 3.4) and plotted in Figure 4-14B. Repeated applications did not lead to increased 
erythema with increasing repeats per mouse (data not shown). 100 mJ 10k dMPAs averaged a 
medium erythema score of 1.8 ± 0.8 at t = 0. Erythema persisted at t = 24 h (1.0 ± 0.0) then 
significantly reduced by 7 days (0.08 ± 0.3, 0 h p < 0.0001 and 24 h p < 0.0001). Therefore, 100 mJ 
push-through application was denoted as a ‘medium application impact’ as defined in Table 2-10. 
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Figure 4-14: Assessment of dermal-targeted microprojection array erythema from 10k-100mJ 
application. (A) Representative erythema of 10k-100 mJ applications at t = 0 h, 24 h and 7 days 
after application, scale bar: 5mm. (B) Quantification of erythema from photos taken at 0 h, 24 h 
and 7 days after application, n = 4-30. 
 
Samples collected on day 63 or 87 of the desensitisation were analysed for cell differentiation 
(BALf) and anti-OVA antibody endpoints (sera). BALf cells of Sensitised-D63 (Figure 4-15A) did 
not follow the same differentiation as previously seen in the sensitisation set-up (Figure 4-15A) 
consisting of a larger presence of neutrophils (55.3 ± 7.7%). This led to no significant difference 
between BALf cell groups at day 63. Sensitised-D87 (Figure 4-15B) replicated BALf differentiation 
seen in sensitisation set-up (Figure 4-15B) with an average of 40.0 ± 7.0% macrophages, 35.0 ± 
6.5% neutrophils, 24.8 ± 11.9% eosinophils and < 1.0% lymphocytes. Therefore, as only 
Sensitised-D87 was consistent with previously reported, only day 87 lung data was further 
analysed. Relative to Sensitised-D87, s.c.-40-D87 resulted in significantly less macrophages (27.9 ± 
6.4%, p = 0.033) and slightly more neutrophils (40.3 ± 19.0%) and eosinophils (31.5 ± 22.2%). 
Both dMPA groups, 10k-0-D87 and 10k-40-D87, resulted in significantly more neutrophils (p = 
0.0034 and p = 0.0099 respectively) and significantly less eosinophils (p = 0.039 and p = 0.044, 
respectively). The mean percent of eosinophils for both 10k-0-D87 (3.96 ± 1.1%) and 10k 40-D87 
(5.08 ± 1.8%) was not significantly different from the i.p. AH-D87 control (Figure 4-15A) of the 
sensitisation set-up (p = 0.090). This data confirms that s.c. desensitisation at 5 µg dose not reduce 
Th2 sensitisation (as seen in other studies [26, 201]). BALf results indicate that 10k-100 mJ  dMPA 
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application non-specifically downregulates airway eosinophilia and upregulates airway 
neutrophilia.  
 
There was no difference of the anti-OVA IgE endpoint titre between day 63 and day 87 for each 
respective group and so both time points were analysed. Anti-OVA IgE endpoints of both 
Sensitised-D63 (Figure 4-16A) and Sensitised-D87 (Figure 4-16B) matched that of the sensitisation 
test (Figure 4-6B). In align with eosinophil results, both s.c. 40-D63 (p = 0.010) and s.c. 40-D87 (p 
= 0.0091) significantly increased OVA-IgE endpoints above respective Sensitised-D63/87 groups. 
Confirming s.c. desensitisation at low doses is not effective at reducing Th2 sensitisation. Yet, 
although dMPA groups had lower eosinophils, this was not the case for anti-OVA IgE. Both 10k-0-
D63 and 10k-40-D87 had similar anti-OVA IgE levels as respective Sensitised-D63/87 groups (i.e. 
s.c.-0-D63/D87 groups). As in s.c.-40-D63/D87 desensitisation, anti-OVA IgE levels were boosted 
for both 10k-40-D63 (50.6 ± 41.0) and 10k-40-D87 (51.2 ± 17.5). Anti-OVA IgG1 was the 
dominate subtype of IgG (over IgG2a) produced by all groups. All groups elected similar anti-OVA 
IgG1 and IgG2a responses (outlier removed from 10k-0-D63 IgG1). However, 10k-40-D63 
desensitisation had significantly more anti-OVA IgG1 (p = 0.0250, 2,730,600 ± 846,000) than 
Sensitised-D63, and the highest level at day 87 (2,949,100 ± 2,136,200). Following a similar trend 
to the IgG produced by the 21k-170 mJ desensitisation group. Overall, dMPAs may non-
specifically downregulated airway eosinophilia but this does not extend to reduced anti-OVA Th2-
mediated antibodies (IgG1 and IgE).  
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Figure 4-15: Desensitisation BALf cells for twice a week and once a week 10k dermal-targeted 
microprojection array treatments applied at 100 mJ into mouse flank skin. Percent of differential 
BALf cells after desensitisation protocols in Figure 4-12, n = 4-6. 
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Figure 4-16: Desensitisation sera antibodies for twice a week and once a week 10k dermal-
targeted microprojection array treatments applied at 100 mJ into mouse flank skin. IgE endpoints 
were determined using rat PCA assay. Endpoints of IgG1 and IgG2a were calculated using ELISA 
(TMB substrate), n = 4-6. 
 
To assess the effects of the 10k-100 mJ dMPA (D87 groups only) on lung pathology, lobe sections 
were stained for mucus with anti-MUC5AC (Figure 4-17). As aforementioned, day 63 lung data 
was not included in analysis as BALf data of Sensitised-D63 was insufficient (indicating a problem 
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during the challenge). It is important to note that lobes from this experiment were stored in 70% 
ethanol (after fixing) for 12 months before transferring to paraffin wax, collapsing some airways 
that were disregarded in analysis. Representative lung histology images of each group indicated 
severe peribronchial inflammation in Sensitised-D87, s.c.-40-D87 and 10k-0-D87 but not in 10k-
40-D87 (Figure 4-17A). Similar to previous reports [142], sensitised airways increased MUC5AC 
to an average of 23.3 ± 4.4% per section (Figure 4-17B). Yet, s.c.-40-D87 desensitisation resulted 
in the highest average with 44.5 ± 24.1% MUC5AC positive airways. Despite low eosinophilia, 
desensitisation with 10k-0-D87 averaged similar levels of MUC5AC (16.4 ± 15.9%) to Sensitised-
D87 albeit with a large spread. In contrast, desensitisation with 10k-40-D87 significantly reduced 
MUC5AC hyper-production (p = 0.020, 6.5 ± 14.6%). Indicating mucus hyperproduction in these 
groups was independent of eosinophils but dependant on specific responses to OVA. All groups 
increased airway obstructions, though s.c.-40-D87 contained the highest percentage (47.4 ± 16.7%), 
the combined average of all four groups was 36.2 ± 16.3% (Figure 4-17C). Therefore, although the 
10k-100mJ dMPA delivering OVA protects against mucus hyperproduction, neither the s.c. nor the 
10k dMPA prevented airway plugging. 
 
Overall, Th2-mediated sensitisation was only consistent at day 87. At this time point, eight doses of 
5 µg via s.c. enhanced both systemic and airway Th2 responses. Although both s.c. and dMPA 
therapy did not inhibit OVA-IgE, eight applications of dMPAs with or without OVA alleviated 
airway eosinophilia. Reduced eosinophils correlated with increased neutrophil presence in both 
dMPA groups. By contrast, only OVA delivered in the 10k-40-D87 group prevented mucus hyper-
production within the airways. 
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Figure 4-17: Desensitisation lung histology for once a week 10k dermal-targeted microprojection 
array treatments applied at 100 mJ into mouse flank skin. (A) Representative image of MUC5AC 
stained airway (5 µm thick) of respective groups from weekly desensitisation, scale bar: 200 µm. 
Red arrows indicate mucus-based obstructions and black arrows indicate cellular-based 
obstructions. (B)Percentage of (i) positive MUC5AC stained airways and (ii) obstructed airways, n 
= 4-5. 
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4.3.5 Eosinophil levels correlate with dermal-targeted microprojection array design irrespective of 
number of applications or dose 
By normalising the percent of eosinophils to the average eosinophils of the respective sensitisation 
group (where average sensitised y = 1.0) of each dMPA experiment, I assessed the effect of 
changing the dMPA design. By first looking at density alone, combined 21k dMPA groups (21k-
100mJ-D47 and 21k-170mJ-D47) activated significantly more eosinophilia then combined 10k 
dMPA groups (10k-170mJ-D31 and 10k-0-D87 and 10k-40-D87) (p = 0.0001) (Figure 4-18Ai). 
Comparing application energies, there was also a slight increase when using the higher application 
energy (p = 0.010) – although most 170 mJ applications were performed with 21k dMPAs (Figure 
4-18Aii, right). Between all groups, there was no significant correlation between total dose (R2 = 
0.09) nor number of dMPA applications (R2 = 0.7753). However, when combining total number of 
projections applied (i.e. 21k p/cm2 applied 3,360 #p and 10k applied 1,600 #p) with application 
energy (170 mJ or 100 mJ) (#p × mJ), the resulting impact per dMPA condition had a strong, 
positive correlation to relative eosinophilia (R2 =0.9901) until mean sensitised was reached (y = 
1.0) (Figure 4-18B). After which, eosinophil levels plateau irrespective of dMPA impact (#p × mJ). 
Therefore, the combined data suggests that the combination of number of applied projections and 
the energy at which they are applied at directly correlates to the level of BALf eosinophilia until 
sensitised levels are reached. 
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Figure 4-18: Combined relative levels of BALf eosinophils for each dermal-targeted 
microprojection array condition. For each experiment (D47, D31 and D87), the percent of 
eosinophils for each dMPA group was normalised to the respective sensitised average percent. (A) 
Relative eosinophils were compared by (i) density (ii) application energy and (iii) dMPA 
application impact of 10k-100 mJ, pink; 10k-170 mJ, purple; 21k-100 mJ, yellow and 21k-170 mJ, 
orange. Including normalised mean sensitisation level of eosinophils respective of each experiment 
(red dashed) and trend line until mean sensitisation is reached (black dotted) with equation and R2 
value. 
 
 
4.4 Discussion 
Desensitisation by AIT is the only treatment available that both reduces symptoms and the need for 
rescue medication while also modulating the immune system for long-term immunity. With therapy 
completion rates as low as 7% [192], allergic patients are in desperate need for a more safe, 
efficient, easy to use and more cost effective alternative for AIT [9, 191]. Although not 
systematically tested, desensitisation of Th2 responses were assessed with two high-density dMPAs 
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(21k with 3,360 projections and 10k with 1,600 projections) applied at high (170 mJ) and medium 
(100 mJ) application energies in an airway challenged mouse model. To summarise results, I found 
after 3-8 applications of dMPA designs, all conditions elicited strong anti-OVA IgG responses like 
other high-density dMPAs [25, 271, 303]. This increase in IgG, however, did not lead to a decrease 
in anti-OVA IgE. Promisingly, eight weekly applications of OVA via 10k-100 mJ dMPAs resulted 
in significantly less airway eosinophilia and mucus than sensitised and dose matched s.c. treated 
mice but increased airway neutrophils. Reduced eosinophilia was also present in placebo 10k-100 
mJ dMPA desensitisation but not in other dMPA conditions tested (10k-170 mJ, 21k-100 mJ and 
21k-170 mJ). This indicates that dMPA application alone could somewhat protect against airway 
eosinophilia but the addition of OVA also protects against airway inflammation. As this was only 
seen in the lowest dMPA impact model it indicates that dMPA protection against airway 
inflammation relies on dMPA density or application energy or a combination of the two variables 
(dMPA impact).  
 
Based on AIT biomarkers, I hypothesised that a device that increased anti-allergen IgG (such as the 
high-density dMPA) would block anti-allergen IgE. When testing a dMPA delivery in a variety of 
desensitisations, this was not the case and so I rejected the first hypothesis. Several reports indicate 
that, during AIT, production of human specific-IgG4 (a Th2 antibody in humans) [339, 340], or 
mouse anti-allergen IgG1 (Th1/2 antibody in mice) and IgG2a (a Th1 antibody in mice) [119, 144], 
correlates with low anti-allergen IgE. Yet, despite 21k–170 mJ having the highest anti-OVA IgG1 
and IgG2a responses and 10k 40-D63/87 groups having the highest anti-OVA IgG1 responses, all 
groups had higher anti-OVA IgE levels than the respective sensitised groups. Suggesting that 
inducing anti-allergen IgG alone is not enough to block specific-IgE in allergy desensitisation. This 
is likely because IgG can be produced under both Th1 (IFN-γ) and Th2 (IL-4, IL-6) conditions, 
where Th1-induced IgG and its respective signalling proteins can downregulate IgE, while Th2-
induced IgG conditions can enhance IgE in mice. Many reports have indicated that different dMPA 
designs can elicit different mouse Th1 and Th2 responses to vaccination. However, the majority of 
mice applied with antigen-only dMPAs produce high Th2 anti-antigen IgG1 responses [118, 144, 
263, 308, 325, 334, 335] while Th1 driven anti-antigen IgG2a responses require additional Th1-
based adjuvants such as CpG [133, 144, 325, 334]. During Th1-adjuvanted dMPA vaccinations, 
both IgG1 and IgG2a increase [144, 263, 325, 334]. Whereby the only dMPA design that boosted 
Th1-mediated IgG2a (and IgG2b) with antigen delivery alone (inactive influenza virus) was a very 
low-density array of five microprojections [263]. Further investigation into high-density dMPAs 
indicates that they activate high expression of IL-6 locally and therefore rely on a Th2 mechanism 
(unpublished data by Ng et al. currently under submission). This is supported by anti-OVA IgE 
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results presented in this chapter and so, high-density dMPAs are less likely to downregulate Th2-
mediated anti-allergen IgE.  
 
To date, only two types of dMPAs have been reported in an allergy mouse model, both of which are 
low-density. A 76 projection array of 250 µm tall dissolvable conical projections with 28 µm wide 
tips by a Kim et al. [206] and a 57 projection array of 1200 µm (H) x 150 µm (W) x 50 µm (D) steel 
dMPA by Shakya et al. [133]. Based on the application protocol (by hand) and erythema (≤ 1 
Draize index,) both of these low-density dMPAs were also low impacting on the skin [206, 264]. 
Multiple applications of allergen with either dMPA resulted in significant increase in anti-allergen 
IgG, indicating dMPAs do not have to be high-density as used here (Figure 4-6 and Figure 4-16) to 
elicit strong IgG. Kim et al. [206] tested their dMPAs in a Dermatophagoides farina (dust mite) 
skin sensitisation model with twice a week desensitisation. Using 10-fold less D. farina than SCIT, 
their dMPA succeeded in reducing skin inflammation, skin eosinophilia (y = 0.43 ± 0.05 relative to 
sensitised) and systemic Th2 responses (IgE, IL-4 and IL-13) while increasing tolerogenic IgG4, 
IL-10 and Foxp3 T cell responses. As no penetration depth data has been reported for this dMPA, it 
is possible (based on my previous experience with blunt ~250 µm long application by hand) that 
this dMPA may not penetrate into the dermis. Therefore Kim et al.’s dMPA may be closer to other 
reported epicutaneous patches that primarily target the epidermis and successfully desensitise mice 
[126, 139, 202]. If so, Kim et al.’s ‘MPA’ desensitisation results are very similar to other 
epicutaneous dust mite tests [122] but may not serve as a good comparison to the dMPA tested here. 
Shakya et al.’s dMPA delivered OVA primarily into the mouse dermis [264]. Using these dMPAs, 
Shakya tested sensitisation capabilities [133] similar to Figure 4-7 where dMPA sensitisation did 
not result increases in Th2 biomarkers (IL-5, IL-13, anti-OVA IgE) but did increase anti-OVA IgG1 
and IgG2a, suggesting suitability for allergy desensitisation [133]. Although, effect on allergy 
desensitisation has not yet been assessed with this design of dMPA. These results support a role for 
low-density dMPAs to protect against anti-allergen IgE but show that both low-density and high-
density (Figure 4-15) dMPAs can protect against airway inflammation. These comparisons suggest 
that protection against specific allergen hypersensitivity is dMPA density dependant per allergen. 
 
Airway eosinophilia was present at a Th2 sensitised level for 21k-170 mJ, 21k-100 mJ and 10k-170 
mJ impact levels (#p × mJ) but was significantly reduced with the 10k-100 mJ impact level (Figure 
4-18). This suggests a correlation between the impact of number of projections applied multiplied 
by application energy used to apply to the skin and its effect on supressing airway eosinophilia. 
Studies show that, separately, a decrease in the number of projections applied [271] or application 
energy used [295] can decrease the (Th2-mediated) IgG responses. As both the 1,600 projection 
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(10k p/cm2) dMPA presented here and the 76 projection  dMPA by Kim et al. resulted in lower 
Th2-mediated responses, it is likely other dMPAs in this density range will produce similar results. 
More specifically, by estimating from the trend line in Figure 4-18, to prevent an average of 50% 
less airway eosinophilia than sensitised (y = 0.5, x = 209340), I would recommend a dMPA of 
1,600 projections or less applied at 130 mJ or less. Furthermore, extrapolating from the same trend 
line, to reach an average of 0% airway eosinophilia (y = 0.0, x = 109340), predictions forecast the 
use of either a dMPA of 1,600 projections applied at 68 mJ or a dMPA of 1,093 projections (i.e. 
6.8k p/cm2) applied at 100 mJ. These recommendations assume dermal penetration into BALB/c or 
BALB/c-like mouse skin with a 16 mm2 application area. Application energy can be reduced by 
decreasing the mass or velocity of application, though reduced application energy will result in a 
more shallow delivery depth [295]. Although no studies have systematically evaluated the 
relationship between the design of the dMPA and its effects on airway inflammation, this chapter 
suggests that dMPA density and application energy should be designed below the aforementioned 
values for mice. 
 
Although 10k-0/40-D87 dMPA groups produced less eosinophils than Sensitised-D87, they also 
had significantly higher neutrophils present in the airways (Figure 4-15). Increased neutrophil 
presence in airways is a key marker for neutrophilic allergic asthma [36]. This occurs when T cells 
are primed in a IL-6 rich environment, as seen in the lung or skin tissue of other low-density 
dMPAs [312, 319] and the skin of high-density dMPA applications (unpublished work by Ng et 
al.). However, when neutrophils are involved in asthma they are usually associated with chronic 
airway narrowing, which was not seen in these groups (Figure 4-17). This suggests the BALf 
neutrophils seen here may be a temporary response to the i.n. challenge. As mice were culled the 
day after the last challenge, no assessment was made on whether or not the neutrophils cleared of 
the airways soon afterwards. An influx of neutrophils in the skin has been observed at MPA 
application sites [25, 321]; neutrophils are the first responders to an injury and are associated with 
wound healing [341]. Shakya et al. [144] was the only other dMPA study found that reported an 
increase in BALf neutrophils, also with or without OVA delivery. Combined, Shakya’s study and 
the results seen here indicate that dMPAs that result in increased skin neutrophils and IL-6 may also 
encourage neutrophil signalling at other sites of inflammation. 
 
In addition to lower eosinophils, 10k-40-D87 dMPAs significantly reduced airway mucus (stained 
for MUC5AC). Again, Shakya et al. [144] was the only other study to date to investigate the effect 
of dMPAs on airway mucus. Interestingly, when delivering 19.2 µg of OVA (x3, total = 57.6 µg), 
Shakya’s low-density dMPA did not protect against mucus hyperproduction in the airways. 
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Interestingly, desensitisation by intradermal injection (10 µg x4, total = 40 µg) also did not protect 
against airway inflammation [342]. This is unlike the results shown in Figure 4-17, where delivery 
of OVA (5 µg x8, total = 40 µg) with the high-density dMPA (10k-40-D87) prevented airway 
mucus. The difference in airway protection is less likely a result of different  treatment regimens 
(Shakya’s pre sensitisation versus Chapter 4’s post sensitisation) as delivery of D. farina allergen 
alone protected against airway mucus when delivered both pre sensitisation  [325] and post 
sensitisation [206]. As the delivered dose is similar, these contradictory results may be due to the 
difference in density. This is a likely as increased density increases the micro-wounds (from dMPA 
insertion) that activate the skins healing processes. In addition to neutrophils at sites of healing skin, 
a plethora of signalling proteins and cells are attracted to the wounds [270], exposing them to the 
delivered allergen. Although not assessed here, it is likely that one or more of these signals in 
combination with the allergen plays a role in decreasing mucus production upon subsequent 
exposures (such as in the challenge phase). Further testing is required to confirm this hypothesis.  
 
Lastly, the importance of ensuring a persistent model before testing was noted after the 2x i.p. 
sensitisation in the 21k desensitisation experiment did not induce a strong eosinophil nor IgE Th2 
responses. The absence of a persistent sensitisation makes it difficult to compare therapeutic test 
groups. The 2x i.p. OVA-AH sensitisation has been published many times in airway challenged 
mouse models (see Table 2-3). However, the success rate of 2x i.p. sensitisation fluctuates widely 
and can not persist after day 84 without further boosting (see Figure 2-6). This explains why the 
Sensitised-D47 was weak at day 47 after a 2x i.p. sensitisation period, while the 3x i.p. model used 
for Sensitised-D31, -D63 and –D87 did persist. The significantly higher percentage of BALf 
eosinophils in Sensitised-D31 to the sensitisation set-up Sensitised-D63/D87 was in agreement with 
observations by others when challenging a short time after sensitisation [123, 124]. It is not known 
why the day 63 groups of the desensitisation test (Figure 4-15) did not replicate the sensitisation set 
up sensitisation results (Figure 4-11). I speculate this was due to contaminated challenge solutions 
that increased the neutrophilic response in all day 63 groups. Overall, it is important to understand 
the limitations of inducing sensitisation in mice for future allergy therapy tests.  
 
 
4.5 Conclusions 
In conclusion, this is the first instance of high-density dMPAs being used to deliver allergen-only 
therapy in a mouse desensitisation model. Although the hypothesis was rejected, dMPAs of lower 
impact on the skin did result in localised protection in the challenged airway. Overall, the dMPAs of 
very high-density (e.g. 21k p/cm2) or very high application energy (e.g. 170 mJ) boosts Th2-
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mediated signalling, while a lower dMPA impact (10k-100 mJ) shows promise in reducing airway 
eosinophilia and inflammation. I confirmed that dMPA induced anti-OVA IgG does not assist in 
preventing anti-OVA IgE and neither dose low dose s.c. desensitisation. I recommend further 
testing of dMPA based desensitisation to be completed with dMPAs of densities lower than 10k 
p/cm2 and/or application energies lower than 100 mJ as both of these parameters tended to correlate 
with lower Th2 responses. 
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Chapter 5 
 
5 Increasing projection density of high-density dermal-targeted microprojection array 
increases Th2-mediated IgG1 
 
This chapter was written in a standalone paper format (excluding methods) and is being prepared 
for publication. The hypothesis was jointly conceived by Dr Germian Fernando, Dr Jacob Coffey 
and Nicole van der Burg (Candidate) and experiments included in thesis chapter were jointly 
planned and executed by Dr Jacob Coffey and Nicole van der Burg. A repeat of the vaccination 
study was made by Dr Jacob Coffey and Dr Hwee Ng for which the data was not included in this 
thesis as the candidate had minimal involvement.  
 
 
Summary 
Chapter 4 confirmed that a strong increase in anti-allergen IgG did not block anti-allergen IgE, 
while device conditions with a lower impact (density and application energy) on the skin resulted in 
lower Th2 responses. Where halving the density from 21k p/cm2 to 10k p/cm2 tended to have the 
most significant effect on protection against Th2-mediated eosinophils. Therefore, in Chapter 5 the 
density of the dMPA was titrated to assess its effect on the skin and producing specific antibodies. 
The dMPAs were made to densities of 5k, 10k, 21k and 30k p/cm2 and all applied at the same 100 
mJ energy with the same delivered dose and similar penetration depths in mouse flank skin. Instead 
of OVA, mice were immunised with a conventional influenza vaccine (Fluvax) that is known to 
induce a strong antibody response from a single immunisation – reducing the complexity of 
multiple boosts required for OVA. Results found that by decreasing the density from 30k to 5k 
p/cm2 both the level of epidermal cell death and the level of specific IgG1 decreased in a density-
dependant manner without an increase in IgG2a. This suggests that the high-density dMPA density 
had a direct adjuvant effect on the production of IgG1 responses through Th2 mediated signalling.  
 
 
5.1 Introduction 
Many therapies require specific-antigen delivery to APCs. These include, but are not limited to, 
infectious disease vaccination [310], AIT [9, 206] and cancer immunotherapy [316]. Delivery by 
i.d. targets significantly more APCs present in the skin than i.m. or subcutaneous injection [113, 
343]. Despite this increase in APC targeting, i.d. administrations are rarely used as a therapeutic 
delivery device as they require specialised training to avoid common dosing inconsistencies. 
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Immunising with an i.d. injection also requires smaller volumes to avoid discomfort, therefore, 
limiting the maximum deliverable dose. A range of complex devices have been developed to 
increase the ease of use and consistency of i.d. injection administration [304]. On the other hand, 
dermal-targeted microprojection arrays (dMPAs) deposit dissolvable coating containing the vaccine 
(also into the dermis of skin) and can be applied with minimal training by either medical staff or the 
patients themselves [301]. Application of placebo dMPAs onto skin has also correlated with APC 
migration out of skin, suggesting a physical adjuvant effect [300]. Many dMPA vaccination studies 
successfully resulted in protective immunity to antigens using 10-100 fold less dose, without the use 
of chemical adjuvants [25, 198, 304, 323].  
 
Downstream effects from APC targeting leads to specific priming of several immune pathways 
including Th1, Th2 and Treg [333]. Where strong responses of Th1 inhibits Th2 and vice versa, 
while strong Treg signalling downregulates both Th1 and Th2 responses to restore balance [84]. For 
example, allergic patients are inflicted with strong allergen-specific Th2 immunity from APC 
priming while treatment with AIT enhances APC-mediated Treg immunity [173]. Contrary to AIT, 
most vaccinations aim to boost both specific Th1 and/or specific Th2 responses. There are several 
injectable Th1 or Th2 chemical or microbial immunostimulants available (often termed 
“adjuvants”).  However, the ability to mix two adjuvants and achieve both Th1 and Th2 responses is 
very limited [111]. Of these, several adjuvants including LPS, Quil-A, CpG oligo deoxynucleotide, 
cholera toxin, Alum [334] and Quillaja saponaria extract 21 (QS-21) [308] have also been delivered 
by dMPA vaccination in mice to boost immunity. For example, co-delivering QS-21 (Th1 adjuvant) 
and influenza antigen (Intanza 2013) by dMPAs increases the Intanza-IgG1 and –IgG2c higher than 
unadjuvanted dMPA [308]. Although adding chemical adjuvants has successfully boosted many 
approved vaccinations, they also add additional unwanted side effects such as granulomas, fever 
and a sore arm at injection site [111].  
 
Several dMPA vaccination studies (without additional adjuvants) show that dMPAs can increase 
either Th1, Th2 or Treg responses, often more so than injectable controls [144, 206, 323]. Thus, 
more studies should investigate whether these contradictory responses can be tailored by dMPA 
design alone. For instance, high-density (> 1k p/cm2) dMPA vaccination indicated a Th2-priming 
mechanism that resulted in a high ratio of vaccine-specific IgG1 to IgG2c antibodies in mice [308]. 
Yet, adding a Th1 adjuvant, created a boosted but balanced Th1:Th2 response without the need for 
multiple adjuvants [308, 334]. On the other hand, low-density (< 1k p/cm2) dMPA vaccination with 
allergens primed Tregs for AIT [206]. Low-density dMPAs have also enhanced proliferation of the 
Th1-mediated CD8+ T cells, which is promising for cancer immunotherapy [312, 334]. The 
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difference between the reported dMPA designs and the different pathways induced is yet to be 
systematically investigated, but differences in design clearly lead to different immune responses 
[229]. Overall, in addition to targeting APCs, it is likely that dMPA designs need to be tailored to 
either enhance immune responses (e.g. vaccination) or restore immune imbalances (e.g. 
immunotherapy) to specific antigens. 
 
Th1 or Th2 dominance is commonly defined by the leading antibody. In mice, Th1-mediation 
results in boosted specific IgG2a, IgG2c, IgG3 and/or IgG4 (depending on the mouse species) while 
Th2-mediation results in boosted specific IgG1 and/or IgE. Although, IgG1 is generally an 
indication of Th2 signalling, it also often increases during Th1 signalling [169]; thus, it is not the 
most reliable biomarker for determination between Th1 and Th2. However, in BALB/c mice, high 
levels of IgG2a (despite an increase in IgG1) are strongly linked to Th1. Therapeutic delivery with 
dMPAs have boosted multiple antibodies including specific IgG1 [133], IgG2a [263], IgG2c [133], 
IgA [319] and IgE [144] antibodies. Again, systematic analysis on the design of the dMPA and its 
effect on antibody differentiation has yet to be reported.  
 
One variable that appears to correlate with dMPA-induced IgG is the level of cell viability in the 
applied skin area [271]. As MPAs physically penetrate the skin, the majority of non-viable (dead) 
cells are presumed to be necrotic based on immediate tissue analyses [271]. An increase in necrosis 
(and necroptosis) in the skin enhances danger-associate molecular pattern signalling (i.e. release of 
extracellular DNA, high-mobility group box 1 protein and intact mitochondria etc.) that can lead to 
Th2 (not Th1) antibody production [243, 344, 345]. During dMPA application, there are several 
variables to consider that may affect the level of necrosis. These include length of projections, 
delivery depth of projections, application energy and projection density. Of these, Depelsenaire et 
al. [271] suggested a strong correlation between increased projection density of high-density 
dMPAs and increased cell death. Doubling the projection density also significantly increased 
Fluvax-IgG. In contrast, a comparison between two low-density dMPAs did not result in a change 
of anti-OVA IgG [264]. Therefore, I hypothesised that increasing the density of high-density 
dMPAs will correlate with an increase in cell death and Th2-mediated IgG1. 
 
Using a single Fluvax-immunisation model, I measured the level of epidermal cell death produced 
from 5k, 10k, 21k and 30k dMPAs applied at a constant application energy (100 mJ) and delivered 
dose (0.1 µg). A strong correlation was found between increasing projection density and number of 
dead cells. Similarly, a second strong correlation resulted between increasing number of dead cells 
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and anti-Fluvax IgG1 but not with IgG2a. In conclusion, high-density dMPAs correlated with 
reduced cell viability in the epidermis whilst increasing Th2-mediated antibody production.  
 
 
5.2 Methods 
See the following sections for relevant methods for Chapter 5: 
 3.1 Animals 
 3.2 Microprojection array fabrication: of 16 mm2 silicon 5k, 10k, 21k, 30k p/cm2. 
 3.3 Antigen coating of microprojection arrays – Fluvax 2016 coating 
 3.4 Application process of microprojection arrays – push-through application 
 3.5 Delivery characterisation of microprojection arrays – delivery efficiency 
 3.6 Discrimination of viable/non-viable cells via microscopy 
 3.7 Anti-Fluvax IgG subtypes via ELISA 
 3.19 Instrumentation 
 3.20 Statistics 
 
In order to determine the effect of dMPA density on Th1/Th2 antibodies, mice were vaccinated with 
0.1 µg Fluvax 2016 (containing A/California/7/2009, A/Hong Kong/4801/2014 and 
B/Brisbane/60/2008) as per timeline in Figure 5-1. dMPAs of 5k (5k-dMPA), 10k (10k-dMPA), 
21k (21k-dMPA) and 30k (30k-dMPA) densities were applied onto the flank skin with the push-
through applicator at 100 mJ for 2 min. A dose matched i.m. vaccination was included as a positive 
control for comparison against minimal skin cell death. An additional Th1 positive control was 
included by adding QS-21 adjuvant to the lowest density (5k-dMPA) which was hypothesised to 
result in the lowest IgG responses without adjuvant relative to higher densities. Blood was sampled 
using the retro-orbital route at day 21 and tested for initial increase in total anti-Fluvax IgG. At day 
63, mice were euthanised by CO2 inhalation before the majority of blood was collected (retro-
orbital); serum was stored at -20 ºC until analysis of anti-Fluvax IgG, IgG1 and IgG2a. The 
vaccination experiment was repeated with 0.1 µg of A/California with the same methods (data not 
included). 
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Figure 5-1: Projection density range of dermal-targeted microprojection array vaccination 
timeline. After hair removal (Nair), mice were vaccinated once with 0.1 µg of Fluvax using i.m. 
injection, 5k-dMPA, 10k-dMPA, 21k-dMPA, 30k-dMPA or 5k-dMPA + 1 µg QS-21 dMPAs. Blood 
samples were collected at day 21 and 63.  
 
 
5.3 Results 
5.3.1 Coating and delivery of each dermal-targeted microprojection array density applied at 100 
mJ was consistent.  
Silicon, conical shaped 5k-dMPA, 10k-dMPA, 21k-dMPA and 30k-dMPAs, coated with 
methylcellulose-based Fluvax solution resulted in even coatings as previously reported [25] (Figure 
5-2). BS-SEM of the coating (darker areas) on the silicon (brighter) indicates that the coating 
becomes thinner per projection as the projection density increases (Figure 5-2A). Whole array BS-
SEM imaging after each dMPA was applied to the mouse flank skin provided visual evidence that 
the majority of coating was removed during application (Figure 5-2B). However, delivery 
efficiency quantification showed that only a portion of the coating actually entered the skin, which 
differed with density. Although 14C-OVA was used to determine delivery efficiency of Fluvax, 
comparison studies previously performed in house found delivery of 14C-OVA or 14C-Fluvax results 
are comparable and so could be used inter-changeably (data not included). Using average delivery 
efficacy of each density from test 1, coating solutions were adjusted to ensure each density 
delivered an average of 0.1 µg during vaccination (Figure 5-3A). Therefore, I can approximate that 
each dMPA delivered an average of 0.1 µg ± 0.004 µg (5k-dMPA), ± 0.003 µg (10k-dMPA) ± 
0.005 µg (21k-dMPA) or ± 0.005 µg (30k-dMPA) Fluvax. Based on previously published 
penetration depths of the same dMPAs applied with the same 100 mJ into the dermis [216], the 
projection surface area within the epidermis increased as density increased (Figure 5-3B). Since the 
projection surface area increased as projection density increased, the thinning of coating seen in 
Figure 5-2A is to be expected as the same amount of coating solution was used on each dMPA 
density. Overall, each dMPA density had consistent coating and coating removal with varied 
delivers of vaccine into the skin that was adjusted for during vaccination so that the main variable 
between the densities was the surface area of the dMPA within the skin. 
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Figure 5-2: Fluvax coating  of projection density range of dermal-targeted microprojection array 
imaged with BS-SEM. (A) Vaccine coating (dark) and silicon conical-MPA (bright) of 5k, 10k, 21k 
and 30k p/cm2 dMPAs, scale bar: 100 µm (inset scale bar: 10 µm). (B) Representative SEMs of 
whole dMPAs after 100 mJ application to flank mouse skin, scale bar: 1 mm (inset scale bar: 10 
µm). 
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Figure 5-3: Projection density range of dermal-targeted microprojection array delivery efficiency 
and epidermal surface area. (A) All dMPA densities were coated with Fluvax coating spiked with 
14C-OVA, applied with 100 mJ to mouse flank skin. Percent of counts was calculated from controls 
and plotted per density, includes average ± SD of Test 1. (B) Schematic of penetration of a 
projection from each density through the stratum corneum, ‘StC’ and viable epidermis, ‘VE’ and 
into the dermis, ‘D’ (to scale by the x-axis). Shading indicates surface area within the epidermis, 
‘E’. Plot incudes total epidermal surface area calculated for each 16 mm2 dMPA. 
 
5.3.2 Epidermal cell death increases as silicon dMPA density increases. 
Confocal imaging of murine BALB/c flank skin subjected to dMPA applications and viability 
staining was used to quantify non-viable (dead) cells for each dMPA density (Figure 5-4). An 
increasing number of dead cells was observed in the epidermis with increasing dMPA density in 
Figure 5-4A. Using cell viability quantification methods, the number of dead cells per 16 mm2 area 
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was extrapolated from 3-4 images of naïve, i.m. injection (31G), 5k-dMPA, 10k-dMPA, 21k-dMPA 
or 30k-dMPA applications (Figure 5-4Bi). The addition of QS-21 to dMPAs was previously 
reported to increase cell death per projection so it was not included in the correlation analysis [308]. 
Within the 16 mm2 area of naïve skin 1760 ± 400 dead cells were measured; i.m. groups slightly 
increased this to 1930 ± 400 (not significant). The number of dead cells in naïve skin is a small 
percentage of the total cells within 16 mm2 similar to that seen in Depelsenaire et al. (3.5 ± 1.9% 
[271]) and would come about from natural cell turnover and handling of the skin. Relative to i.m., 
mean number of dead cells increased from 5k-dMPA (5,700 ± 800, p = 0.0076), 10k-dMPA (8,700 
± 3,400, p = 0.0759), 21k-dMPA (20,100 ± 3,000, p = 0.0011) to 30k-dMPA (29,000 ± 10,900, p = 
0.0498) (Figure 5-4Bi). On average, the number of dead cells ranged from 4.6–7.6 per projection 
(Appendix 10.17).  Although application energy was kept constant in this chapter (100 mJ), 
correlations to dMPA impact were still presented as epidermal surface area multiplied by 
application energy for an easier comparison between chapters. A direct, positive correlation 
between the average number of dead epidermal cells and the epidermal surface area of the array 
(multiplied by 100 mJ) was found (Figure 5-4Bii, R2  = 0.9808). In addition to BALf eosinophils 
(Figure 4-18), the number of applied projections (see Table 3-1) (multiplied by 100 mJ for 
consistency between chapters) directly correlated with number of dead epidermal cells (Figure 
5-4Biii, R2 = 0.9948). In summary, there was a linear correlation between projection density within 
the epidermis and epidermal cell death within 5k – 30k conical p/cm2.  
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Figure 5-4: Projection density range of dermal-targeted microprojection array cell viability in 
epidermis of mouse flank skin. (A) Representative 3D reconstructed image of flank skin (~50 µm 
deep) of viable (live, green) and non-viable (dead, pink) cells immediately after 100 mJ application 
of 5k-dMPA, 10k-dMPA, 21k-dMPA and 30k-dMPA, scale bar: 200 µm. (Bi) Quantification of dead 
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cells in a 16 mm2 area, n = 3-4 mice per group. (ii) Correlation between number of dMPA 
projections used and number of dead cells within the epidermis. (iii) Standardised plot of number of 
dead cells within the epidermis per projection for each dMPA density. 
 
5.3.3 Fluvax-IgG response increases with increasing dermal-targeted microprojection array 
density. 
After a single vaccination with 0.1 µg of Fluvax via i.m. or 5k-dMPA, 10k-dMPA, 21k-dMPA or 
30k-dMPA, blood samples were collected at day 21 and day 63 (Figure 5-1). Anti-Fluvax-IgG at 
day 21 resulted in a mild increase with increasing density (Appendix 10.18).  The trend was clearer 
by day 63 when IgG production was at its reported peak. The curves for day 63 dilutions are plotted 
in Appendix 10.19 and the mean ± SD with statistically significant differences to naïve and 5k-
QS21 control are listed in tables in Appendix 10.20. Plotting the average endpoint resulted in an 
increase in anti-Fluvax IgG (Figure 5-5A, left) and IgG1 titres (Figure 5-5B, left) with density, but 
not IgG2a (Figure 5-5C, left). As expected, adding QS21 significantly increased anti-Fluvax IgG 
titres (p = 0.0011), resulting in the highest anti-Fluvax IgG (2,880 ± 700), IgG1 (28,800 ± 16,100) 
and IgG2a (1400 ± 400) mean endpoint titres at day 63 (Figure 5-5, left). The repeated vaccination 
with A/California influenza resulted in a similar anti-A/Cal IgG increase as the anti-Fluvax at day 
63 (data not included in thesis). 
 
All unadjuvanted vaccinations also significantly increased anti-Fluvax IgG to naïve levels. Mean 
anti-Fluvax IgG endpoint tires increased with increasing dMPA density (from titre 320 up to 1,600), 
albeit not as strong as the 5k-QS21 vaccination (2,900 ± 715). The differential IgG response was 
due to an increased response of anit-Fluvax IgG1 subtype (Figure 5-5B, left). Interestingly, the 
IgG1 response in the 30k-dMPA group (19,200 ± 9,000) was similar to the 5k-QS21 group. While, 
none of the unadjuvanted vaccinations boosted anti-Fluvax IgG2a, with a combined average of 56 ± 
79 endpoints (Figure 5-5C, left), all of which are significantly less than the boost seen in the 5k-
QS21 group (see Appendix 10.20). These results indicate dMPA density is Th2 mediated but the 
addition of a Th1 adjuvant can boost both Th1 and Th2 responses.   
 
Separately, to determine a possible correlation between antibody subtypes and cell death, the mean 
cell death for each density was plotted against endpoint titres of each IgG (Figure 5-5, right). A one-
way ANOVA (Kruskal-Wallis test) was used to assess differences between the densities cell death 
and respective antibody (in brackets in graph title).  Both anti-Fluvax IgG (p = 0.0010) and IgG1 (p 
= 0.0023) correlated significantly with level of cell death. Linear R2 were added to assess the 
strength of the correlation. An R2 value of 0.975 (Figure 5-5A, right) then 0.992 (Figure 5-5B, 
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right) supports a positive correlation between increased cell death and anti-Fluvax IgG, specifically  
IgG1. With minimal subtype production an R2 value of 0.588 (Figure 5-5C, right), anti-Fluvax-
IgG2a did not correlate with dMPA density. Taken together, a positive correlation between 
antibody titres and cell death was measured in influenza-specific IgG and -IgG1, but not IgG2a, 
indicating density of high-density dMPAs can directly influence the level of Th2 but not Th1 
mediation in mice. 
 
 
5.4 Discussion 
Variables that need consideration following switching from a macro insertion injectable liquid 
(needle) to micro insertions of dissolvable coatings (such as dMPAs) include: time of therapeutic 
absorption, number of APCs targeted, concentration of therapeutic per APC, types of APCs 
targeted, type of inflammatory signalling and level of inflammatory signalling, to name a few [19, 
22, 229]. Here, I addressed the effect of density for high-density dMPAs on the level of 
inflammatory signalling within the epidermis (via cell death) and, in turn, its effect on Th1 and Th2 
antibody production. Most importantly, results found that the level of cell death strongly correlated 
with Th2-mediated IgG1, but not with Th1-mediated IgG2a, an effect not found elsewhere in other 
MPA reports. Additionally, this was the first report to immunise with a density as high as 30k p/cm2 
MPA, whereby the previous highest density was 21k p/cm2. Here we found that increasing the 
density beyond 21k p/cm2 continues to increase the IgG1 response, indicating the maximum 
potential of high-density dMPAs for Influenza immunisation has not yet been reached.  
 
Altering the dMPA density alone to increase the level of epidermal cell death increased the Th2 
antibody response in an influenza-based vaccination. Further analyses on the type of cytokine 
profile produced by the dMPAs would confirm if the response is Th1 or Th2 mediation. Increases 
of specific IgG1 has been reported in mice for both unadjuvanted dMPAs [25, 264, 271, 295] and 
injectable vaccinations [113]. The downside when requiring higher specific-IgG responses with 
injectable delivery is that either the dose or number of vaccinations must increase [25, 346]. 
Therefore, boosting responses in injectable vaccination often requires adjuvants and/or more 
administrations, increasing unwanted side effects and the cost of the vaccination. On the other hand, 
when Crichton et al. [25] compared a higher density of thin projections to a lower density of wide 
projections (keeping total cell death constant) they observed an increased cell death per projection 
(increasing from 21.8 to 54.7 dead cells per projection) that correlated with a significant increase in 
anti-Fluvax IgG (+35.6 ± 4.4%). Even though this indicates that an increase in cell death around 
each projection enhances the immune response, the wide projections also delivered deeper into the  
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Figure 5-5: Projection density range of dermal-targeted microprojection array vaccination IgG 
levels at day 63. Indirect ELISA measuring anti-Fluvax (A) -IgG, (B) -IgG1 and (C) -IgG2a 
endpoint titres after 0.1 µg Fluvax administered by single dMPA application at 100 mJ, n = 4-5. 
Endpoint titres with significance compared to naïve (*) and 5k-QS21 (#) on the left and endpoints 
plotted against mean number of dead cells as per Figure 5-4B with a linear trend line (dotted), 
trend line equation and R2 value on the right. Correlations on the right were assessed with a one-
way ANOVA (Kruskal-Wallis test), significance is presenting in the graph title for each. 
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skin, targeting more dermal cells. Number of dead epidermal cells per projection of dMPAs tested 
in this chapter were very similar (Appendix 10.17) as was the penetration depth. Yet, Th2 
antibodies continued to increase with increasing projection density. This suggests that IgG1 
responses are more likely influenced by a total increase in cell death within a given area of the skin 
(e.g. 16 mm2) than increased cell death per projection. This is further supported by assessing a 
single, but large insertion such as i.m. injection that resulted in an average of 173 dead epidermal 
cells upon insertion but did not boost the IgG1 beyond even the 5k-dMPA. Therefore, I suggest that 
the increase of Th2 antibodies is due to the total number of dead cells in the deliverable area, and 
not the number of dead cells per projection. This supports the co-localisation effect between 
delivered antigen and the surrounding immune cells as discussed in section 2.5.3. 
 
Whether or not a Th2 response is useful depends on the therapeutic and disease mechanisms. Using 
the level of MPA cell death to increase Th2 antibody responses is likely to have its lower and upper 
limits. For example, when comparing low-density dMPAs (<1,000 p/cm2), there is no significant 
difference in IgG levels despite changes in dose, penetration depth and/or density [264]. This could 
be due to the difference in APCs numbers targeted between low-density and high-density dMPAs. 
For example, Fernando et al. [271] estimated a dose delivered by a 21k-dMPA will reach 
approximately 2000 LCs and 500 dDCs in the skin, while a dMPA of <1k projections is likely to 
target ~20x less APCs by extrapolation. On the other end of the scale, Depelsenaire et al. [271], 
who also reported an increase in anti-Fluvax IgG between 10k-dMPAs and 21k-dMPAs, found a 
level of cell death that exceeds the upper threshold of increasing IgG response by applying 3 x 21k-
dMPAs to the same area of skin. The 3x 21k-dMPA had significantly less IgG than 1 x 21k-dMPA. 
As the 21k-dMPA used by Depelsenaire et al. [271] was like those used here, the surface area in the 
epidermis was approximated to equal 3 x 5.81 mm2 (17.43 mm2 within 16 mm2 or 1.09 mm2/mm2) 
which is larger than the given surface area and so overlap of applications within the same skin area 
must have occurred. When applying dMPAs with densities of 5k – 30k (0.08 – 0.46 mm2/mm2), the 
anti-Fluvax IgG1 continued to increase (Figure 5-5). These results suggest that the upper limit of 
increased cell death occurs between 30k and 3x 21k dMPA density and inducing cell death beyond 
that reduces the number of live cells to take up the vaccine to the point that IgG can no longer 
increase. I estimate that the number of live cells required correlates with between 0.46 – 1.09 mm2 
inserted/multi-inserted per 1 mm2 of skin. Importantly, this chapter suggests dMPAs can be 
designed to elicit a specific level of Th2-mediated antibody response when vaccinated with 
influenza antigen. I hypothesis that this response would be similar with other antigens as well. 
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Tailoring the Th1/Th2/Treg immune responses is evident by comparing AIT studies of different 
skin-based delivery routes. That is, AIT devices that induce strong cell death signalling will result 
in strong Th2-mediated responses while passive delivery leads to Treg-mediated responses. For 
example, tape stripping the skin prior to application of Viaskin® (DBV Technologies) loaded with 
100 µg of OVA [126] or peanut protein extract [221] elevated specific IgE, interluken-4 and 
interluken-13 (Th2). Application of the Viaskin without tape stripping (same dose) resulted in 
significantly more specific IgG2a [221] and infiltration of Tregs [347]. It is unknown if lower Th1 
and Th2 antibody responses seen here (5k-dMPA) indicate a switch to Treg responses or just a lack 
of immune response (similar to a low-density dMPA [133]). Further testing to assess regulatory 
effects of MPAs with a similar insertion area to the 5k-dMPA (1.28 mm2 in the epidermis) is 
required. Alternatively, increasing the width of low-density dMPAs increased CD8+ T cell activity 
(Th1) but none were as efficient as a single large insertion given by an i.d. [312]. This was further 
supported by Pearson et al. [311], who found stronger Th1 CD8+ T cell responses with i.d. 
vaccination of viral vectors than a dose matched 21k-dMPA. Strengthening the opposing correlation 
between density of insertion into skin and Th1 or Th2 responses. An increase in Th1 responses was 
not seen in the projection density range tested here, suggesting that Th1-based immunity requires < 
5k dMPA density.  Additionally, i.d. delivers a relevantly high therapeutic concentration to low cell 
death ratio [271]. Overall these reports suggest that stronger Th1 responses rely on higher 
therapeutic dose to lower cell death per projection (e.g. from lower density) than Th2.  
 
 
5.5 Conclusion 
In conclusion, this is the first instance of systematically comparing the effect of changing the 
density of high-density dMPAs in specific IgG responses. Overall, high-density dMPAs within 5k – 
30k induce Th2-mediated IgG1 but not Th1-mediated IgG2a, supporting the hypothesis. I 
confirmed that increasing dMPA density, and therefore impact on the skin, increased the epidermal 
cell death at the application site that positively correlated with an increase in anti-Fluvax IgG1. I 
recommend future testing of high-density dMPAs that require a Th2 mediated response to utilise 
densities of 5k and above (or dMPAs with a similar level of cell death). Additionally, I recommend 
future testing of high-density dMPAs that require neither Th1 or Th2 mediated antibody responses 
to utilise densities below 5k (or less than the 5k level of cell death). Although further testing is 
required to clarify the maximum density threshold at which neither anti-Fluvax IgG1 nor IgG2a are 
boosted above the naïve level. 
 
182 
 
Chapter 6 
 
6 Design, development and characterisation of a low-inflammatory microprojection array 
for epidermal-targeted delivery in mice  
 
This Chapter includes two parts. Part A is a stand-alone submitted manuscript titled “A low 
inflammatory, Langerhans cell-targeted microprojection patch to deliver ovalbumin to the 
epidermis of mouse skin” authored by Nicole M.D. van der Burg, Alexandra C.I. Depelsenaire, 
Michael L. Crichton, Paula Kuo, Simon Phipps and Mark A. Kendall. Within this manuscript, 
NMDvdB completed 90% of the experimental procedures, 90% of data analyses and 50% of the 
writing of the manuscript. The manuscript includes methods of very close similarity to those given 
in subsections in Chapter 3. Alternations to the submitted manuscript include addition of heading 
numbers and synchronisation of references to the thesis document. All “SUPP” figures are listed 
under Appendix 10.21. Chapter 6 Part B describes an additional epidermal MPA design using an 
alternative applicator and has some repeats of the data from part A for an easier comparison. 
Repetition of figures from Part A has been clearly highlighted in the figure legends.  
 
 
Summary 
In Chapter 4 and 5 the use of high-density, dMPAs to deliver therapeutics to the skin without 
inducing Th2 responses required lower impact on the skin and a lower density than originally 
hypothesised. As tolerance to allergens does not require strong immune responses, the ideal allergen 
exposure should only require uptake by antigen presenting cells rather than an increased immunity. 
The epidermis strata (and the Langerhans cells, LCs within) maintains tolerance in the steady state 
during exposure and so it could be a prime target for delivering allergens without promoting 
immune defence. However, there has been no report of a MPA design that can delivery primarily to 
the epidermis of mouse skin. Therefore, Chapter 6 assessed both conical and slit shaped projections 
applied at a variety of application energies with both the in-house push-through applicator and the 
more clinically relevant projectile applicator. Findings suggested that the slit-shaped projection 
MPA benefits the shallow delivery required in mouse skin and it could be applied with a minimal 
impact on skin inflammation. The epidermal-targeted MPA (eMPA) specifically enhanced LCs to 
migrate out of the skin with lower levels of a T cell priming receptor (MHC II). Therefore, eMPAs 
provide a more promising MPA design for allergen delivery without inducing unwanted immune 
responses. 
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Chapter 6A: Submitted Reviewed Manuscript 
 
Abstract 
In a low inflammatory skin environment, Langerhans cells (LCs) – but not dermal dendritic cells 
(dDCs) – contribute to the pivotal process of tolerance induction. Thus LCs are a target for specific-
tolerance therapies. LCs reside just below the stratum corneum, within the skin’s viable epidermis. 
One way to precisely deliver immunotherapies to LCs while remaining minimally invasive is with a 
skin delivery device such as a microprojection arrays (MPA). Today’s MPAs currently achieve 
rapid delivery (e.g. within minutes of application), but are focussed primarily at delivery of 
therapeutics to the dermis, deeper within the skin. Indeed, no MPA currently delivers specifically to 
the epidermal LCs of mouse skin. Without any convenient, pre-clinical device available, 
advancement of LC-targeted therapies has been limited. In this study, we designed and tested a 
novel MPA that delivers ovalbumin to the mouse epidermis (eMPA) while maintaining a low, local 
inflammatory response (as defined by low erythema after 24 hours). In comparison to available 
dermal-targeted MPAs (dMPA), only eMPAs with larger projection tip surface areas achieved 
shallow epidermal penetration at a low application energy. The eMPA characterised here induced 
significantly less erythema after 24 hours (p = 0.0004), less epidermal swelling after 72 hours (p < 
0.0001) and 52% less epidermal cell death than the dMPA. Despite these differences in skin 
inflammation, the eMPA and dMPA promoted similar levels of LC migration out of the skin.  
However, only the eMPA promoted LCs to migrate with a low MHC II expression and in the 
absence of dDC migration. Implementing this more mouse-appropriate and low-inflammatory 
eMPA device to deliver potential immunotherapeutics could improve the practicality and cell-
specific targeting of such therapeutics in the pre-clinical stage. Leading to more opportunities for 
LC-targeted therapeutics such as for allergy immunotherapy and asthma. 
 
 
6.1 Introduction 
Many therapies aimed at immune downregulation – such as allergy immunotherapy (AIT) [348], 
asthma [349], chronic obstructive pulmonary disease [350] and type I diabetes [351] – require 
specific, tolerogenic priming via APCs. One example of an APC able to serve this function is the 
Langerhans cell (LC) which resides in the skin’s viable epidermis. LCs play an important role in 
both immune defence and immune tolerance for skin infections, inflammations and tumours [236]. 
During homeostasis, LCs are pre-committed to support the maintenance of tolerance, unlike 
antigen-primed dermal dendritic cells (dDC) that often induce immunogenicity [252]. Therefore, 
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therapy to boost immune tolerance ideally requires specific delivery of antigens to the LCs within 
the viable epidermis.  
 
LCs are competent in presenting antigens through both MHC I and MHC II to CD8+ and CD4+ T 
cells, respectively [236]. They can also induce either specific effector Th2 [352] or specific 
regulatory T cell (Treg) responses [249, 253, 257]. This ability to induce contradictory T cell 
responses to the same antigen depends on the local inflammatory environment or adjuvant that the 
LC is exposed to. That is, high levels of inflammation in the viable epidermis (e.g. removing the 
stratum corneum via tape-stripping) increases the expression of MHC II on LCs that migrate to the 
draining lymph nodes and bias signalling towards either Th1 or Th2 differentiation [171, 221, 251, 
353]. Conversely, lower levels of inflammation in the viable epidermis (e.g. topical application of 
antigen, [171]), favours regulatory pathways including Tregs, and the secretion of interleuken-10 
and tumour growth factor-beta [126, 221]. Continuously sampling LCs in the low inflammatory 
homeostasis state can present antigens to both resident memory Tregs in the skin and circulate to 
Tregs within the skin draining lymph node [253].  Below the viable epidermis, the dermis contains a 
large support network for priming of the Th1 and Th2 pathways and thus is better suited for Th1 
and Th2 activation-based therapies [219, 352].  Targeting the viable epidermis creates a unique 
opportunity to enhance specific-Treg responses without activating inflammatory cells within the 
dermis below.  
 
Targeting and activating LCs in the thin epidermis using the common mouse model is notoriously 
difficult for several reasons.  First, the target site is much thinner than its human counterpart (mouse 
and human viable epidermal thicknesses, are respectively ~20 µm and ~50-100 µm).  Second, small 
therapeutics do not specifically target the viable epidermis and instead often enter systemic 
circulation, increasing the chance of an inflammatory response to the antigen [275, 335]. Third, 
most of the therapeutics used for AIT are too large to diffuse readily into the skin (i.e. > ~500 
daltons). Therapies below this size delivered by traditional topical patches can take hours to days of 
application to deliver the required dose [226, 335].  
 
The unmet challenge is for a range of molecules to effectively bypass the stratum corneum, while 
targeting the viable epidermis, with low-inflammation. To do this, the stratum corneum must be 
either removed, penetrated or hydrated. For example, combining topical patches with devices that 
removes the stratum corneum, such as tape-stripping certainly increases delivery efficiency [354] 
and LC activation [251]. However, removing the stratum corneum, induces local skin inflammation 
including  prolonged skin erythema (over 24 h) and activating Th2-mediated differentiation [86, 
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251], rather than tolerance. A review by Larraneta et al. [19] on transdermal devices highlights the 
importance of reducing local erythema, particularly for repetitive treatments (such as AIT) to 
maintain patient compliance. Overall, topical patches require an excess of therapeutic drug and long 
application times making them costly and difficult for patients to comply with but cannot feasibly 
delivery large sized therapeutics such as AIT quickly without mediating inflammation. Clearly, a 
more practical delivery device is required for quicker, low inflammatory viable epidermis targeting. 
 
Current research and development efforts are directed at producing transcutaneous devices to 
deposit therapies either with quick epidermal delivery or alongside a low skin inflammation in mice 
but not with both characteristics. Quick delivery is defined here as application within 15 min and is 
vitally important for both consistent dosing through the skin and patient compliance [306, 355, 
356]. Such rapid delivery methods include biolistic microparticle delivery  [139], ultrasound-
enhanced delivery [269] and ablative micro-fractional laser [357]. While biolistic microparticle 
delivery and ablative micro-fractional laser can target the viable epidermis within minutes they are 
also highly inflammatory (e.g. [358]) relative to the lower-inflammatory hydration chamber device 
chamber called Viaskin® [122]. Viaskin® relies on actively enhancing diffusion through the 
stratum corneum but remains slow to delivery. Indeed, no mouse-based viable epidermis device is 
available to both deliver quickly whilst inducing only a low level of skin inflammation. A class of 
device with the potential to meet this need is the microprojection array (MPA), which make up part 
of the microneedle field.  
 
MPAs are defined here as patches with an array of solid or dissolvable projections no taller 1 mm 
high each. The primary interest for MPA research and development in the last two decades has been 
on vaccination. MPAs are a more practical device than other skin delivery devices and is more 
tolerated by medical staff and patients alike [301]. Additionally, their micro wound delivery 
mechanism elicits activation of the immune response, mitigating the need for additional chemical 
adjuvants [271]. Most MPAs tested on human skin have penetrated into the epidermis and dermis, 
though some may indicate epidermal-only penetration is achievable with current conical-projection 
designs since the human epidermis is much thicker than mice, though no specific penetration 
measurements were reported [34]. However, there have been no pre-clinical mouse immune tests 
with MPAs that successfully  penetrate only into the epidermis, causing a gap the translation of 
delivering therapeutics to the epidermis between mice and human trials. Dermal-targeted MPAs 
(dMPAs) have a broad design range to induce a variety of skin inflammation responses. For 
example, a dMPA of with five projections each 750 µm (H) applied to mouse skin by hand resulted 
in erythema that cleared within 24 h [263]. Using a higher density of projections such as dMPAs of 
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21,000 projections/cm2, ranging in length of 40-190 µm applied to mouse skin by a spring loaded 
applicator resulted in persistent erythema up to 48 h [290]. Applicators can maintain a consistent 
MPA application into the skin, but can impart additional energy into the skin and increase the 
inflammatory skin response. Indeed, dMPAs have been designed and used in many shapes, densities 
and materials and have been extensively reviewed elsewhere [22]. An MPA to specifically target 
the mouse epidermis, with low inflammation, however, is yet to be reported. 
 
Here, we hypothesised that an epidermal-targeted MPA (eMPA) with low, local inflammatory 
characteristics would specifically target coated therapeutics to LCs without enhancing an 
inflammatory response. To test this hypothesis, we first designed and tested the delivery parameters 
of an eMPA for mice. We then characterised the local skin inflammatory response of the application 
area of the eMPAs. Thirdly, we assessed the effect of eMPA application on LC migration. We 
found that in order to combine epidermal delivery with a low inflammatory application energy, the 
eMPA projection design required a higher tip surface area (relative to a dMPA). This eMPA elicited 
low epidermal inflammation and, concurrently, increased LC activation with low MHC II 
expression without inducing dermal dendritic cell (dDC) migration. These findings of LC-
activating, low-inflammatory mouse eMPAs could have wide-reaching implications, providing a 
more practical delivery platform to deliver tolerant based therapeutics in a pre-clinical model.  
 
 
6.2 Methods 
Animals 
Female 6-8 week old BALB/c mice were obtained from the Australian Research Council (Perth, 
W.A.). Animals were maintained in accordance with The University of Queensland Animal Ethics 
guidelines. All experimental procedures were approved under ethics AIBN/556/12, AIBN/042/16 
and AIBN/043/16. When applying MPAs, animals were anaesthetised by intraperitoneal injection 
with a Ketamine (50 mg/kg) and Xylazil (10mg/kg) mix (both Troy laboratories, Smithfield, 
Australia) and its action reversed with atipamezole (Antisedan; Pfizer, Australia) diluted 1:10 in 
Phosphate Buffered Solution (PBS). Twenty-four hours prior to MPA application, dorsal and flank 
hair was removed using electric hair clippers (Wahl, Stirling IL, USA), then chemically removed 
with a depilatory cream (Nair, Church & Dwight, Trenton NJ, USA). After 24 h, histological 
analysis of the Nair skin compared to naïve skin found that Nair did not affect the skins thickness or 
cellular infiltration as previously reported [326]. All injections were performed using a 31G needle. 
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Microprojection array fabrication 
Silicon MPA fabrication 
Silicon MPAs were fabricated as previously described [327] with assistance from the Australian 
National Fabrication Facility Queensland Node. The area of the silicon wafer within 90% 
consistency was isolated and used for moulding (‘silicon master’). Projection designs included 
conical-shaped, 207 µm ± 5 µm tall projections at 10,000 (10k) projections/cm2 (p/cm2), herein 
referred to as conical-MPA (Figure 6-1A) or slit shaped, 110 µm ± 3 µm tall projections at 7k p/cm2 
(Figure 6-1B), herein referred to as slit-MPA. A similar conical-MPA design was first reported in 
Depelsenaire et al. [271] (previously named ‘Nanopatch’) and slit-MPA design in Crichton et al. 
[25] (previously named ‘Transdermal patch’). Silicon MPAs were imaged using secondary scanning 
electron microscopic (SEM) imaging (Hitachi, SU3500).  
 
Polycarbonate hot embossing of MPAs 
To fabricate polycarbonate MPAs, a polydimethylsiloxane (PDMS) mould was made by pouring a 
1:12 Sylgard-184 mixture over a salinized silicon master (using trichloro(octadecyl)silane, Sigma 
Aldrich 104817). Polycarbonate projections were hot embossed at 3,500 N as per Yeow et al. [327] 
with the following stacking: bottom platen, 1 mm polycarbonate foil, PDMS mould, top platen, 1 
mm-thick graphite pad. Repeated use of PDMS mould (over 5 repeats) required 3,600 – 4,000 N 
pressure to continue producing consistent projections. Conical-MPA projections became 190 ± 4.7 
µm tall (Figure 6-1C) and slit-MPA projections became 95 ± 2.4 µm tall (Figure 6-1D). Finally, 
polycarbonate MPAs were diced to 4 x 4 mm squares using a 0.1 mm nickel blade EVG dicer and 
treated with oxygen plasma prior to formulation coating to increase wettability. MPAs with a 
surface area of 16 mm2 had 1,600 projections per Conical-MPA and 1120 projections per slit-MPA. 
Polycarbonate MPAs were splutter coated with iridium then imaged using back-scatter scanning 
electron microscopic (BS-SEM) imaging (Hitachi, SU3500). Surface area of projections within the 
epidermis was calculated by measuring 10-20 projections from SEM images. The height (H) used 
was the average depth of the epidermis calculated in this report (26 µm). The following equations 
were used to calculate the average surface area of one projection then multiplied by the number of 
projections per MPA. 
 
 Lateral surface area of a cylinder for conical: A=2πr26 × 1600 projections (µm2) 
 Surface area for slit (i.e. 2 × trapezoid + 2 × equilateral triangle surface areas): 
   ቆ2 ൬ቀଶ଻ାௐଶ ቁܪ൰ቇ ൅ ൬2 ቀ
ு∗஽
ଶ ቁ൰ × 1120 projections (µm2) 
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Therapeutic coating of microprojection arrays 
Polycarbonate MPAs were coated as previously described [303]with a final concentration of 100 
mM PBS and 1% methylcellulose (HG 60). Either ovalbumin (OVA, Sigma, Grade V, 98%, filtered 
through 0.22 µm) diluted in PBS or PBS alone (placebo) was added to the coating solution. A 14C-
OVA-based coating assay was used  to calculate delivered dose [21]. The mean delivery efficiency 
of each condition (see SUPP 1) was measured and coating formulations adjusted to ensure each 
OVA-coated MPA delivered 0.1 µg of OVA while the concentration of the excipients stayed the 
same for each (e.g. an MPA condition with a delivery efficiency of 10% would be coated with 1 µg 
OVA). To coat the formulations, MPAs were fixed in place on a coating rig with a vacuum before 
formulation was dispensed. The rotating MPA was dried with a jet stream of nitrogen gas at 23 °C. 
Consistent coating was confirmed with BS-SEM (Hitachi, SU3500) (SUPP 2). 
 
Application of microprojection arrays to skin 
To prepare the skin for application, a fold of flank skin was extended and fixed as described in 
Coffey et al. [216]. The skin was not over stretched and was applied to in its natural tension (Figure 
6-1E insert). A push-through spring loaded applicator was used to accelerate the MPA over 1 - 2 
mm of space before contacting the skin fold as previously described [295]. The MPA was removed 
after 2 min, after which the desired dose of formulation was deposited in the skin, as confirmed 
previously [303]. A maximum of eight applications could be applied per mouse without 
applications overlapping (Figure 6-1E). The 36 gram (g) plunger of the push-through applicator was 
loaded to deliver MPAs with application velocities (and energies) of 0.9 m/s (15 mJ), 1.3 m/s (30 
mJ), 1.8 m/s (60 mJ), 2.3 m/s (100 mJ) or 3.1 m/s (170 mJ). 
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Figure 6-1: Representative images of MPA array design and application using a mouse model. 
Secondary SEM image of silicon masters of (A) conical-MPA projections and (B) slit-MPA 
projections. BS-SEM image of polycarbonate moulded MPAs coated in iridium of (C) conical-MPA 
and (D) slit-MPA. Scale bar for A-D is 100 µm. (E) Photograph of flank positioning during MPA 
application on a mouse, insert depicts close up of 4 x 4 mm MPA applied to flank skin fold with 
push-through applicator plunger visible. 
 
Measurement of penetration depth and epidermal displacement 
Fluorescent penetration tracks were measured using histology to quantify skin penetration depth. 
Polycarbonate MPAs were coated with an OVA-based formulation including 0.05% yellow-green 
200 nm FluoSpheres (F8811, Thermo Fischer scientific, USA), applied to mouse skin for 2 min and 
penetration depth analysed as previously published [20]. A minimum of three 20 µm thick cyro-
sections from n = 3 mice were imaged at 20x and analysed using the Zeiss confocal microscope 
LSM510 with Zen software 2010 respectively. Only MPA conditions that resulted in visual 
fluorescent penetration were imaged for quantification. 
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Assessment of epidermal inflammation 
To assess skin erythema, OVA-coated eMPA and dMPAs were applied to mouse flanks and then 
imaged at t = 0, t = 24 and t = 72 h after application. Images were scored using the Draize Index as 
per [262, 328]. Representative images for each condition can be found in SUPP 3. Viable 
epidermal-specific swelling was quantified after eMPA, dMPA or a 20 µl i.d (31 G) injection. 
Applied skin was excised (~2 mm deep) at t = 24 or t = 72 h, fixed (10% Neutral Buffered Formalin 
for 2 h), embedded in paraffin and sectioned to 10 µm thick. Sections were stained with 
heamatoxylin (HHS32, Sigma-Aldrich) and eosin (E4009, Sigma-Aldrich) (H&E) and mounted 
under dibutylphthalate polystyrene xylene, DPX (3197, Ajax, Thermo Fischer, USA). Stained 
sections were imaged with an Aperio slide scanner microscope and epidermal and dermal 
thicknesses were measured at 20x using ImageScope software. The thickness of each application 
condition was compared to naïve skin of three mice. Note here that skin thickness in paraffin 
embedded sections were consistently thinner than cyro-sections and so comparisons were made to 
naïve skin within respective mediums. 
 
Discrimination of viable/non-viable cells via microscopy 
To discriminate between live and dead cells, the viability dyes Acridine Orange and Ethidium 
Bromide were used as described elsewhere (e.g. [271, 358]), with the following adaptions for 
thicker flank skin compared to previously used ear skin. Briefly, OVA-coated and applied eMPAs 
and dMPAs or intradermal injection (i.d.) applied flank areas were excised immediately after 
euthanasia with at least 3 mm excess border around the site. Skin was submerged under a mix of 
Acridine Orange (15 µg/ml) and Ethidium Bromide (50 µg/ml) in PBS and incubated at 37 °C for 
1.5 hr. MPA-applied skin was imaged (20x, 40-70 µm deep at 1 µm z-stack intervals) using the 
Zeiss LSM510 confocal microscope. Ethidium Bromide positive dead cells were quantified using 
Imaris software (assuming a 5.18 µm cell diameter). The number of dead cells in an MPA contact 
area of 16 mm2 were extrapolated from 3-4 3D-images (1.095-1.460 mm2) of each application 
repeat.  
 
Flow cytometry 
Flow cytometry was used to identify skin APCs migrating to the inguinal draining lymph node 
(dLN) after eMPA or dMPA application compared to naïve dLNs. Total numbers of DCs, and LC 
and dDC subsets were quantified per flow sample of each dLN at either t = 24, 48 or 72 h after a 
PBS MPA (left dLN) and a 0.1 µg OVA MPA (right dLN) application. dLNs were processed 
individually, however, based on Kool et al. [329], an ipsilateral cross over of cell migration from 
skin application can make up to 20% of the opposite dLNs cell content. dLN were digested with 
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collagenase D (1 mg/ml) and DNase I (0.2 mg/ml) for 30 min at 37oC. dLNS were individually 
homogenised, washed through a 0.22 µm strainer and resuspended in sterile 0.1% foetal calf serum 
(in PBS) dilution buffer. Aqua (cat:L34966, Thermo Fisher) was used for live/dead differentiation 
and anti-mouse monoclonal antibody to CD16/32 (2.4G2, cat:553142, BD Pharmingen) blocked 
exposed Fc sites. Then anti-mouse monocolonal antibodies against CD11c (N418, cat:25-0114-82, 
eBioscience), CD11b (M1/70, cat:101226, BioLegend), CD326 (EpCAM) (G8.8, cat:118214, 
BioLegend), MHC II (M5/114.15.2, cat11-5321.85, eBioscience) were added, and associated 
isotypes were used for controls (spleen). Cells were incubated, washed and analysed as previously 
published [330]. Cells were acquired using the Gallios cytometer and analysed with Kaluza 
software. 
 
Statistics 
Statistics were performed in Graphpad Prism (version 6 or 7 for Windows; GraphPad 140 Software, 
La Jolla, CA) using unpaired t-tests assuming Gaussian distribution between either naïve or 
sensitised and treated groups. Statistical differences between a number of comparable groups was 
assessed using a one-way ANOVA (Supplementary figures only). P-values of ≤ 0.05 were 
considered as significant. All values are expressed as mean ± standard deviation (SD) unless 
otherwise stated. All groups that resulted in a significant (p ≤ 0.05) difference with another group 
within the graph was denoted with an asterisks equal to the significance grouping: *p ≤ 0.05, **p ≤ 
0.01, *** p ≤ 0.001, **** p ≤ 0.0001. All non-significant results (p > 0.05) have no symbol in 
graphs. 
 
 
6.3 Results 
6.3.1 Slit-shaped polycarbonate MPAs primarily deliver coating to the epidermis 
To establish MPAs for epidermal targeting, we first manufactured MPAs in polycarbonate material. 
As reported previously by Yeow et al. [327], polycarbonate is a well-suited material for MPA 
fabrication including relatively low cost, high modulus and high impact strength. The hot 
embossing procedure of the same silicon master also allows for easy replication of consistent MPA 
projections unlike the dry etching process of silicon MPA fabrication.  Here, hot embossing of high-
density projections required optimisation of the PDMS mould to increase flexibility. Here, we 
found a ratio of 1:12 curing agent to PDMS was better suited (i.e. fewer breakages) for repeated, 
high-pressure hot embossing (SUPP 4), which differed from the recommended 1:10 ratio. By 
optimising the PDMS mould and hot embossing procedure, we were able to reproduce silicon 
master MPAs into polycarbonate MPAs using the same mould multiple times. The polycarbonate 
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projections retained the same base width but were 10-15% (20 µm) shorter than their silicon 
masters (compare Figure 6-1A to C and B to D). Polycarbonate slit-MPA tips increased in width 
(see Figure 6-2A) from an average of 0.71 ± 0.15 µm to 2.16 ± 0.35 µm (Figure 6-2B) similar to 
Yeow et al. [327]. Figure 6-2C indicates that conical-MPA or slit-MPAs that penetrate 15 µm 
equate to the surface area of the bevel of a 27 – 31G needle used for intradermal injections into 
mouse skin. The polycarbonate projections were significantly blunter than the master but 
maintained > 85% projection length and 100% projection width and depth of the master projections. 
Figure 6-2: Surface area of polycarbonate projections. (A) BS-SEM image of slit-MPA tip from (i) 
silicon or (ii) iridium-coated polycarbonate MPA, scale bar: 10 µm. (B) Plot of tip width 
quantification for silicon, ‘Si’, and polycarbonate, ‘PC’, slit-MPA projections. (C) Calculated total 
projection surface area of a polycarbonate MPA (y-axis) that would be present in the skin 
depending on the depth of penetration (x-axis) including background shading of average depth of 
stratum corneum, ‘StC’, viable epidermis, ‘VE’, and dermis, ‘D’. Plot includes surface area of 
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intradermal (i.d.) affected area using a 27, 29 and 31G needle assuming only bevel of needle is 
inserted.  
 
To target the epidermis specifically, polycarbonate conical- and slit-MPAs were applied at a range 
of application energies (15, 30, 60 or 100 mJ) and BS-SEM confirmed consistent removal of 
coating (Figure 6-3A). As BS-SEM is not a reliable method to assess penetration depth due to skins 
viscoelasticity during application, penetration was assessed by histological analysis of applied skin 
sections using fluorescently coated MPAs. (Figure 6-3B). As the mouse epidermis (StC + viable 
epidermis) in the flank averages 26.5 ± 4.6 µm thick (Figure 6-3C), we initially tested shorter (75 
µm), conical-MPAs. The combination of short and blunt projections did not penetrate the skin at a 
low application energy (data not shown), unlike similar short (40 µm) but sharp conical-MPAs 
reported to penetrate mouse flank skin [290]. On the contrary, Figure 6-3D shows penetration of 
190 µm long conical-MPAs deposited coating beyond the epidermis at the lowest application 
energy (15 mJ, 31.5 ± 9.0 µm). However, the slit-MPA consistently delivered coating into the 
viable epidermis (15.7 ± 9.2 µm) using a 30 mJ application energy. Based on these observations, we 
defined the slit-MPA applied at 30 mJ as the ‘eMPA’ and the conical-MPA applied at 100 mJ as the 
‘dMPA’ for comparison (which delivered to a depth of 75.2 ± 26.3 µm, Figure 6-3D). Figure 6-3E 
represents the total projection surface area / volume within the skin strata based on the average 
depth of penetration for both eMPA and dMPA given in Figure 6-3D. Once applied, the total 
surface area of the eMPA and dMPA projections is 1.09 ± 0.64 mm2 and 5.22 mm2 within the viable 
epidermis respectively (Figure 6-3F, left). This equates to a displacement volume of 0.002 ± 0.001 
mm3 (0.47%) or 0.055 mm3 (13.32%) within the 0.416 mm3 (i.e. 4 x 4 x 0.025 mm) volume of the 
viable epidermis respectively (Figure 6-3F, right). Although an intradermal injection bevel insertion 
affected a smaller surface area in the epidermis (0.869 mm2, based on a 10 degree insertion) than 
the MPAs, it displaced an order of magnitude more volume (0.032 mm2) than the eMPA and an 
order of magnitude less than the dMPA. Plotting the epidermal surface area multiplied by the 
application energy (mm2 × mJ) highlights the log10 correlation between the three devices (SUPP 5). 
Note here that the energy of the i.d. injection was approximated to 0.83 mJ based on previously 
published insertion energies [359]. Additionally, the total tip surface area of the eMPA (0.062 ± 
0.01 mm2) was 1.5-fold higher than dMPA (0.041 ± 0.01 mm2) (Figure 6-3G). By normalising the 
energy of application to the total tip surface area, the eMPA was applied at 5x less energy per mm2 
than the dMPA (483 and 2439 mJ / mm2, respectively).  Taken together, these results provide 
evidence that slit-MPAs, with significantly higher tip surface areas than conical-MPAs, are better 
suited for epidermal only delivery using low application energies. By contrast, even when using the 
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lowest application energy tested, higher density conical-MPAs deliver beyond the viable epidermis 
into the dermis and therefore were deemed not suitable for epidermal only delivery. 
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Figure 6-3: Slit-MPAs applied at 30 mJ deposited coating to the epidermis of mouse skin. (A) BS- 
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SEM of applied OVA-coated MPA per projection shape and application energy. Images indicate 
areas of coating (dark) and removed coating (light), inset include black arrow of length of coating 
removed, scale bars: 100 µm, 10 µm inset. (B) Confocal images of 20 µm sections of green 
FluoSpheres delivered by MPAs into mouse flank skin, scale bar: 200 µm. Arrow indicates one of 
the projection tracks per image (arrow 75 µm long). (C) Depth of the epidermis using cryo 
preserved sections of naïve skin. (D) Skin penetration depth measurements of MPA projections from 
n = 3 mice, totalling n = 41-117 measurements, mean ± SD. (E) An outline of the average depth of 
eMPA and dMPA penetration into the skin, based on Figure 2D, shading indicates the area of the 
projection within epidermis. (C-E) The average skin strata thicknesses: orange (‘StC’ stratum 
coreum), green (‘VE’ viable epidermis) and pink (‘D’, dermis), where StC + viable epidermis 
together make up the epidermis, ‘E’. (F) Calculated epidermal surface area (left) and volume 
displaced (right) of an applied 31G needle bevel (i.d.), eMPA or dMPA. eMPA includes error based 
on penetration depth while dMPA epidermal area and volume does not differ within the SD of 
penetration. (G) Total surface area of polycarbonate tips for conical-MPA or slit-MPA, n = 7 and 
14 projection tip measurements respectively. 
 
6.3.2 Application of eMPAs resulted in a lower inflammatory response than dMPAs 
Skin inflammation of the applied area was assessed by erythema, epidermal thickness and cell 
viability quantification. Progression of erythema was captured by photographic images taken at 5 
min (t = 0 h), t = 24 h and t = 72 h after application (SUPP 3). Photo images were then scored using 
Draize score index for erythema (Figure 6-4A). Immediately after application, the application site 
of MPA or i.d. bleb was clearly visible (SUPP 3). The eMPA induced significantly less erythema 
than the dMPA at t = 0 h (p = 0.0002), t = 24 h (p = 0.0004) and t = 72 h (p = 0.025) (Figure 6-4B). 
All i.d. injections received a Draize score of zero. 
 
Next, we assessed the effect of the eMPA application alone (PBS coating) on the swelling of the 
viable epidermis using H&E-stained histology sections (Figure 6-5A). The thickness of the naïve 
viable epidermis averaged 15.9 ± 5.0 µm and the thickness of the dermis averaged 178.4 ± 29.6 µm. 
The dermis became thinner 24 h after each application (dMPA p < 0.0001, eMPA p = 0.007, i.d. p < 
0.0001, SUPP 6). Twenty-four hours after both the dMPA (p < 0.0001, 19.8 ± 5.4 µm) and eMPA 
application (p = 0.002, 18.6 ± 6.1 µm) the viable epidermis increased in thickness (Figure 5B). 
Concurrently, the thickness of the viable epidermis after i.d. injection reduced slightly at 24 h (p = 
0.038, 13.4 ± 7.9 µm) but had returned to naïve thickness by 72 h (15.4 ± 6.2 µm).  By 72 h, the 
eMPA viable epidermis thickening had dissipated (14.1 ± 6.2 µm) while the dMPA maintained an 
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inflamed viable epidermis (20.36 ± 6.8 µm). These results show that the eMPA induces 
significantly less local inflammation in the viable epidermis than the dermal-targeted device. 
 
 
Figure 6-4: eMPA resulted in lower erythema than dMPA at t = 0, 24 and 72 h. (A) Representative 
images of MPA-applied flank skin that scored (left to right), 1, 2 and 3 using Draize scoring, scale 
bar: 1 mm. (B) Plot of Draize score of application sites t = 0, 24 and 72 h after dMPA or eMPA 
application, n = 3 – 9 mice and n = 6 – 18 applications. 
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Figure 6-5: eMPA evoked less swelling of the viable epidermis than dMPA. Swelling of the 
epidermis and dermis 24 h and 72 h post application of placebo formulation/injection. (A) 
Representative image of H&E-stained flank skin sections (10 µm) of (A) naïve, (B) 24 h post-dMPA, 
(C) 72 h post-dMPA (D), 24 h post-eMPA, (E) 72 h post-eMPA, (F) 24 h post-20 µl i.d. and (G) 72 
h post-20 µl i.d. (H, scale bar: 200 µm. (B) Epidermal skin thickness measured from H&E-stained 
sections of n = 3 mice and n = 54-179 measurements per condition, dotted line indicates mean of 
naive measurements (n = 3 mice with n = 4 sections each). 
 
The physical application of devices to the skin, such as tattoo needles [360] and the Nanopatch™ (a 
high-density dMPA applied to the skin to deliver vaccine [271]) are known to induce localised cell 
death. As cell death is associated with an increased pro-inflammatory response [361-363], we 
sought to quantify the effect of the MPAs used here by quantifying non-viable cells in 16 mm2 of 
the epidermis (Figure 6-6). Individual non-viable (dead) cells could only be quantified immediately 
after application (t = 0) by confocal microscopy. Even though Draize scores for eMPA were low 
(typically 0-1) for eMPA and not present for i.d. at t = 24 h, images taken at t = 24 h and t = 72 h 
confirmed the presence of non-viable cells (Figure 6-6A and B). At t = 24 h, the cell death appears 
to have spread further than at t = 0 h which may be due to either easier accessibility of the ethidium 
bromide dye staining disintegrating cells at each site or additional cell death such as necroptosis 
[243]. At t = 0 h the dMPA had visually induced the highest proportion of dead cells that seemed to 
lyse similar to the eMAP at t = 24 h (Figure 6-6C). This was reflected in Figure 6-6D, where 
quantification of dead cells at t = 0 h resulted in a clear trend of increasing number of dead cells 
from i.d. < eMPA < dMPA. Plotting the total number of dead cells against the epidermal mm2 × mJ 
indicated that mm2 × mJ on a log10 scale correlated with the number of dead cells. Overall, the 
eMPA resulted in significantly more total cell death (9614 ± 1359, p=0.0005) within the epidermis 
than the i.d. injection (1227 ± 904), while the dMPA (18297 ± 1271) resulted in the most epidermal 
cell death (i.d. p < 0.0001, eMPA p = 0.0013, Figure 6-6D). Although it is important to note that not 
all non-viable cells would have been accounted for during the larger volumes displaced in the 
epidermis by the i.d. and dMPA – as apparent by the black spaces in the images (Figure 6-6, t = 0 
h). This analysis further supports that the eMPA application to skin results in a relatively low local 
skin inflammation. Additionally, the cell death imaging specifically highlights the prolonged effect 
microprojection skin penetration has on the epidermal cells (i.e. cell death still visible up to 72 h, 
despite Draize scores of zero). 
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Figure 6-6: Application of eMPA induces less epidermal cell death than dMPA. Quantification 
and representative 3D reconstructed image of flank skin (~50 µm deep), 20x magnification, images 
of skin stained  for viable/live (green) and non-viable/dead (pink) cells taken at time points 0 h, 24 h 
201 
 
and 72 h after application of (A) 20 µl i.d. 31G, (B) eMPA and (C) dMPA, scale bar: 200 µm.  (D) 
Quantification of dead cells in the epidermis at t = 0 h, n = 3 mice, mean ± SD. 
 
6.3.3 eMPA application induces LC migration but not dDC migration 
To assess whether the eMPA targeted specific resident APCs in the flank skin, we excised inguinal 
dLNs at t = 24, 48 and 72 h after eMPA or dMPA application (with PBS-based or OVA-based 
coating). During this time-frame (in naïve mice), DCs are only expected to migrate out of the skin 
in response to the MPA application based on previous reports on DCs in skin after MPA application 
[232, 300, 364]. Therefore, DC re-population of the skin after application was not assessed. Multi-
colour flow cytometry was used to identify distinct DC subsets, including ‘total DC’ which subsets 
to resident DC, ‘Res DC’ or migratory DC ‘Mig DC’. Mig DC further subsets to migratory LC 
‘Mig LC’ or migratory dDC ‘Mig dDC’ (see Figure 6-7A for the gating strategy). These 
populations were defined by: total DCs (CD11c+ MHC II(lo/hi)) cells that were subdivided using 
mean florescent intensity (MFI) histograms into Res DC (CD11c+ MHC II (lo)) and Mig DC 
(CD11c+ MHC II (hi)). Mig DCs were then further sub-populated to Mig LCs (CD11c+ MHC II 
(hi) CD11b+ EpCAM+) and Mig dDCs (CD11c+ MHC II (hi) CD11b+ EpCAM(lo)). 
 
Compared to dLNs from naïve mice, there were no significant differences between the numbers of 
live, single cells in any condition (SUPP 7). Concurrently, within each application group, there was 
no difference between total number of cells between time points t = 24, 48 or 72 h, nor between 
delivery of PBS or OVA within the Mig LC population nor within the Mig dDC population (SUPP 
7). We henceforth compared eMPA and dMPA by combining data from all three time points and 
both formulations (PBS and OVA, n = 18). The total number of DCs between naïve, eMPA and 
dMPA was similar (p = 0.57) (SUPP 8), while the dMPA-treated dLNs demonstrated the presence 
of more Mig DCs, although not significantly (p = 0.053) (SUPP 8). Expression levels (MFI) of 
MHC II were significantly higher on the dMPA Mig DCs (naïve p = 0.0008, eMPA p < 0.0001) 
than the eMPA Mig DCs (p = 0.0003) (Figure 6-7B, right). Conversely, the eMPA dLNs contained 
more Res DCs than both the naïve (p < 0.0001) and dMPA (p < 0.0001) (SUPP 8). Both eMPA Res 
DCs (Figure 6-7B, left) and Mig DCs (Figure 6-7B, right) expressed lower levels of MHC II than 
respective dMPA populations (p < 0.0001). Overall, the eMPA and dMPA induced LC migration 
while only the dMPA resulted in dDC migration (Figure 6-7C and D). Compared to naïve, the 
eMPA increased Mig LCs (number p < 0.0001, percent p = 0.0003) slightly more than the dMPA 
(number p = 0.0004, percent p = 0.0016), although this was not significant between the two MPAs 
(p = 0.83). While, the dMPA induced significantly more Mig dDCs than the eMPA (number p = 
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0.0014, percent p < 0.0001). Therefore, the eMPA preferentially targeted LCs while the dMPA 
targeted both LCs and dDCs. 
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Figure 6-7: eMPAs result in specific migration of epidermal LCs. Quantification of migratory LCs 
and dDCs in inguinal dLN from combined time points and antigen conditions of either eMPA (▼) 
or dMPA (●) applications compared to naïve (-) mice. (A) Gating strategy to identify and quantify 
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cell populations. (B) Graphs of the Mean Fluorescence Intensity (MFI) of MHC II for Res DC (left) 
and Mig DC (right). (C) Total number of Mig LC (left) and Mig dDC (right) cell populations. (D) 
Percent of Mig LC (left) and Mig dDC (right) cell populations from DC population. MPA groups 
included n = 9 mice with n = 18 dLNs per group; naïve group n = 4 mice (n = 8 dLN). Graph: 
mean ± SD. 
 
 
6.4 Discussion  
This is first reported study (to our knowledge) of the rapid delivery of biomolecules targeted to 
viable epidermis of mice, whilst maintaining a low local inflammatory response.  In achieving this, 
our findings open up exploration of the capabilities of the mouse model for therapies that would 
benefit from low inflammatory LC targeting such as asthma, AIT and chronic obstructive 
pulmonary disease. The study used polycarbonate MPAs, which is an inexpensive material that is 
well tolerated well by the skin’s immunity [286]. Thus, a polycarbonate eMPA is a suitable 
candidate for repetitive, immune downregulating therapies such as AIT. We have shown that blunt-
tipped eMPA designs deliver OVA antigen primarily to the epidermis of mouse flank skin, and 
preferentially induce LC migration. This is achieved with lower levels of skin inflammation than is 
induced by a dMPA. Additionally, Cohn et al. [306] showed that patient compliance significantly 
increases if AIT treatment duration is less than 15 min [306, 355, 356]. As is consistent with MPA 
application times previously reported in the literature [229, 310], the eMPA delivered the desired 
dose of OVA (0.1 µg) within 2 min. Although coating methods used in this report were crude, 
leading to a low delivery efficiency (SUPP 1), using a more efficient coating method such as dip 
coating or inkjet coating would improve dose sparing effects of eMPA delivery to Langerhans cells 
[144, 365]. 
 
Conical-MPA and slit-MPA projections were designed and tested at a variety of set application 
energies. In agreement with previous work of the microneedle field [21, 295, 312, 366] , conical-
MPAs were unable to deliver to the shallow mouse epidermis alone. For example, when Crichton et 
al. [295], used a similar application energy (26 mJ), the conical-MPA penetrated into the dermis of 
ear skin. Conversely, the slit-MPAs were initially reported to increase penetration depth into mouse 
skin [25]. Yet, using polycarbonate slit-MPAs with a larger (blunter) tip surface area (Figure 6-1F), 
led to reduced penetration into the skin that could be maintained at a lower application energy 
(Figure 6-3), thus generating less cell death (Figure 6-6) and ultimately less skin inflammation 
(Figure 6-4 and Figure 6-5). This study is the first to show MPAs can be re-designed to not only 
target the epidermis but also maintain low skin inflammation despite a relatively high-density 
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(7,000 projection/cm2). This approach builds upon insights into the viscoelasticity of the skin and 
the mechanical application of MPAs thereof [295, 367, 368].  
 
The closest epidermal-targeted MPA design to the eMPA previously reported is by Crichton et al. 
[295], which delivered OVA to the epidermal-dermal junction of mouse skin when applied by hand. 
Crichton et al. investigated the same MPA applied using a spring applicator at a range of 
application energies that led to penetration from the epidermal-dermal junction into approximately 
one third into mouse dermis. Interestingly, when application energy decreased, anti-OVA IgG 
response decreased (now known to be Th2-biased from unpublished data). Suggesting that lower 
application energies are necessary to avoid immune-activating responses. Additionally, 
Depelsenaire et al. reported that by halving the number of dMPA projections per MPA (from 3360 
to 1600) induced a significantly lower titre of anti-Fluvax IgG after delivery of influenza vaccine 
[271]. This indicates that MPA surface area applied to the skin can correlate with the level of 
immune activation. This avenue of changing the MPA design and application conditions to alter 
specific immunity is yet to be explored systematically. Together, these studies suggest that the 
combination of decreased application energy and delivery surface area (i.e. mm2 × mJ) would also 
lead to a reduced immune-activating response. The eMPA has a significantly lower mm2 × mJ than 
the dMPA, supporting its suitability to avoid the induction of immune-activating responses. 
 
The LCs of the skin are well known to elicit either an antigen-specific immune regulation (e.g. 
Treg) [369, 370] or immune activation (e.g. Th1/Th2) [86, 113], however, the inflammatory 
threshold for LC-induced immune activation is yet to be determined. The eMPA defined here 
induces less skin inflammation than the dMPA, primarily penetrating into the epidermis, resulting 
in strata-specific APC migration (Figure 6-7). In comparison to more inflammatory (erythema 
present > 24 h) mouse epidermal-based delivery devices tested for AIT, such as ablative micro-
fractional laser, OVA only administration increased allergic responses (Th2) and so additional Th1 
adjuvants were required to prevent Th2 activation  [201, 274]. While, delivery methods with low 
associated inflammatory responses, such as Viaskin®, enhanced Treg responses and prevented 
specific-Th2 activation in challenged mice [225, 347]. Although Viaskin® has shown great promise 
in AIT [122] by targeting delivery to the epidermis [126], each application repeat still takes 48 h 
[222].  Even though T cell responses are still to be investigated for the eMPA, we hypothesis that 
the eMPA would preferentially activate tolerance similar to Viaskin®. 
 
While delivery into the epidermis was achieved, it was also important in this study to assess that 
potential therapies would be taken up by the resident LCs and presented in the skin dLNs. Here, we 
206 
 
have shown that the eMPA specifically activated only LC migration while dMPA activated both LC 
and dDC migration (Figure 6-7). Interestingly, despite only inducing half the number of dead cells 
in the epidermis (Figure 6-6D), the eMPA dLNs contained the same number of migrating LCs (Mig 
LCs) as the dMPA. This is supported by Fernando et al. [291] who predicted that a dMPA of 16 
mm2 (as used here) would target therapeutic to approximately 2000 out of the 10,000 LCs available 
to migrate in mouse skin. It is possible that here, we have highlighted that there is a localised 
threshold of number of dead cells required to activate LC migration. So, even though the eMPA 
killed the lowest number of cells (relative to the dMPA and Fernando’s dMPA), the number of dead 
cells killed by the eMPA is likely to still be above the minimal threshold to activate the same ratio 
of LCs as higher levels of cell death. This, however, does not address the maturation state of the 
migrated LC. Nakano (2012) [371] reported higher MHC II expression on DCs is required for Th2 
priming in mice (and rats [372]) and correlates with an increase in Th1 activation. Therefore, 
because the expression of MHC II on Mig DC after eMPA was significantly lower than the Mig 
DCs of the dMPA (Figure 6-7B), the dMPA Mig DCs are significantly more likely to prime for 
effector T cell responses than the eMPA. Based on previous reports of MPAs similar to the dMPA, 
Ng et al. [323] found high-density dMPAs preferentially activated CD8+ T cells, while Shakya et 
al. [133] found low-density dMPAs induced a Th1-skewed response. Additionally, the eMPA dLNs 
contained a higher ratio of Res DCs than the dMPA similar to ratios seen in Viaskin® application, a 
device that has several promising results in AIT [126]. We hypothesise that as the eMPA does not 
activate dDC migration nor high levels of skin inflammation, it is less likely to activate immunity 
like the dMPAs and is more likely to deliver antigen to the LCs for specific tolerance. To test this, 
eMPAs should be investigated in future mouse model experiments of low inflammatory LC targeted 
immunotherapies such as asthma, AIT and chronic obstructive pulmonary disease. 
 
 
6.5 Conclusion 
Here, we describe an MPA specifically targeting the epidermal layer of skin in mice – the eMPA. 
The eMPA caused a lower level of skin inflammation response relative to a dMPA. To achieve this, 
the eMPA was designed to have a high-density of blunt tipped projections which was applied with a 
low energy. Additionally, the eMPA device can specifically target the LCs of the skin without 
activating dDC. Due to the specific cell targeting, eMPAs could lead to higher therapy efficiency 
using lower doses (i.e. making them safer and cheaper), increasing availability of the treatment and 
patient compliance. Therefore, this device provides a valuable tool for the necessary studies to 
advance LC targeting with a practical device from pre-clinical tests in mice to epidermal-based 
therapies in patients. 
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Chapter 6B: Additional data  
 
 
Summary 
Chapter 6A characterised the targeting of OVA into the epidermis of mouse skin via a low 
inflammatory eMPA delivery device. However, the in-house push-through applicator of Chapter 6A 
does not represent equipment that would be used in a more clinically relevant setting. Although the 
study in Chapter 6A aimed to find suitable device conditions specifically for the mouse model, the 
overall goal was the delivery of therapeutics to LCs in mice for a more accurate translation to 
humans. Therefore, in Chapter 6B I tested a spring-loaded projectile applicator designed to be more 
clinically relevant for use in humans on the mouse model. I assessed the penetration characteristics 
and skin inflammation of MPAs applied via the projectile applicator and compared them to the 
results of the push-through applicator described in Chapter 6A. Results show that the projectile 
applicator could be adjusted to deposit OVA primarily into the epidermis of mouse skin (P/eMPA) 
and maintained significantly less impact on the skin than the dMPA. Although the P/eMPA 
maintained a similar impact on the skin as the eMPA it resulted in significantly higher numbers of 
epidermal cell death, deviating from the trend seen when using the in-house applicator. Changes in 
epidermal cell death can influence the induction of immune responses. Therefore, if mice are used 
in the pre-clinical testing, it is important to assess clinically relevant equipment in mice before 
testing in humans as differences in pre-established trends in mice with in-house equipment can 
change when the mechanisms by which the application occurs is changed. 
 
 
6.6 Introduction 
Skin delivery devices such as the MPA are often altered from designs used in the mouse model 
when tested in a clinical setting. Alterations are usually made due to the size difference between 
mouse and human and the translation from in-house equipment to easy to use and package clinical 
designs. Evaluating the effect these alterations have on the MPA impact on the skin between the 
two species can be difficult and there is little comparative data. The push-through application of 
MPAs to mouse skin exploits a stand that can hold the whole mouse body in place, adhesives to fix 
skin in place and adjustable equipment so that many variables can be tested (see Figure 3-4). As the 
push-through applicator used here relies on manual compression of a heavy plunger, it does not 
translate well to the clinic because medical devices require easily useable equipment that can be 
reproduced en masse. Such clinical devices have reduced adjustability but tighten repeatability and 
are significantly different from in-house applicators [289]. These changes can include changes to 
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MPA size, projection length, applicator design and application energy (compare [295] and [373] in 
mice to [289] and [374] in humans respectively).  Even when keeping the MPA design the same, 
changing the application velocity, mass and overall energy used can significantly alter the 
inflammation of the skin and subsequent immune responses [295, 298]. Therefore, I hypothesised 
that using a similar MPA and a similar spring-loaded but clinically relevant projectile applicator, 
the applicator parameters could be adjusted to apply an MPA to the epidermis of mouse skin 
(P/eMPA) with a similar level of inflammation tot eh push-through applied eMPA.  
 
The projectile applicator is loaded via spring compression and was designed to apply high-density 
100 mm2 silicon conical-MPAs of 10k density (termed the NanopatchTM) to human skin [289, 375]. 
Mechanistically, the projectile applicator applies the MPA using a high velocity plunger that 
projects the semi-fixed MPA so that it travels approximately 1 cm before impacting the skin with 
the mass of the patch construct only (see Figure 3-5). The projectile applicator is a high velocity 
(17-20 m/s), low mass (0.56 g) applicator unlike the previously tested eMPA push-through 
applicator of low velocity (1.3 m/s) and high mass (36 g). Additionally, the projectile applicator is 
hand held and requires a larger surface area for application than the push-through applicator (see 
section 3.4). Therefore, four applications can be made per mouse without overlap of application 
sites. By adjusting the spring compression internally, the projectile applicator velocity can be set to 
a single application velocity but the mass delivered stays constant. From this, I aimed to determine 
the conditions at which the 16 mm2 slit-MPA (7k density) could penetrate primarily into the 
epidermis, characterise the skin application of the P/eMPA and assess its effects on skin 
inflammation. 
 
 
6.7 Methods 
See the following sections for relevant methods for Chapter 4: 
 3.1 Animals 
 3.2 Microprojection array fabrication: of 16 mm2 silicon 7k and polycarbonate 7k p/cm2. 
 3.3.1 Coating of therapeutic onto microprojection arrays – Ovalbumin coating 
 3.4.2 Application process of microprojection arrays to skin –  Projectile application 
 3.5 Characterisation of microprojection array delivery 
 3.6 Discrimination of viable / non-viable cells via microscopy 
 3.19.1 Hitachi 3500 scanning electron microscope 
 3.19.2 Zeiss confocal / multi-photon laser scanning microscope 
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 3.20 Statistics 
 
 
6.8 Results 
6.8.1 Silicon slit-microprojection arrays applied at 85 mJ with a projectile applicator deposit the 
majority OVA into the epidermis of mouse skin. 
The delivery of 14C-OVA coating was used to assess the whether the patch contacted the skin and 
the reproducibility of contact. I first tested the same polycarbonate eMPA as described in Chapter 
6A with the projectile applicator at the lowest velocity of 12 m/s without a spacer in the patch 
construct. The wide-tipped polycarbonate slit-MPA did not penetrate well delivering only 0.2 ± 
0.1% of the coating formulation into the skin (Figure 6B-8). Since sharp silicon conical-MPAs were 
already proven to penetrate human skin at 17-20 m/s, I continued to assess the projectile applicator 
with only the silicon slit-MPAs [289]. Applied at 12 m/s the silicon slit-MPA showed minimal 
improvement, delivering 0.8 ± 0.3% into the skin. The velocity was then increased to 18 m/s but 
application of the silicon slit-MPAs resulted in a large variation of penetration deliveries without 
the spacer present in the patch construct (7.7 ± 5.2%). This was likely to be due to large variations 
in skin deflection upon impact. By adding a 1.2 mm spacer, the delivery efficiency became more 
consistent, averaging 2.5 ± 1.3% of the coating delivered into the skin. This last condition was 
defined as the P/eMPA with an application energy of 85 mJ. The addition of the 1.2 mm spacer 
increased the space between the 12 mm wide carbon tab, reducing the initial high-velocity impact 
area to the 4 mm wide P/eMPA. 
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Figure 6B-8: Delivery efficiency using 14C-OVA to determine projectile applicator parameters. 
Testing included polycarbonate (PC) slit-MPAs versus silicon (Si) slit-MPAs applied at 12 m/s 
application velocity and the later at 18 m/s with or without 1.2 mm spacer in patch construct. The 
chosen P/eMPA condition (18 m/s with 1.2 mm spacer) with average ± SD above. Schematics on the 
right depict the cross-sectional arrangement of the patch construct without the spacer and with the 
spacer. 
 
The P/eMPA consistently delivered OVA coating into the epidermis. Imaging via BS-SEM 
confirmed consistent removal of coating from the tips (Figure 6B-9A). Penetration characteristics of 
the P/eMPA condition were assessed by histological analysis of applied skin sections using 
fluorescently coated MPAs (Figure 6B-9B). The P/eMPAs penetration averaged 24.8 ± 9 µm into 
the skin (Figure 6B-9C) and so some coating was deposited into the epidermal-dermal junction, 
however, the majority was delivered to the epidermis. The average P/eMPA penetration depth is 
approximately 36% deeper than the eMPA of Chapter 6A which was reflected in the 1.5-fold higher 
delivery efficiency (Figure 6B-8). Using the average width of the silicon slit-MPA tip (0.72 ± 0.15 
µm, Figure 6B-9D), the surface area of 10 projection tips was calculated and multiplied by the 
1,120 projections applied per P/eMPA, resulting in an average penetrating tip surface area of 0.019 
± 0.001 mm2. Once applied, the total surface area of the P/eMPA projections is 2.10 ± 1.01 mm2  
within the epidermis (Figure 6B-9F, left) and the volume displaced is 0.0091 ± 0.0060 mm3 (Figure 
6B-9F, right). The surface area and volume of the P/eMPA in the epidermis is higher than the 
eMPA (2-fold and 4.5-fold respectively) but lower than the dMPA (2.5-fold and 6-fold 
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respectively) of Chapter 6A. Overall, the P/eMPA does not match the penetration characteristics of 
the eMPA but does deliver primarily into the epidermis of mouse skin. Additional manipulation of 
the application, such as lower application velocity with a spacer in the patch construct may result in 
a penetration depth and surface area to the more similar to the push-through eMPA but this was not 
directly tested due to difficulties in changing the projectile velocity. 
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Figure 6B-9: Characterisation of silicon slit-MPA when applied to mouse skin with an 85 mJ 
projectile applicator. (A) BS-SEM of applied OVA-coated silicon P/eMPA indicating coating (dark 
areas) and removed coating from tips (lighter areas) after application into skin, inset depicts 
removal area of coating (black arrow). Scale bars: 100 µm, 10 µm inset. (B) Confocal image of 20 
µm section of green FluoSpheres delivered by P/eMPA into mouse flank skin, scale bar: 200 µm. 
Arrow indicates one of the projection tracks (75 µm long). (C) Skin penetration depth 
measurements of P/eMPA projections from n = 3 mice, n = 69 measurements. (D) Width of silicon 
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P/eMPA tips measured from BS-SEM images, n = 10 projections (mean ± SD). (E) Total surface 
area of silicon tips for slit-P/eMPA, n = 10 projections (mean ± SD). (F) Calculated epidermal 
surface area (left) and volume displaced (right) of an applied P/eMPA including error based on 
penetration depth. NOTE for (F): i.d., eMPA and dMPA data is repeated from Chapter 6A. 
 
6.8.2 Projectile epidermal-targeted microprojection array application maintains low erythema and 
epidermal swelling with increased epidermal cell death. 
Skin inflammation of the applied area was assessed by erythema, epidermal thickness and cell 
viability quantification. Progression of erythema was captured by photographic images taken at 5 
min (t = 0 h), t = 24 h and t = 72 h after application (Appendix 10.22). Photo images of t = 0 h and t 
= 24 h were then scored using the Draize score index for erthema (Figure 6B-10A). Immediately 
after application, the P/eMPA site was clearly visible, with an average Draize score of 0.83 ± 0.4 in 
erythema. This dissipated quickly resulting in a score of zero after 24 h, therefore, no scoring was 
completed for t = 72 h. Erythema score of P/eMPA was significantly lower than that after dMPA at 
both t = 0 h (p < 0.0001) and t = 24 h (p > 0.0001). In agreement with erythema scores, at 24 h after 
application there was no difference between the P/eMPA and naïve epidermal thickness (P/eMPA 
averaging 17.0 ± 4.9 µm). Swelling after P/eMPA was also significantly less than the swelling 
caused by the eMPA (p = 0.0281) and the dMPA (p = 0.0009) (Figure 6B-10Bii). However, the 
P/eMPA induced an increased number of dead cells per projection (relative to the eMPA) as 
observed when the skin was stained and imaged for cell viability (Figure 6B-10Ci). As such, the 
projectile applicator elicited a similar level of cell death (17800 ± 1500 dead cells) to that of the 
dMPA and significantly more than the eMPA (1.8-fold, p = 0.0023) and the i.d. injection (p = 
0.0020). This increase in P/eMPA cell death to the eMPA could be due to the 2-fold increased 
epidermal surface area (mm2) or the 2.8-fold increase in application energy (mJ). However, plotting 
the total number of dead cells against the MPA epidermal mm2 × mJ on a log10 scale highlighted a 
shift in the trend when using the alternative projectile applicator mechanism (Figure 6B-10Cii). 
Therefore, despite differences in penetration characteristics, the P/eMPA induced similar low levels 
of erythema and epidermal swelling as the eMPA but higher levels of epidermal cell death either 
due to an increase in epidermal surface area or application energy but not the combination of both 
as seen in the low velocity injections and push-through applications. 
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Figure 6B-10: Projectile epidermal-targeted microprojection array application causes less 
inflammation of the skin despite higher epidermal cell death than push-through epidermal-
targeted microprojection array. (A) Plot of Draize score of application sites at t = 0, 24 and 72 h 
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after dMPA, eMPA, or P/eMPA applications, n = 3-9 mice and n = 6-18 applications. (B) Swelling 
of the epidermis 24 h post application of placebo formulation/injection including (i) representative 
H&E-stained histology image of the P/eMPA and (ii) quantification of epidermal skin thickness 
measured from H&E-stained sections of n = 3 mice and n = 54 – 179 measurements per condition, 
dotted line indicates mean of naïve measurements. (C) Analysis of cell death in the skin including 
(i) representative 3D reconstructed image of flank skin (~50 µm deep), 20x magnification, stained 
for viable/live (green) and non-viable/dead (pink) cells taken at time t = 0 h after application of 
P/eMPA and (ii) quantification of dead cells in the epidermis at t = 0 h, n = 3 mice. Dotted line 
joins the means of each low-velocity application from Chapter 6A and the solid line depicts the 
deviation from the trend when using a projectile applicator. NOTE for (A, Bii and Cii): i.d., eMPA 
and dMPA data is repeated from Chapter 6A. 
 
After developing the eMPA and the P/eMPA, both were tested using the allergy desensitisation 
model set up in Chapter 4 (Appendix 10.23). However, the positive control resulted in very high 
eosinophilia and anti-OVA IgE and so the data was considered insufficiently supported. 
 
 
6.9 Discussion 
Translation of medical devices from mouse models to humans often requires modifications to the 
in-house devices (such as MPA applicators) that may affect the mechanism of delivery into the skin. 
In this study, I found a more clinically relevant applicator made for human use could be adjusted for 
epidermal delivery into mouse skin (Figure 6B-9). This required higher velocities than expected (18 
m/s), equalling those used in human studies to apply the NanopatchTM [289, 375]. Interestingly, the 
approximate surface area of the penetrating tip of the NanopatchTM (0.018 ± 0.012 mm2, calculated 
from reported SEM images) is very similar to the P/eMPA (Figure 6B-9E) [289]. Yet, despite a 
similar penetrating tip surface area and application energy used for both NanopatchTM and P/eMPA, 
the mouse P/eMPA only penetrated ~24 µm into the skin while the human MPA reported ~100 µm 
penetration (calculated from SEM image). This may be due to the differences in the ratio of skin 
viscoelasticity : stiffness between mouse and human [233]. The higher stiffness of human skin leads 
to less deflection than in mouse skin during high-velocity application, increasing the transferable 
energy to penetration of the skin [233, 295]. I hypothesise that the higher impact deflection in 
mouse skin is also responsible for the lack of penetration when using blunter polycarbonate slit-
MPAs. Whereby only projection tips of about 1 µm or less have the initial penetrating ability to 
subsequently ‘grip’ the skin during initial impact at high-velocity’s. Comparable application of the 
polycarbonate slit-MPAs with the additional 1.2 mm spacer is required to confirm this hypothesis. 
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Applications made by the P/eMPA resulted in less erythema and epidermal swelling than both the 
eMPA and dMPA but did increase the localised level of epidermal cell death (Figure 6B-10). This 
was a striking difference compared to findings of Chapter 6A that suggested increases in application 
energy and, by extension, epidermal cell death leads to increases in the skin erythema and 
epidermal swelling. The variables that could have affected skin erythema/swelling include: increase 
in P/eMPA application velocity, increase in epidermal cell death and decrease in application mass 
decreased. As neither the higher velocity or cell death have been shown to cause lower skin 
erythema before, this indicates that the change from to a low mass application device could assist 
with maintaining low skin erythema/swelling. In contrast, persistent erythema was reported up to 
day 7 when using the projectile applicator to deliver the NanopatchTM with either no coating, 
placebo coating or influenza vaccine into human skin [289, 375]. As both the P/eMPA and the 
NanopatchTM have an approximately equivalent penetrating tip surface area, deposit the majority of 
coating into the respective epidermis of mouse or human skin and were applied for the same 2 min 
at a similar velocity (17.5-20 m/s), the difference in erythema likely to be species related. This 
increase in erythema when applying to human skin was supported by another spring-loaded 
application (12.8 Newtons, approximately 60.5 mJ assuming a distance 0.005 metre) of an 800 µm 
tall, low-density (230 p/cm2), dissolvable MPA with a Draize score of 1 in mice [373] but a Draize 
score of 3 in humans [374] 24 h after application. Although it is unclear if the same 12.8 Newton 
application force was used in both dissolvable MPA studies.  
 
Alternatively, the total MPA surface area (and therefore total cell death, see Chapter 5) would be 
greater with the human NanopatchTM application than the P/eMPA due to the deeper penetration 
depth. As immune cell distributions are similar between mouse and human skin, the higher 
NanopatchTM surface area will activate more skin immune cells in the human skin than the P/eMPA 
in the mouse skin - possibly prolonging the erythema [224, 246]. As a systematic comparison of the 
same solid MPA design and applicator design applied to mouse and human skin alike has not been 
reported, it is difficult to determine whether the additional human erythema response is related to 
species or surface area or differences or a combination of the two. However, I hypothesise that the 
erythema difference between the two species is likely due to the difference in MPA surface area 
within the skin. 
 
Although the P/eMPA did not fit the same mm2 × mJ to cell death trend as the push-through 
applications, the P/eMPA did follow the same trends of mm2 and mJ separately. Compared to the 
eMPA, the P/eMPA has almost twice the surface area within the epidermis (mm2) and almost twice 
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the level of epidermal cell death (Appendix 10.24) in a similar trend to results in Chapter 5. While 
increasing the application energy (85 mJ) increased epidermal cell death to a similar level as the 
dMPA (100 mJ) (Appendix 10.25). The deviation from the mm2 × mJ trend highlights how different 
mechanisms of application can shift the impact on the skin. Using the i.d. injection or push-through 
applicator with high mass (> 10 g) and low velocity (< 1.3 m/s) delivery mechanics will increase 
the cell death as the mm2 × mJ increases on a log scale. However, changing the mechanics to a high 
velocity, low mass delivery (projectile) changes the relationship between cell death and the mm × 
mJ applied in the skin. This is a key difference for application of AITs as an increased cell death, 
such as the extra 3000+ epidermal dead cells seen in the P/eMPA than expected based on push-
through application trends, is hypothesised to increase the level of unwanted Th2 signalling in the 
skin (see section 2.4.3) [24]. Therefore, altering the applicator delivery mechanism can cause 
deviations to previously determined trends with in-house equipment and so should be re-assessed to 
ensure clinical-based changes do not alter the required outcome.  
 
 
6.10 Conclusion 
Overall, the more clinically relevant projectile applicator deposited OVA primarily into the 
epidermis of mouse skin. This required the use of a lower impact surface area, higher application 
velocity and sharper tipped silicon slit-MPAs to ‘grip’ the mouse skin during deflection. The 
resulting high velocity application induced a low level of inflammation at the skin site likely due to 
the low mass applied. Yet, changing the mechanisms by which the MPA is applied caused the level 
of cell death to deviate from previous trends and so may alter other downstream processes such as 
immune signalling. Therefore, although the majority of parameters assessed were similar between 
the two spring-loaded applicators in mice, it is still imperative to re-check defined trends seen in 
mice with devices more closely related those used in human clinical studies. 
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Chapter 7 
 
 
7 Preventing airway allergic inflammation by vaccinating with OVA delivered by 
epidermal-targeted microprojection arrays 
 
The results of this chapter are presented in chronological order. 
 
 
Summary 
Although Chapters 4 and 5 found that lower density and application energies of high-density 
dermal-targeted MPAs (dMPAs) could reduce impact on the skin and airway inflammation, dMPAs 
still induced Th2-mediated antibody responses. The low-impact epidermal-targeted MPA (eMPA) 
developed in in Chapter 6 is likely to improve MPA-based allergen delivery further without 
enhancing unwanted immunity. Yet, as with other skin delivery devices, therapeutic delivery of 
allergen via the novel eMPA required optimisation of the dose, number of repeats and timing. An 
allergy vaccination model uses significantly less time than an allergy desensitisation model to 
determine if the eMPA can provide protection. However, only a handful of studies have reported 
protection against allergic sensitisation via an allergy vaccination regimen. Therefore, Chapter 7 
tested both the eMPA and P/eMPA routes from Chapter 6 against the intranasal vaccination route in 
an airway hypersensitivity mouse model. Control groups of each study were first carefully assessed 
to ensure each repeated study was able to be compared to one another. Results indicated the eMPA 
route required 10- to 100-fold less OVA dose delivered than either intranasal or intradermal routes 
to prevent Th2 sensitisation. Additionally, eMPAs maintained much healthier airways and 
prevented the build of airway inflammation significantly better than other routes. Therefore, the 
mechanism behind eMPAs preventing or maintaining airway health should be further investigated, 
not just in airway allergies but also in a variety of airway inflammation diseases. 
 
 
7.1 Introduction 
Allergic disease effects up to 20% of the population at some point in life [1]. Although up to 75% of 
food allergies self-tolerate by the age of 6-20 years old, this is not the case for airway based 
allergies [1, 376]. Only 6% of patients choose to undergo immune modulating allergy AIT due to 
high time and cost commitments [9, 10]. As such, treating the symptoms of allergies in Australia 
alone cost $7 billion annually (half of which is paid by the patient) and hospital admissions for life 
threatening anaphylaxis are on the rise [75]. However, as with most immune diseases, prevention of 
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allergy sensitisation by building up immune tolerance (as in healthy/tolerant people) would be 
significantly more beneficial to both the health care systems and patients alike. Unfortunately, there 
are no approved vaccination methods to prevent allergic disease from developing, only suggestive 
guidelines (see section 2.1.2) from regional organisations on how to maintain a balanced immunity 
and when best be exposed or avoid allergens [62, 63, 377]. Ideally, collation of allergy prevention 
findings should result in a vaccination treatment that replicates a healthy exposure to inhaled 
allergens. 
 
Very few studies in mice report vaccination to prevent airway allergy development [26, 109, 119, 
144]. These can be grouped into allergen vaccinations with or without additional mediators. So far, 
the most promising preventative vaccinations with additional mediators include the addition of 
Helicobacter pylori [378], Escherichia coli [109], CpG oligonucleotides [144] or high doses of LPS 
[56] to boost Treg or Th1 responses. Both Th1 and Treg can downregulate allergic Th2 responses, 
however, specific Treg responses are pivotal as they downregulate inflammation caused by both 
Th1 and Th2-mediated responses [88]. These four studies with mediators could not provide 
protection with allergen alone. Although the dose of LPS endotoxin, which is present in OVA, was 
reported to protect at both 1 ng and 100,000 ng vaccination doses a dose of 100 ng LPS induced 
Th2 sensitisation and therefore must be carefully evaluated in each study. However, the addition of 
these mediators can increase adverse reactions to the vaccine and so are best to be avoided if 
possible.  
 
Successful allergen-only studies indicate that activating allergen airway tolerance depends on the 
dose of the allergen [5], the number of repeats [9] and/or the route of administration [144]. In 
general, infrequent exposure to low doses of allergen increases the risk of sensitisation. For 
example, Von Garnier et al. [134] provided protection against allergic disease by administering a 
medium dose of 28 µg of OVA via s.c. injection but when this dose was reduced to 0.28 µg Th2 
sensitisation was induced. Likewise, when Fox et al. [163] vaccinated with 0.01% of OVA via an 
aerosol chamber inhalation, mice were protected when vaccinated with 5-12 repeats but when this 
was reduced to 1-4 vaccination repeats Th2 sensitisation was induced. Currently, the most efficient 
allergen-based airway vaccination routes tested in mice are aerosol [119] or i.n. [118] which are 
administered prior sensitisation. These findings give promise to the hypothesis that, with the correct 
timing and dose, a vaccination could be developed against primary allergic sensitisation without the 
use of adjuvants. 
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When developing a vaccination, determining the optimal route is the first important variable to 
consider, as this influences both the dose required and number of repeats. Most allergic airway 
prevention studies administer allergen to the airways, but it is clear that the skin also functions to 
induce tolerance to a variety of substances in mice that has been translated to humans [17, 18, 220].  
Allergen applied to the skin of naïve mice has resulted in both systemic sensitisation to [379], 
induced tolerance to [206] or low levels of immunity against [133] a variety of allergens. Only three 
studies were found to vaccinate via the skin route against Th2 sensitisation [26, 113, 144]. These 
studies indicated that high levels of  inflammation caused by tape stripping causes unwanted 
sensitisation to OVA [113], dermal targeted delivery may require Th1 adjuvants [144] (depending 
on the allergen [325]), while delivery into the epidermis may not require addition of adjuvants [26].  
 
A relatively fast and low-cost skin delivery device available is the MPA patch. A low-density (< 1k 
p/cm2) solid dMPA [144] and a dissolvable dMPA [325] have both reported promising results for 
allergy vaccination. Although, dMPA delivery of OVA required the addition of a Th1 adjuvant to 
provide better protection.  High-density MPAs are significantly more able to elicit immunogenic 
responses than i.d. vaccination, resulting in up to 100-fold dose sparing of an influenza vaccine [25, 
380]. This is a favourable condition for allergy therapies as high doses of allergen increase the risk 
of anaphylaxis.  
 
Chapter 6 presented the newly developed high-density MPA that could primarily target coated 
OVA to the epidermis of mice, termed the eMPA. The eMPA was shown to activate Langerhans 
cells (LCs) to migrate to skin dLNs but not dDC migration. As the steady state of epidermal LCs is 
to survey the epidermis for antigens and build specific tolerance [252], they are ideal targets for 
inducing allergen tolerance by vaccination [249, 256]. Although there are currently no studies that 
assess how effective vaccines delivered by high-density eMPAs are at protecting against allergic 
airway inflammation, there are several studies of high-density dMPA vaccinations protecting 
against viral infection of the airways [198, 263, 319, 381]. This confirms a strong link between 
penetrating-based skin immunisation and induction of immunity in the airways.  
 
In this chapter, I hypothesise that OVA vaccination delivered by low inflammatory eMPA results in 
protection against a Th2-based allergic airway inflammation challenge. I aimed to vaccinate mice 
with a range of doses and dosing regimens to build tolerance prior to i.p. sensitisation and intranasal 
challenge. I found that eMPA vaccination required significantly less OVA delivered to protect the 
airways against Th2-induced eosinophilia and anti-OVA IgE than both i.n. and i.d. controls. These 
are the first results of an MPA study to vaccinate with allergen alone to prevent mucus hyper-
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production and peribronchial inflammation. Therefore, I conclude that eMPAs are a prime 
candidate to deliver allergy vaccinations without the use of adjuvants. 
 
 
7.2 Methods 
See the following sections for relevant methods for Chapter 7 
 
 3.1 Animals 
 3.2 Microprojection array fabrication: of 16 mm2 silicon 7k and polycarbonate 7k p/cm2. 
 3.3.1 Antigen coating of microprojection arrays -  Ovalbumin coating 
 3.4 Application process of microprojection arrays 
 3.7.1 Sensitisation – Intraperitoneal with aluminium hydroxide 
 3.9 Vaccination with ovalbumin to prevent airway hypersensitivity 
 3.10 Ovalbumin airway challenge 
 3.11.2 Cell differentiation of bronchial alveolar lavage fluid – Flow Cytometry 
Note: Neutrophils were not assessed for Vaccination 4 due to a lack of anti-CD11b marker. 
 3.12 Anti-OVA IgE via passive cutaneous anaphylaxis assay 
 3.13 Anti-OVA IgG subtypes via ELISA 
 3.14 Quantification of MUC5AC and obstruction in lung histology 
 3.17 Quantification of IL-5 levels in BALf 
 3.18 Eotaxin-2 levels in BALf 
 3.19.3 Instrumentation – Flow cytometry instruments 
 3.20 Statistics 
 
7.2.1 Summary of Vaccination studies 
Vaccinations 1-7 tested various doses and vaccination regimens to prevent airway eosinophilia and 
sera anti-OVA IgE in a 1x i.p. model. Vaccination 8 tested the most successful eMPA regimen from 
Vaccinations 1-7 to protect against airway inflammation in a 2x i.p. model. Vaccination 
experiments were repeated eight times. Total combined number mice of each group tested over the 
eight vaccinations is listed in Table 7-1. 
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Table 7-1: Groups assessed for vaccination against OVA airway hypersensitivity including 
number of mice (N) per vaccination repeat per test group. Group name nomenclature is devised 
from (route)-(total dose of vaccination)-(hours between repeat vaccinations). All challenges began 
7 days after sensitisation except for group eMPA 0.4-72/31 (31 days after sensitisation). 
Group name N 
TOTAL 
Vaccination number: 1 2 3 4 5* 6* 7 8#
Sensitised-1  2 4 4 5 4 3  13 
Sensitised-2        7 7# 
i.n. 80-24 (no i.p.) 4        4 
i.n. 0-24 5        5 
i.n. 20-24       4  4 
i.n. 80-24 4 4 4 4 3 4 4  20 
i.n. 200-24       4 8 4 + 8# 
i.d. 8-24  4   6    4 
i.d. 0.8-24  4       4 
i.d. 0.08-24  4       4 
i.d. 0.4-72     10    - 
eMPA 8-24 (no i.p.) 5        6 
eMPA 0-24 4        4 
eMPA 8-24 6  6      12 
eMPA 0.4-24    6     6 
eMPA 0.8-24  6 6 6     18 
eMPA 0.08-24   6      6 
eMPA 0.4-72    6 6 6  7 6 + 7# 
eMPA 0.4-72/31      6   - 
P/eMPA 0.4-24    6     6 
P/eMPA 0.4-72    6     6 
*Results from Vaccinations 5 and 6 were disregarded due to insufficient controls 
#Vaccination 8 tested a chronic airway challenge. 
 
 
7.2.2 Endotoxin readings 
Samples of reconstituted OVA, PBS and solutions used for i.n. vaccination were sent to the Protein 
Expression Facility (University of Queensland) for measurement of endotoxin levels. Tests were 
performed using an Endosafe-PTS Limulus Amebocyte Lysate  test kit of 1 – 0.01 EU/ml or 5 – 
0.05 EU/ml detection range (Charles River Laboratory). 
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7.3 Results 
7.3.1 Vaccination regimens did not affect mouse health (by weight) 
To examine if OVA delivery via the eMPA could protect against Th2-mediated airway 
hypersensitivity, eMPAs were applied with a variety of coated doses, repeats and dosing regimens 
(Vaccinations 1 – 8, Table 7-1). There were no significant differences in mouse weight between 
groups of each vaccination (data not shown) nor between vaccination studies (total average: 21.03 ± 
1.0 g, Figure 7-1). There was also no difference in mouse weight between the 1x i.p. protocol 
(Vaccinations 1-7) and the chronic 2x i.p. protocol (Vaccination 8). This indicated that these 
treatments has no significant adverse effects on the overall health of the mice. 
Figure 7-1: Final body weights of mice after vaccination study (V). Recording occurred 
immediately after overdose was administered, n = 15-38. Weights were not collected for 
Vaccinations 1-3. 
 
7.3.2 Validation of control groups for each vaccination study 
To ensure repeatability of each vaccination, first the sensitised group (negative control) of each 
vaccination study was analysed for BALf eosinophils by flow cytometry and IgE levels by rat PCA 
assay (Figure 7-2). Sensitised groups of vaccination repeats with less than 20% average BALf 
eosinophils and less than 1:6 anti-OVA IgE endpoint were regarded as insufficiently sensitised and 
thus the whole vaccination study was disregarded (zero vaccination studies were disregarded by this 
condition). If the BALf eosinophils were low (< 20%) but the sera anti-OVA IgE was high (> 6), 
then the airway challenge was considered compromised and all lung-based data was disregarded 
(Vaccination 3 lung-data was disregarded by this condition). If the BALf eosinophils were high (> 
20%) but the sera anti-OVA IgE was low (< 6), then the i.p. sensitisation was considered 
compromised and all data was disregarded (zero vaccination studies were disregarded by this 
condition). For the 1x i.p. protocols (Vaccinations 1-7), 2/31 mice did not sensitise while chronic 2x 
i.p. mice were all sufficiently sensitised. 
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Figure 7-2: BALf eosinophils (left axis, ) and sera anti-OVA IgE (right axis, ) from sensitised 
mice across vaccination studies (V). No IgE was analysed for V2 or V6. Sufficient response refers 
to average eosinophils over 20% and average anti-OVA IgE over titre 6, n = 3-9. Unresponsive 
mice refers to the number of mice per vaccination that had a non-sufficient response. 
 
After validation of negative controls, the intranasal vaccination groups (positive controls) from each 
vaccination study were analysed for relative BALf eosinophils normalised to the sensitised control 
(average sensitised: y = 1.0) (Figure 7-3). I.n. groups with a relative BALf eosinophil average above 
0.60 were regarded as insufficiently vaccinated and thus the whole vaccination was disregarded 
(Vaccinations 5 and 6 were disregarded under these conditions, Appendix 10.26). Note here that 
Vaccination 8 was not disregarded under this condition as it tested a chronic challenge model to 
assess protection against airway inflammation rather than eosinophilia. Vaccinations without an i.n. 
group averaging below 0.60 were disregarded (except Vaccination 8). From this, Vaccinations 5 
and 6 were disregarded. Following this initial analysis, Vaccinations 1, 2, 3 (serum data only), 4, 7 
and 8 results are discussed below. 
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Figure 7-3: Relative BALf eosinophil levels of intranasal groups normalised to sensitised group 
for each vaccination study (V). Each sensitised group eosinophil average % was normalised to 
‘1.0’, i.n. control groups were compared within each vaccination study. V1 includes i.n. 80-24 (no 
i.p.) baseline group (clear box). V2 re-used V1 sensitised group due to similar timing of studies, 
batch of mice and batch of materials used. The cut-off of ‘0.60’ indicates mean eosinophil % were 
reduced by at least 40% relative to the sensitisation group (green dashed line). Sufficient response 
refers to relative mean eosinophil % below 0.60. Percent of protection against BALf eosinophilia 
refers to the number of mice per i.n. group that had 40% or more relative reduction of eosinophils, 
n = 3-7. 
 
7.3.3 Establishing a model of airway allergy vaccination using epidermal-targeted 
microprojection arrays 
The first objective was to establish a vaccination model and record the baseline, negative control 
(sensitised) and positive control (i.n.) outcomes. Group name nomenclature is devised from (route)-
(total dose of vaccination)-(hours between repeat vaccinations). To ensure i.n. and eMPA 
applications did not induce Th2 sensitisation alone, each were tested without i.p. sensitisation and 
used as a baseline reading for this model (i.n. 80-24 (no i.p.) and eMPA 8-24 (no i.p.)). The 
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“Sensitised-1” groups of Vaccination 1 refer to groups that delivered 0 µg OVA (i.n. 0-24 and 
eMPA 0-24) but were sensitised with the 1x i.p. protocol. The i.n. vaccination was applied eight 
times every 24 h with 10 µg OVA (i.n. 80-24), matching the maximal number of repeated eMPAs 
that could be applied to a mouse. The maximum eMPA deliverable dose was compared to the i.n., 
delivering 1 µg OVA (eMPA 8-24) using the same eight day schedule (Figure 7-4). Table 7-2 
outlines the groups tested in Vaccination 1. To test protective strength of the vaccination against 
Th2-mediated airway hypersensitivity, seven days after the last vaccination mice were primed with 
a single i.p. sensitisation. Despite Conrad et al. [382] reporting the s.c. route is superior to the i.p. 
for sensitisation, the i.p. can induce strong airway inflammation responses when combined with an 
adjuvant such as AH [382]. All mice were rested nine days before the three-day challenge to 
coincide with the beginning of detectable IgE responses after i.p. sensitisation in line with 
previously reported studies [109, 126, 140].  
 
Figure 7-4: Vaccination 1, 2 and 3 timelines for preventing OVA-based airway hypersensitivity in 
mice. Vaccinations 1-3 consisted of OVA delivered (0.1 – 10 µg) by either i.n., i.d. (into the flank) 
or eMPA (flank) at 24 h intervals within the first 10 days. Sensitisation occurred 7 days after 
vaccination (i.p. of 10 µg OVA and 1 mg AH). Challenge occurred 9 days after sensitisation (daily 
i.n. of 50 µg OVA for three days). Samples were then collected 24 h after last challenge. 
 
According to #666, a total dose of 1 ng or 100,000 ng of LPS endotoxin was assisted allergy 
vaccination, while 100 ng of LPS induced sensitisation. Therefore, they do not recommend an 
allergy vaccination that contains 100 ng of LPS or similar endotoxin. The OVA used here was 
known to contain some endotoxin and so endotoxin dose would vary with OVA dose and OVA 
batch. It is unknown where the threshold dose between 1 ng of LPS for protection and 100 ng of 
LPS lies, nor if total protocol dose of LPS changes these results. To explore the importance of 
endotoxin dose during the protocol, the total level of endotoxin units (EU, measured in ng) was 
recorded for both the vaccination and the entire protocol (vaccination + sensitisation + challenge). 
The majority of the EU in OVA is LPS. None of the Vaccination 1 groups included 100 ng or more 
EU (Table 7-2) and so none were not likely to induce endotoxin-based sensitisation from 
227 
 
vaccination alone. After i.p. sensitisation and/or challenge, both i.n. 80-24 (no i.p.) and i.n. 80-24 
groups had accumulative doses above the recommended 100 ng [56]. 
 
Table 7-2: Vaccination 1 groups including endotoxin unit (EU) dose per group for vaccination 
only and total vaccination + sensitisation + challenge. Red highlighted EU indicates values above 
reported sensitising dose (100 ng) [56]. 
Code Group name Route Dose Repeats Interval 
EU of 
vaccination 
(ng) 
Total EU 
(ng) 
 i.n. 80-24 (no i.p.) 
(or ‘Baseline’) 
i.n. 10 µg ×8 24 h 43.70 123.90 
 eMPA 8-24 (no i.p.) (or ‘Baseline’) eMPA 1 µg ×8 24 h 5.46 85.66 
 i.n. 0-24 
(or ‘Sensitised-1’) 
i.n. 0 µg ×8 24 h - 85.54 
 eMPA 0-24 (or ‘Sensitised-1’) eMPA 0 µg ×8 24 h - 85.54 
 i.n. 80-24 i.n. 10 µg ×8 24 h 43.70 129.24 
 eMPA 8-24 eMPA 1 µg ×8 24 h 5.46 91.00 
 
There were no significant differences between BALf cell differentiation in baseline groups (i.n. 80-
24 (no i.p.) and eMPA 8-24 (no i.p.)) (Figure 7-5A) nor in the total number of BALf cells (i.n. 80-
24 (no i.p.): 23,038 ± 6,387 and eMPA 8-24 (no i.p.): 17,941 ± 6,458 cells, Appendix 10.27) and so 
the results of these two groups were combined as “Baseline” from this point onward. Baseline 
groups elicited low levels of eosinophils (8.7 ± 5.2%, Figure 7-5A). Baseline groups did not boost 
anti-OVA IgE (1.0 ± 1.4) or IgG endpoint titres (1,877 ± 1,906) (Figure 7-5B). This indicated that 
neither i.n. (despite a total EU over 100 ng) nor eMPA delivery of OVA alone can prime for Th2 
hypersensitivity. There were no significant differences between BALf cell differentiation in 
Sensitised-1 groups (i.n. 0-24 and eMPA 0-24) (Figure 7-5A) and so the results of these two groups 
were combined from this point onward. The 1x i.p. sensitisation model (Sensitised-1) led to a BALf 
cell distribution of 7.8 ± 3.5 % MHCII+ macrophages, 4.6 ± 2.8% neutrophils, 53.1 ± 10.7% 
eosinophils, 6.2 ± 3.4% lymphocytes and an increase in sera anti-OVA IgE endpoint titre to 7.1 ± 
3.8. Sensitised-1 groups resulted in and increased cellular influx into the lungs compared to baseline 
(50,447 ± 10,809, p < 0.0001, Appendix 10.27). Sensitised-1 had significantly more BALf 
eosinophils (p < 0.0001) (Figure 7-5A) and sera anti-OVA IgE (p = 0.0012) and anti-OVA IgG (p < 
0.0001), specifically subtype IgG1 (p = 0.0083), compared to Baseline (Figure 7-5B). Relative to 
the Sensitised-1 groups, the i.n. 80-24 positive control group was associated with significantly 
reduced Th2 hypersensitivity (despite a total EU over 100 ng) as noted by the significant decrease 
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in BALf eosinophils (p = 0.0093) and sera anti-OVA IgE (p = 0.0008). Total BALf cells of the i.n. 
80-24 vaccination also elicited less cells on average (31,344 ± 20,109, Appendix 10.27). I.n. 80-24 
also resulted in a mild increase in neutrophils (p = 0.0371). Protection by i.n. 80-24 vaccination 
group led to a BALf cell distribution of 7.5 ± 0.6% MHCII+ macrophages, 11.9 ± 4.4% neutrophils, 
21.3 ± 13.3% eosinophils, 7.0 ± 2.9% lymphocytes and a low sera endpoint titre of 0.5 ± 1 anti-
OVA IgE (Figure 7-5). However, i.n. 80-24 did not alter the production of anti-OVA IgG, 
suggesting an endotoxin- and IgG-independent protection. Overall, the i.n. and eMPA vaccinations 
did not induce Th2 sensitisation alone (Baseline), the 1x i.p. sensitisation induced Th2-mediated 
hypersensitivity (Sensitised-1) and the i.n. vaccination was sufficient to protect against the 1x i.p. 
sensitisation (i.n. 80-24). Additionally, the total EU dose reaching 100 ng does not appear to effect 
protective i.n. responses against Th2 sensitisation. 
 
The first vaccination trial with the eMPA tested the maximum deliverable dose of OVA (1 µg) 
delivered daily for the maximum number of delivery repeats (x8) in mice. Vaccination with eMPA 
8-24 did not prevent Th2 hypersensitivity. Although there was a slight decrease in MHCII+ 
macrophages (p = 0.0141), there were no other significant differences in BALf cell differentiation 
between eMPA 8-24 vaccination and Sensitised-1 groups. Where the eMPA 8-24 vaccination led to 
a BALf cell distribution of 3.9 ± 1.8% MHCII+ macrophages, 1.5 ± 1.7% neutrophils, 58.0 ± 16.4% 
eosinophils and 6.3 ± 3.7% lymphocytes (Figure 7-5A). In contrast to the i.n. 80-24 vaccination, the 
eMPA 8-24 had the lowest percentage of neutrophils (p = 0.0138). Also, eMPA 8-24 vaccination 
led to a similar anti-OVA IgE, IgG, IgG1 and IgG2a production to Sensitised-1 groups (Figure 
7-5B). This indicates that the eMPA 8-24 vaccination regimen does not protect against Th2 
hypersensitivity.  
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Figure 7-5: Vaccination 1 BALf cells and serum antibodies. Responses from day 29 after 
vaccination, 1x i.p. sensitisation and 3x daily challenge. Groups without i.p. sensitisation were 
termed ‘Baseline’ and groups that received placebo vaccination were termed ‘Sensitised’. (A) Cells 
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were identified using flow cytometry and presented as a percentage of gated single cells. (B) 
Endpoint dilutions of anti-OVA IgE were calculated from rat PCA assay and anti-OVA IgG and 
subsets were determined using ELISA (ABTS substrate), n = 4-6. 
 
To confirm the higher percentage of BALf eosinophils seen in Sensitised-1 groups were attracted 
into the lung mucosa via Th2 signalling, both Th2 cytokines interlukin-5 (IL-5) and Eotaxin-2 were 
assessed. IL-5 is a major cytokine involved in eosinophil maturation and proliferation [90] and 
Eotaxin-2 is a chemoattractant of eosinophils [383]. Baseline group levels of IL-5 (0.28 ± 0.15 
pg/ml) were significantly increased in Sensitised-1 BALf supernatant (1.49 ± 0.29 pg/ml, p = 
0.0003) (Figure 7-6), at a similar ratio (1 : 5.3)  to the BALf eosinophil percentage (1 : 6.1) (see 
Figure 7-5A). Vaccination of mice with i.n. 80-24 led to an increase of IL-5 to Baseline (1.0 ± 0.26 
pg/ml, p = 0.006) and a decrease of IL-5 compared to Sensitised-1 (p = 0.0341) (Figure 7-6), also in 
a similar ratio to the BALf eosinophil percentage. Eotaxin-2 concentrations also positively 
correlated with BALf eosinophils from baseline, Sensitised-1 and i.n. 80-24 groups, where 
Sensitised-1 groups (928 ± 228 pg/ml) contained a significantly higher percentage than both 
baseline (122 ± 23 pg/ml, p < 0.0001) and i.n. 80-24 (235 ± 101 pg/ml, p < 0.0001) (Figure 7-6). 
However, the eotaxin-2 levels of eMPA 8-24 vaccinated mice were significantly lower than the 
Sensitised-1 (p < 0.0001) unlike the trend seen if percentage of BALf eosinophils. This suggests 
that eMPA 8-24 eosinophilia was eotaxin-2 independent. Overall, both IL-5 and Eotaxin-2 levels 
confirmed BALf eosinophilia was Th2-mediated in Sensitised-1 groups.  
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Figure 7-6: Vaccination 1 BALf supernatant cytokines. Responses from day 29 after vaccination, 
1x i.p. sensitisation and 3x daily challenge. Groups without i.p. sensitisation were termed 
‘Baseline’ and groups that received placebo vaccination were termed ‘Sensitised’. IL-5 was 
assessed in a sample of i.n. 80-24 (no i.p.) (‘Baseline’) and i.n. 0-24 (‘Sensitised-1’) and compared 
against i.n. 80-24 vaccination, n = 3-5. Eotaxin-2 was measured from each BALf supernatant of 
Vaccination 1, n = 4-6. 
 
7.3.4 Improved eMPA vaccination with 1/10th of the intradermal dose 
Based on initial results of Vaccination 1, the second objective was to assess the dose range of the 
skin vaccination using i.d. administration. As the difference in immunogenicity between the i.d. and 
eMPA routes is not known I started with the same dose as Vaccination 1 (i.d. 8-24). This was then 
titrated down to a 10th (i.d. 0.8-24) and a 100th (i.d. 0.08-24) of the V1 dose. Additionally, as the 
eMPA is estimated to activate approximately 2000 LCs (Chapter 6), I tested a 10th of the dose of 
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OVA (eMPA 0.8-24) than Vaccination 1, hypothesising that reducing the allergen dose to the large 
number of LCs targeted would reduce the allergen-specific response.  
 
Vaccination 2 groups listed in Table 7-3 were tested using the same vaccination regimen (Figure 
7-4) as Vaccination 1. Results of Sensititation-1 from Vaccination 1 was used for comparison in 
Vaccination 2 as both studies ran at similar times with mice and materials from similar batches. 
Although Vaccination 1 showed the total protocol EU dose did not affect the level of Th2-based 
immunity as previously reported, each experiment continued to take note of the EU level. None of 
the Vaccination 2 groups included 100 ng or more EU (Table 7-3) and so were deemed unlikely to 
induce endotoxin-based Th2 sensitisation from vaccination alone. The i.d. 0.8-24, i.d. 0.08-24 and 
eMPA 0.8-24 groups all delivered a vaccination dose of less than 1 ng endotoxin, previously 
reported to assist protection [56]. After i.p. sensitisation and airway challenge, the i.n. 80-24 group 
delivered a total EU dose above the recommended 100 ng [56], which was shown in Vaccination 1 
not to induce sensitisation. 
 
Table 7-3: Vaccination 2 groups including endotoxin unit (EU) dose per group for vaccination 
only and total vaccination + sensitisation + challenge. Red highlighted EU indicates values above 
reported sensitising dose (100 ng), green highlight indicates values below reported protective dose 
(1 ng) [56]. 
Code Group name Route Dose Repeats Interval 
EU of 
vaccination 
(ng) 
Total EU 
(ng) 
 i.n. 80-24 i.n. 10 µg ×8 24 h 43.70 129.24 
 i.d. 8-24 i.d. 1 µg  ×8 24 h 4.37 89.91 
 i.d. 0.8-24 i.d. 0.1 µg ×8 24 h 0.44 85.98 
 i.d. 0.08-24 i.d. 0.01 
µg 
×8 24 h 0.04 85.59 
 eMPA 0.8-24 eMPA 0.1 µg ×8 24 h 0.44 85.98 
 
Similar to Vaccination 1, Vaccination 2 i.n. 80-24 prevented BALf eosinophilia with average cell 
percentages of 7.9 ± 2.9% MHCII+ macrophages, 12.3 ± 6.1% neutrophils, 19.6 ± 12.9% 
eosinophils and 5.6 ± 1.6% lymphocytes (Figure 7-7A). Vaccination with i.n. 80-24 (Vaccination 2) 
also elicited a similar number of total BALf cells (30,438 ± 10,121) as Vaccination 1 (Appendix 
10.27). Protection against anti-OVA IgE was also replicated in i.n. 80-24 (endpoint titre 2.0 ± 2.0) 
(Figure 7-7B). Again, skin-based vaccination increased the percentage of BALf eosinophils where 
the greatest infiltration resulted from vaccination with i.d. 0.8-24 (72.4 ± 3.3%), which was a 
significant increase compared to i.n. 80-24 (p = 0.0027, Figure 7-7A). Increasing the dose (i.d. 8-
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24) resulted in similar percentage of protection against BALf eosinophilia (30.5 ± 29.2%) to the i.n 
80-24, protecting three out of four mice (75% protection). Also, the highest i.d. vaccination dose 
(i.d. 8-24) protected against anti-OVA IgE production (3.2 ± 3.2). Reducing the i.d. dose to 1/10th 
(i.d. 0.8-24) significantly increased the production of anti-OVA IgE (to i.d. 8-24 p = 0.0479; to i.n. 
80-24 p = 0.0421) and so neither i.d. 0.8-24 (22 ± 12) nor i.d. 0.08-24 (20 ± 15) vaccinations 
protected against production of anti-OVA IgE. Anti-OVA IgG levels were primarily due to 
increases in anti-OVA IgG1 subtype, whereby i.d. 0.8-24 once again led to the highest levels for 
anti-OVA IgG (89,600 ± 25,600) and anti-OVA IgG1 (1,433,600 ± 409,600). However, IgG titre 
did not trend with i.d. vaccination dose as i.d. 0.8-24 IgG production was higher than both i.d. 8-24 
and i.d. 0.08-24 (IgG p = 0.0089 and IgG1 p = 0.0089). There was no significant increase in IgG2a. 
Together, this data indicates that i.d. vaccination requires repeated doses of 1 µg or more to initiate 
protection against Th2 hypersensitivity, which is a similar result to that described in Yasuda et al. 
[113]. Protective i.d. vaccination presented here may also correlate with EU delivered during 
vaccination i.e., ~4 ng of endotoxin delivered by i.d. provides better protection against sensitisation 
than 0.04-0.4 ng of EU. 
 
A decreased eMPA OVA dose (and decreased endotoxin dose) (eMPA 0.8-24) delivered in 
Vaccination 2 relative to Vaccination 1 led to three out of six mice with low eosinophil percentage 
(50% protection). This was unlike the result after the same dose delivered by i.d. (i.d. 0.8-24). 
Although there was no difference between BALf MHCII+ macrophages and lymphocytes for each 
treatment, eMPA vaccination resulted in the lowest percentage of BALf neutrophils (4.0 ± 3.2%) as 
in Vaccination 1. The eMPA 0.8-24 also protected the same three out of six mice against anti-OVA 
IgE responses (19.6 ± 24.8, three low responders: 0-4 titres). However, these were not the same 
three mice with low anti-OVA IgG and IgG1 responses, leading to a mixed IgG responder/non-
responder result. This indicates that eMPA vaccination responds well to lower doses than i.d. 
vaccination. Both i.d. and eMPA skin-based vaccinations show protection against Th2 sensitisation 
independent of IgG or neutrophil responses. Eosinophil and anti-OVA IgE results indicate that 
successful protection against airway Th2 hypersensitivity may be dose dependant for each route.  
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Figure 7-7: Vaccination 2 BALf cells and serum antibodies. Responses from day 29 after 
vaccination, 1x i.p. sensitisation and 3x daily challenge. (A) Cells were identified using flow 
cytometry and presented as a percentage of gated single cells. (B) Endpoint dilutions of anti-OVA 
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IgE were calculated from rat PCA assay and anti-OVA IgG and subsets were determined by ELISA 
(ABTS substrate), n = 4-6. 
 
To check Th2-based signalling was responsible for increased eosinophilia in Vaccination 2 as seen 
in Vaccination 1, all BALf supernatant samples were assessed for Eotaxin-2. As Vaccination 2 
samples were assessed on the same plate as the Vaccination 1 samples, their results can be directly 
compared. As with Vaccination 1, i.n. 80-24 resulted in low levels of Eotaxin-2 production (176 ± 
91 pg/ml) (Figure 7-8) that is expected from a low BALf eosinophil response. However, all skin-
based vaccinations had low Eotaxin-2 levels, despite high or low BALf eosinophil percentages. 
Combined, all Eotaxin-2 levels of Vaccination 2 (229 ± 23 pg/ml) were significantly less than 
Sensitised-1 groups of Vaccination 1 (p < 0.0001). This indicates that resulting airway eosinophilia 
after skin vaccination with i.d. 0.8-24, i.d. 0.08-24 and eMPA 0.8-24 is not Eoxtain-2 dependant. 
 
Figure 7-8: Levels of Eotaxin-2 detected in BALf supernatants from Vaccination 2. Responses 
from day 29 after vaccination, 1x i.p. sensitisation and 3x daily challenge, n = 4-6. 
 
To assess the impact of vaccination on airway mucus and obstruction, lung sections were stained for 
MUC5AC, a gel-forming mucin of mucus [102]. Healthy airways do not produce mucus nor do 
obstructions occur and so any increase in these factors indicates inflammation of the lungs. 
Representative histology images of Vaccination 2 group airways depict significantly less 
peribronchial inflammation (Figure 7-8A) than desensitisation lungs stained in Chapter 4. Each 
vaccination route was associated with increased presence of airway mucus (Figure 7-8Bi) and 
obstructions (Figure 7-8Bii) to a similar level, regardless of dose or vaccination route. Although, the 
three lowest readings of MUC5AC for eMPA 0.8-24 (0 – 9%) were also the same three mice that 
had lower BALf eosinophilia and less serum anti-OVA IgE. The eMPA 0.8-24 vaccination led to 
the lowest level of peribronchial cellular inflammation, which was significantly lower than both i.d. 
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8-24 (p = 0.0012) and i.d. 0.8-24 (p = 0.0058). In general, all vaccinations assessed did had some 
increase in airway mucus and obstruction relative to a healthy lung. However, without assessing 
Sensitised-1 airways, the effect of vaccination on protection against airway inflammation is unclear.  
 
Figure 7-9: Vaccination 2 lung mucus (MUC5AC), obstruction and peribronchial cellular 
inflammation histology within mid-right lobe. Inflammation from day 29 after vaccination, 1x i.p. 
sensitisation and 3x daily challenge. (A) Representative image of MUC5AC stained airway per 
vaccination group, scale 200 µm. (B) Quantified percent of (i) MUC5AC+ staining in airways and 
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(ii) obstructions made from mucus (red arrow) or cellular clumps (black arrows) in airways and 
(iii) airway-associated peribronchial inflammation (white arrows), n = 4-6. 
 
7.3.5 Eight applications of 0.01-1 µg via eMPA does not prevent production of anti-OVA IgE 
Since Vaccination 2 eMPA vaccination resulted in 50% protection against Th2-based sensitisation 
by reducing the dose, the objective of Vaccination 3 was to further explore the effect of dose 
delivered by the eMPA. Both the 1x i.p. Sensitised-1 from the Vaccination 1 study and i.n. 80-24 of 
Vaccination 1 and 2 control groups were repeated. Starting with the highest dose eMPA from 
Vaccination 1 (eMPA 8-24) that was expected not to protect, eMPA vaccination doses were titrated 
to 1/10th (eMPA 0.8-24) and 1/100th  (eMPA 0.08-24) of this dose. Vaccination 3 groups are listed 
in Table 7-4 and used the same vaccination regimen as Vaccinations 1 and 2 (Figure 7-4).  
 
The dose of EU delivered per vaccination and total protocol per group continued to be recorded. 
None of the Vaccination 3 groups received 100 ng or more EU (Table 7-4) and so were unlikely to 
induce endotoxin-based Th2 sensitisation from vaccination alone. The eMPA 0.8-24 and eMPA 
0.08-24 each delivered a vaccination dose of less than 1 ng EU, which was previously reported to 
assist protection [56]. After i.p. sensitisation and challenge, i.n. 80-24 had an accumulative EU dose 
above the recommended 100 ng [56], although, both Vaccinations 1 and 2  indicate the total 
protocol dose does not affect the Th2 sensitisation the same way the vaccination only EU dose does. 
 
As shown in Figure 7-2, the i.n. 80-24 (V3) did not sufficiently prevent BALf eosinophilia which 
was likely a result of insufficient challenge (see Methods section 7.2). This was confirmed by 
assessing the level of BALf supernatant IL-5, of which there was no difference between Sensitsed-1 
(0.68 ± 0.11 pg/ml) and i.n. 80-24 (0.63 ± 0.15 pg/ml) groups (Figure 7-10). The Sensitised-1 IL-5 
level was also significantly lower (p = 0.0012) than IL-5 of Sensitised-1 in Vaccination 1 (Figure 
7-6). Therefore, only the serum antibodies were assessed for systemic Th2 responses in Vaccination 
3. 
 
Th2-based OVA sensitisation in Vaccination 3 was confirmed by an increase in anti-OVA IgE 
endpoint titre in the Sensitised-1 group (8 ± 0, Figure 7-11). As per Vaccination 1 and 2, i.n. 80-24 
protected against anti-OVA IgE production (0 ± 0). Despite a 100-fold range in delivered dose, 
eMPA vaccinated groups displayed similar levels of anti-OVA IgE to Sensitised-1 (eMPA 8-24: 6.3 
± 2.6; eMPA 0.8-24 6.3 ± 2.6; eMPA 0.08-24 7.6 ± 4.8). The majority of anti-OVA IgG produced 
was of the subtype IgG1, as each group had increased levels of anti-OVA IgG1 (above Vaccination 
1 baseline) but there were no significant differences between treatment groups. Therefore, 
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Vaccination 3 indicated that eMPA vaccination against Th2-mediated specific antibody responses is 
not dose-dependant.  
 
Table 7-4: Vaccination 3 groups including endotoxin unit (EU) dose for vaccination only per 
group and total vaccination + sensitisation + challenge per group. Red highlighted EU indicates 
values above reported sensitising dose (100 ng), green highlight indicates values below reported 
protective dose (1 ng) [56]. 
Code Group name Route Dose Repeats Interval 
EU of 
vaccination 
(ng) 
Total EU 
(ng) 
 Sensitised-1 - - - - - 85.54 
 i.n. 80-24 i.n. 10 µg ×8 24 h 43.70 129.24 
 eMPA 8-24 eMPA 1 µg ×8 24 h 4.37 89.91 
 eMPA 0.8-24 eMPA 0.1 µg ×8 24 h 0.44 85.98 
 eMPA 0.08-24 eMPA 0.01 
µg 
×8 24 h 0.04 85.59 
 
 
Figure 7-10: Levels of IL-5 in BALf supernatant from Vaccination 3. Responses from day 29 after 
vaccination, 1x i.p. sensitisation and 3x daily challenge. Only control groups of Sensitised-1 and 
i.n. 80-24 groups were assessed, n = 4. 
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Figure 7-11: Vaccination 3 serum antibodies. Responses from day 29 after vaccination, 1x i.p. 
sensitisation and 3x daily challenge. Endpoint dilutions of anti-OVA IgE were calculated from rat 
PCA assay and anti-OVA IgG and subsets were determined by ELISA (ABTS substrate), n = 4-6. 
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7.3.6 Improved eMPA vaccination response with 72 h repeats or using the projectile applicator 
As Vaccination 2 indicated a lower dose of eMPA may be beneficial for protecting airway 
inflammation while Vaccination 3 indicated that any dose with the current protocol did not reduce 
anti-OVA IgE responses, Vaccination 4 tested fewer vaccination repeats and different vaccination 
regimens (Figure 7-12). Both the 1x i.p. Sensitised-1 from Vaccinations 1 and 3 and the i.n. 80-24 
from Vaccinations 1-3 control groups were repeated again in Vaccination 4. The eight applications 
of eMPA at 1/10th of the dose from Vaccination 2 and 3 was also repeated again (eMPA 0.8-24). 
Since Shakya et al. [133] achieved some protection against Th2 sensitisation after just three 
applications of a dMPA, half the number of repeats was tested (x4, eMPA 0.4-24). Additionally, as 
the eMPA does cause some epidermal swelling after 24 h that resolved by 72 h (Chapter 6A) half 
the number of repeats (x4) was reapplied every 72 h (eMPA 0.4-72). In addition to testing the same 
eMPA application methods as Vaccination 1-3 (defined in Chapter 6A), Vaccination 4 also 
vaccinated with the P/eMPA as defined in Chapter 6B with four repeats at 24 h intervals (P/eMPA 
0.4-24) and 72 h intervals (P/eMPA 0.4-72). Groups tested for Vaccination 4 are listed in Table 7-5.  
 
The dose of EU delivered per vaccination and total protocol per group continued to be recorded. 
None of the Vaccination 4 groups delivered 100 ng or more EU (Table 7-5) and so were unlikely to 
induce endotoxin-based Th2 sensitisation from vaccination alone. While all eMPA and P/eMPA 
groups received a vaccination dose of less than 1 ng endotoxin, previously reported to assist 
protection [56]. After sensitisation i.p. and challenge, i.n. 80-24 had a total EU dose above the 
recommended 100 ng [56], which was shown in Vaccination 1, 2 and 3 not to induce sensitisation.  
 
Figure 7-12: Vaccination 4 timeline for preventing OVA-based airway hypersensitivity in mice. 
The Vaccination 4 study protocol consisted of OVA delivered by either i.n. (10 µg), eMPA (0.1 µg 
into the flank) or P/eMPA (0.1 µg, flank) at 24 or 72 h intervals within the first 10 days. 
Sensitisation occurred 7 days after vaccination (i.p. of 10 µg OVA and 1 mg AH). Challenge 
occurred 9 days after sensitisation (daily i.n. of 50 µg OVA for three days). Samples were then 
collected 24 h after last challenge. 
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Table 7-5: Vaccination 4 groups including endotoxin unit (EU) dose per group for vaccination 
only and total vaccination + sensitisation + challenge. Red highlighted EU indicates values above 
reported sensitising dose (100 ng), green highlight indicates values below reported protective dose 
(1 ng) [56]. 
Code Group name Route Dose Repeats Interval 
EU of 
vaccination 
(ng) 
Total EU 
(ng) 
 Sensitised-1 - - - - - 85.98 
 i.n. 80-24 i.n. 10 µg ×8 24 h 43.7 129.24 
 eMPA 0.8-24 eMPA 0.1 µg ×8 24 h 0.44 85.76 
 eMPA 0.4-24 eMPA 0.1 µg ×4 24 h 0.22 85.76 
 eMPA 0.4-72 eMPA 0.1 µg ×4 72 h 0.22 85.76 
 P/eMPA 0.4-24 P/eMPA 0.1 µg ×4 24 h 0.22 85.76 
 P/eMPA 0.4-72 P/eMPA 0.1 µg ×4 72 h 0.22 85.76 
 
The Sensitised-1 group in Vaccination 4 demonstrated similar BALf cell differentiation percentages 
to Vaccination 1 with 10.9 ± 0.9% MHCII+ macrophages, 45.6 ± 7.8% eosinophils and 8.7 ± 1.0% 
lymphocytes (Figure 7-13A). Total number of BALf cells of Sensitised-1 in Vaccination 4 were 
also similar to Vaccination 1 (52,952 ± 21,029, Appendix 10.27). Th2-based OVA sensitisation in 
Vaccination 4 was confirmed by serum anti-OVA IgE the in Sensitised-1 group (6.5 ± 3.0, Figure 
7-13B). The positive control of Vaccination 4, i.n. 80-24, also followed a similar pattern to 
Vaccination 1 with 12.9 ± 2.8% MHCII+ macrophages, 18.1 ± 8.0% eosinophils and 13.4 ± 4.2% 
lymphocytes (Figure 7-13A). As per Vaccinations 1-3, i.n. 80-24 protected against anti-OVA IgE 
production (0.5 ± 0.5, p = 0.0258, Figure 7-13B). Similar to Vaccinations 1-3, the anti-OVA IgG 
titre of the i.n. 80-24 group mostly consisted of IgG1 subtype (588,800 ± 711,293). However, there 
were no significant differences between anti-OVA IgG, IgG1 or IgG2a levels in Vaccination 4 
groups. These results confirm that Vaccination 4 mice were sufficiently sensitised and challenged 
and that i.n. 80-24 continues to elicit strong protection against airway eosinophilia and anti-OVA 
IgE independent of anti-OVA IgG2a (Th1) responses.  
 
By decreasing the number of application repeats and/or increasing the rest time between repeats, the 
physical impact on the skin from the eMPA application decreases. That is, from highest to lowest 
impact is eMPA 0.8-24, eMPA 0.4-24 then eMPA 0.4-72. Similar to Vaccination 2, eMPA 0.8-24 
vaccination was associated with fewer MHCII+ macrophages than both Sensitised-1 (p = 0.0010) 
and i.n. 80-24 groups (p = 0.0094, Figure 7-13A). This increased slightly as eMPA impact 
increased. The lowest percentage of BALf lymphocytes was seen in the eMPA 0.4-72 vaccinated 
group (Sensitised-1: p = 0.0142, i.n. 80-24: p = 0.0154) but there were no other differences in BALf 
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cell subsets between groups. In contrast to Vaccination 2, none of the mice vaccinated with eMPA 
0.8-24 had decreased eosinophil levels (46.0 ± 10.3%). Additionally, fewer repeats of the eMPA 
applied every 24 h also provided no protection against BALf eosinophilia (50.4 ± 5.4%). However, 
by increasing the time between the repeats to 72 h, the eMPA 0.4-72 significantly reduced the 
airway eosinophilia (22.0 ± 19.7%, p = 0.0344), protecting four out of six mice (66%).  
 
Both 24 h eMPA groups resulted in the induction of anti-OVA IgE responses (eMPA 0.8-24: 14.8 ± 
10.3, eMPA 0.4-24: 9.3 ± 3.2, Figure 7-13B). The eMPA 0.4-72 protected against anti-OVA IgE 
(5.5 ± 6.3) in the three out of the four mice that also had low BALf eosinophils (50% Th2 
protection). The eMPA 0.4-72 vaccination also produced a relatively low titre of anti-OVA IgG1 
(76,933 ± 77,491) and IgG2a (1,217 ± 1,545). These results show that repeated application of 
eMPAs every 24 h can result in only intermittent protection against eosinophilia, while, longer 
resting periods between repeats leads to more a consistent protection against both eosinophilia and 
anti-OVA IgE that is independent of IgG1 and IgG2a. 
 
Application with the P/eMPA did not significantly reduce the percentage of BALf eosinophils. 
Unlike eMPA vaccinations, P/eMPA vaccination groups resulted in similar levels of MHCII+ 
macrophages to control groups (Figure 7-13A). However, the P/eMPA 0.4-24 vaccination resulted 
in low levels of anti-OVA IgE (4.3 ± 2.9), which was not the case for the P/eMPA 0.4-72 
vaccination (8.0 ± 5.0, Figure 7-13B). Protection from P/eMPA 0.4-24 correlated with stronger anti-
OVA IgG2a responses (4,033 ± 4,873) than the protective eMPA 0.4-72 group. This indicates that 
P/eMPAs may rely more on boosting Th1 to reduce anti-OVA IgE and therefore could require 
different vaccination regimen optimisation to eMPAs.  
 
Overall, the level of EU administered during vaccination nor during the entire protocol for each 
group did not affect the protective or activate Th2 response.  
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Figure 7-13: Vaccination 4 BALf cells and serum antibodies. Responses from day 29 after 
vaccination, 1x i.p. sensitisation and 3x daily challenge. Vaccinations were applied either every 24 
h (closed symbols) or 72 h (open symbols). (A) Cells were identified using flow cytometry and 
presented as a percentage of gated single cells. (B) Endpoint dilutions of anti-OVA IgE were 
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calculated from rat PCA assay and anti-OVA IgG and subsets were determined by ELISA (ABTS 
substrate), n = 4-6. 
 
To confirm eosinophil presence in BALf, BALf supernatant was assessed for Eotaxin-2 (Figure 
7-14). Despite consistently high eosinophilia (Figure 7-13A), Sensitised-1 group demonstrated a 
lower level of Eotaxin-2 (483 ± 312 pg/ml) than Vaccination 1. Yet, i.n. 80-24 vaccination had a 
similar decreased concentration of Eotaxin-2 (139.1 ± 57.1 pg/ml) to Vaccinations 1 and 2. 
Corresponding with eosinophil infiltration patterns, vaccination with eMPA 0.8-24 (354 ± 55 
pg/ml) induced significantly more Eotaxin-2 than i.n. 80-24 (p = 0.0102) and P/eMPA 0.4-24 (p = 
0.0066) groups. However, the three groups with the lowest levels of Eotaxin-2 in BALf supernatant 
were consistent with the three lowest BALf eosinophil groups (i.n. 80-24, eMPA 0.4-72 and 
P/eMPA 0.4-24). Specifically, the same four eMPA 0.4-72 mice with low eosinophils also had very 
low Eotaxin-2 levels averaging 42 ± 7 pg/ml. In general, the Eotaxin-2 levels followed the same 
trend as both BALf eosinophils and serum anti-OVA IgE, albeit at lower concentrations than 
previously reported in Vaccinations 1 and 2. This is unlike earlier eMPA vaccination tests that 
showed increased eosinophil infiltration was independent of Eotaxin-2. Therefore, the results from 
Vaccination 4 led me to conclude that eMPA eosinophilia is somewhat Eotaxin-2 dependant. 
 
Figure 7-14: Levels of Eotaxin-2 in BALf supernatant from Vaccination 4. Responses from day 29 
after vaccination, 1x i.p. sensitisation and 3x daily challenge. Vaccinations were applied either 
every 24 h (closed symbols) or 72 h (open symbols), n = 4-6. 
 
To assess the impact of Vaccination 4 on airway mucus and obstruction, lung sections were stained 
for MUC5AC. Representative images of airways depict significantly less peribroncial inflammation 
than desensitisation lungs stained in Chapter 4 (Figure 7-15A). On average, there was very little 
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mucus produced in Vaccination 4 across groups (Figure 7-15Bi). Apart from an outlier in P/eMPA 
0.4-72 the mean percent of MUC5AC+ stained cells ranged from 1.37 – 6.73 % of airways across 
all groups. Sensitised-1 did not result in airway mucus hyper production (2.4 ± 3.5%). There were 
also no significant differences between the percent of obstructed airways for Vaccination 4 across 
groups (combined: 12.2 ± 12.7%). Overall, the single i.p. sensitisation does not elicit strong airway 
mucus and obstructions, making it difficult to compare possible protective effects of the eMPA 
vaccination. Promisingly, eMPA vaccination did not enhance mucus production. 
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Figure 7-15: Vaccination 4 lung mucus (MUC5AC) and obstruction histology within mid-right 
lobe. Inflammation from day 29 after vaccination, 1x i.p. sensitisation and 3x daily challenge. 
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Vaccinations were applied either every 24 h (closed symbols) or 72 h (open symbols). (A) 
Representative image of MUC5AC stained airway per vaccination group, scale 200 µm. (B) 
Quantified percent of (i) MUC5AC+ staining in airways and (ii) obstructions made from mucus 
(red arrow) or cellular clumps (black arrows) in airways, n = 4-6. 
 
7.3.7 Less repeats of a higher dosed i.n. vaccination is more protective against lung inflammation 
The lung histology of the i.n. 80-24 groups of Vaccinations 2 and 4 presented mixed results in 
protecting lungs against inflammatory mucus and peribronchial inflammation. However, the eMPA 
vaccination groups indicated they may provide better protection against airway inflammation, 
though without a sufficient positive control it is difficult to conclude upon. Therefore, the objective 
of Vaccination 7 was to investigate a more suitable i.n. positive control against airway 
inflammation. A similar i.n. positive control to Vaccination 1-4 was repeated (i.n. 70-24) with a 
similar protocol (Figure 7-16). To ensure minimal impact on the lungs during i.n. vaccination was 
tested with less repeats (x2) at the same dose (i.n. 20-24) and a 10-fold higher dose (i.n. 200-24), as 
listed in Table 7-6. Less repeats and higher dose was modelled off [118] and [56] both of which 
resulted in low or no airway eosinophilia.  
 
The dose of EU delivered per vaccination and total protocol per group continued to be recorded. 
Group i.n. 200-24 received more than the recommended 100 ng EU during vaccination (Table 7-6) 
and so is at risk of inducing endotoxin-based Th2 sensitisation from vaccination alone [56]. After 
i.p. sensitisation and challenge, i.n. 70-24 had an accumulative EU dose above the recommended 
100 ng [56], which was shown in Vaccinations 1-4 not to induce sensitisation but in did induce 
sensitisation. 
 
 Figure 7-16: Vaccination 7 timeline for preventing OVA-based airway hypersensitivity in mice. 
The Vaccination 7 study protocol consisted of OVA delivered by i.n. (10 or 100 µg), at 24 h 
intervals with the first 10 days. Sensitisation occurred 8 days after vaccination (i.p. of 10 µg OVA 
and 1 mg AH). Challenge occurred 9 days after sensitisation (daily i.n. of 50 µg OVA for three 
days). Samples were then collected 24 h after last challenge. 
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Table 7-6: Vaccination 7 groups including endotoxin unit (EU) dose per group for vaccination 
only and total vaccination + sensitisation + challenge. Red highlighted EU indicates values above 
reported sensitising dose (100 ng) [56]. 
Code Group name Route Dose Repeats Interval 
EU of 
vaccination 
(ng) 
Total EU 
(ng) 
 Sensitised-1 - - - - - 79.40 
 i.n. 70-24 i.n. 10 µg ×7 24 h 34.74 114.14 
 i.n. 20-24 i.n. 10 µg ×2 24 h 10.53 89.93 
 i.n. 200-24 i.n. 100 µg ×2 24 h 102.56 181.96 
 
The Sensitised-1 group in Vaccination 7 demonstrated similar BALf cell differentiation percentages 
to Vaccinations 1 and 4 with 3.3 ± 0.5% MHCII+ macrophages, 2.3 ± 1.6% neutrophils, 73.8 ± 
2.2% eosinophils and 11.8 ± 1.1% lymphocytes (Figure 7-17A). Percent of Vaccination 7 
Sensitised-1 eosinophils was significantly higher than Vaccinations 1 and 4 combined (p = 0.0007). 
Total BALf cells were slightly increased (80,280 ± 12,752, p = 0.0358) compared to Sensitised-1 of 
Vaccinations 1 and 4 (Appendix 10.27). Sensitised-1 also increased anti-OVA IgE endpoint titre 
(10.67 ± 4.6) in Vaccination 7 serum (Figure 7-17B), confirming Th2 sensitisation.  
 
Since the percent of BALf MHCII+ macrophages of Sensitised-1 was less than previous 
vaccinations, the i.n. 70-24 group consisted of significantly more MHCII+ macrophages (p = 
0.0193). Yet, the mean range of Vaccination 7 MHCII+ macrophages of all i.n. groups (combined: 
6.5 ± 1.9%) was no different from Vaccinations 1, 2 and 4. Although the i.n. 70-24 vaccination 
BALf eosinophil percentage was significantly higher (40.8 ± 14.5%, Figure 7-17A) than any of the 
previous vaccination i.n. 80-24 groups, the relative decrease of eosinophil percentage compared to 
Sensitised-1 (0.55) was similar to that of Vaccination 2 (0.54, Figure 7-2). Both i.n. 20-24 and i.n. 
200-24 also resulted in less eosinophil percentages (55.1 ± 11.1% and 49.1 ± 10.8% respectively), 
but not significantly so. Vaccination with i.n. 200-24 elicited the significantly less total BALf cells, 
similar to the Baseline levels of Vaccination 1 (p = 0.0020, 15,747 ± 15,551, Appendix 10.27). 
Therefore, although i.n. 200-24 elicited a similar percentage of eosinophils to Sensitised-1, the total 
number of eosinophils would be significantly less (i.e. Sensitised-1: 73.8% × 80,280 cells = 59,246 
eosinophils; i.n. 200-24: 49.1% × 15,747 cells = 7,731 eosinophils, Appendix 10.28). Out of all the 
vaccination studies, this is the only instance where the total number of eosinophil cells did not 
follow the same trend as the percent of eosinophils (Appendix 10.28). There were no significant 
difference between neutrophil and lymphocyte percentages in the BALf between Vaccination 7 
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groups. All three i.n. vaccination groups continued to protect against increases in anti-OVA IgE 
endpoint titre (combined: 1.2 ± 0.8). The IgG ELISA analysis cannot be directly compared to 
Vaccinations 1 – 6 (due to a change in substrate) but there was still no significant differences 
between the groups for anti-OVA IgG1 nor IgG2a, indicating protective responses are independent 
of IgG. So, in addition to the i.n. 70-24 vaccination continuing to provide protecting against Th2 
sensitisation, the i.n. 200-24 group also provided protection (despite 100 ng EU delivered during the 
i.n. 200-24 vaccination).  
 
To assess the effect of repeats and dose of i.n. vaccination on airway mucus and inflammation, lung 
sections were stained with MUC5AC. Representative images depict higher inflammation was 
present in Sensitised-1 and i.n. 70-24 (Figure 7-18A). Again, the 1x i.p. Sensitised-1 did not result 
in a strong airway mucus hyper-production response (7.8 ± 6.5%) (Figure 7-18Bi) but continued to 
contain some obstructions (24.2 ± 4.9%) (Figure 7-18Bii). However, a large number of Sensitised-1 
airways were associated with peribronchial inflammation (63.8 ± 6.4%, Figure 7-18Biii).  
 
The i.n. 70-24 airway contained a similar percentage of boosted mucus (15.9 ± 11.9%, Figure 
7-18Bi) and obstructions (26.5 ± 12.6%, Figure 7-18Bii) as Vaccination 2 (Figure 7-9) and 
Sensitised-1. Though i.n. 70-24 did have significantly less peribronchial inflamed airways (p = 
0.0005) (Figure 7-18Biii). Despite no significant difference between the mucus and obstructions for 
Vaccination 7, i.n. 200-24 (3.8 ± 7.7%) protected three out of four mice from airway mucus (75% 
protection) and had the lowest average obstructions (18.1 ± 14.4%) and peribronchial inflamed 
airways (19.3 ± 22.4%). Overall, analysis of the lungs show that less repeats of a higher dose may 
be more beneficial for protection against lung inflammation. Together, the i.n. 200-24 vaccination 
regimen elicited protective responses against both Th2 sensitisation and airway inflammation and so 
would make a better positive control for assessment of airway inflammation. 
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Figure 7-17: Vaccination 7 BALf cells and sera antibodies. Responses from day 29 after 
vaccination, 1x i.p. sensitisation and 3x daily challenge. (A) Cells were identified using flow 
cytometry and presented as a percentage of gated single cells. (B) Endpoints of anti-OVA IgE were 
calculated from rat PCA assay and anti-OVA IgG and subsets were determined by ELISA (TMB 
substrate), n = 3-4. 
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Figure 7-18: Vaccination 7 lung mucus (MUC5AC), obstruction and peribronchial cellular 
inflammation histology within mid-right lobe. Inflammation from day 29 after vaccination, 1x i.p. 
sensitisation and 3x daily challenge. (A) Representative image of MUC5AC stained airway per 
vaccination group, scale 200 µm. (B) Quantified percent of (i) MUC5AC+ staining in airways, (ii) 
obstructions made from mucus (red arrow) or cellular clumps (black arrows) in airways and (iii) 
airway-associated peribronchial inflammation (white arrows), n = 3-4. 
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7.3.8 The eMPA route protects against airway mucus and peribronchial cellular inflammation in a 
chronic sensitisation model 
Since the eMPA groups of Vaccinations 2 and 4 resulted in the least airway mucus, I aimed to 
assess if this protection persists in a chronic airway hypersensitivity model. However, the 1x i.p. 
sensitisation followed by 3x i.n. challenge (Sensitised-1) was an insufficient negative control. 
Therefore the number of i.p. sensitisations and i.n. challenges were doubled based on McMillan et 
al. [112] (Figure 7-19). The negative control group for this schedule was called Sensitised-2 (Table 
7-7). As Vaccination 7 found that i.n. 200-24 resulted in the least airway inflammation this was 
used as the positive control. The eMPA 0.4-72 vaccination was then compared to these controls in 
Vaccination 8.  
 
The dose of EU delivered per vaccination and total protocol per group continued to be recorded. 
Group i.n. 200-24 received 100 ng EU during vaccination (Table 7-7) and so is at risk of inducing 
endotoxin-based Th2 sensitisation from vaccination alone [56], although this was not seen in 
Vaccination 7. While eMPA 0.4-72 received a vaccination dose of less than 1 ng EU, previously 
reported to assist protection [56]. After sensitisation i.p. and challenge, all groups had an 
accumulative EU dose above the recommended 100 ng [56], which may add to Th2-based 
signalling. 
 
Figure 7-19: Vaccination 8 timeline for preventing OVA-based chronic airway hypersensitivity in 
mice. The Vaccination 8 study design consist of OVA delivered by i.n. (100 µg) at a 24 hr interval 
or eMPA (0.1 µg) 72 h intervals with the first 10 days. Sensitisation occurred 7 days and 14 days 
after vaccination (i.p. of 10 µg OVA and 1 mg AH). Challenge occurred 9 days after last 
sensitisation (daily i.n. of 50 µg OVA for six days). Samples were then collected 24 h after last 
challenge. 
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Table 7-7: Vaccination 8 groups including endotoxin unit (EU) dose for vaccination only per 
group and total vaccination + sensitisation + challenge per group. Red highlighted EU indicates 
values above reported sensitising dose (100 ng), green highlight indicates values below reported 
protective dose (1 ng) [56]. 
Code Group name Route Dose Repeats Interval 
EU of 
vaccination 
(ng) 
Total EU 
(ng) 
 Sensitised-2 - - - - - 158.80 
 i.n. 200-24 i.n. 100 µg ×2 24 h 99.25 258.05 
 eMPA 0.4-72 eMPA 0.1 µg ×4 72 h 0.20 159.00 
 
When boosting the mice with a second i.p. and additional challenges, the cellular differentiation 
percentage of the BALf was altered and antibody production in the sera was boosted in all groups 
(Figure 7-20). Relative to Vaccinations 1, 4 and 7, Sensitised-2 BALf maintained similar levels of 
MHCII+ macrophages (3.8 ± 1.2%) and lymphocytes (11.4 ± 2.6%) but with less neutrophils (0.09 
± 0.09%) and more eosinophils (76.6 ± 4.4%, Figure 7-20A). Sensitised-2 elicited the highest 
number of total BALf cells (84, 394 ± 13,584) out of all vaccination studies presented (Appendix 
10.27). Sensitised-2 also increased the anti-OVA IgE endpoint dilution to 22 ± 11 (Figure 7-20B). 
Leading to a strong, chronic Th2-based sensitisation, similar to McMillian et al. [112].  
 
Vaccination with i.n. 200-24 resulted in significantly more MHCII+ macrophages (p = 0.0049) and 
significantly less eosinophils (p = 0.0357) than Sensitised-2 (Figure 7-20A). Compared to i.n. 200-
24 group of Vaccination 7, the i.n. 200-24 group of Vaccination 8 induced similar levels of BALf 
MHCII+ macrophages (6.5 ± 1.7%), neutrophils (3.0 ± 4.6%) and lymphocytes (11.7 ± 1.9%) to i.n. 
200-24 of Vaccination 7. As with Vaccination 1, 2 7, the i.n. group resulted in the highest 
neutrophil response, indicating it is dependant of inducing neutrophils into the BALf. However, the 
Vaccination 8 i.n. 200-24 eosinophilia (67.2 ± 9.8%) is still significantly higher than Vaccination 7 
i.n. 200-24 (p = 0.0332). The i.n. 200-24 vaccination did not protect against the increase of anti-
OVA IgE endpoint titre after the 2x i.p. sensitisation (17 ± 12). Showing that i.n. 200-24 
vaccination cannot protect against the Th2 sensitisation of a 2x i.p. chronic model.  
 
Vaccination with eMPA 0.4-72 resulted in significantly more MHCII+ macrophages (p = 0.0319, 
5.6 ± 1.4%) and significantly less lymphocytes (p = 0.0161, 8.0 ± 1.7%) than Sensitised-2. It also 
resulted in low neutrophil levels (0.3 ± 0.4%), however, the eMPA 0.4-72 did not protect against 
eosinophilia (74.1 ± 6.2%). The eMPA 0.4-24 vaccination also increased the anti-OVA IgE 
endpoint titre (41 ± 15). All anti-OVA IgG1 and IgG2a response were higher than in vaccination 7 
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but there was no significant difference between the groups, indicating the responses are independent 
of IgG. From this data, it is clear the eMPA 0.4-72 vaccination also cannot protect against the Th2 
sensitisation of a 2x i.p. chronic model. 
 
MUC5AC stained sections confirmed that the Sensitised-2 group in Vaccination 8 sufficiently 
boosted airway inflammation. Representative images depict strong airway inflammation was 
present in Sensitised-2 and i.n. 200-24 (Figure 7-21A).  In agreeance with results previously 
reported [112], chronic Sensitised-2 airways had higher percentages of mucus (30.9 ± 14.5%, 
Figure 7-21Bi) and peribronchial inflammation (48.3 ± 20.7%, Figure 7-21Biii). Vaccination with 
i.n. 200-24 reduced percent of mucus, although not significantly due to a large spread (13.2 ± 
16.7%). However, percent of peribronchial inflammation (36.0 ± 25.6%) of i.n. 200-24 vaccination 
was similar to Sensitised-2 levels. Meanwhile, the eMPA 0.4-72 vaccination significantly protected 
against boosted mucus levels (6.3 ± 10.5%, p = 0.0040) and peribronchial inflammation (9.1 ± 
7.8%, p = 0.0018). As per Vaccinations 2, 4 and 7, there were no significant differences between 
the percentages of obstructions in Vaccination 8, overall averaging 18.0 ± 16.4% (Figure 7-21Bii). 
Together, the chronic model sufficiently increased airway mucus and peribronchial inflammation 
levels (Sensitised-2) of which the eMPA 0.4-72 vaccination protected against. 
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Figure 7-20: Vaccination 7 BALf cells and sera antibodies. Responses from day 36 after 
vaccination, 2x i.p. sensitisation and 6x daily challenge. (A) Cells were identified using flow 
cytometry and presented as a percentage of gated single cells. (B) Endpoints of anti-OVA IgE were 
calculated from rat PCA assay and anti-OVA IgG and subsets were calculated from ELISA (TMB 
substrate), n = 7-8. 
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Figure 7-21: Vaccination 7 lung mucus (MUC5AC) and obstruction histology within mid-right 
lobe. Inflammation from day 36 after vaccination, 2x i.p. sensitisation and 6x daily challenge. (A) 
Representative image of MUC5AC stained airway per vaccination group, scale 200 µm. (B) 
Quantified percent of (i) MUC5AC+ staining in airways, (ii) obstructions made from mucus (red 
arrow) in airways and (iii) airway-associated peribronchial inflammation (white arrows), n = 7-8. 
 
 
7.4 Discussion 
Desensitisation treatment for established airway allergies can take years to be effective, yet animal 
models have reported as little as one high dose of i.n. administration could prevent IgE-based 
sensitisation [168]. Although prevention of sensitisation seems theoretically simpler, allergen 
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vaccination relies on a delicate balance of dose, number of repeats, timing of repeats, age of the 
subject and allergic risk susceptibility of the subject per antigen. Hence, to date allergen vaccination 
has not been implemented clinically. In this chapter, I found that protection against the induction of 
airway Th2 responses (airway eosinophilia and serum IgE) via different routes was most successful 
with different doses. That is, the i.n. vaccination was most successful at 70-200 µg total delivered 
dose, while i.d. vaccination required approximately 1/10th of this (8 µg) and the eMPA required 
1/20th of the i.d. dose (0.4 µg). Additionally, the eMPA route required delivery conditions that 
resulted in a lower physical impact on the skin than i.n. or i.d., such as longer time intervals 
between repeats, which is a new factor to consider for MPA-based allergy vaccinations. These 
results suggest that protective vaccination against allergic Th2 responses depends on the routes 
immune environment (i.e. the level of inflammatory and LC cells) and inversely correlates to total 
delivered dose of allergen (Schematic 7-1). However, only eMPA vaccination significantly 
protected against airway mucus hyperproduction and peribronchial cellular infiltration. This 
suggests optimal protection of allergic-based airway inflammation could be route specific 
(Schematic 7-1).    
 
 
Schematic 7-1: Representation of variables that affect protection against allergy sensitisation in 
Chapter 7. Where routes that impact the skin’s inflammatory response more and target more LCs 
require lower allergen doses to protect against Th2-based eosinophilia and anti-OVA IgE and vice 
versa. Vaccination regimens that result in higher impacts on the skin (such as large number of 
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repeats of applications over a short period of time) during vaccination at any dose induces Th2 
sensitisation. However, stronger protection against airway mucus and peribronchial inflammation 
may be depend more route of vaccination delivery, favouring routes such as the eMPA (blue 
arrow). 
 
7.4.1 Preventing Th2 sensitisation 
Holt et al. [46] proposed a biphasic dose-dependent sensitisation to inhaled allergens supported by 
readings of indoor inhaled allergen concentrations and aerosol mouse studies (see Figure 2-2). 
Results of inhaled OVA dose and other key studies have been overlaid onto Holt et al.’s biphasic 
concept (Schematic 7-2). Reports of repeated aerosol inhalation in adult mice that accumulated to a 
high dose exposure of 9% or more (e.g. 9x 1% w/v aerosol exposures) was generally more 
protective against Th2 sensitisation than and medium accumulative dose of 3.02%. Based on other 
independent studies, these percentages of exposure to delivery dose, each equates to approximately 
31 µg (9%) and 10 µg (3%) total OVA deposited in the mouse lungs respectively [119]. Allergen 
avoidance represents the low dose of this biphasic curve, where avoidance of inhaled allergens 
before two years of age also decreased the risk of sensitisation in children [47].  
 
As a broad range of total dose delivered by i.n. inhalation has resulted in both protection and 
sensitisation (see Figure 2-7B), here I confirmed that eight daily i.n. inhalations of 10 µg OVA (80 
µg total) protected against a single i.p. sensitisation and subsequent airway challenge (Vaccinations 
1-4). Since i.n. administration results in approximately 36% of the dose deposited in the lungs 
[121], to compare against the aforementioned reported aerosol data, a total i.n. dose of 80 µg 
delivered approximately 28.8 µg into mouse lungs. This dose is similar to the protective dose 
deposited of the aerosol studies. Lower percentage of BALf eosinophils and titres of serum anti-
OVA IgE in i.n. 80-24 groups were associated with an increased BALf neutrophilia. Eisenbarth et 
al. [56] also found an increase in neutrophil response when the total i.n. vaccination (300 µg OVA 
or 108 µg delivered) included 100,000 ng of LPS EU (but not with 100 ng LPS EU), a significantly 
higher amount than administered here (43.7 ng EU). This suggests that the increase in neutrophils in 
i.n. vaccination groups was not likely due to the presence of endotoxin. However, a persistent 
increase in the number of neutrophils in the lungs can lead to unwanted neutrophilic asthma [384]. 
As the mice were assessed 24 h after the last challenge I was unable to conclude if the neutrophils 
had persisted or not. None-the-less, the high repeats of low-dose i.n. vaccination prevented airway 
eosinophilia and increases in anti-OVA IgE over several studies and so provides a repeatable 
allergy vaccination positive control. 
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Interestingly, Eisenbarth et al. also reported that 100 ng of LPS EU (i.e. 0.0003 µg LPS to 1 µg 
OVA), significantly increased BALf eosinophilia. This was not found here despite a similar ratio of 
doses (0.0005 µg endotoxin to 1 µg OVA), which confirms that effects of endotoxin dose on airway 
eosinophilia depends solely on the dose of endotoxin delivered and not the endotoxin to allergen 
ratio. By comparing the EU doses received during protective i.n. Vaccinations 1-4, this data tightens 
the threshold gap previously reported by Eisenbarth et al. where the protective dose of 1 ng EU 
received during i.n. vaccination can now be extended to 1-43.7 ng EU dose. Although the EU dose 
received during i.n. vaccination may affect the sensitisation outcome, the total EU dose 
administered over the entire vaccination/ sensitisation/ challenge protocol did not correlate with the 
level of Th2 sensitisation. Additionally, less repeats of a higher dose of EU, such as in Vaccination 
7 seems to reduce the effect of EU on Th2 sensitisation.  
 
Schematic 7-2: Association of inhaled endotoxin dose and ovalbumin dose per inhalation route 
relative to the proposed biphasic dose dependency of sensitisation/protection. Emboldened doses 
are taken from results presented in Chapter 7. Key studies included were all OVA vaccinated then 
either sensitised or challenged or both. Other studies referred to include: ^ [56], @ [119], % [120] 
and & [168]. Modified with permission, from Holt et al. [46].  
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Under initial inspection, i.d. allergy vaccinations also appear to follow the same biphasic dose-
dependent curve as inhaled allergens (trend depicted in first row of Schematic 7-3). That is, in 
Vaccination 2 ‘medium’ doses of i.d. (total delivery of 0.08 - 0.8 µg) led to an increase in Th2 
hypersensitivity, which is similar to the 1.2 µg total dose also reported to increase sensitisation  
[113].  While, an increase to a higher dose (e.g. to 8 µg of Vaccination 2) protected mice from 
BALf eosinophilia and serum anti-OVA IgE. This high dose could be extended to 12-120 µg total 
dose also reported to provide protections against Th2 sensitisation [113]. None-the-less, i.d. has 
rarely been used as a route for allergen vaccination since i.n. and aerosols have generally provided 
better levels of protection. However, here I show i.d. can provide similar protection with a 10th of 
the i.n. dose, indicating i.d. vaccination may just require a more thorough titration of the dose rather 
than testing dose-matched delivery as previously reported [342].  
 
To my knowledge, no other studies have tested doses within the range of 0.08 – 120 µg via i.d. 
vaccination to protect against Th2 sensitisation in mice. Therefore, it is difficult to place ‘low’, 
‘medium’ and ‘high’ doses of i.d. vaccination within the context of the biphasic dose exposure 
hypothesis. As aforementioned, the i.d. vaccination may follow the same trend as the inhaled 
biphasic dose exposure, however, in comparison to other skin routes, it may follow also an inverse 
curve as depicted in the second row of Schematic 7-3. If the i.d. route follows the inverse skin route 
trend proposed it would also further support of the relationship between dose and LC activation 
summarised in Schematic 7-1. Where the 20-fold shift in protective dosing between the i.d. and the 
eMPA is likely to be due to i.d. inflicting a lower level of epidermal cell death leading to reduced 
LC migration (see Chapter 6). The faster clearance of the i.d. dose from the skin compared to 
epidermal routes also means that i.d. dose has less time to be internalised by skin LCs [201].  
 
In contrast to trends seen in inhaled vaccination, eMPA vaccination may follow the newly proposed 
skin-based inverse dose exposure trend (Schematic 7-3). As neither low dose eMPAs (total delivery 
of 0.08 µg) nor high dose eMPAs (0.8 – 8 µg) protected against Th2 sensitisation (Vaccinations 1-
3). While the medium dose of 0.4 µg provided protection for 50-66% of mice against BALf 
eosinophilia and serum anti-OVA IgE (Vaccination 4). This upper limit was supported by the failed 
protection from Shakya et al.’s high dose dMPA vaccination (total dose of 59.1 µg) [144]. 
Although, each dose threshold will likely differ per antigen as demonstrated by Shakya et al. using 
the same schedule as the OVA vaccination [144] with Dermatophagoides pteronyssinus allergen 
but the latter showing improved vaccination protection [325]. Importantly, as the OVA dose of i.d. 
and eMPA decreased so did the endotoxin levels. In which case, the dose of allergen for schematic 
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7-3 could also be replaced with dose of endotoxin but no epicutaneous vaccination studies have yet 
to be reported to this effect in allergy models.  
 
 
 
Schematic 7-3: Proposed inverted biphasic association of ovalbumin dose via skin exposure to 
sensitisation/protection. Emboldened doses are taken from results presented here. Key studies 
included were all OVA vaccinated then either sensitised or challenged or both. Modified, with 
permission, from Holt et al. [46]. Other studies referred to include: # [113] and $ [144].  
 
An additional factor that comes into play when delivering allergen via MPAs is the physical impact 
the projections have upon the skin. For instance, a non-protective eMPA 0.8-24 was applied eight 
times and so was estimated to kill an average of 76912 ± 10872 keratinocytes in the epidermis 
while protective eMPA 0.4-72 was applied four times and so only killed half of that (38456 ± 5436) 
(Chapter 6A). As dead or injured keratinocytes are known to release pro-inflammatory signals in 
the form of DAMPs (such as from tape stripping [113]), it could be hypothesised that reducing 
epidermal cell death would reduce the likelihood of activating Th2 responses. Keratinocyte cell 
death also activates epidermal LCs [237] and so leads to the question: what is the optimal number 
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of dead keratinocytes within a given area to activate LCs while avoiding Th2 activation? If MPA 
vaccination relies more on the level of impact it has on skin inflammation, the relationship would 
revert back to the same biphasic concept as inhaled dose. That is, higher levels of cell death (such as 
levels seen in UVB irritation of the skin,) may enhance a strong Treg response [385], while medium 
levels (e.g. 8x eMPA application) leads to sensitisation, and lower levels (e.g. 4x eMPA 
applications) provides protection. Further investigation is required to determine whether eMPAs 
follow an inverse biphasic association with sensitisation by delivered allergen dose (Schematic 7-3) 
or an inhalation-like biphasic association with sensitisation by application-induced skin 
inflammation  
 
I previously showed that LC migration from skin to dLN after eMPA application continues between 
24 and 72 h after application (Chapter 6A). This is slower than high inflammatory tape stripping of 
skin and i.d. injection [251]. By attempting to avoid overlap of peak LC migration, eMPAs applied 
every 72 h were much more effective at protecting against sensitisation than applied every 24 h 
(Vaccination 4). Optimal timing of eMPAs was different when the application mode was changed 
to the P/eMPA. This may be due to the significant increase in cell death caused by the P/eMPA 
(four applications = 71168 ± 6032 dead cells) or the significant decrease in epidermal swelling at t 
= 24 h (Chapter 6B). Overall, I recommend that the epidermis can be targeted by high-density 
eMPAs to deliver de novo allergens to healthy, mature skin to protect against Th2-based 
sensitisation. To do so, the dose and level of impact on skin inflammation will be key variables that 
will require optimisation for each allergen. In essence, epidermal based allergen vaccination could 
replicate the natural progression of exposure for allergens, significantly decreasing the prevalence 
of allergies. 
 
7.4.2 Preventing airway inflammation 
High presence of airway mucus can lead to fatal outcomes in allergic asthmatics [103]. Th2-induced 
airway mucus (as tested in Vaccination 8) was previously reported to depend on infiltrating Th2-
associated cells but not on IgE mechanisms (i.e. not by IL-4 [143]) nor eosinophilia [92]. Therefore, 
even if both IgE and BALf eosinophils are downregulated, this does not necessarily reduce airway 
inflammation. This effect was best observed in Vaccination 2, as vaccinations led to a range of 
eosinophilia and anti-OVA IgE responses, however, each group maintained similar levels of airway 
mucus. Additionally, vaccination with the eMPA 0.4-72 before chronic sensitisation no longer 
protected against Th2 responses (airway eosinophilia and sera anti-OVA IgE) but did significantly 
protect against airway mucus and peribronchial inflammation (Vaccination 8). As eluded to in 
Chapter 4, Shakya et al. is the only other MPA study that has prevented airway mucus by including 
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CpG (Th1 adjuvant) into the dMPA vaccination [144, 325]. Alternatively, OVA immunisation with 
a epidermal powder immunisation device (EPI) that targeted the epidermis also protected against 
lung inflammation similar to the eMPA 0.4-72 in Vaccination 8 [26]. One of the major differences 
between non-protective skin vaccination routes and high-density eMPA or EPI application is the 
level of localised skin wounds caused by penetration. Skin microwounds have been shown to attract 
neutrophils [386], upregulate Th1 mediators such as TLR-9 and IL-12 [281, 387] and attract 
plasmacytoid DCs that release type I IFNs [145], but skin wounds are not associated with mucus 
enhancing cytokines such as IL-13 or IL-25 [115, 388]. Further studies into skin wound healing 
signalling and anti-airway inflammation may assist in elucidating how the eMPA provides 
protection. No other MPA or i.d. studies were found to prevent mucus hyperproduction without the 
use of adjuvants. Therefore, this is the first study to present protection by an allergen-only eMPA 
against chronic Th2-induced airway inflammation. 
 
 
7.5 Conclusion 
 
In conclusion, this is the first instance of high-density eMPAs being used to deliver allergen-only 
therapy to successfully protect against airway hypersensitivity in mice. These findings support both 
the sub hypothesis of this chapter and the overall hypothesis that the use of high-density eMPAs for 
delivery of allergy therapy requires low-impact conditions. Overall, the eMPAs applied eight times 
or every 24 h increased the impact on the skin and failed to prevent Th2-mediated sensitisation, 
while fewer applications applied at larger time intervals shows promise in preventing both airway 
inflammation and anti-OVA IgE. I confirmed that eMPAs require significantly lower doses than i.d. 
injection or i.n. inhalation vaccination while providing superior protection against airway mucus 
hyper-production. Therefore, I recommend low-impact eMPAs of 7k p/cm2 density or less (i.e. 
>1.09 mm2 within the epidermis) applied at 30-85 mJ or lower (depending on the application device 
mechanism) as a viable device to deliver allergen to the skin for the prevention of allergen-based 
airway inflammation. Further testing is required to assess the mechanism behind MPA-based 
protection of airway inflammation and to define the optimal dose and timing for other allergens. 
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Chapter 8 
 
8 Conclusions 
 
The focus of this thesis was to establish if high-density (>1k p/cm2) microprojection arrays (MPAs) 
could be used to delivery allergen to the skin and elicit a favourable immune environment to 
prevent subsequent allergic responses. Each study outlined in Chapters 4-7 assessed the effect of 
MPA design on both the level of impact on the skin and the subsequent specific immunity. I found 
supporting evidence for all Hypotheses presented in Schematic 1-1 of Chapter 1 except for 
hypothesis 1 of Chapter 4, which was rejected. Therefore, the goal to solely increase OVA-specific 
IgG for AIT was dismissed. Instead, Chapter 4 found airway eosinophilia was reduced when the 
impact of the applied dMPA (i.e. density and application energy) was reduced. This led to the 
investigations seen in Chapter 5, where changing the density of dMPAs was found to have a 
positive correlation with both the level of epidermal cell death and the level of Th2-mediated 
immunity. These results provided a clearer distinction between high-density dMPA designs 
previously reported to produce strong pro-inflammatory responses ideal for boosting immunity and 
dMPA designs that are better suited to specifically delivering allergen to the skin without boosting 
pro-inflammatory immunity. However, each dMPA tested continued to produce unwanted specific 
Th2 antibody responses (IgG1 and IgE) despite also boosting Th1 antibody responses (IgG2a) and 
were associated with an increase in airway neutrophilia. Therefore, an eMPA was designed 
specifically for mouse skin in order to deliver OVA more specifically to the tolerant-inclined LCs in 
the epidermis rather than the immunity-inclined dDCs in the dermis (Chapter 6A). In doing so, the 
eMPA required a significantly larger tip surface area and a much lower application energy when 
applied with the push-through applicator. These conditions led to a significantly lower impact on 
the skin, which it turn activated LCs to migrate out of the skin with lower T cell activation receptor 
expression (MHC II) than the dMPA. This was the first instance of an antigen rapidly delivered to 
the epidermis in mice by an MPA (or any skin-delivery device) without eliciting strong skin 
inflammation. MPA application conditions were also tailored to deliver to the epidermis with a 
more clinically relevant projectile applicator, despite different application mechanisms (Chapter 
6B). These new MPA designs fill a crucial gap in skin-delivery devices for pre-clinical tests in mice 
prior to translation to human.  
 
Previous reports of devices that quickly target therapeutics to epideraml LCs utilised high-
inflammatory means such as tape stripping, ablative fractional laser or epidermal powder 
immunisation devices, and so where unsuitable for allergy therapeutics without the use of 
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adjuvants. Both increases in airway eosinophilia and serum anti-OVA IgE were prevented when 
mice were vaccinated with a significantly lower dose via low-impact eMPAs in a Th2-based airway 
hypersensitivity challenged model (Chapter 7). This is important because higher doses can result in 
unwanted reactions in an allergic patient or could induce allergy sensitisation. As the impact of 
eMPAs on skin was higher than the i.d. (particularly in number of epidermal dead cells from 
application), eMPA vaccination worked best when the number of repeats was reduced and the 
timing between repeats was lengthened. These are important variables to consider when optimising 
skin delivery devices such as MPAs, which speed up the application time by increasing the impact 
on the skin (relative to topical devices).  
 
Airway health, including the presence of mucus hyper-production and peribronchial airway 
inflammation was significantly protected against only when mice were vaccinated via the eMPA. 
Highlighting a potentially crucial role for eMPAs to improve the performance of therapeutics 
against potentially fatal airway inflammation such as in asthma, chronic obstructive pulmonary 
disease and cystic fibrosis. As the MPAs only delivered OVA into the skin, it is likely that the 
mechanism behind protection of the airways results from the interaction of the OVA with the skin 
immune cells. This in turn suggests the mechanism by which the MPA is delivering the OVA is 
modulating the immune system for a more permanent downregulation of airway inflammation, 
making it a superior alternative to symptom-treating drugs currently available. 
 
Overall, I found that the MPA design including the density, application energy and penetration 
depth played an important role in adjusting the inflammatory impact on the skin. In turn, these 
design parameters altered the immune response to the delivered OVA, which had not been reported 
before. Delivery of allergy therapeutics favoured densities lower than 10k p/cm2 (or similar surface 
area within the skin), application energies below 100 mJ and delivery to the shallow layers of the 
skin, particularly the epidermis. These results provide tighter parameters for MPA design that could 
be used in future allergy therapeutic tests. This is an important step forward for high-density MPAs 
that were previously only tested in infectious disease vaccinations. This is also an important step 
forward in skin-based allergen deliver devices, particularly for airway-based allergies, that 
previously required lengthy applications of high allergen doses and often the addition of adjuvants. 
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8.1 Key findings 
This thesis presented the first results of high-density dermal-targeted and epidermal-targeted MPAs 
(dMPA and eMPA, respectively) used in allergy desensitisation or vaccination in an OVA-based 
airway hypersensitivity mouse model. The key findings are: 
 
I) Decreasing the density or penetration depth of high-density dMPAs decreases skin 
inflammation and skin-induced Th2-mediated immunity. 
i. Decreasing the density from 21k to 10k p/cm2 (both applied at 100 mJ) resulted in 
lower Th2 responses with 80% less eosinophils and no further increase in anti-OVA 
IgE above sensitise (Chapter 4). 
ii. Decreasing the dMPA density incrementally from 30k to 5k p/cm2 resulted in a near 
1:1 positive correlation with the level of Th2-enhancing epidermal cell death 
(Chapter 5). 
iii. Dose-matched delivery of decreasing density from incrementally 30k to 5k p/cm2 
resulted in a near 1:1 positive correlation with the level of specific IgG1 (Th2) but 
did not correlate with IgG2a (Th1) antibody production (Chapter 5). 
iv. Decreasing the penetration depth by using an eMPA (~ 15 µm deep) instead of a 
dMPA (~ 75 µm deep) reduced erythema and swelling of skin (Chapter 6A). 
v. Decreasing the penetration depth from by using an eMPA instead of a dMPA 
induced LC migration with about a 60% lower expression of the MHC II receptor 
and without inducing dDC migration above naive (Chapter 6A). 
 
II) Penetrating tip surface area and the type of applicator used are key variables in 
adjusting penetration depth and impact within mouse skin. 
i. Increasing the penetrating tip surface area (~2-fold) from the conical-MPA to the 
slit-MPA reduced the penetration depth potential when applied with a high-
mass/low-velocity applicator (Chapter 6A). 
ii. A lower penetrating tip surface area of the slit-MPA can also achieve mouse 
epidermal delivery when applied with a more clinically relevant low-mass/high-
velocity applicator (Chapter 6B). 
iii. Changing the mechanism of the applicator from IIi to IIii to become more clinically 
relevant can alter trends previously seen in mice and so clinical conditions should be 
pre-tested in the appropriate animal model before human application. 
 
272 
 
III)  OVA-coated MPAs of 10k p/cm2 or less (with ≤ 5.22 mm2 surface area within 
the epidermis) applied with 100 mJ energy or less can reduce OVA-specific airway 
inflammation 
i. Very high-density dMPAs (21k) applied at 100-170 mJ, or 10-21k dMPAs applied 
with very high energy (170 mJ) increased undesirable specific-Th2 inflammation 
(Chapter 4). 
ii. High-density dMPA application (10k at 100 mJ) led to reduced airway eosinophilia 
with increased airway neutrophilia (Chapter 4). 
iii. High-density eMPA delivery of OVA (7k at 30 mJ) resulted in reduced airway 
eosinophilia (Chapter 4 and 7). 
iv. Both high-density dMPA and eMPA delivery of OVA (≤ 10k at ≤ 100 mJ) resulted 
in reduced airway mucus hyper-production and peri-bronchial cellular influx in 
chronic sensitisation models (Chapter 4 and 7). 
 
 
8.2 Limitations 
As the thesis assessed both the fields of biomedical engineering and immunology the limitations 
within each field is listed below (including appropriate measures made to account for each 
limitation): 
 
I) Biomedical engineering-based limitations: 
i. Manufacturing silicon MPA via deep-ion reactive etching process is difficult to 
reproduce the exact shape and length of projections when the density is altered and 
so the MPA surface areas in the skin did not always scale with density (Chapter 4 
and 5). 
Therefore: The surface area and volume displaced in the skin was measured per MPA design for 
easier comparisons between designs. 
 
ii. Reproducing MPAs using hot-embossing required projection width to be at least 30 
µm wide and so densities were not always directly comparable between silicon and 
polycarbonate MPAs (Chapter 3). 
Therefore: The silicon MPA designs chosen were above 30 µm wide where possible. 
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iii. Lower density MPAs with a low projection height cannot penetrate the mouse skin 
without increasing the projection height which may result in deeper penetration than 
desired. (Chapter 6A). 
Therefore: The study progressed with the high-density design with the shorter projection height. 
 
iv. The projectile applicator could not be loaded to less than 12 m/s without causing the 
projected patch construct to destabilise during flight (Chapter 6B). 
Therefore: MPAs with higher surface areas were used to prevent deeper penetration into the skin. 
 
v. The polycarbonate and silicon slit-MPA were not tested at 12 m/s with the spacer 
due to difficulties of changing between velocities, which could have resulted in a 
penetration depth more similar to the eMPA (Chapter 6B). 
Therefore: The projectile applicator was assessed with the closest penetration depth condition that 
resulted from the 18 m/s velocity. 
 
II) Allergy and immunology-based limitations: 
i. OVA is a model protein not responsible for allergic airway diseases in humans, 
so, MPA delivery of other allergens (such as grass or dust mite) may require a 
different dose but will likely retain dose sparing effects seen with the MPA 
(Chapters 4, 6 and 7). 
Therefore: Exact doses used are relevant for OVA-based mouse models only, which is helpful when 
comparing to the plethora of literature on OVA-based hypersensitivity.   
 
ii. BALf was differentially counted in Chapter 4 but assessed via flow cytometry in 
Chapter 7 and so the data from each chapter was not comparable. 
However: Both methods are used widely in literature and the trends between sensitised mice 
remained the same between the two methods. 
 
iii. Th1 and Th2-mediated responses were based on antibody subtype responses 
without additional assessment of signalling proteins such as cytokines (Chapters 
4, 5 and 7). 
Therefore: Type of immunity was based on downstream effects of mediated response though the 
resulting cells and antibodies assessed are well known indicators of Th response types. 
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iv. Very high-density dMPAs were only assessed on ear skin that contains more mast 
cells than flank skin and therefore may have a minimum threshold for priming 
sensitisation (Chapter 4). 
Therefore: Subsequent studies after the first study were made using the flank skin of mice which 
more closely represents human skin. 
 
v. Skin dLN cells did not undergo a recall assay and so LC and dDC activation level 
was based on level of MHC II staining (Chapter 6A).  
Therefore: Only MHC II based activation assumptions were made. However, MHC II is an 
important marker for CD4+ T cell activation and the relatively lower expression seen in eMPAs is a 
promising start for use in allergy therapeutics. 
  
vi. Protective responses from the eMPA 0.4-72 vaccination group was only repeated 
once each for 1 x i.p. and 2 x i.p. airway sensitisation models and would require 
an additional (successful) repeats of each to confirm results (Chapter 7). 
Therefore: The combination of results from the eMPA 0.4-72 groups in both the 1x and 2x i.p. 
model was taken into consideration when presenting the results. The eMPA 0.4-72 with the 1x i.p. 
model was also tested twice more in Vaccination 5 and 6, however, the controls were not sufficient 
to include the data. 
 
vii. All allergy model samples were collected 24 h after the last challenge (peak 
challenge response) and so peak immunisation responses could not be assessed 
(Chapter 4 and 7). 
Therefore: Only peak challenge responses were assessed to ensure the therapy could provide 
protection at the strongest point of the allergic challenge. 
 
viii. All allergy model samples were collected 24 h after the last challenge and so 
assessment of persistent biomarkers of protection versus temporary influx could 
not be determined (Chapter 4 and 7). 
Therefore: Only the short-term biomarkers of protection were assessed which are good indicators 
for long-term biomarkers of protection. 
 
ix. In order to keep the assay as short as possible the allergy vaccination model 
challenged mice at the start of IgE release (day 9) after the i.p. sensitisation and 
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not at the peak IgE release (day 28), challenging at the later time point would 
likely reduce the variation per group (Chapter 7). 
Therefore: More repeats of the allergy vaccination study were able to be completed due to the 
shorter time frame while still providing insight into the protection provided by the eMPA at various 
doses and regimens. 
 
 
8.3 Future experimental recommendations 
There were several findings that lead me to make additional hypotheses that, if explored further, 
could add the understanding of results presented here and to the mechanisms behind both MPAs 
and other epicutaneous immunotherapy devices.  
 
The following hypotheses for mouse studies were made based on both findings and limitations 
listed above: 
 
I) There is a minimum and maximum threshold of skin cell death produced by different 
MPA densities that protects against airway eosinophilia in mice. 
i. TO TEST: Apply four repeats of placebo MPAs with densities that that induce 
epidermal cell death within a range between 1,000-20,000 dead epidermal cells in 16 
mm2. Use a 1 x i.p. sensitisation regimen and challenge at peak IgE (+28 days) to 
determine the relationship between total level of epidermal cell death and 
inflammatory cell influx into the airways. 
ii. ADDITIONAL TEST: Compare prospective conditions to an allergy vaccination 
peak IgE 2x i.p. sensitisation to determine if the protection can resist chronic 
sensitisation. 
 
II) There is a maximum level of skin cell death produced by dMPAs around or below 5k 
p/cm2 (i.e. 1.29 mm2 within epidermis), below which no Th2-mediated IgG1 is elicited 
in mice.  
i. TO TEST: Vaccinate once with dose-matched dMPAs ranging in density from 0.1k 
– 10k p/cm2 then sample at the time of peak antibody production for each antibody 
subtype 
ii. ADDITIONAL TEST: Assess the regulatory signals (e.g. Treg cells, IL-10, TGF-β 
etc) from each to determine threshold between Th2 activation and regulatory 
function seen in homeostasis. 
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III)  A level of epidermal cell death less than caused by the eMPA (i.e. <9600 dead 
cells) would result in the migration of fewer LC to dLNs. 
i. TO TEST: Design eMPAs with lower densities that penetrate to the same depth, 
assess the number of dead cells and the number of migratory LCs in the dLN. 
ii.  ADDITIONAL TEST: Assess the activation state of LC that has migrated by adding 
additional markers in flow panel and by assessing the supernatant after ex vivo 
stimulation tests. 
iii. ADDITIONAL TEST: Assess immune cell profile that has migrated daily from the 
skin to the dLN until the profile returns to baseline before application of MPA. 
 
IV) The P/eMPA applied at a lower application energy (e.g. 12 m/s) with a spacer in the 
patch construct would penetrate at a similar depth to the eMPA, resulting in similar 
epidermal cell death levels. 
i. TO TEST: Repeat Chapter 6B tests at 12 m/s with spacer. 
 
V) Skin-based allergy vaccination relies on an inverse dose curve to inhalation 
vaccination. 
i. TO TEST: Vaccinate with 2-4 repeats (keep the same) of allergen in five 10-fold 
dilutions of delivered dose* (i.e. OVA at 100, 10, 1, 0.1, 0.01 µg) with i.n. 
inhalation, an eMPA and a hydration skin delivery method (to control for penetration 
cell death) in an allergy vaccination model (using peak IgE challenge). 
*Note: For most accurate results, both i.n. and skin routes should be tested for delivered dose into 
the lung and skin respectively, not administered dose.  
 
VI) The OVA-based eMPA application produces signals in the skin that prevent airway 
mucus production and peribronchial inflammation upon a challenge to the airway. 
i. TO TEST: Repeat Vaccination 8 and assess airways for known markers of mucus 
upregulation (e.g. IL-13) and downregulation (e.g. IFN-γ). Compare markers that 
differ between controls and eMPA group to those upregulated in the skin and skin 
dLN during eMPA application using either mRNA expression analysis of the skin, 
flow cytometry analysis of cells in the skin and/or skin and dLN cell stimulation 
assays.  
ii. ADDITIONAL TEST: To confirm better lung health, add the analysis of collagen in 
the airways and test the function of the lungs via plesmethography. 
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iii. ADDITIONAL TEST: Compare to various airway allergens, such as grass pollen or 
house dust mite, to determine if the downregulation is only OVA-specific.  
 
VII) High-density eMPAs require lower doses than low-density eMPAs for allergy 
vaccination. 
i. TO TEST: Deliver a few repeats (e.g. x4) of allergen in three 10-fold dilutions (i.e. 
OVA at 1, 0.1 and 0.01 µg) with a low-density eMPA (within 0.01k – 0.5k p/cm2) 
and a high-density eMPA (within 2k – 7k p/cm2) each matched in mJ/projection and 
dose delivered in an allergy vaccination model (using peak IgE challenge). 
ii. ADDITIONAL TEST: To confirm range of tolerance induction, the Treg cells from 
each group can be isolated and transferred into naïve mice whom are then 
challenged.  
 
VIII) The lower inflammatory eMPA applied with less repeats and lower dose would 
result in better AIT than the tested dMPAs. 
i. TO TEST: Repeat 87 day desensitisation of eMPA and dMPA treated mice at a low 
dose (e.g. 0.1 µg) and a higher dose (e.g. 1 µg) alongside a positive control group at 
once every 2 two weeks treatment and once a week treatment regimes. Assess BALf, 
antibody and lung health responses. 
 
IX) Combining the eMPA with an anti-IgE could prevent both systemic anti-allergen 
IgE and airway inflammation.  
i. TO TEST: Repeat Vaccination 8 with a pre-administration of anti-IgE therapy (at the 
recommended time to deplete IgE) and re-assess the systemic and local airway Th2-
mediated inflammation responses. 
 
 
8.4 Final outlook 
This thesis reports the first instance of high-density MPA devices used for allergen delivery in both 
allergy desensitisation and vaccination. Overall, the dMPA density and application energy were 
important additional variables that affected the impact on the skin and immunotherapy outcome. 
These variables are in addition to those in other epicutaneous immunotherapy devices. However, I 
confirmed that increasing anti-OVA IgG1 and IgG2a does not assist in blocking anti-OVA IgE in 
the mouse model, which was likely due to the increased skin inflammation caused by the dMPA 
application. Promisingly, high-density MPAs were redesigned to maintain low skin inflammation 
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while delivering primarily to the epidermis and the tolerant-inclined LCs within. Vaccination 
experiments with the low-impact eMPA design found the dose and timing between repeats were 
important variables that affected the protection level against Th2-mediated sensitisation and airway 
inflammation. Therefore, I highly recommend further investigation of high-density MPAs for 
delivery of therapeutics in order to prevent airway inflammation. In doing so, this low-impact skin 
delivery device will provide a safer, cost effective and more tolerable delivery system of which the 
large population of allergic patients sorely require.  
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10.1 Appendix 1: EAACI presentation 
 
Preventing allergic airway eosinophilia with an epidermal microprojection patch. 
N.M.D. van der Burg1, P.G. Holt2, S. Phipps3, A.C.I. Depelsenaire4, M.A.F. Kendall 1, 5 
 
1Australian Institute for Bioengineering and Nanotechnology, Brisbane, Australia. 
2Telethon Kids Institute, Perth, Australia. 
3QIMR Berghofer Medical Research Institute, Brisbane, Australia. 
4Vaxxas, Translational Research Institute, Brisbane, Australia 
5Faculty of Medicine and Biomedical Sciences, Brisbane, Australia. 
 
Background: While guidelines for allergen exposure are improving, only a handful of studies have been 
reported on the active prevention of allergic sensitisation, such as an allergy vaccine. Following the tolerance 
model for preventing sensitisation, a vaccine would require allergen to be targeted to an antigen presenting 
cell that is capable of inducing allergen–specific tolerance such as Langerhans cells (LCs). Using the skin 
route for administration, a vaccine can be targeted to LCs that reside in the epidermis stratum. However, both 
quickly and specifically targeting the epidermis has proven difficult. 
Method: Here we have designed an epidermal-targeted microprojection array (eMPA) patch to quickly (2 
min) deliver allergen primarily into the skin epidermis, with the aim of preventing allergic sensitisation in 
female, BALB/c mice. Mice were exposed in three stages: vaccination, sensitisation (with alum) and airway 
challenge. Using the model allergen ovalbumin (ova), we tested the dose (0.1 µg – 10 µg) and number of 
repeats (x4 – x8) required for our eMPA to prevent allergic sensitisation. In addition, no adjuvants were used 
to boost vaccination, reducing adverse reactions.  
Results: The eMPA prevented airway eosinophilia in up to 60% of mice and, notably, required a lower dose 
(0.1 µg) with fewer vaccination repeats (x4) than intradermal injection (i.d., 1 µg, x8) and intranasal 
inhalation (i.n., 10 µg, x8). This may be due, in part, to the increase in local physical stimulation of LCs 
evoked by the eMPA application. Additionally, eMPA vaccinated mice had significantly less airway mucus 
and obstructions than both i.d. and i.n. vaccination as quantified by muc5a staining. However, only the i.n. 
vaccination reduced anti-ova IgE. 
Conclusion: To date, we have developed and tested a skin-based allergic vaccination patch to prevent 
allergic airway eosinophilia in mice without additional adjuvants. These findings warrant further research in 
allergy prevention through vaccination. 
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Figure 10-1: Presentation slides of N.M.D. van der Burg, et al.: Preventing allergic airway 
eosinophilia with a Langerhans cell targeted microprojection patch. Presented at European 
Academy for Allergy and Clinical Immunology, Germany (2018). 
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10.2 Appendix 2: BioNano presentation 
 
Targeting allergy immunotherapies to the epidermis, for improved allergy desensitisation 
 
Nicole M.D. van der Burg*, Patrick G. Holt, Simon Phipps, Michael L. Crichton, Alexandra C.I. 
Depelsenaire, Mark A.F. Kendall 
  
Bldg #75, Cnr College and Cooper Rds,  
University of Queensland, St Lucia 
Australian Institute for Bioengineering and Naotechnology 
Brisbane, Queensland, Australia 
 
Recent studies suggest that epidermal skin-targeted allergy immunotherapy (AIT) can resolve symptoms 
within months without a systemic reaction. However delivering a consistent dose to the epidermis layer, 
which is ~100 micons thick (in humans), has proven difficult. Common methods of epidermal delivery 
include painful tape stripping or lengthy topical absorption application (lasting days), neither of which are 
ideal for a repetitive treatment like AIT. Additionally, introducing inflammation to the delivery site (such as 
tape stripping) can activate an unwanted inflammatory response to the immunotherapy. While lacking any 
inflammation at the site can require AITs that last for years. Here we discuss our progress on a 
microprojection array (MPA) capable of quickly delivering AIT to the epidermis of mice (e.g. minutes) and 
detail its effect on local skin inflammation during allergic tolerance. 
 
MPA projections were 120 µm tall and fabricated in an array of 7,000 projections/cm2. Using a shorter 
tolerance protocol (not AIT), mice were treated daily with different ovalbumin doses to activate tolerance 
then sensitised intraperitoneally and challenged via intranasal inhalation. Treatment administrations included 
intranasal inhalation, intradermal injection (i.d.) and epidermal MPA for no, low and increased skin 
inflammation respectively. Local skin inflammation and swelling was assessed by the number of cells killed 
during administration and by skin histology. Tolerance was assessed by eosinophil influx into bronchial 
alveolar lavage fluid and ova-specific IgE and IgG subtypes in sera.  
 
The epidermal MPA (66% tolerance) required one tenth the dose (0.1 µg) of an i.d. (75% tolerance) and half 
the number of administrations, to achieve a similar tolerance percentage. To account for this large dose 
reduction, we hypothesised that local skin inflammation played a role in activating an ovalbumin-specific 
tolerance. Subsequently, epidermal MPAs induced 14 times more cell death at the delivery site than i.d.. 
Interestingly, epidermal MPAs with higher doses (> 1 µg) nor dermal MPAs (65 times cell death) induce 
allergic tolerance, suggesting a correlation between inflammation and tolerance in epidermal-based AIT. 
 
Our work has shown the potential for quick and precise epidermal AIT whilst using smaller doses than 
previous technologies. The level of allergen and inflammation both appear important and this presentation 
will discuss how these may be translated into a practical device. 
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Figure 10-2: Presentation slides of N.M.D. van der Burg, et al.: Targeting allergy 
immunotherapies to the epidermis, for improved allergy prevention. Presented at BioNano 
Innovation, Australia (2017). 
 
311 
 
10.3 Appendix 3: CBNS presentation 
 
Invited presentation. 
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Figure 10-3: Presentation slides of N.M.D. van der Burg, et al.: Targeting therapies to the 
epidermis of the skin. Presented at ARC Centre of Excellence in Convergent Bio-Nano Science & 
Technology, Australia (2017). 
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10.4 Appendix 4: AIBN presentation 
 
Invited presentation. 
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Figure 10-4: Presentation slides of N.M.D. van der Burg, et al.: Improved allergy desensitisation 
by targeted delivery to the immune cells within the skin strata. Presented at the Australian 
Institute for Bioengineering and Nanotechnology, Australia (2016). 
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10.5 Appendix 5: TRI presentation 
 
Invited presentation. 
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Figure 10-5: Presentation slides of N.M.D. van der Burg, et al.: Setting up a working mouse 
model to test alternative skin targeted allergy desensitisation immunotherapy methods. Presented 
at Translational Research Institute Immunology Series, Australia (2015). 
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10.6 Appendix 6: ASI poster 
 
Preventing allergies by inducing tolerance with an epidermal microprojection patch. 
N.M.D. van der Burg1 P.G. Holt2 S. Phipps3 A.C.I. Depelsenaire1 M.A.F. Kendall1, 4 
1 Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, Brisbane, 
Australia. 
2 Telethon Kids Institute, Subiaco, Perth, Australia. 
3 QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia. 
4 Faculty of Medicine and Biomedical Sciences, Royal Brisbane Women’s Hospital, The University of 
Queensland, Brisbane, Australia. 
 
Allergic sensitisations affect up to 50% of the population. While guidelines for allergen exposure are 
improving, few studies have been reported on the active prevention of allergies such as an allergy vaccine. In 
general, allergies result from a Th2-biased immune response combined with a lack of tolerance to an 
allergen. Langerhans cells (LC), residing within the epidermis of the skin, promote regulatory T-cells that are 
essential for allergen tolerance as seen in healthy subjects. Therefore, we have designed and tested a novel 
skin patch for rapid and precise targeting of allergen to the epidermis, with the aim of inducing allergic 
tolerance.  
Ovalbumin protein was delivered into the epidermis using a custom-designed epidermal microprojection 
array (eMPA) patch applied for 2 minutes. To test for allergy prevention capabilities, we adapted a tolerance 
test. This included treating naïve mice repeatedly with an ovalbumin coated eMPA followed by a 
sensitisation event and airway challenge respectively. Control treatments included intranasal inhalation (10 
µg) or intradermal injection (i.d., 1 µg). Tolerance was assessed by eosinophil and mucus influx into the 
airway and ova-specific IgE and IgG subtyping in sera. Additionally, local skin inflammation at the site of 
eMPA treatment was assessed by skin histology and enumeration of dead cells.  
Relative to i.d., eMPA required 0.1 µg of ovalbumin and half the number treatments to generate a similar 
tolerance. We hypothesised that this eMPA dose reduction may be due, in part, to the effects of local skin 
inflammation. Subsequently, we demonstrated that eMPAs induced 14-fold more cell death and 1.2-fold 
more epidermal swelling at the delivery site than i.d. These findings provide a promising platform as a 
potential skin-based allergic tolerance approach worthy of further investigation.  
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Figure 10-6: Poster of N.M.D. van der Burg, et al.: Preventing allergies with an epidermal 
microprojection patch. Presented at Australasian Society for Immunology (ASI), Australia (2017). 
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10.7 Appendix 7: Immunotherapy@Brisbane poster 
 
Does introducing inflammation to the skin during allergy immunotherapy reduce the required 
dosages? 
 
Nicole M.D. van der Burg1, Patrick G. Holt2, Simon Phipps3, Michael L. Crichton1, Alexandra C.I. 
Depelsenaire1, Mark A.F. Kendall1, 4 
1 The University of Queensland, Delivery of Drugs and Genes Group (D2G2), Australian Institute for Bioengineering and Nanotechnology, Brisbane, Australia. 
2 Telethon Kids Institute, Subiaco, Perth, Australia. 
3 The University of Queensland, School of Biomedical Sciences, Brisbane, Australia. 
4 The University of Queensland, Faculty of Medicine and Biomedical Sciences, Royal Brisbane Women’s Hospital, Brisbane, Australia. 
 
Recent studies suggest that epidermal skin-targeted allergy immunotherapy (AIT) can resolve symptoms 
within months without a systemic reaction. Current standard administrations include subcutaneous injections 
or sublingual absorptions. Both routes activate a relatively low local inflammatory response, therefore, the 
effect of local inflammation during AIT administration is not well studied. However, local inflammation 
responses are being induced by alternative administration devices devised to deliver to the epidermis. Here 
we aim to assess the local inflammation produced by epidermal microprojection arrays (MPA) and its effect 
on AIT, specifically allergic tolerance, using a mouse model. 
 
Mice were treated daily with different ovalbumin doses to activate tolerance then sensitised intraperitoneally 
and challenged via intranasal inhalation. Treatment administrations included intranasal inhalation for no skin 
inflammation, intradermal injection for low skin inflammation and epidermal MPA which increases skin 
inflammation. Local skin inflammation was assessed by the number of cells killed during administration and 
skin histology. Tolerance was assessed by eosinophil influx into bronchial alveolar lavage fluid and ova-
specific IgE and IgG subtypes in sera.  
 
Tolerance was induced in 80% of intranasal, 75% of intradermal and 50% of epidermal MPA treated mice, 
receiving 10, 1 and 0.1 µg, respectively. Assessing inflammation, epidermal MPA caused 14-fold more skin 
cell death and significantly more epidermal swelling than an intradermal injection. However, epidermal 
MPAs applied at high doses (>1 µg) or evoking higher local inflammation (65-fold higher than intradermal) 
failed to tolerate mice, suggesting a correlation between inflammation and tolerance in skin-based AITs.  
 
Overall, these findings suggest that the dose used for AIT may depend on the level of local inflammation the 
administration elicits.  
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Figure 10-7: Poster of N.M.D. van der Burg, et al.: Does introducing inflammation to the skin 
during allergy immunotherapy reduce the required dose? Presented at 
Immunotherapy@Brisbane, Australia (2017). 
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10.8 Appendix 8: ASCIA poster 
 
TAKING ADVANTAGE OF TOLERANCE TESTS IN THE MOUSE MODEL TO SCREEN 
ALTERNATIVE MICROPROJECTION PATCH DESIGNS FOR ALLERGY IMMUNOTHERAPY  
 
Nicole M.D. van der Burg1, Patrick G. Holt2, Simon Phipps3, Michael L. Crichton1, Alexandra C. 
Depelsenaire1, Mark A.F. Kendall1 
 
1 Australian Institute of Bioengineering and Nanotechnology, University of Queensland, Brisbane, Australia. 
2 Telethon Kids Institute, Subiaco, Perth, Australia. 
3 School of Biomedical Sciences, University of Queensland, Brisbane, Australia.  
 
BACKGROUND    Allergy immunotherapy is currently a costly, prolonged process, requiring 
approximately 100 injections over 5 years and can lead to local or systemic side effects. Some of 
these drawbacks can be overcome by alternative routes such as intradermal or epicutaneous 
desensitisation. Here, we present a novel cutaneous delivery device, a microprojection array 
(MPA) which has been previously used in skin-based vaccination, as a means to overcome some 
of the challenges of cutaneous administration. MPAs are an array of coated projections that 
pierce the skin, delivering substances into the skin strata. A challenge of these devices is that they 
generate imflammation when applied to the skin, which may be detrimental for allergen 
desensitisation and therefore a new design is required. However, time taken for desensitisation in 
the mouse model can be significant. Using tolerance tests can reduce such time by replicating the 
immune response of desensitisation within days instead of weeks. Here, we hypothesised that an 
accelerated tolerance test can be used to screen a range of MPA designs for allergy 
immunotherapy potential. 
 
METHODS            MPA conditions for epidermal targeting were tested using florescent markers 
and assessed by histology. For tolerance tests, BALB/c mice were exposed daily to ovalbumin 
(OVA) through MPAs for eight days, followed by an induced sensitisation challenge 
intraperitoneally. Sensitisation prevention was assessed by eosinophil proliferation in bronchial 
lavage fluid and OVA-specific IgE in sera. 
 
RESULTS              MPA designs induced a high sensitisation responses, inappropriate for 
immunotherapy. Optimising MPA design conditions led to reduced local and systemic 
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Figure 10-8: Poster of N.M.D. van der Burg, et al.: Taking advantage of tolerance tests in the 
mouse model to screen alternative microprojection patch designs for allergy immunotherapy 
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(Screening microprojection patch designs for allergy immunotherapy potential). Presented at 
Australasian Society for Clinical Immunology and Allergy (ASCIA), Australia (2016). 
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10.9 Appendix 9: Immunotherapy@Brisbane poster 
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Figure 10-9: Poster of N.M.D. van der Burg, et al.: Investigating the use of microneedles in 
allergy Desensitisation. Presented at Immunotherapy@Brisbane, Australia (2015). 
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10.10 Appendix 10: Ethics certificate of AIBN/556/12 
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Figure 10-10: Ethics certificate. 
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10.11 Appendix 11: Ethics certificate of AIBN/042/16 
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Figure 10-11: Ethics certificate. 
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10.12 Appendix 12: Ethics certificate of AIBN/043/16 
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Figure 10-12: Ethics certificate. 
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10.13 Appendix 13: Hot embossing of PDMS (Chapter 3) 
 
Figure 10-13: See SUPP 4 of Appendix 21. 
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10.14 Appendix 14: Coated microprojection arrays (Chapter 3) 
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Figure 10-14: Representative photographs of therapeutic coated MPAs. Coating was evenly 
spread over the majority of the projections with thicker coating around the edge for each MPA type. 
Silicon patches photographed also had ~15 nm of gold sputter coated onto the surface, coating 
morphology did not differ between gold and silicon surfaces.  
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10.15 Appendix 15: linear regression of IL-5 standard (Chapter 3) 
 
 
Figure 10-15: Optical density (OD) of IL-5 standard dilutions. Samples were interpolated off a 
linear line of best fit that has an R2 value of 0.9956 and demonstrates homoscedasticity. 
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10.16 Appendix 16: hyperbola regression of Eotaxin-2 standard (Chapter 3) 
 
 
Figure 10-16: Optical density (OD) of Eotaxin-2 standard dilutions. Samples were interpolated off 
a hyperbola line of best fit that has an R2 value of 0.9982.  
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10.17 Appendix 17: Number of dead cells per projection (Chapter 5) 
 
 
Figure 10-17:  Plot of number of epidermal dead cells per projection. Total number of epidermal 
dead cells per dMPA density divided by number of projection inserted, n= 3.  Includes a line of 
means. 
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10.18 Appendix 18: Total IgG of day 21 (Chapter 5) 
 
 
Figure 10-18: Anti-Fluvax of total IgG in serum at day 21 post Fluvax vaccination. Background 
(490 OD) was removed before plotting both (Top) dilution curves and (Bottom) readings at 1:800 
dilution, n = 4-5. 
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10.19 Appendix 19: Dilution curves at day 63 (Chapter 5) 
 
 
Figure 10-19: Dilution curves of serum at day 63 after Fluvax vaccination. Background (OD490) 
was removed before plotting curves for (Top) anti-Fluvax of total IgG, (Middle) anti-Fluvax IgG1 
and (Bottom) anti-Fluvax IgG2a, n = 4-5. 
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10.20 Appendix 20: Tables of anti-Fluvax ELISA statistics (Chapter 5) 
 
Table 10-1: Projection density range of dermal-targeted microprojection array vaccination 
Fluvax- IgG statistics 
Fluvax - IgG Mean ± SD p (Naïve) p (5k – QS-21) 
Naive <100 - - - 
i.m. 31G 120 44 ** 0.0039 ### 0.0010 
5k-dMPA 320 109 ** 0.0028 ## 0.0011 
10k-dMPA 680 268 ** 0.0048 ## 0.0012 
21k-dMPA 1100 685 * 0.0351 ## 0.0049 
30k-dMPA 1600 0 **** <0.0001 # 0.0161 
5k – QS21 2880 715 *** 0.0008 - 
 
Table 10-2: Projection density range of dermal-targeted microprojection array vaccination 
Fluvax-IgG1 statistics 
Fluvax –IgG1 Mean ± SD p (Naïve) p (5k – QS-21) 
Naive <100 - - - 
i.m. 31G 140 54 **0.0046 # 0.0379 
5k-dMPA 3680 2629 * 0.0352 ns 0.0510 
10k-dMPA 6560 4248 * 0.0260 ns 0.0665 
21k-dMPA 13760 11626 ns 0.0572 ns 0.1739 
30k-dMPA 19200 9051 ** 0.0090 ns 0.3407 
5k – QS21 28800 16106 * 0.0374 - 
 
Table 10-3: Projection density range of dermal-targeted microprojection array vaccination 
Fluvax-IgG2a statistics 
Fluvax –IgG2a Mean ± SD p (Naïve) p (5k – QS-21) 
Naive 0 - - - 
i.m. 31G 0 - - ## 0.0060 
5k-dMPA 60 54 ns 0.0705 ## 0.0063 
10k-dMPA 60 54 ns 0.0705 ## 0.0063 
21k-dMPA 80 178 ns 0.3739 ## 0.0037 
30k-dMPA 80 109 ns 0.1778 ## 0.0054 
5k – QS21 1400 400 ** 0.0060 - 
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10.21 Appendix 21: Supplementary figures of Chapter 6A manuscript 
 
 
 
Figure 10-20: SUPP 1: Percentage of coated 14C- labelled ova delivered into the skin, n = 10-15, 
min-max box and whisker plot. 
 
 
Figure 10-21: SUPP 2: BS-SEM of coating (dark) consistency observation on an iridium plated (20 
nm) slit-MPA. Brighter areas depict thinner coating e.g. on base of MPA. 
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Figure 10-22: SUPP 3: Erythema in skin 5 min (t = 0h), 24 h and 72 h post application of ova-
based formula.  Representative image of erythema at t = 0 h, 24 h and 72 h after application (A) 
dMPA, (B) eMPA and (C) 20 µl i.d. using a 31 G needle. Skin was marked on the corners of the 
MPA application daily for traceability. I.d. bleb was circled and needle insertion site was 
partitioned, arrow indicated approximate needle insertion direction. Scale bar: 5 mm. 
 
 
Figure 10-23: SUPP 4: Manufacture results for moulding polycarbonate conical and slit 
projections from silicon moulds. Each line represents a single PDMS mould cured at the ratio 
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indicated by the legend. The number of successful hot embossing repeats of each mould is plotted, 
where “0” success did not produce any viable projections. Includes recommended forces for hot 
embossing before and after five uses of PDMS mould. 
 
 
Figure 10-24: SUPP 5: Mean epidermal surface area from Figure 2F multiplied with application 
energy used to insert into the skin. 
 
 
Figure 10-25: SUPP 6: Thickness of the epidermis and dermis 24 h post application of placebo 
formula. Dermis skin thickness measured from H&E stained sections of n = 3 mice and n = 48 - 93 
measurements. Graph shows mean ± SD. 
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Figure 10-26: SUPP 7: Number of cells in skin inguinal dLN flow sample at t = 24, 48 and 72 h 
after dMPA or eMPA application with ova or PBS. Statistics: One-way ANOVA (in graph title), ns 
p > 0.05, * p < 0.05 
 
 
Figure 10-27: SUPP 8: Number of cells in skin inguinal dLN from combined time points and 
formulation of dMPA and eMPA applications. Statistics: One-way ANOVA (in graph title) and 
Welsh corrected student t-test (within graph), ns p > 0.05, ****p < 0.0001. 
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10.22 Appendix 22: P/eMPA erythema and dermal thickness of skin (Chapter 6B) 
 
 
Figure 10-28: Projectile applied eMPA (P/eMPA) impact on skin. (Left) Representative image of 
erythema in skin 5 min (t = 0h), 24 h and 72 h post application of ova-based formula after 
application of P/eMPA. Skin was marked on the corners of the MPA application daily for 
traceability. (Right) Repeat of SUPP 6 including P/eMPA dermis skin thickness after 24 h 
application to skin measured from H&E stained sections of n = 3 mice and n = 48 - 93 
measurements. Graph shows mean ± SD. 
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10.23 Appendix 23: Disregarded desensitisation experiment groups 
 
The following experiment (Table 10-4) was completed as per the protocol outlined in Figure 4-12B 
and assessed for BALf cell differentiation and anti-OVA IgE. As the positive control group (s.c. 
400-W) resulted in similar levels of eosinophils and anti-OVA IgE as the Sensitised-D87 group, the 
experiment was disregarded (data not shown). 
 
Table 10-4: Desensitisation groups of 3x i.p. sensitised mice treated for OVA allergy 
desensitisation at a weekly interval using101k dMPAs on mouse flank. Nomenclature of treatment 
group names are as follows: (route of desensitisation) – (application energy) – (Total days of 
experiment). 
Desensitisation group 
name Route Repeats 
Ova 
dose 
(µg) 
Interval 
(per 
week) 
Total 
dose 
(µg) 
Total 
EU dose 
(ng) 
N 
Sensitised-D87 - x8 - - - 966.1 8 
s.c. 400-W s.c. x8 50 1 400 3179.8 7 
i.d. 0.8-W i.d. x8 0.1 1 0.8 982.6 8 
dMPA 0.8-W dMPA x8 0.1 1 0.8 973.5 8 
eMPA 0.8-W 
eMPA 
x8 0.1 1 0.8 973.1 8 
Projectile eMPA 0.8-W x8 0.1 1 0.8 972.0 8 
Projectile eMPA 0.4-W x4 0.1 1 0.4 969.1 8 
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10.24 Appendix 24: Epidermal surface area to average cell death (Chapter 6B) 
 
 
Figure 10-29: Skin device epidermal surface does not correlate with average epidermal cell death 
level between different applications, n =3.  
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10.25 Appendix 25: Application energy to average cell death (Chapter 6B) 
 
 
Figure 10-30: Skin device application energy does positively correlate with average epidermal cell 
death level between different applications, n = 3.  
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10.26 Appendix 26: Vaccination studies disregarded (Chapter 7) 
 
Table 10-5: Vaccination 5 groups including endotoxin unit (EU) dose for vaccination only per 
group and total vaccination + sensitisation + challenge per group. Red highlighted EU indicates 
values above reported sensitising dose (100 ng), green highlight indicates values below reported 
protective dose (1 ng) [56]. 
Code Group name Route Dose Repeats Interval EU (ng) / vaccination 
Total EU 
(ng) 
 Sensitised-1 - - - - - 82.42 
 i.n. 80-24 i.n. 10 µg ×8 24 h 42.14 124.56 
 i.d. 8-24 i.d. 1 µg  ×8 24 h 5.30 87.72 
 i.d. 0.4-74 i.d. 0.1 µg  ×4 72 h 0.81 83.23 
 eMPA 0.4-72 eMPA 0.1 µg ×4 72 h 0.35 82.77 
 
 
Table 10-6: Vaccination 6 groups including endotoxin unit (EU) dose for vaccination only per 
group and total vaccination + sensitisation + challenge per group. Red highlighted EU indicates 
values above reported sensitising dose (100 ng), green highlight indicates values below reported 
protective dose (1 ng) [56]. 
Code Group name Route Dose Repeats Interval EU (ng) / vaccination 
Total EU 
(ng) 
 Sensitised-1 - - - - - 82.42 
 i.n. 80-24 i.n. 10 µg ×8 24 h 42.14 124.56 
 eMPA 0.4-72 eMPA 0.1 µg ×4 72 h 0.35 82.77 
 eMPA 0.4-72/31 eMPA 0.1 µg ×4 72 h 0.35 82.77 
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10.27 Appendix 27: Total BALf cells analysed per allergy vaccination (Chapter 7) 
 
Figure 10-31: Total number of single cells per vaccination gated from flow sample. The same 
volume of each sample was analysed.  
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10.28 Appendix 28: Number of eosinophils (Chapter 7) 
 
Figure 10-32: Total number of eosinophils cells per vaccination gated from flow sample. The 
same volume of each sample was analysed. 
